

Finnish statistics on medicines 2021

Kela[®] fimea

Finnish Medicines Agency Fimea

Mannerheimintie 166
P.O. Box 55
FI-00034 Fimea
Finland
salesstatistics@fimea.fi
Tel. +358 29 522 3341

Social Insurance Institution

Nordenskiöldinkatu 12
P.O. Box 450
FI-00056 Kela
Finland
tilastot@kela.fi
Tel. +358 20 634 11


ISSN 2737-3592

Key figures for medicine sales and their reimbursement in 2021

Total sales of pharmaceuticals

Sales to hospitals and other health care institutions (at wholesale prices)
861 million euros,
5.0% change from 2020

OTC medicines
(at pharmacy prices with VAT)
359 million euros,
-2.0% change from 2020




Prescription medicines
(at pharmacy prices with VAT)
2,400 million euros,
2.9% change from 2020

Reimbursement of medicine costs

Additional Refunds
228 million euros,
5.0% change from 2020

Basic Refunds
311 million euros,
0.9% change from 2020



Special Refunds
1,172 million euros,
5.7% change from 2020



Contents

List of figures	5	7. Tables: Sales statistics according to medicine group	81
List of tables	6	A Alimentary tract and metabolism	82
1. Basic information about the compilation of statistics on medicines	9	B Blood and blood forming organs	102
Concepts in Finnish statistics on medicines	10	C Cardiovascular system	111
Material used for the statistics	13	D Dermatologicals	126
Abbreviations, definitions and symbols	13	G Genito urinary system and sex hormones	136
Calculating drug consumption	14	H Systemic hormonal preparations, excl. sex hormones and insulins	145
Structure of the ATC system	15	J Antiinfectives for systemic use	151
2. Current issues in pharmacy	16	L Antineoplastic and immunomodulating agents	164
Key events in the pharmaceutical field in 2021	17	M Musculo-skeletal system	181
Pharmaceutical year 2021	18	N Nervous system	189
3. Finnish population and hospital districts	26	P Antiparasitic products, insecticides and repellents	205
4. Drug control and pharmaceutical services	29	R Respiratory system	208
Distribution of medicine sales	30	S Sensory organs	220
Pharmacies and hospital pharmacies	31	V Various	228
5. National health insurance and reimbursement of medicine expenses	34	Nicotine replacement therapy	236
Medicine reimbursement system and approval of medicine prices	36	OTC medicines in outpatient care	238
Reimbursable medicines, confirming wholesale prices and the reference price system	44	Figures on sales statistics	262
6. Tables: Reimbursement of medicine costs	51	Appendices	279
Medicine costs and their reimbursement annually and according to hospital district	52	Appendix 1. Alterations to ATC classification, valid as of January 2022	280
Medicine costs and their reimbursement in diseases entitling patients to special refund	55	Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2022	281
Medicinal products eligible for restricted basic refund	72	Appendix 3. Deflators for converting expenditure items to 2021 money, 2000–2021	282
Clinical nutritional preparations	75		
Medicine costs and their reimbursement according to prescriber	76		



List of figures

1. Basic information about the compilation of statistics on medicines	9	Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2021	266
2. Current issues in pharmacy	16	Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2021	267
Figure 2.1. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2021	18	Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2021	268
Figure 2.2. Consumption and sales of nicotine products in 2005–2021	25	Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2021	269
3. Finnish population and hospital districts	26	Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2021	270
Figure 3.1. Age structure of the Finnish population at the end of 2021	27	Figure 7.10. Consumption of hormonal contraceptives in 2006–2021	270
Figure 3.2. University hospital regions and hospital districts in 2021	27	Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2021	271
4. Drug control and pharmaceutical services	29	Figure 7.12. Consumption of antibacterials (J01) in 2006–2021	271
Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2021, EUR 1,000	30	Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2021	272
Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2021	32	Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006–2021	272
Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2021	33	Figure 7.15. Consumption of most common OTC analgesics in 2006–2021	273
5. National health insurance and reimbursement of medicine expenses	34	Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2021	273
The medicine supply chain and the role of various organisations in oversight and reimbursement	35	Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2021	274
Reimbursements for medicine expenses in 2021	42	Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2021	274
Figure 5.1. Reimbursement of medicine costs in 2000–2021 according to Refund Category	43	Figure 7.19. Consumption of antidepressants (N06A) in 2006–2021	275
6. Tables: Reimbursement of medicine costs	51	Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2021	275
Figure 6.1. Percentages of medicine prescribers, 2021	76	Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2021.....	276
7. Tables: Sales statistics according to medicine group	81	Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2021	277
Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2021	262	Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2021	278
Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2021	263	Appendices	279
Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2021	264		
Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2021	265		



List of tables

1. Basic information about the compilation of statistics on medicines	9	6. Tables: Reimbursement of medicine costs	51
2. Current issues in pharmacy	16	Table 6.1. Medicine costs and their reimbursement in 2005–2021	52
Table 2.1. Top 10 medicines sold in 2021 (wholesale)	19	Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2021	54
Table 2.2. Top 10 medicines by consumption in 2021	20	Table 6.3. Payback payments for conditional reimbursements in 2019-2021.....	54
3. Finnish population and hospital districts	26	Table 6.4. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2021	55
Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2021	28	Table 6.5. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2021	62
Table 3.2. Population according to university hospital regions by age groups, 31 December 2021.....	28	Table 6.6. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2021	66
4. Drug control and pharmaceutical services	29	Table 6.7. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2021	72
Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2021	30	Table 6.8. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2021	75
Table 4.2. Statistics for pharmacies in 2021	31	Table 6.9. Medicine prescribers, 2015 – 2021	76
Table 4.3. Dispensations dispensed by pharmacies in 2005–2021	32	Table 6.10. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2021 (only those dispensations entitled to reimbursement are included)	77
5. National health insurance and reimbursement of medicine expenses	34	Table 6.11. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2021	79
Table 5.1. Reimbursement numbers adopted in 2021, basic reimbursement	39		
Table 5.2. Reimbursement numbers discontinued in 2021, basic reimbursement	39		
Table 5.3. Reimbursement numbers adopted in 2021, special reimbursement	40		
Table 5.4. Reimbursement numbers discontinued in 2021, special reimbursement	40		
Table 5.5. Medicines added to existing reimbursement numbers in 2021, basic reimbursement	41		
Table 5.6. Medicines added to existing reimbursement numbers in 2021, special reimbursement	41		
Table 5.7. Medicine costs and their reimbursement in 2021	43		
Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2021	49		
Table 5.9. New active substances in 2021	49		
Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2021	50		
Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2021	50		



7. Tables: Sales statistics according to medicine group 81

A01 Stomatological preparations 83

A02 Drugs for acid related disorders 84

A03 Drugs for functional gastrointestinal disorders 86

A04 Antiemetics and antinauseants 88

A05 Sapeneritystä lisäävät valmisteet ja maksan suoja-aineet 88

A06 Drugs for constipation 89

A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents 91

A08 Antiobesity preparations, excl. diet products 93

A09 Digestives, incl. enzymes 93

A10 Drugs used in diabetes 94

A11 Vitamins 97

A12 Mineral supplements 99

A14 Anabolic agents for systemic use 100

A16 Other alimentary tract and metabolism products 100

B01 Antithrombotic agents 103

B02 Antihemorrhagics 105

B03 Antianemic preparations 107

B05 Blood substitutes and perfusion solutions 108

B06 Other hematological agents 110

C01 Cardiac therapy 112

C02 Antihypertensives 114

C03 Diuretics 115

C04 Peripheral vasodilators..... 116

C05 Vasoprotectives 117

C07 Beta blocking agents 118

C08 Calcium channel blockers 120

C09 Agents acting on the renin-angiotensin system 121

C10 Lipid modifying agents 124

D01 Antifungals for dermatological use 127

D02 Emollients and protectives 128

D03 Preparations for treatment of wounds and ulcers 128

D04 Antipruritics, incl. antihistamines, anesthetics, etc. 129

D05 Antipsoriatics 129

D06 Antibiotics and chemotherapeutics for dermatological use 130

D07 Corticosteroids, dermatological preparations 131

D08 Antiseptics and disinfectants 133

D09 Medicated dressings 133

D10 Anti-acne preparations 134

D11 Other dermatological preparations 135

G01 Gynecological antiinfectives and antiseptics 137

G02 Other gynecologicals 138

G03 Sex hormones and modulators of the genital system 139

G04 Urologicals 143

H01 Pituitary, hypothalamic hormones and analogues 146

H02 Corticosteroids for systemic use 148

H03 Thyroid therapy 149

H04 Haiman hormonit 149

H05 Calcium homeostasis 150

J01 Antibacterials for systemic use 152

J02 Antimycotics for systemic use 156

J04 Antimycobacterials 157

J05 Antivirals for systemic use 158

J06 Immune sera and immunoglobulins 162

J07 Vaccines 163



L01	Antineoplastic agents	165	S01	Ophthalmologicals	221
L02	Endocrine therapy	175	S02	Otologicals	226
L03	Immunostimulants	177	S03	Ophthalmological and otological preparations	227
L04	Immunosuppressants	178	V01	Allergens	229
M01	Antiinflammatory and antirheumatic products	182	V03	All other therapeutic products	230
M02	Topical products for joint and muscular pain	184	V04	Diagnostic agents	232
M03	Muscle relaxants	185	V06	General nutrients	233
M04	Antigout preparations	186	V07	All other non-therapeutic products	233
M05	Drugs for treatment of bone diseases	187	V08	Contrast media	234
M09	Other drugs for disorders of the musculo-skeletal system	188	Appendices		279
N01	Anesthetics	190			
N02	Analgesics	192			
N03	Antiepileptics	194			
N04	Anti-parkinson drugs	196			
N05	Psycholeptics	197			
N06	Psychoanaleptics	200			
N07	Other nervous system drugs	203			
P01	Antiprotozoals	206			
P02	Anthelmintics	207			
P03	Ectoparasitocides, incl. scabicides, insecticides and repellents	207			
R01	Nasal preparations	209			
R02	Throat preparations	211			
R03	Drugs for obstructive airway diseases	212			
R05	Cough and cold preparations	216			
R06	Antihistamines for systemic use	218			
R07	Other respiratory system products	219			

1. Basic information
about the compilation
of statistics on
medicines



Concepts in Finnish statistics on medicines

Active substance

The effective ingredient contained in a medicinal product. This is the most detailed (5th) level of ATC classification.

Additional Refund

A patient becomes eligible for Additional Refund payments if his/her personal payments for the non-reimbursed part of his/her medicines, clinical nutritional preparations and basic topical ointments exceed a certain limit during a calendar year. In such a case, the patient pays a fixed deductible of EUR 2.50 per reimbursable medicine purchased, and the rest is refunded in full under the National Health Insurance Scheme.

Annual deductible (ceiling)

This is the upper limit for annual out-of-pocket-cost. If this is exceeded, the customer is entitled to an additional refund. The purpose of the additional refund is to ensure that no individual faces unreasonably high medicine costs.

ATC classification

A pharmaceutical classification system developed and maintained by the World Health Organization (WHO). In this anatomic-therapeutic-chemical (ATC) classification, medicinal agents are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. The Finnish statistics on medicines follows the most recent version of ATC classification, which is commonly used for statistics on the consumption of medicines. Please also see the section on the structure of the ATC system.

Basic Rrefund

The National Health Insurance Scheme reimburses 40% of the cost of medicines in the Basic Refund Category.

Biosimilar

A biological medicine containing the same active substance as the corresponding original biological medicine and designed to be identical and comparable to the original.

Conditional reimbursement

A risk sharing method used in Finland which aims to control the introduction of new pharmaceuticals at the beginning of their life cycle. Conditional reimbursement hinges on confidential agreements between the Pharmaceuticals Pricing Board and pharmaceutical companies. So far, the agreements concluded have been financial agreements concerning a payback payment to Kela.

Cost/Medicine costs

The total cost of a medicine before the deduction of the reimbursement paid under the National Health Insurance Scheme. The costs listed in the register 'Dispensations reimbursable under the National Health Insurance Scheme' from Kela include the costs of medicines purchased at pharmacies, at retail price inclusive of tax, i.e. including the pharmacy markup, delivery fees and VAT. Please also see the figures for wholesale sales of medicines.

Defined Daily Dose (DDD)

The DDD is a unit of measurement of pharmaceutical consumption. Please also see Calculation of consumption of pharmaceuticals.

Direct refundreimbursement

Generally, customers are credited refunds on their medicines at the pharmacy once their initial deductible limit has been met. The pharmacy deducts the refund from the price of the medicine, and the customer pays the rest. Pharmacies verify eligibility for refunds using the Kela's direct reimbursement inquiry service for every purchase of medicines. The query service also informs pharmacies about customers' entitlement to refunds. Pharmacies have access to up-to-date information on the accrual of initial and annual deductibles. As of the beginning of 2020, direct reimbursements also apply to additional refunds. Additional refunds are applied at pharmacies to purchases that exceed the predetermined ceiling.

Dispensation (filled prescriptions)

The batch of a medicinal product dispensed by a pharmacy at any one time. A medicine prescribed for a period of one or two years is recorded as several dispensations, because the National Health Insurance Scheme only permits refunds for purchases of a three-month supply of medicines.



Generic medicine

A medicinal product that entered the market after the expiry of the patent on the original preparation, containing the same active agent as the original and having the same dosage and form. Also referred to as generic preparation.

Generic Substitution

Generic substitution places the pharmacy under an obligation to substitute a prescribed medicinal product with a less expensive alternative containing the same active substance. However, a medicinal product cannot be substituted if the prescriber has forbidden substitution on medical or therapeutic grounds by marking the prescription accordingly or if the customer forbids substitution. The list of substitutable medicinal products is approved by the Finnish Medicines Agency Fimea.

Initial deductible

Customers will be reimbursed for medicines after their combined purchases have exceeded the initial deductible. The initial deductible is EUR 50 per calendar year. It is applicable from the beginning of the year of the customer's 19th birthday.

Marketing authorisation

A new medicinal product can only be sold or otherwise released for consumption with marketing authorisation granted by the Finnish Medicines Agency Fimea or the European Commission.

Medicinal product

The term refers to a medicine released for consumption in the manufacturer's package. A medicinal product may contain one or more chemical entities.

Medicinal Products Eligible for Restricted Basic Refund / Medicinal Products Eligible for Restricted Special Refund

Certain restrictions apply to the Basic and Special Refunds available for a number of particularly expensive medicines. These costly but clinically valuable medicines are reimbursed only when used to treat specified medical conditions where reimbursement is considered medically justifiable. To qualify the patient must provide a doctor's certificate. In certain cases, an addendum to the prescription sheet will suffice.

Medicine

A substance or preparation, the purpose of which is to treat, alleviate or prevent a disease of its symptoms, or which is used in the diagnosis of a health condition or disease.

Out-of-pocket-cost

The amount of a medicine cost payable by the patient. Please also see Initial deductible and Annual deductible.

Prescription

An order, issued by a doctor or dentist, for a pharmacy to supply a medicinal product to a patient. Some licensed nurses also have a limited right to prescribe medicines to a patient. Previously, the term 'prescription' was also used to refer to the batch of a medicine given out by a pharmacy at any one time, but the current term for this is 'dispensation'.

Purchase

A purchase usually refers to the medicines, clinical nutritional preparations and basic topical ointments prescribed for the treatment of chronic skin ailments that are bought from a pharmacy for one person during one transaction. The statistics describing the number of purchases according to refund category, however, consider one purchase being the medicines, clinical nutritional preparations or basic topical ointments in the same refund category that are bought from a pharmacy for one person during one transaction.

Rational pharmacotherapy

Pharmacotherapy that is effective, safe, of high quality, cost-effective and equal.

Reference price system

Under the reference price system the reimbursement payment for a medicinal product is calculated from its reference price. Under the reference price system, substitutable medicinal products containing the same active substance in an equal composition, and being sold in comparable package sizes, are grouped together in the same reference price group. The reference price groups are based on the list for substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. A reference price constitutes of the price of the most inexpensive product within the group and an additional EUR 0.50. Reference prices are determined on a quarterly basis by the Pharmaceuticals Pricing Board. The cost in excess of the reference price is payable by the customer should one/he/she forbid substitution. If the substitution is forbidden by the prescribing doctor, or a product at the reference price is not available nationwide, the customer's reimbursement is calculated from the full purchase price.



Refund/Reimbursement of medicine costs

A reimbursement of medicine costs refers to the proportion of the price of a medicine which is reimbursed by the National Health Insurance Scheme. Prescription-only medicines, deemed necessary for the treatment of an illness, are reimbursed under the National Health Insurance Scheme provided that their reimbursability and reasonable wholesale price have been approved. Some over-the-counter (OTC) medicines are also reimbursable when prescribed by a doctor. In addition to medicines, reimbursement is also paid for clinical nutritional preparations used in some serious illnesses, basic topical ointments used for the treatment of chronic skin ailments as well as for dosage service charges.

Special permit

The Finnish Medicines Agency Fimea may allow drugs without marketing authorisation to be released for consumption in individual cases on special medical grounds. For outpatient care the special permit is issued on a named-patient basis. For inpatient care the permit is issued separately for each institution, and it may cover several patients. The special permit is valid for one year from the day of issue.

Special Refund

Special refunds apply to certain serious and chronic diseases. The diseases qualifying customers for special refunds are divided into a higher special refund category and a lower special refund category. In the lower special refund category, the National Health Insurance Scheme covers 65% of the cost of medications. In the higher special refund category, the patient only pays a deductible of EUR 4.50 per medication, the remainder being reimbursed in full (100%). Patients must apply for eligibility from Kela and provide a doctor's statement.

Wholesale sales of medicines

Wholesale sales means the sales of medicines by pharmaceutical wholesale suppliers to pharmacies and institutions. In this publication, wholesale sales of medicines are presented at recommended wholesale prices exclusive of VAT. See also Cost/Medicine costs.



Material used for the statistics

Drug sales register maintained by the Finnish Medicines Agency (Fimea)

The consumption figures in Finnish statistics on medicines are based on the sales of human medicines with marketing authorisation to pharmacies and hospitals by the three largest medicine wholesalers in Finland, Oriola, Tamro and Magnum Medical. Inpatient care institutions also buy medicines from other wholesalers or directly from pharmaceutical companies. Furthermore, they may import medicines themselves. The recommended wholesale figures of medicines do not include value added tax. Changes in ATC classification and DDD values are considered in the reference data as well as images. The figures for 2020 are not fully comparable to the figures in previous editions of the Finnish Statistics on Medicines. Due to a technical error, some data were missing from the previous editions. Additionally, the current figures no longer include medicines supplied to veterinarians. The figures in this year's edition are comparable with those in the 2020 edition.

Special Refund Entitlement Register of Medicines

The register maintained by Kela includes data both about the patients and the medicine refund entitlements granted by Kela.

Dispensations reimbursable under the National Health Insurance Scheme register (previously Kela's Prescription Register)

A register created from pharmacy accounts, comprising all purchases of medicines directly reimbursed upon purchase at the pharmacy, as well as all purchases of medicines within the reimbursement system made before the initial deductible limit has been met. The register includes information, derived from the prescription, relating to the patient, the medicine, the prescribing doctor as well as the cost and reimbursement paid for the medicine.

Register of Statistical Information on National Health Insurance General Benefit Payments

These statistics comprise data about all reimbursement payments paid during the year and are maintained by Kela. The database includes reimbursements applied for retroactively and not included on the 'Dispensations reimbursable under the NHI scheme' register.

Abbreviations, definitions and symbols

Abbreviations

ATC	Anatomical Therapeutic Chemical classification
DDD	Defined Daily Dose
UD	Unit dose (for example one tablet or 5 ml of mixture)
U	Unit
TU	Thousand units
MU	Million units
mcg	Microgram
I	Inhalative
N	Nasal
O	Oral
P	Parenteral
SL	Sublingual
TD	Transdermal
V	Vaginal

Definitions

0	} Less than half of unit employed
0.0	
0.00	

Symbols

-	Magnitude nil
.	Category not applicable
..	Data no available or too uncertain for presentation, or subject to secrecy



Calculating drug consumption

In Finnish Statistics on Medicines, drug consumption is expressed using the unit Defined Daily Dose (DDD). The calculations are based on the volume of wholesale sales, in other words, the amount of medicine in units of weight or volume as well as an internationally agreed medicine-specific theoretic daily dose. The recommended wholesale figures of medicines do not include value added tax.

The following example shows how simvastatin consumption is calculated:

DDD of simvastatin	0.03 g
Sales	2,031,368 g/year
Population	5,556,508

1. Total consumption of simvastatin in grams is first converted into DDDs using the following equation:

$$\frac{2,031,368 \text{ g}}{0.03 \text{ g}} = 67,712,273 \text{ DDD}$$

2. The number of DDDs is then adjusted to the population and the number of days per year.

$$\frac{67,712,273 \text{ DDD}}{\left(\frac{5,556,508}{1,000}\right) * 365} = 33.4 \text{ DDD}/1,000 \text{ inhabitants/day}$$

The figure of 33.4 DDD/1,000 inh/day indicates how many people (in this case 33.4) per 1,000 of the population may, in theory, have received that standard dose (30 mg) of simvastatin.

When interpreting the figures, it should be remembered that the DDD is only a technical expedient and is not necessarily equal to the real dose. The DDD of a drug can be very difficult to establish, as the drug dose depends on indications, individuals and therapeutic practices. When using sales figures provided by wholesalers, it is worth noting that some drugs sold may still be unused, either in dealer stores or in patient homes. The DDD figure is generally calculated in relation to the total population, although drug use may be concentrated in certain age groups or a particular sex.

In retrospective studies, changes in DDD units and the ATC classification should always be considered. Changes made in each year are listed in Appendices of Finnish Statistics on Medicines. In case the DDD of an active substance has changed, the consumption figures of different years should be altered so that they are comparable. This is done by converting the consumption expressed as DDD back to its initial value, in other words the consumption in units of weight or volume, after which it is possible to calculate the new figure by using the new DDD.



Structure of the ATC system

In the Anatomical Therapeutic Chemical (ATC) classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties.


In the ATC system drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.

The complete classification of simvastatin (C10AA01) illustrates the structure of the code:

ATC code	ATC name
C	Cardiovascular system (1st level, anatomical main group)
C10	Lipid modifying agents (2nd level, pharmacological subgroup)
C10A	Lipid modifying agents, plain (3rd level, pharmacological subgroup)
C10AA	HMG CoA reductase inhibitors (4th level, pharmacological subgroup)
C10AA01	Simvastatin (5th level, chemical substance)


Source: Guidelines for ATC classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology, Oslo 2021.

2. Current issues in pharmacy





Key events in the pharmaceutical field in 2021





Pharmaceutical year 2021

Leena K. Saastamoinen, PhD (Pharm.), Adjunct professor, Research Manager, Kela

Tiina Kuosa, M.Sc. (Pharm.), Senior Specialist, Fimea

Kati Sarnola, PhD (Pharm.), M.Sc. (Econ.), Senior Researcher, Kela

Tinna Voipio, B.Sc. (Pharm.), Researcher, Fimea


In the pharmaceutical year 2021, total medicine sales continued on the same growth path as in previous years. Total sales were boosted by nicotine, for example, which was once again the best-selling medicine in Finland in euro terms. At the same time, nicotine sales were increasingly concentrated outside pharmacies. The growth in sales was partly curbed by price competition from generics and biosimilars, which reduced the sales of certain medicine groups despite an increase in consumption.

Medicine sales

In 2021, medicine sales totalled EUR 3,620 million. This figure consists of retail sales of prescription medicines in outpatient care (EUR 2,400 million) and over-the-counter medicines in outpatient care (EUR 359 million), as well as wholesale sales to hospitals and other institutions (EUR 861 million). The total sales and outpatient prescription medicine sales both increased by 2.9% while that of hospital medicines grew by 5%. The sales of over-the-counter medicines decreased by 2.2%.

The sales of medicines by medicine group described in this article are indicated as wholesale sales in euros. Hospital sales are reported at public wholesale prices not subject to competitive tendering, so sales at actual tendered prices are lower than the reported figures. Currently, no statistics are compiled for sales at actual competitive prices.

Figure 2.1. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2021





Reimbursements for medicine expenses grew by nearly EUR 80 million

A total of EUR 1.71 billion was paid in reimbursements for medicine expenses in 2021, increasing by 4.7%, or EUR 76 million, from the previous year. A total of 3.77 million consumers purchased reimbursable medicines, with 2.96 million receiving reimbursements for their medicine expenses. The number of recipients of reimbursements increased by just 0.1%, or about 3,400 consumers. As a result, the previous year's trend of medicine reimbursements concentrating on an increasingly small number of recipients continued. Under the payback arrangements, the total amount paid to Kela by pharmaceutical companies as conditional reimbursements amounted to EUR 38 million (see conditional reimbursement p. 10).

The costs forming the basis for the reimbursements of medicines was EUR 2.25 billion. Additional reimbursements for costs exceeding the annual deductible were paid to approximately 308,500 consumers, totalling EUR 228 million.

Special refunds accounted for the majority of medicine reimbursements, 68%, with EUR 1,172 million paid to 1,257,400 consumers. Special refunds are paid on a discretionary basis for certain illnesses. Basic refunds accounted for EUR 311 million, paid out to 2,847,500 consumers.

Cancer medicine pembrolizumab rose to the top 10 of sales

The highest-selling medicine in Finland in euros was nicotine, the sales of which increased by 5%. The second highest-selling medicine was infliximab, the sales of which remained unchanged. In the treatment of hepatitis C, the anticoagulant apixaban overtook the sofosbuvir and velpatasvir combination product, the sales of which declined for the second year running. The sales of apixaban increased by 19%. Rivaroxaban, also an anticoagulant, also climbed two places in the list of the ten highest-selling medicines with a 7% increase in sales. Sales of both apixaban and rivaroxaban grew significantly, albeit slightly less than in the previous year.

Sales of trastuzumab, one of the highest-selling medicines last year, fell by 12%, leaving it outside the ten highest-selling medicines. Sales of normal human immunoglobulin declined and was overtaken by rivaroxaban and the cancer medicines enzalutamide (9%) and lenalidomide (11%), which increased their sales. A new medicine, pembrolizumab, which is used exclusively in hospitals to treat several types of cancers, made it to the list of the ten highest-selling medicines after sales increased by 50%.

Table 2.1. Top 10 medicines sold in 2021 (wholesale)

Medicine	ATC code	Wholesale sales, EUR 1,000	Change from 2020, %
Nicotine	N07BA01	75,207	+5
Infliximab	L04AB02	64,429	+1
Apixaban	B01AF02	56,798	+19
Sofosbuvir and velpatasvir	J05AP55	50,135	-14
Adalimumab	L04AB04	44,756	-5
Rivaroxaban	B01AF01	40,303	+7
Enzalutamide	L02BB04	35,784	+9
Lenalidomide	L04AX04	35,168	+11
Normal human immunoglobulin for intravascular use	J06BA02	34,397	-14
Pembrolizumab	L01FF02	33,503	+50

Source: Finnish Medicines Agency Fimea, Drug Sales Register

The top 10 medicines by consumption fall far behind the top 10 in sales

The top ten medicines in terms of consumption remained the same as in 2020. However, their rankings have changed slightly. Eight of the top ten medicines by consumption are used to treat cardiovascular diseases. The top spot is occupied by the calcium channel blocker amlodipine, overtaking the angiotensin II inhibitor ramipril. The consumption of the cholesterol medicine rosuvastatin continued strong growth, with a 26-per cent increase from the previous year.

However, the top medicines by consumption, with the exception of ibuprofen and paracetamol, fell far behind from the top 10 medicines by sales in euros. All of the top medicines by consumption have been on the market for a long time, so there are several products on the market with the same active pharmaceutical ingredient. As a result, price competition has significantly reduced their prices.

**Table 2.2. Top 10 medicines by consumption in 2021**

Medicine	ATC code	Consumption, DDD/1,000 inhabitants/day	Change from 2020, %
Amlodipine	C08CA01	72.8	+5
Ramipril	C09AA05	72.6	-2
Atorvastatin	C10AA05	71.0	+13
Acetylsalicylic acid	B01AC06	62.2	0
Candesartan	C09CA06	54.4	+11
Losartan	C09CA01	52.1	+5
Ibuprofen	M01AE01	50.9	+2
Rosuvastatin	A02BC02	48.1	+26
Bisoprolol	C07AB07	42.3	0
Paracetamol	N02BE01	40.5	-2

Source: Finnish Medicines Agency Fimea, Drug Sales Register

Macrogol overtook lactulose as the most consumed laxative

The consumption (337.7 DDD/1000 inhabitants/day) and sales (EUR 333 million) of the gastrointestinal diseases and metabolic diseases group (A) both continued to grow, now by 4%. A total of 1,217,500 consumers purchased the reimbursable medicines in this group.

The consumption and sales of proton pump inhibitors increased to 70.9 DDD/1000 inhabitants/day (+2%), the sales in euros decreasing to EUR 22 million (-5%). The trend is similar to the past

three years. Reimbursable proton pump inhibitors were purchased by 710,200 consumers. Pantoprazole remained the most commonly used proton pump inhibitor (39.8 DDD/1000 inhabitants/day), accounting for 56% of the total consumption of proton pump inhibitors. In terms of wholesale sales however, the highest-selling proton pump inhibitor was esomeprazole, which accounted for 47% (EUR 10 million). Esomeprazole was the second-most widely consumed (16.0 DDD/1000 inhabitants/day) proton pump inhibitor.

In ten years, the consumption of laxatives has increased by 13% and sales in euros by 48%. Both their consumption (53.3 DDD/1000 inhabitants/day) and sales (EUR 30 million) increased by 4% from the previous year. Over the years, the proportion of lactulose and stimulant laxatives has decreased, having been replaced by macrogol, which is currently the most popular laxative (consumption 19.3 DDD/1000 inhabitants/day, sales EUR 12 million).

In ten years, the consumption of antidiarrhoeal medicines has grown by 28% and sales by 43%, a slightly slower pace than the sales of constipation medicines. Their consumption, 13.6 DDD/1000 inhabitants/day, remained at the previous year's level while their sales at EUR 30 million showed an increase of 2%. Mesalazine and sulfasalazine, which are used for inflammatory bowel diseases, comprise the majority of antidiarrhoeal medicines.

The consumption of semaglutide tablets increased several-fold

Consumption of antidiabetics (109.1 DDD/1000 inhabitants/day) increased by 7% and their sales (EUR 181 million) by 6%. Insulin consumption (30.2 DDD/1000 inhabitants/day) decreased for the second year running, now by 3%, and sales decreased by 6% to EUR 55 million.

Insulin consumption breaks down mainly into fast-acting insulin (10.7DDD/1000 inhabitants/day) and long-acting insulin (18.8 DDD/1000 inhabitants/day). The consumption of fast-acting insulin increased by 1% while sales decreased by 10%. In recent years, biosimilars have appeared on the fast-acting insulin market, and their prices may also affect the price-setting for other products.

The consumption of long-acting insulin (18.8 DDD/1000 inhabitants/day) and sales (EUR 40 million) both decreased by 5%. The consumption and sales of insulins glargine and detemir have decreased by 7% for glargine and by 19% for detemir. However, the consumption (3.8 DDD/1000 inhabitants/day) and sales (EUR 9 million) of degludec have both increased by 21%.

The consumption (78.9 DDD/1000 inhabitants/day) and sales (EUR 126 million) of medicines other than insulins that reduce blood glucose levels both increased by 12%. The majority of this consumption was accounted for by metformin (34.4 DDD/1000 inhabitants/day), increasing by 2%. The next most widely used medicines are DPP4 inhibitors, the consumption of which (12.5 DDD/1000 inhabitants/day) decreased by 1%.

Among the subgroups of antidiabetic medicines, the consumption of GLP-1 analogues (11.1 DDD/1000 inhabitants/day) grew the fastest,



doubling in 2021. Their sales increased by 26% to EUR 41 million. The increase was due to the soaring consumption of semaglutide. In April 2021, the semaglutide tablet became the first GLP-1 analogue to be included in the list of medicines that are reimbursable and reimbursable at the special rate.

Acetylsalicylic acid is the most-consumed antithrombotic

Both the consumption (146.1 DDD/1000 inhabitants/day) and sales (EUR 296 million) of blood disorder medicines (B) grew by 4% on the previous year. The number of consumers who bought reimbursable medicines was 461,700.

The total consumption (116.9 DDD/1000 inhabitants/day) and sales (EUR 163 million) of antithrombotic medicines grew by 1% and 5%, respectively. The fourth most-consumed medicine in Finland, acetylsalicylic acid (62.2 DDD/1000 inhabitants/day), accounts for the majority of consumption. The majority of the sales, EUR 104 million, comes from the sale of direct factor Xa inhibitors, with sales increasing by 14% and consumption (24.1 DDD/1000 inhabitants/day) by 15%. Among them, the most-consumed medicines were apixaban and rivaroxaban, which are also among the highest-selling medicines in euros.

The decline in sales of cardiovascular medicines continues

The consumption of cardiovascular medicines (682.4 DDD/1000 inhabitants/day) increased by 4% while their sales (EUR 131 million) decreased by 5%. Reimbursable cardiovascular medicines were purchased by 1.7 million consumers. The consumption of this group of medicines has almost invariably increased over the past ten years. Sales, however, have declined for the fifth year running.

In the most-consumed group, medicines affecting the renin-angiotensin system, consumption (281.0 DDD/1000 inhabitants/day) increased by 2% and sales (EUR 34 million) decreased by 11%. Lipid medicines (167.3 DDD/1000 inhabitants/day) were the next most-consumed medicines, with the fastest growth rate of 13%. Their sales, nonetheless, decreased by 6% to EUR 22 million. In calcium channel blockers, consumption (104.3 DDD/1000 inhabitants/day) grew by 5% while sales in euros decreased by 3% (EUR 11 million).

Meanwhile, the consumption of both beta blockers (63.9 DDD/1000 inhabitants/day, a decrease of 3%) and diuretics (50.2 DDD/1000 inhabitants/day, a decrease of 1%) decreased. Like with other cardiovascular medicines, sales of beta blockers (EUR 18 million) decreased by 5%. Sales of diuretics (EUR 9 million), on the other hand, increased by 1%.

Sales of dupilumab in treating atopic dermatitis increased

The costs of dermatological medicines (EUR 47 million) increased by 10%. Among the groups of dermatological medicines, topical corticosteroids are the highest-selling medicines, with sales (13 million euros) increasing by 2%. Sales grew fastest (EUR 9 million, +55%) in the group of other dermatological medicines, where the sales of dupilumab used in the treatment of severe asthma and atopic dermatitis among other conditions, more than doubled, reaching EUR 6 million (+131%).

Price competition continues in medicines for prostatic hyperplasia

The consumption of medicines for genitourinary disorders (139.3 DDD/1000 inhabitants/day) remained almost unchanged, growing by only 1%, while their sales (EUR 92 million) decreased by 12%. The most significant decreases were witnessed in the sales of estradiol (EUR 12 million, a decrease of 37%) and of medicines for benign prostatic hyperplasia (EUR 12 million, a decrease of 28%), although the consumption of both increased. The decline in the sales of prostate medicines is largely due to price competition in the dutasteride and tamsulosin combination product market. Sales of estradiol have decreased, especially in over-the-counter medicines.

The consumption of antibacterials continued to decrease during the second year of the pandemic

The consumption (13.3 DDD/1000 inhabitants/day, decrease of 4%) and sales (EUR 245 million, decrease of 5%) of systemic anti-infectives decreased further in the second year of the COVID-19 pandemic. A total of 948,300 consumers purchased reimbursable systemic anti-infective medicines, 11% fewer than in the previous year.

Most of the consumption of the group of systemic anti-infectives (11.3 DDD/1000 inhabitants/day) came from systemic antibacterial medicines, with sales at 39 million euros. In total, the consumption of systemic antibacterials decreased by 5% and there was a decrease in all groups of antibacterials. Cephalexin continued to be the most widely used antibacterial medicine with a consumption of 1.5 DDD/1000 inhabitants/day, showing a reduction of 3%. In 2021, many of the regional restrictions and recommendations related to the COVID-19 pandemic remained in place, which affected the prevalence of infectious diseases and the use of medicines in general.

Meanwhile, the majority of sales in the group of systemic anti-infectives, EUR 128 million, came from the sales of systemic antivirals. Their sales remained unchanged from the previous year. The consumption of antivirals stood at 1.6 DDD/1000



inhabitants/day, representing an increase of 3% on the previous year. The majority of the sales of antiviral medicines, 65%, or EUR 83 million, come from the sales of hepatitis C medicines, which decreased by 2%.

The entrance of biosimilars onto the market affects the value of sales for TNF α inhibitors and growth factors

The sales of cancer medicines and immune response modifiers stood at EUR 895 million, with growth in sales picking up pace at 10%. In euros, the growth amounted to EUR 82 million. Reimbursements for cancer medicines and immune response modifiers amounted to EUR 615 million, with 163,400 consumers purchasing reimbursable medicines. The amount of reimbursements represented an increase of 7% on the previous year.

Immunosuppressant sales (EUR 413 million) increased by 8%. Of these, tumour necrosis factor alpha (TNF- α) inhibitors were the highest-selling at EUR 162 million, and selective immunosuppressants the second highest-selling at EUR 100 million. The total sales of TNF- α inhibitors started showing decline two years ago due to the price changes that followed the introduction of biosimilars to the market. The sales have now decreased by 1%. Two of the fastest-declining medicines in terms of sales were etanercept, decreasing by 9% (EUR 22 million), and adalimumab, decreasing by 5% (EUR 45 million).

Sales of antineoplastics, which mainly include medicines used in cancer treatment, increased by 16% to EUR 382 million. The majority of sales, EUR 189 million, came from monoclonal antibodies. The next highest-selling medicines in this group were protein kinase inhibitors with EUR 102 million.

Sales of endocrinological medicines totalled EUR 73 million, an increase of 4%. Nearly half of the group's sales were sales of enzalutamide, which is used to treat prostate cancer and is one of the ten highest-selling medicines in Finland (EUR 36 million). The group includes several interchangeable medicines and medicines governed by the reference price system, the sales of which are decreasing.

Immunostimulants, on the other hand, totalled EUR 27 million in sales. Their sales decreased by 12%. Among the growth factors included in the group, sales of pegfilgrastim (EUR 8 million) decreased by 15% and that of filgrastim (EUR 2 million) by 20%. Several biosimilars have appeared on the market for both medicines. Sales of interferons (EUR 7 million) also decreased by 10%, while sales of glatiracetate, used to treatment multiple sclerosis, fell by 14% (EUR 5 million).

The range of the most widely used painkillers remains unchanged

The sales of medicines for musculoskeletal disorders (EUR 100 million) increased by 2% and their consumption (99.9 DDD/1000 inhabitants/day) by 1%. The sales and consumption of these medicines has remained relatively unchanged in the past ten years. A total of 1,354,400 consumers purchased reimbursable medicines for musculoskeletal disorders, showing a growth of less than one per cent from the previous year.

Sales of NSAIDs and DMARDs totalled EUR 42 million with their consumption at 78.3 DDD/1000 inhabitants/day. Consumption increased by 1% while sales decreased by 1%. The majority of NSAID consumption (50.9 DDD/1000 inhabitants/day) comprised ibuprofen, which increased by 2%. Sales of ibuprofen amounted to EUR 29 million, up 1%. The second most-used painkiller in Finland is paracetamol, with a consumption of 40.5 DDD/1000 inhabitants/day and sales of EUR 26 million. Paracetamol consumption decreased by 2%, for the first time in years. Over the same period, its sales in euros decreased by 5%.

The top position of ibuprofen and paracetamol is difficult to challenge: the consumption of the next most widely used analgesic, etoricoxib, was 11.6 DDD/1000 inhabitants/day. Relatively, etoricoxib is clearly less expensive than ibuprofen and paracetamol, and its sales amounted to just EUR 2 million. The total cost is likely to be affected by factors such as the wholesale prices of over-the-counter ibuprofen and paracetamol, which are not regulated by determining a reasonable wholesale price in the same way as for reimbursable prescription medicines.

Overall, opioid consumption was slightly higher than that of etoricoxib, 13.0 DDD/1000 inhabitants/day. Opioid sales totalled EUR 24 million. Their consumption and sales both decreased by 3%. The consumption of the most-consumed opioid, combinations of codeine and paracetamol, was 5.4 DDD/1000 inhabitants/day, showing a decrease of 5%. Their sales stood at EUR 3 million, showing a decrease of 8% on the previous year.



Denosumab is the most widely used medicine against osteoporosis

The consumption (12.0 DDD/1000 inhabitants/day) and sales (EUR 18 million) of medicines affecting bone structure are increasing. In 2021, consumption increased by 4% and sales by 6%. The majority of the consumption and sales of medicines affecting bone structure comes from denosumab consumption (8.6 DDD/1000 inhabitants/day, + 6%) and sales (14 million euros, + 7%). Denosumab has been the most commonly used medicine against osteoporosis for years.

Sales of migraine medicines are increasing

The total sales (EUR 328 million) and consumption (294.2 DDD/1000 inhabitants/day) of central nervous system medicines grew by 2%. A total of 1,744,400 consumers purchased the reimbursable medicines in this group.

The consumption (3.5 DDD/1000 inhabitants/day, increase of 11%) and sales (EUR 28 million, increase of 8%) of migraine medicines continued to increase. The consumption of triptans (2.5 DDD/1000 inhabitants/day) increased by 7%, although their sales (EUR 8 million) decreased 2%. The combined consumption of calcitonin gene-related peptide (CGRP) antagonists erenumab, galcanezumab and fremanezumab (1.0 DDD/1000 inhabitants/day) increased by 23% and their sales (EUR 20 million) by 13%.

The treatment of neuropathic pain is reflected in the consumption of antiepileptic medicines

The use of antiepileptic medicines has been slowly increasing for years. In the pharmaceutical year 2021, the consumption of antiepileptic medicines (25.1 DDD/1000 inhabitants/day) increased by 4%, while their sales (EUR 47 million) decreased by 1%. The most commonly used group of antiepileptics is 'other antiepileptic medicines', which includes the vast majority of the latest antiepileptic medicines. Their consumption increased by 7%, to 17.4 DDD/1000 inhabitants/day.

The most widely used antiepileptic medicine is pregabalin, which, in addition to epilepsy, is used in the treatment of neuropathic pain and generalised anxiety disorder, for example. Their consumption increased by 6%, to 5.9 DDD/1000 inhabitants/day. Similarly, the antiepileptic medicine gabapentin, used to treat neuropathic pain, has caught up with pregabalin, with its consumption (4.7 DDD/1000 inhabitants/day) increasing by 12%. For nine consecutive years, sales of pregabalin have fallen, and decreased again by 20% on the previous year to EUR 5 million. In contrast, gabapentin sales increased by 4%, to EUR 7 million.

Melatonin increases the total consumption of sleep aids

The consumption of antipsychotics (23.1 DDD/1000 inhabitants/day) continues to increase, albeit slowly, at a rate of 1%. Their sales amounted to EUR 53 million, showing an increase of 2%. The most widely consumed antipsychotics were olanzapine (6.7 DDD/1000 inhabitants/day), quetiapine (5.5 DDD/1000 inhabitants/day), and aripiprazole (2.9 DDD/1000 inhabitants/day).

The consumption of anti-anxiety medicines and tranquilisers, most of which are benzodiazepine derivatives, (14.5 DDD/1000 inhabitants/day) continued to decrease at the rate of 6%. Their sales increased moderately, by 2% to EUR 7 million. The consumption of sleep aids increased by 3%, to 49.3 DDD/1000 inhabitants/day. This increase is mainly due to an increase in melatonin consumption (29.5 DDD/1000 inhabitants/day, an increase of 12%) as the consumption of benzodiazepine derivatives and benzodiazepine-like medicines has decreased. Melatonin is also sold as nutritional supplements outside pharmacies, but for the purpose of the present statistics, only melatonin preparations classified as medicines are included in these statistics.

The consumption of antidepressants (85.2 DDD/1000 inhabitants/day) increased by 5%, a rate that has been consistent in recent years, both during and before the COVID-19 pandemic. Sales of antidepressants stood at EUR 38 million, showing an increase of 6%. The most-consumed antidepressants are escitalopram (19.1 DDD/1000 inhabitants/day), sertraline (11.9 DDD/1000 inhabitants/day), and venlafaxine (11.9 DDD/1000 inhabitants/day).

The use of ADHD medicines continues to grow rapidly

One of the fastest-growing group of medicines in terms of consumption and sales are central nervous system stimulants, which mainly consists of medicines used in the treatment of ADHD. The consumption of the group of medicines increased by as much as 28% (8.6 DDD/1000 inhabitants/day) and their sales by 25% (EUR 20 million). The most-consumed ADHD medicines are methylphenidate (6.2 DDD/1000 inhabitants/day) and lisdexamphetamine (1.9 DDD/1000 inhabitants/day), of which lisdexamphetamine consumption increased the fastest of all ADHD medicines, by 45%.



The consumption of combination products for respiratory disorders is on the increase

Consumption of medicines for respiratory disorders was 198.0 DDD/1000 inhabitants/day and sales were EUR 151 million, both increasing by 2%. A total of 1,092,100 consumers purchased reimbursable medicines for respiratory disorders.

The most popular and highest-selling subgroup are medicines for obstructive respiratory disorders, which mainly includes medicines used in the treatment of asthma and COPD. The consumption of medicines for obstructive respiratory disorders stood at 81.0 DDD /1000 inhabitants/day and their sales at EUR 90 million. Of these, the consumption of adrenergic inhalants was 47.1 DDD/1000 inhabitants/day and their sales totalled EUR 51 million. Their consumption had decreased by 2% and their sales fell by 3%.

The group of adrenergic inhalants also includes corticosteroid combinations. In terms of consumption (29.3 DDD/1000 inhabitants/day), it is the most significant of the medicines used in the treatment of asthma. In 2021, the so-called triple combinations of adrenergic inhalants, anticholinergics and glucocorticoids were of particular interest. Sales for the group of medicines increased by 12% (EUR 11 million), and their consumption rose by 9% (3.7 DDD/1000 inhabitants/day). The consumption of

glucocorticoids alone (18.6 DDD/1000 inhabitants/day, decrease of 6%) and their sales (EUR 15 million, decrease of 11%) decreased from the previous year.

Sales of biological medicines for asthma on the increase

There are currently a number of biological medicines for asthma on the market. They are among the other systemically used medicines for obstructive respiratory disorders, the sales of which have been increasing since they entered the market. Currently, the sales stand at EUR 9 million, having increased by 8% on the previous year. In particular, sales of omalizumab (EUR 4 million, up by 12%) and mepolizumab (EUR 3 million, an increase of 10%) increased.

The consumption of systemic antihistamines continues to grow, as has been the trend for several consecutive years. Their current consumption has increased by 10% to 78.4 DDD/1000 inhabitants/day, and their sales by 7% to EUR 18 million. Both the consumption (35.4 DDD/1000 inhabitants/day) and sales (EUR 8 million) of the most commonly used antihistamine, cetirizine, grew by 8% on the previous year.

Over-the-counter medicines

In terms of both consumption and euros, the highest-selling medicines were those for gastrointestinal conditions (83.2 DDD/1000 inhabitants/day, EUR 61 million at wholesale prices). The group includes medicines such as those used in the treatment of hyperacidity, laxatives as well as vitamins and minerals. The most commonly used medicine in this group was macrogol (17.2 DDD/1000 inhabitants/day, 11 million euros), whereas the use of other laxatives, especially lactulose, decreased or remained unchanged. The use of macrogol increased by 14% from the previous year.

Among over-the-counter painkillers, ibuprofen (23.0 DDD/1000 inhabitants/day, EUR 21 million) was clearly the most commonly used medicine, its consumption increasing slightly (3%) from the previous year but still remaining lower than in 2018 and 2019. However, the use of paracetamol, the second-most commonly used painkiller (6.1 DDD/1000 inhabitants/day, EUR 13 million), decreased significantly (13%).

In 2022, an amendment to the Medicines Act entered into force, allowing pharmacies to decide on the pricing of over-the-counter medicines they sell. The price of an over-the-counter medicine is determined so that it does not exceed the retail price based on the pharmaceutical tariff, but is no lower than the nationally applicable wholesale

price. It remains to be seen whether the change will have an impact on the consumption of over-the-counter medicines and their sales in euros.


Nicotine

In terms of euros, nicotine was again the highest-selling medicine in Finland in 2021, with total sales of EUR 75 million. Over 90% were non-pharmacy sales, up by 5% in 2021, while sales from pharmacies showed a decrease (0.2%).


The sale of nicotine replacement therapy products was expanded outside of pharmacies in 2006. Their consumption increased 3.6-fold and wholesale sales in euros rose 4.3-fold between 2005 and 2021.



Figure 2.2. Consumption and sales of nicotine products in 2005–2021



Source: Finnish Medicines Agency Fimea, Drug Sales Register



Source: Finnish Medicines Agency Fimea, Drug Sales Register

3. Finnish population and hospital districts





Figure 3.1. Age structure of the Finnish population at the end of 2021



Source: Kela's population data.


Figure 3.2. University hospital regions and hospital districts in 2021

University hospital regions

- A. Helsinki University Central Hospital region (HYKS)
- B. Turku University Central Hospital region (TYKS)
- C. Tampere University Hospital region (TaYS)
- D. Kuopio University Hospital region (KYS)
- E. Oulu University Hospital region (OYS)

Hospital districts

- | | |
|----------------------|--------------------------|
| 0. Åland | 15. South Ostrobothnia |
| 3. Southwest Finland | 16. Vaasa |
| 4. Satakunta | 17. Central Ostrobothnia |
| 5. Kanta-Häme | 18. North Ostrobothnia |
| 6. Pirkanmaa | 19. Kainuu |
| 7. Päijät-Häme | 20. Länsi-Pohja |
| 8. Kymenlaakso | 21. Lapland |
| 9. South Karelia | 25. Helsinki and Uusimaa |
| 10. South Savo | |
| 11. Itä-Savo | |
| 12. North Karelia | |
| 13. North Savo | |
| 14. Central Finland | |



Source: Kela. Suomen karttatiedosto - Map file of Finland.

**Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2021**

Hospital district	Total	Male	Female	Population % aged 65 or over	The proportion % of population in receipt of Special Refunds of medicines
Whole country	5,556,508	2,748,350	2,808,158	23.0	22.5
Helsinki and Uusimaa	1,715,070	839,993	875,077	18.1	17.7
Southwest Finland	486,848	238,948	247,900	24.0	21.6
Satakunta	214,421	106,336	108,085	28.1	25.2
Kanta-Häme	170,523	84,518	86,005	26.3	25.0
Pirkanmaa	545,461	269,130	276,331	22.6	22.4
Päijät-Häme	208,975	102,109	106,866	27.7	24.6
Kymenlaakso	161,850	80,166	81,684	29.2	27.1
South Karelia	126,249	62,932	63,317	28.5	24.8
South Savo	96,695	47,891	48,804	31.7	29.5
Itä-Savo	39,694	19,562	20,132	34.4	31.2
North Karelia	163,479	81,435	82,044	27.9	28.7
North Savo	243,915	120,589	123,326	26.3	28.6
Central Finland	253,118	126,113	127,005	23.4	24.0
South Ostrobothnia	191,876	95,905	95,971	26.6	26.4
Vaasa	169,687	85,938	83,749	23.5	21.6
Central Ostrobothnia	77,119	38,577	38,542	24.6	24.2
North Ostrobothnia	413,227	208,647	204,580	20.5	23.7
Kainuu	71,312	36,170	35,142	29.8	30.8
Länsi-Pohja	58,846	29,607	29,239	28.5	27.0
Lapland	117,821	58,711	59,110	25.6	26.7
Åland	30,322	15,073	15,249	23.4	16.2


Source: Kela's population data, Register of Statistical Information on National Health Insurance General Benefit Payments.

Table 3.2. Population according to university hospital regions by age groups, 31 December 2021

Hospital region	Gender	Total	0-15 years	16-64 years	65 or over
A HYKS	Male	1,085,200	187,717	704,768	192,715
	Female	1,126,944	179,027	689,714	258,203
B TYKS	Male	446,295	73,448	272,760	100,087
	Female	454,983	70,309	260,482	124,192
C TaYS	Male	449,553	75,809	276,712	97,032
	Female	458,307	72,167	264,126	122,014
D KYS	Male	395,590	61,497	237,357	96,736
	Female	401,311	59,129	225,821	116,361
E OYS	Male	371,712	68,849	223,613	79,250
	Female	366,613	66,190	207,859	92,564
Total		5,556,508	914,142	3,363,212	1,279,154
Proportion of total population, %		100.0	16.5	60.5	23.0

Source: Kela's population data.

4. Drug control and pharmaceutical services






Distribution of medicine sales

Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2021¹

ATC code	Sales at wholesale prices, EUR 1,000	Pharmacies, %	Hospitals, %	Total
A Alimentary tract and metabolism	333,239	11.1 (92.4)	0.9 (7.6)	12.0 (100.0)
B Blood and blood forming organs	295,792	8.0 (74.9)	2.7 (25.1)	10.6 (100.0)
C Cardiovascular system	130,578	4.1 (87.0)	0.6 (13.0)	4.7 (100.0)
D Dermatologicals	47,210	1.6 (95.4)	0.1 (4.6)	1.7 (100.0)
G Genito-urinary system and sex hormones	91,992	3.1 (92.6)	0.2 (7.4)	3.3 (100.0)
H Systemic hormonal preparations, excl. sex hormones and insulines	45,877	1.3 (81.0)	0.3 (19.0)	1.6 (100.0)
J Antiinfectives for systemic use	244,852	2.0 (23.1)	6.8 (76.9)	8.8 (100.0)
L Antineoplastic and immunomodulating agents	895,552	18.1 (56.3)	14.1 (43.7)	32.2 (100.0)
M Musculo-skeletal system	99,580	2.9 (80.0)	0.7 (20.0)	3.6 (100.0)
N Nervous system	328,013	9.8 (83.4)	2.0 (16.6)	11.8 (100.0)
P Antiparasitic products, insecticides and repellents	6,329	0.2 (96.3)	0.0 (3.7)	0.2 (100.0)
R Respiratory system	150,912	5.2 (96.3)	0.2 (3.7)	5.4 (100.0)
S Sensory organs	70,730	1.4 (55.5)	1.1 (44.5)	2.5 (100.0)
V Various	41,348	0.2 (15.0)	1.3 (85.0)	1.5 (100.0)
Total	2,782,004	(69.1)	(30.9)	(100.0)

1 The percentages given in brackets indicate the sales distribution within the group.
Source: Finnish Medicines Agency Fimea, Drug Sales Register.

Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2021, EUR 1,000



Source: Finnish Medicines Agency Fimea, Drug Sales Register.



Pharmacies and hospital pharmacies

In Finland, medicines may be sold to the public by pharmacies, subsidiary pharmacies, pharmacy service points and pharmacies' online services. OTC nicotine products can also be sold from outlets other than pharmacies, e.g. grocery shops and kiosks, under a permit issued by the municipal authorities. A pharmacy will dispense prescription-only medicines against a prescription issued by a doctor, dentist, veterinary surgeon or (in certain cases) nurse.

Pharmacies are privately owned and licensed. After announcing a vacancy the Finnish Medicines Agency grants a licence to own and operate a pharmacy to an applicant of its choice. Proprietary pharmacists are required to hold the qualification of a Master of Science (Pharmacy) and be a citizen of any state belonging to the European Economic Area. In addition to the privately owned pharmacies, the University of Helsinki has the statutory right to operate one pharmacy in the city of Helsinki, and up to 16 subsidiary pharmacies with permission granted by the Finnish Medicines Agency. The University of Eastern Finland also has the statutory right to operate one pharmacy in the city of Kuopio.

A turnover-based pharmacy tax was introduced at the beginning of 2017. It is a state tax payable by proprietary pharmacists and replaces the pharmacy fee. The purpose of the pharmacy tax is to guarantee nationwide access to pharmacy services and to reduce differences in revenue among pharmacies.

The Finnish Medicines Agency may permit hospitals and other health care institutions to operate a hospital pharmacy or a medicine dispensary. The director of a hospital pharmacy is required to hold the qualification of a Master of Science (Pharmacy) and the director of a medicine dispensary is required to hold the qualification of a Master of Science (Pharmacy) or a Bachelor of Science (Pharmacy).

Hospital pharmacies and medicine dispensaries issue medicines only to their own wards and other departments; they are not allowed to sell medicines to patients or directly to the public. Only on special occasions may patients, who are being discharged or temporarily transferred to outpatient care, be issued medicines from the hospital to ensure the continuation of their medication. These medicines are supplied without charge and normally for one or two days only

Table 4.2. Statistics for pharmacies in 2021

	Private pharmacies	University pharmacies
Number of pharmacy outlets	800	18
Pharmacies	624	2
Subsidiary pharmacies	176	16
Number of prescriptions in thousands	60,867	6,252

Source: Finnish Medicines Agency Fimea.




Table 4.3. Dispensations dispensed by pharmacies in 2005–2021

Year	Number of pharmacies	Dispensations		
		Number in thousands	Per capita	Per doctor
2005	606	42 161	8,0	1 686
2006	608	43 468	8,2	1 676
2007	610	45 747	8,6	1 721
2008	613	48 252	9,1	1 774
2009	617	48 725	9,1	1 666
2010	618	50 364	9,4	1 668
2011	620	48 498	9,0	1 556
2012	618	51 698	9,5	1 615
2013	616	51 724	9,5	1 586
2014	615	53 381	9,8	1 616
2015	612	55 791	10,2	1 665
2016	613	58 812	10,7	1 560
2017	616	61 250	11,1	1 824
2018	618	63 300	11,4	1 874
2019	623	65 668	11,7	1 857
2020	626	67 120	12,1	1 893
2021	632	71 476	12,9	1 966

Source: Finnish Medicines Agency Fimea.


Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2021



Source: Finnish Medicines Agency Fimea.




Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2021



Hospital pharmacies and medicine dispensaries have not been taken into account.

Source: Finnish Medicines Agency Fimea.


5. National health insurance and reimbursement of medicine expenses





The medicine supply chain and the role of various organisations in oversight and reimbursement

- How medicines reach customers
- Government authority, oversight and marketing authorisations
- Government authority, reimbursement process
- Oversight and marketing authorisations
- Reimbursement process



The chart only includes the organisations relevant in the context of the Finnish Statistics on Medicines.



Medicine reimbursement system and approval of medicine prices

Jaana Kruuti, Chief Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Jaana Harsia-Alatalo, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Miia Djerf, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

General information

The medicine reimbursement system was first implemented in Finland in 1964 pursuant to the Health Insurance Act (sairausvakuutuslaki 1224/2004). The system covers all residents of Finland, regardless of age, wealth or address. The Health Insurance Scheme is administered by the Social Insurance Institution of Finland (Kela).

The Health Insurance Scheme reimburses some of the necessary costs of prescription-only medicines which are used for the treatment of an illness. An over-the-counter product may also be granted reimbursement status if the product is prescribed by a physician and considered, on medical grounds, to be an indispensable medicinal product. Basic topical ointments prescribed for the treatment of chronic skin ailments are also reimbursable, as are clinical nutritional preparations used in the treatment of a serious illness. Reimbursement is also

paid to a limited group of patients for the dosage service fee charged by pharmacies.

The payment of reimbursement is possible only after the Pharmaceuticals Pricing Board has approved the reimbursement status of the medicine, basic topical ointment or clinical nutritional preparation and confirmed its reasonable wholesale price. The Pharmaceuticals Pricing Board operates under the auspices of the Ministry of Social Affairs and Health.

The Finnish medicine reimbursement system consists of three categories: the Basic Refund Category, and the Lower and Higher Special Refund Categories. The categories are graded according to medical criteria based on the severity of the disease and the necessity of the drug treatment. Up to three months' supply of medicines can be reimbursed at any one transaction. However, a maximum of one month's supply of the medicine is reimbursed at any one time if there is a pack size available on the market whose retail price exceeds EUR 1,000 (inclusive of VAT). The customers usually have their medicine costs refunded directly at the pharmacy, after the pharmacy has verified their

eligibility for the reimbursement with Kela's direct reimbursement inquiry service.

In 2015, all pharmacies adopted a real-time data transmission procedure, which applies to medicine purchases. Real-time transmission of data relating to medicine purchases between pharmacies and Kela was a prerequisite for the adoption of the initial deductible limit at the beginning of 2016. The exceptional medicine-specific copayment for Higher Special Refund and Additional Refund categories, charged for each new week of treatment, was adopted at the same time. This also enabled real-time transmission of purchasing data on dose-dispensed medicines from pharmacies to Kela. In addition to dose-dispensed medicines, the exceptional medicine-specific copayment also applies to purchases of medicines containing clozapine, peritoneal dialysis solutions and medicinal oxygen. As of 1 January 2017, the exceptional medicine-specific copayment is also applicable to a supply of a maximum of one month's treatment in case of an expensive medicine, or if a medicinal product is prescribed by a physician, on therapeutic grounds, to be purchased in several batches. The exceptional medicine-specific copayment amounts

to 1/12 of the medicine-specific deductible for three months of treatment.

Determining the price of medicines

The Government Decree on the Price List of Drugs regulates the sale prices of medicines and the pharmacy margin for the sale of medicines. The purpose of the price list is to keep the prices of medicines on a reasonable level. In addition, the price list ensures that the prices of medicines are the same in every pharmacy.

The retail price of a medicine is determined on the basis of the price list of drugs and the nationwide wholesale price of the medicine in question. The price list uses separate formulas for calculating the prices of prescription-only medicines and over-the-counter medicines.

A new Government Decree on the Price List of Drugs was issued in 2014. This decree adjusted the principles of calculating the retail prices of prescription-only medicines, reducing the prices of the most expensive prescription-only medicines and increasing the prices at the lower end of the price range. In addition, the processing fee charged by pharmacies increased from EUR 0.43 to EUR 2.39



(inclusive of VAT). The goal of this reform was, for example, to guarantee the continued availability of medicines throughout the country and ensure that pharmacies have sufficient resources for expert tasks and statutory medication counselling. The changes made to the price list of drugs were anticipated to cut the cost of reimbursement payments made under the Health Insurance Scheme. The savings generated in this way made it possible to reduce the patients' annual deductible, i.e. the maximum limit on annual out-of-pocket medicine expenses, in 2014.

The price list of drugs was adjusted in 2015 in connection with the implementation of real-time transmission of data relating to dose-dispensed medicines. To prevent the total costs of the dosage service fees from exceeding the amount the customer needs to pay for each three-month supply of dose-dispensed medicines, the Government Decree on the Price List of Drugs was amended to include a processing fee for each transaction involving dose-dispensed medicines. The fee is EUR 0.20 (inclusive of VAT) for each new week of treatment. This amounts to 1/12 of the processing fee for a three-month supply of medicine.

Reference Price System

A reference price system was introduced in Finland in 2009 to complement generic substitution, which had started in 2003. Under the reference price system, substitutable medicinal products that contain the same active ingredient and are biologically equivalent are grouped together in the same reference price group. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. The reference price groups, and the reference price for each group, must be confirmed by the Pharmaceuticals Pricing Board. As of 1 January 2017, the reference price is calculated by adding EUR 0.50 to the price of the most inexpensive product within the group. The reference price is the maximum price used as the basis for calculating reimbursement payments. If the medicine purchased is less expensive than the reference price, reimbursement is calculated from the medicine's purchase price. If a customer does not wish to change the prescribed medicine to an alternative at or below the reference price, the cost in excess of the reference price, in addition to the non-reimbursable portion of the medicine cost, is paid by the customer. The cost in excess of the reference price will not count towards the annual deductible (see Annual deductible). The prescribing physician may only forbid substitution on medical and therapeutic grounds. In that event, the reimbursement to the customer is calculated from the retail price of the medicine.

Drugs in the Basic Refund Category

Forty per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal product belonging to the Basic Refund Category is reimbursed to the patient. As a general rule, reimbursement for a medicinal product in the Basic Refund Category is paid to all individuals covered by the Finnish Health Insurance Scheme. Decisions relating to medicinal products eligible for reimbursement under the Basic Refund Category are made by the Pharmaceuticals Pricing Board. A medicinal product for the treatment of a disease can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for the therapeutic indications listed therein. The Pharmaceuticals Pricing Board also has the authority to restrict the basic reimbursement status of certain medicinal products to clearly defined indications. These products form a group known as Medicinal Products Eligible for Restricted Basic Refund, and they will only generate the Basic Refund if the need for such medication can be proved by providing a separate statement, as specified by Kela. The separate statement can either be in the form of a Medical Certificate B or an addendum to the prescription sheet. The reason for creating the sub-group was to target and limit the payment of the Basic Refund to patients who, based on existing knowledge and scientific evidence, are likely to gain most from these costly treatments.

Drugs in the Special Refund Categories

The provisions on diseases that entitle medicinal products used in their treatment to be included in the Special Refund Categories are given by Government decree. The Higher Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic and where drug treatment is necessary for the patient and where the drug restores or replaces normal bodily functions. Insulin treatment for diabetes mellitus and drugs used to treat malignant diseases are examples of drugs belonging to the Higher Special Refund Category. The purchase price or reference price of a medicinal product is reimbursed to the patient in full (100%), including the pharmacy's processing fee charged for each transaction. The patient pays a non-reimbursable sum of EUR 4.50 per transaction for each medicinal product in the Higher Special Refund Category. In addition, the patient will also pay any part of the medicine price exceeding the reference price.

The Lower Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic. The most common diseases in this group are hypertension, asthma, coronary heart disease and, since 1 January 2017, also diabetes (other than insulin treatment). Sixty-five per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal



product belonging to the Lower Special Refund Category is reimbursed to the patient.

Decisions relating to medicinal products eligible for reimbursement under the Special Refund Categories are made by the Pharmaceuticals Pricing Board. Special reimbursement status may be granted for a medicinal product that is indicated for the treatment of serious or chronic diseases, which are defined by Government decree. The Pharmaceuticals Pricing Board may also restrict the special reimbursement status of a medicinal product to certain forms or grades of the disease. In such a case the product is eligible for Restricted Special Refund.

Drugs in the Special Refund Categories are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. The separate statement shall always be in the form of a Medical Certificate B. For certain medicinal products, an addendum to the prescription sheet is also needed.

Clinical nutritional preparations

Either 40% or 65% of the cost of a clinical nutritional preparation, prescribed for the treatment of a serious disease, is reimbursed to the patient, provided that the preparation is used to replace or augment, either fully or partially, the patient's diet. Decisions relating to the reimbursement status of clinical nutritional preparations are made by the

Pharmaceuticals Pricing Board. The reimbursement status may be granted for a nutritional preparation used for the treatment of serious or chronic diseases, which are defined by Government decree. Clinical nutritional preparations are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. In the case of clinical nutritional preparations, the required statement is in the form of a Medical Certificate B.

Initial deductible

A calendar year-specific initial deductible was introduced at the start of 2016. Reimbursement under the medicine reimbursement system is not paid until the sum paid by the customer exceeds the initial deductible, which is EUR 50. Reimbursable medicines, clinical nutritional preparations and basic topical ointments purchased on prescription count towards the initial deductible. The initial deductible is not applicable to children and youth. It is applicable from the beginning of the year during which one turns 19.

Both pharmacies and Kela have real-time data on the amount of each customer's initial deductible. Once the initial deductible is met, the reimbursement is refunded to the customer directly at the pharmacy. The initial deductible counts towards the annual deductible (maximum limit on annual out-of-pocket medicine expenses).

Annual deductible (maximum annual limit on out-of-pocket medicine expenses)

If the total amount spent by the customer on reimbursable medicines, basic topical ointments and clinical nutritional preparations exceeds the annual deductible (the maximum annual limit on out-of-pocket medicine expenses), the customer is entitled to an additional reimbursement. In 2021 the annual deductible was set at EUR 579,78. The cost-of-living index is used to review the limit annually. After the annual deductible is exceeded, the customer pays a fixed non-reimbursable sum of EUR 2.50 per transaction for each reimbursable medicinal product, basic topical ointment and clinical nutritional preparation purchased as well as any portion of the medicine's price exceeding the reference price. Additional Refunds are usually paid to the customers directly at the pharmacy, after the pharmacy has verified their eligibility for Additional Refunds with Kela's direct reimbursement inquiry service. Until 2019, customers claimed additional reimbursement from Kela for the part of the purchase exceeding the annual maximum. Since the beginning of 2020, customers have received the additional reimbursement in real time at the pharmacy also for purchases exceeding the annual maximum.

Dosage service

Dosage service, or dose dispensing service, refers to a service whereby patients receive up to a fortnight's supply of tablets or capsules from a pharmacy pre-packed into individual single doses. Pharmacies charge from the customer a dose-dispensing fee for the service, which is partially reimbursed by Kela to a specific group of customers in accordance with the Health Insurance Act (sairausvakuutuslaki 1224/2004). The customer is reimbursed 40% of the pharmacy's service fee. However, the maximum fee eligible for reimbursement per week is EUR 3.15. Patients over 75 years of age are entitled to this reimbursement provided that at the start of the service they use at least six reimbursable medicinal products suitable for the dosage service. Moreover, the patient's medication needs to be reviewed in order to eliminate any unnecessary or overlapping medication. The treating physician must also consider the dosage service to be medically justified for the patient.

**Table 5.1. Reimbursement numbers adopted in 2021, basic reimbursement**

Number and name	Disease	Valid from
3040 Burosumab	Hypophosphatemia	01/01/2021
3041 Dacomitinib	Lung cancer	01/01/2021
3042 Vedolizumab	Ulcerative colitis and Crohn's disease	01/02/2021
3043 Combination product containing ivacaftor and lumacaftor	Cystic fibrosis	01/04/2021
3044 Combination therapy with ivacaftor and tezacaftor	Cystic fibrosis	01/04/2021
3045 Combination therapy with elexacaftor, ivacaftor and tezacaftor	Cystic fibrosis	01/04/2021
3046 Cannabidiol	Epilepsy	01/04/2021
3047 Emicizumab (haemophilia A, without inhibitors)	Haemophilia A	01/05/2021
3048 Filgotinib	Rheumatoid arthritis	01/05/2021
3049 Encorafenib (colorectal cancer)	Colorectal cancer	01/07/2021
3050 Entrectinib	Solid tumours and lung cancer	01/07/2021
3051 Liraglutide (obesity)	Obesity	01/07/2021
3052 Avatrombopag	Immune thrombocytopenia (ITP)	01/08/2021
3053 Anakinra	Still's disease, familial Mediterranean fever and Cryopyrin-associated periodic syndromes	01/09/2021 ¹
3054 Enzalutamide	Prostate cancer	01/11/2021 ²
3055 Combination product containing bupropion and naltrexone	Obesity	01/11/2021
3056 Ataluren	Duchenne muscular dystrophy	01/12/2021
"Avatrombopag (Addendum to the prescription)"	Thrombocytopenia in chronic liver disease	01/03/2021

1 Previously available for basic reimbursement under number 331, a new reimbursement number was assigned for anakinra on 01/09/2021

2 Previously available for basic reimbursement under number 352, a new reimbursement number was assigned for enzalutamide on 01/11/2021.

Table 5.2. Reimbursement numbers discontinued in 2021, basic reimbursement

Number and name	Disease	Valid from
354 Ivabradine	Chronic cardiac insufficiency	01/01/2021
Oseltamivir and zanamivir (Addendum to the prescription)	Influenza	01/11/2021

Eligibility for reimbursements was discontinued as redundant.

**Table 5.3. Reimbursement numbers adopted in 2021, special reimbursement**

Number and name	Disease	Valid from
1519 Osimertinib	Lung cancer	01/03/2021
1520 Emicizumab (haemophilia A, without inhibitors)	Haemophilia A	01/05/2021
1521 Brigatinib	Lung cancer	01/07/2021
1522 Midostaurin	Acute myeloid leukemia	01/08/2021
1523 Enzalutamide	Prostate cancer	01/11/2021 ^{1*}
250 Dapagliflozin and empagliflozin	Cardiac insufficiency	01/06/2021
251 Benralizumab	Asthma	01/08/2021
252 Anakinra	Still's disease, familial Mediterranean fever and Cryopyrin-associated periodic syndromes	01/09/2021 ²
253 Vedolizumab	Ulcerative colitis and Crohn's disease	01/12/2021
297 Mepolizumab	Asthma	01/01/2021
298 Upadacitinib	Rheumatoid arthritis	01/02/2021
299 Apremilast	Psoriatic arthritis	01/05/2021

1 Previously available for special reimbursement under number 163, a new reimbursement number was assigned for enzalutamide on 01/11/2021.

2 Previously available for special reimbursement under number 281, a new reimbursement number was assigned for anakinra on 01/09/2021.

Table 5.4. Reimbursement numbers discontinued in 2021, special reimbursement

Number and name	Disease	Valid from
283 Ivabradine	Chronic cardiac insufficiency	01/01/2021 ¹

1 A special reimbursement has been available for ivabradine since 01/01/2021 under reimbursement number 201.



Table 5.5. Medicines added to existing reimbursement numbers in 2021, basic reimbursement












Number	Medicinal agent	Disease	Added as of
338.	Lanadelumabi	Perinnöllinen angioedeema (HAE)	01/04/2021
388.	Inklisiraani	Familiaalinen hyperkolesterolemia	01/10/2021
3015.	Inklisiraani	Hyperkolesterolemia ja sekamuotoinen dyslipidemia	01/10/2021
313.	Guselkumabi	Nivelpsoriaasi	01/12/2021
3035.	Solriamfetoli	Narkolepsia	01/12/2021

Table 5.6. Medicines added to existing reimbursement numbers in 2021, special reimbursement

No new pharmaceutical agents were added in 2021 to existing reimbursement entitlements.



Reimbursements for medicine expenses in 2021

EUR 0 Initial deductible	EUR 50 Reimbursement for medicine expenses			EUR 579.78 Additional reimbursement			
<p>Customers pay full price for medicines covered by the reimbursement system up to 50 euros. Persons under 19 are exempt from the initial deductible.</p> 	<p>Once the customer has reached the initial deductible limit, the pharmacy will deduct the reimbursement from the price of purchased medicines. The rate of reimbursement depends on the specific medicine and illness.</p> <table border="0"> <tr> <td data-bbox="780 587 1162 778"> <p>Basic rate of reimbursement</p>  </td> <td data-bbox="1170 587 1493 778"> <p>Lower special rate of reimbursement</p>  </td> <td data-bbox="1501 587 1841 778"> <p>Higher special rate of reimbursement</p>  </td> </tr> </table>			<p>Basic rate of reimbursement</p> 	<p>Lower special rate of reimbursement</p> 	<p>Higher special rate of reimbursement</p> 	<p>Customers' out-of-pocket payments and the initial deductible count towards an annual maximum limit on medicine expenses. Once customers exceed the annual maximum limit, they are entitled to an additional reimbursement.</p> 
<p>Basic rate of reimbursement</p> 	<p>Lower special rate of reimbursement</p> 	<p>Higher special rate of reimbursement</p> 					
<p>Rate of reimbursement per medicine and per purchase 0%</p> <p>Customer's out-of-pocket share per medicine and per purchase 100%</p>	<p>40%</p> <p>60%</p>	<p>65%</p> <p>35%</p>	<p>100%</p> <p>EUR 4.50 (copayment)</p>	<p>100%</p> <p>EUR 2.50 (copayment)</p>			

Calendar year



Table 5.7. Medicine costs and their reimbursement in 2021

Costs of reimbursed medicines¹

	EUR 1,000
Total cost	2 251 245
Basic Refund Category (40%) ²	618 681
Restricted Basic Refund Category (40%)	190 240
Higher Special Refund Category (100%)	760 815
Lower Special Refund Category (65%)	679 845

Reimbursement of medicine costs

	EUR 1,000
Total reimbursements ³	1 711 347
Basic Refund Category (40%) ²	235 520
Restricted Basic Refund Category (40%)	75 574
Higher Special Refund Category (100%)	740 205
Lower Special Refund Category (65%)	431 474

Number of recipients of reimbursement

	Recipients
Total	2 956 849
Basic Refund Category (40%) ²	2 838 948
Restricted Basic Refund Category (40%)	87 498
Higher Special Refund Category (100%)	501 653
Lower Special Refund Category (65%)	993 098


1 The figures do not include purchases that did not clear the initial deductible limit.

2 Purchases of medicines eligible for restricted basic refund not included.

3 Includes reimbursements for dosage service charges and Additional Refunds.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Figure 5.1. Reimbursement of medicine costs in 2000–2021 according to Refund Category



Source: Register of Statistical Information on National Health Insurance General Benefit Payments.



Pharmaceuticals Pricing Board, reimbursable medicines, confirming wholesale prices and the reference price system

Kaarina Koskela, Lawyer, Pharmaceuticals Pricing Board

Ulla Kurkijärvi, Principal Pharmaceutical Officer, Pharmaceuticals Pricing Board

A pharmaceutical company can introduce a medicinal product onto the market and make it available to consumers after marketing authorisation has been granted. The inclusion of a medicinal product into the system of medicine reimbursement under the Health Insurance Scheme requires a decision by the Pharmaceuticals Pricing Board, which operates under the auspices of the Ministry of Social Affairs and Health. The product is included in the reimbursement system after its reimbursement status and wholesale price have been approved.

The role of the Pharmaceuticals Pricing Board as a decision-maker

The task of the Pharmaceuticals Pricing Board is to decide which medicinal products are to be included in the reimbursement system and confirm their wholesale prices and refund categories. The Pricing Board also makes decisions regarding wholesale price increases of reimbursable medicines. The decisions are based on applications submitted by Marketing Authorisation Holders. Moreover, the

Pricing Board makes decisions relating to the reference price system, including decisions regarding the reference price groups, reference prices and the products to be included in the reference price groups.

The Pharmaceuticals Pricing Board consists of seven members and their deputies nominated by the Ministry of Social Affairs and Health. The Board members represent the Ministry of Social Affairs and Health, the Social Insurance Institution of Finland (Kela), the Finnish Medicines Agency Fimea, the National Institute for Health and Welfare and the Ministry of Finance. The Board members must cover medical, pharmaceutical, legal and economic expertise. The Pharmaceuticals Pricing Board works closely with a group of experts and the Board's Secretariat. Cases are presented at the Board meetings by the Chief Pharmaceutical Officers and Pharmaceutical Officers of the Board's Secretariat. The group of experts linked to the Pricing Board consists of seven members and their personal deputies, and it comprises experts from the fields of medicine, pharmacology and health insurance. The presenting official of the group of experts is the Senior Medical Officer of the Board's Secretariat.

The decision is based on the application process, and the decision must be issued within a set time period. The application process is based on the provisions laid down in the Health Insurance Act (sairausvakuutuslaki 1224/2004) and the Administrative Procedure Act (hallintolaki 434/2003). In certain circumstances, as provided in the Health Insurance Act, the Pricing Board may decide to review both the reimbursability and wholesale price of a medicinal product on their own initiative.

A decision issued by the Pharmaceuticals Pricing Board regarding the reimbursement status and reasonable wholesale price of a medicinal product containing a new active substance is valid for up to three years. Decisions regarding all other products are valid for up to five years. Decisions regarding the reimbursement status and maximum wholesale price of products to be included in the reference price system are valid for an indefinite period. The applicant retains the right to appeal against the decisions to the Supreme Administrative Court.

Inclusion of a medicinal product into the reimbursement system

Medicinal products included in the reimbursement system are subject to price regulation. The inclusion of a product into the reimbursement system requires a decision which approves both the reimbursement status of the product and its wholesale price. A medicinal product with a valid marketing authorisation may be marketed in Finland without its wholesale price having been confirmed by the authorities. However, reimbursement for the cost of the medicinal product can only be paid under the Health Insurance Act if the Pharmaceuticals Pricing Board has approved the product for reimbursement and confirmed its wholesale price. A confirmed wholesale price refers to the maximum price at which the product may be sold to pharmacies. The actual reimbursement payment is based on the retail price (inclusive of VAT), which cannot be higher than the confirmed wholesale price plus the pharmacy's profit margin (Table 5.8.) at the rate prescribed by the Government Decree on the Price List of Drugs (713/2013) and VAT (10%).



The medicine cost will remain fully payable by the patient if the Marketing Authorisation Holder fails to apply for reimbursement status and wholesale price for the product, or if the product's reimbursement status and wholesale price proposed by the Marketing Authorisation Holder have not been approved. Likewise, the cost remains payable by the patient if the Marketing Authorisation Holder has removed the product from the list of reimbursable medicines, or if its reimbursement status and wholesale price have been removed. The removal of a medicine from the reimbursement system by the Marketing Authorisation Holder is possible on a quarterly basis.

Basic reimbursement status and reasonable wholesale price

An application for basic reimbursement status and wholesale price is submitted by the Marketing Authorisation Holder. The application must include, in addition to the proposed wholesale prices, a well-grounded evaluation of the benefits and costs incurred should the product be included in the reimbursement system with the proposed prices. Applications for reimbursement status and wholesale price are processed simultaneously by the Pharmaceuticals Pricing Board.

The application must include a statement on the intended use and therapeutic value of the medicinal product and the benefits expected to be gained with reimbursement status as compared with other medicinal products used to treat the same illness. The application must also include a detailed and well-grounded statement regarding the average daily dose and the cost of the drug treatment based on this dose. Moreover, the application must include the validity period of the pharmaceutical patent or the supplementary protection certificate, an estimate of the sales volume and number of users of the product as well as the approved prices and grounds for reimbursement of the product in other EEA countries. The application is also to include any other trade names under which the product is marketed in other EEA countries, and the respective prices. Applications must contain a health economic evaluation, if the medicinal product contains a new active substance or the reimbursement status is going to be significantly extended.

A renewal application submitted by the Marketing Authorisation Holder shall contain a description of the changes to the aspects affecting the reasonableness of the wholesale price if a higher wholesale price than the previously confirmed wholesale price is being proposed for the product.

Before reaching decisions regarding basic reimbursement status and a reasonable wholesale price, the Pricing Board may request that Kela submit a statement, if necessary. In the statement, Kela will assess whether the criteria for granting reimbursement status are fulfilled and evaluate the reasonableness of the proposed price in terms of the Health Insurance Scheme. The statement will also include an estimate of the cost effect of the product on the Health Insurance Scheme. The Pricing Board may also request an opinion from the expert group before making a decision, for example, in case a pharmaceutical company is applying for basic reimbursement status for a product containing a new active substance or if the reimbursement status of a medicine is extended to a new indication.

When deciding about basic reimbursement status, the Pharmaceuticals Pricing Board assesses the therapeutic value of the product. A medicinal product for the treatment of an illness can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for indications listed therein. The Summary of Product Characteristics must be approved by the marketing authorisation authorities. A medicinal product is not considered eligible for reimbursement under the Basic Refund Category if, for example, the therapeutic value of the product is not considered significant or if the product is used for purposes other than the treatment of an illness. The Pharmaceuticals Pricing Board also has the authority to restrict, when necessary, the eligibility for basic reimbursement to clearly defined indications (Medicinal Products Eligible for Restricted Basic Refund).

An over-the-counter product may be granted basic reimbursement status only if the product is considered, on medical grounds, to be an indispensable medicinal product.



When considering the reasonableness of the proposed wholesale price, the Pharmaceuticals Pricing Board takes into account the cost of the drug therapy and the benefits to be gained from its use as regards both the patient and the overall health care and social costs. The Pricing Board will also consider the benefits and costs of treatment alternatives, the prices of comparable medicinal products in Finland, the price of the medicine in question in other EEA countries as well as the funds available for reimbursement payments. It is also possible to consider manufacturing, research and development costs in the decision-making, provided that sufficiently detailed, comparable and reliable product-specific data relating to these costs have been submitted.

The wholesale price confirmed for a first generic alternative can be a maximum of 50 per cent of the confirmed wholesale price of the corresponding product, and for a first biosimilar product, a maximum of 70 per cent of the confirmed wholesale price of the corresponding product. For a generic alternative including a new dose dispensing device, the confirmed wholesale price can be a maximum of 60 per cent of the confirmed wholesale price of the corresponding product.

The use of new medicines is often shadowed by uncertainty about the overall costs, cost effects and therapeutic value. In Finland, a new method to control this uncertainty, the so-called provisional reimbursement status, has been launched. The possibility of being granted provisional reimbursement status primarily concerns new medicinal therapies. In practice, this refers to new active pharmaceuticals or new significant indications for pharmaceutical products already included in the reimbursement system. The Pharmaceuticals Pricing Board will assess the preconditions for initiating negotiations concerning provisional reimbursement status on a case by case basis. While the negotiations are underway, the processing time of the relevant application is suspended. If the negotiations end up with a positive result, the final decision will be accompanied by an agreement between the Marketing Authorisation Holder and the Pharmaceuticals Pricing Board concerning the terms and conditions for the monitoring and management of the uncertainty linked with the product. If no agreement is reached through negotiations, the processing of the application will continue as a normal application procedure. The regulations concerning the provisional reimbursement status are valid for a fixed period, until the end of 2025.

Special reimbursement status and reasonable wholesale price

Certain medicines that are used to treat serious and chronic illnesses are eligible for reimbursement payments under the Special Refund Categories. Medicinal products granted special reimbursement status attract higher reimbursement payments than those granted basic reimbursement status. The illnesses that make medicinal products used in their treatment eligible for inclusion in the Special Refund Categories are decided by the Finnish Government. The Pharmaceuticals Pricing Board decides which medicinal products are to be granted special reimbursement status; these decisions are product-specific. In order to qualify for special reimbursement status the medicinal product must be used to treat an illness defined by Government decree, and it must be deemed necessary in the treatment of a serious and chronic illness.

The application for special reimbursement status, submitted by the Marketing Authorisation Holder, must demonstrate that the product fulfils the criteria for special reimbursement status. Moreover, the application must include a statement regarding the cost-effectiveness of special reimbursement status and a market forecast which takes into account competing products. The application must also include an evaluation of the envisaged cost effects following the granting of special reimbursement status.

When making decisions on special reimbursement status, the Pharmaceuticals Pricing Board will consider the nature of the illness and the therapeutic value, indispensability, replacement or remedial effects, necessity and cost-effectiveness of the medicine as proven in clinical practice and by research, as well as the funds available for special reimbursement payments. The Board also has the opinions of both the group of experts and Kela at its disposal.

A medicinal product may be granted special reimbursement status if it is already included in the Basic Refund Category, and if sufficient clinical experience and research data are available on the product meeting the criteria for special reimbursement (therapeutic value, usefulness in comparison with treatment alternatives, indispensability, replacement or remedial effects, necessity and cost-effectiveness). The special reimbursement status of a medicinal product can also be restricted to certain forms or grades of the disease. With an application for special reimbursement status, the reasonableness of the price is always reassessed.



Reference Price System

Under the reference price system, reimbursement for a medicinal product is calculated from a reference price, which is determined separately. If the medicine purchased is more expensive than the reference price, and the patient declines substitution, the cost in excess of the reference price is paid by the patient. Reimbursement under the Health Insurance Scheme can only be paid for the price of a medicine that exceeds the reference price if the prescribing physician forbids substitution on medical or therapeutic grounds.

Under the reference price system, medicines are divided into reference price groups. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. Medicinal products with a corresponding pharmaceutical form and pack size and which contain equal amounts of the same active substance are grouped together in the same reference price group. Products grouped in the same reference price group are interchangeable with each other.

Reference prices are based on the retail price of the medicinal products (inclusive of VAT), and they are updated every three months on the basis of price

notifications submitted to the Pharmaceuticals Pricing Board by Marketing Authorisation Holders. A reference price is calculated from the least expensive product within the group by adding EUR 0.50 to its retail price (inclusive of VAT).

In December 2021, more than a half (64%) of all reimbursable medicinal product packages with marketing authorisation were included in the reference price system.

Reimbursement status and maximum wholesale price in the reference price system

The application process applied under the reference price system entails the Pharmaceuticals Pricing Board confirming the reimbursement status and maximum wholesale price for a new product to be included in the system. The Marketing Authorisation Holder must apply for reimbursement status for a new medicinal product under the reference price system, if the product is eligible for generic substitution and other corresponding products marketed are already included in the reference price system.

The application process in the reference price system places the Marketing Authorisation Holder under an obligation to provide the same documentation, as far as is appropriate, as described above for applications regarding basic and special reimbursement status. The application must also include a proposal for the maximum wholesale price of the product.

The confirmed maximum wholesale price must not exceed the price level of corresponding products. The maximum wholesale price refers to the maximum price at which the product may be sold to pharmacies. When deciding on the reimbursement status of medicinal products to be included in the reference price system the Pharmaceuticals Pricing Board considers corresponding matters as described above for decisions concerning basic and special reimbursement status.

Matters regarding reimbursement status and price processed in 2021

In 2021, the Pharmaceuticals Pricing Board processed 823 applications for reimbursement status and price (Table 5.10.). The majority of these applications, i.e., 89%, were approved, 4% were rejected and 7% were withdrawn. The applications processed by the Board refer to a specific product.

The renewal of reimbursement status and wholesale price approved for a fixed period was the most common type of application. There were 372 renewal applications, and 351 of these applications were approved, 3 were rejected and 18 withdrawn. A total of 42 applications for reimbursement status relating to the reference price system were processed..

There were a total of 49 applications for reimbursement status and price concerning a new active substance or other new pharmaceutical product; 36 of these applications were applications for basic reimbursement status and price, and 13 for special reimbursement status and price. Of the applications for basic reimbursement status and price, 20 were approved, and 11 applications for special reimbursement status and price were approved. During 2021, a total of 16 new active substances were included in the reimbursement system, and 10 new active substances were granted special reimbursement status (Table 5.9.).



Time taken to process an application

The Pharmaceuticals Pricing Board is under an obligation to issue its decisions on applications within a set time period. A decision regarding reimbursement status and wholesale price must be issued to the applicant within 180 days of receipt of the application. Should the information supporting the application be insufficient, the Board may suspend the application process until the applicant has provided the required information. If necessary, the Director may intervene. The final decision must be issued to the applicant within 180 days of the receipt of the requested additional information. Should the decision be made regard only an increase of a previously confirmed wholesale price, and not the reimbursement status of the medicinal product, the decision must be issued to the applicant within 90 days of receipt of the application. When the number of applications for price increases is exceptionally high, the Board may extend the process time by 60 days.

The decision issued by the Pharmaceuticals Pricing Board will enter into force at the beginning of the second calendar month following the issue date, unless otherwise specified in the decision.

The average processing times of applications in 2021 are presented in Table 5.11. The applications are grouped according to the type of application. The median time taken to reach a positive decision ranged from 13 to 151 days, and that of a negative decision from 78 to 176 days depending on the type of application. The median time to reach a positive decision on an application for basic reimbursement status and price concerning a new active substance was 151 days, whereas the median time taken to reach a negative decision was 158 days. The median time to reach a positive decision on an application for special reimbursement status and price concerning a new active substance was 88 days and the median time taken to reach a negative decision was 176 days.

Issuing a decision may be preceded by several requests to the applicant for detailed additional information to support the application. Moreover, in order to make an assessment the Board may request the opinion of relevant specialists, and in certain cases also hear evidence from the applicant. It is also possible for the applicant to request the processing of the application to be suspended.

The Pharmaceuticals Pricing Board is able to transfer the decision-making directly to the Director of the Board in cases where the application refers to a new strength of the medicinal product, generic alternatives, biosimilars, parallel imports, a new pack size or a new pharmaceutical form. Decisions regarding products in the reference price system may also be transferred to the Director. The processing times of decisions issued by the Director are usually considerably shorter.

**Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2021****Prescription medicine**

Wholesale price euros	Retail price
– 9.25	1.45 x wholesale price
9.26 – 46.25	1.35 x wholesale price + 0.92 euro
46.26 – 100.91	1.25 x wholesale price + 5.54 euro
100.92 – 420.47	1.15 x wholesale price + 15.63 euro
420.48 –	1.1 x wholesale price + 36.65 euro

Over the counter medicine

Wholesale price euros	Retail price
– 9.25	1.5 x wholesale price + 0.50 euro
9.26 – 46.25	1.4 x wholesale price + 1.43 euro
46.26 – 100.91	1.3 x wholesale price + 6.05 euro
100.92 – 420.47	1.2 x wholesale price + 16.15 euro
420.48 –	1.125 x wholesale price + 47.68 euro

Source: Government Decree on the Price List of Drugs (713/2013).

Table 5.9. New active substances in 2021

Basic reimbursement, approved	Special reimbursement, approved	Basic reimbursement, rejected	Special reimbursement, rejected
Ataluren	Apremilast	Esketamine	
Avatrombopag	Avatrombopag	Fedratinib	
Entrectinib	Benralizumab	Fostamatinib	
Filgotinib	Brigatinib	Chlormethine	
Inclisiran	Darolutamide	Mexiletine	
Ivacaftor	Midostaurin	Melatonin	
Ivacaftor and lumacaftor	Ondansetron	Romosozumab	
Ivacaftor and tezacaftor	Osimertinib	Ropeginterferon alfa-2b	
Cannabidiol	Turoctocog alfa pegol	Cenobamate	
Lanadelumab	Vedolizumab	Siponimod	
Sodium zirconium cyclosilicate		Teduglutide	
Ofatumumab		Trientine	
Opicapone			
Ponesimod			
Solriamfetol			
Turoctocog alfa pegol			

Source: Pharmaceuticals Pricing Board.

**Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2021¹**

Type of application	Approved	Rejected	Withdrawn
Applications for reimbursement status and price	731	34	58
Medicinal products with marketing authorization	626	22	32
New active substance or other new product, basic reimbursement status	20	14	2
New active substance or other new product, special reimbursement status	11	2	-
New combination of active substances	2	-	-
New pharmaceutical form	6	-	-
New strength	24	-	-
New package size/form	34	-	-
Expansion of reimbursement status	42	2	7
Generic product	30	-	1
Parallel import	62	-	1
Biosimilar	3	-	-
Reimbursement status in reference price system	41	-	1
Price increase application	-	1	2
Renewal of a price and reimbursement status approved for a fixed-period	351	3	18
Clinical nutritional preparations²	8	1	1
Basic topical ointments	2	-	1
Non-registered medicinal products	95	11	24

1 Each application includes all reimbursement categories and subsequent strengths, pharmaceutical forms and package sizes.

2 Includes products belonging to refund categories of 40% and 65%.


Source: Pharmaceuticals Pricing Board.

Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2021

Type of application	Approved	Rejected
Applications for reimbursement status and price		
Medicinal products with marketing authorization		
New active substance or other new product, basic reimbursement status	151	158
New active substance or other new product, special reimbursement status	88	176
New combination of active substances	77	-
New pharmaceutical form	107	-
New strength	21	-
New package size/form	13	-
Expansion of reimbursement status	102	172
Generic product	15	-
Parallel import	15	-
Biosimilar	35	-
Reimbursement status in reference price system	22	-
Price increase	-	78
Renewal of a price and reimbursement status approved for a fixed-period	127	168

Source: Pharmaceuticals Pricing Board.

6. Tables: Reimbursement of medicine costs





Medicine costs and their reimbursement annually and according to hospital district

Table 6.1. Medicine costs and their reimbursement in 2005–2021

All refunds¹

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3 261 540	62,1	1 076 908	1 598 998	20 872	28 796
2006	3 584 719	67,9	1 100 344	1 588 395	24 583	32 801
2007	3 674 582	69,3	1 142 074	1 638 996	26 417	35 061
2008	3 723 521	69,9	1 242 879	1 744 381	27 515	36 781
2009	3 756 438	70,2	1 244 758	1 768 848	28 890	39 208
2010	3 801 154	70,7	1 225 445	1 719 013	29 255	39 889
2011	3 855 198	71,4	1 262 066	1 753 506	29 646	40 588
2012	3 866 724	71,2	1 303 129	1 812 241	30 267	41 608
2013	3 829 177	70,2	1 273 049	1 811 263	29 574	40 317
2014	3 843 226	70,2	1 306 453	1 860 024	29 945	40 687
2015	3 811 748	69,4	1 377 934	1 948 772	31 268	43 991
2016	3 136 095	56,9	1 411 990	1 947 443	28 033	40 506
2017	3 036 110	55,0	1 386 661	1 938 802	28 758	41 844
2018	3 034 776	54,9	1 460 140	2 003 219	29 482	43 400
2019	3 042 434	54,9	1 550 985	2 088 902	30 376	45 198
2020	2 953 465	53,3	1 634 903	2 168 295	29 972	46 123
2021	2 956 849	53,2	1 711 347	2 251 245	30 543	48 390

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.

Basic Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3 100 214	59,0	369 861	879 037	14 216	19 635
2006	3 465 440	65,7	366 551	870 280	17 591	23 459
2007	3 563 435	67,2	368 732	877 974	19 114	25 422
2008	3 619 457	68,0	395 494	941 888	20 009	26 924
2009	3 659 959	68,4	402 717	963 650	21 121	29 049
2010	3 705 813	68,9	377 545	908 516	21 347	29 568
2011	3 760 290	69,6	357 149	860 191	21 600	30 048
2012	3 771 227	69,5	354 338	852 663	22 041	30 860
2013	3 729 090	68,4	297 673	827 010	21 356	29 678
2014	3 740 015	68,3	298 518	859 694	21 575	29 916
2015	3 709 187	67,6	310 080	891 529	22 302	32 104
2016	3 022 273	54,9	316 104	837 187	19 097	28 467
2017	2 925 270	53,0	318 145	831 281	19 560	29 171
2018	2 925 818	52,9	307 056	802 044	19 787	29 864
2019	2 934 104	53,0	316 354	822 783	20 222	30 870
2020	2 839 771	51,3	308 455	802 273	19 642	31 183
2021	2 847 500	51,2	311 094	808 921	20 051	32 829

Table continued



Table 6.1. continued

Higher Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	454 512	8,6	370 102	380 498	2 098	2 738
2006	468 291	8,9	393 324	402 305	2 223	2 820
2007	480 712	9,1	432 580	441 672	2 345	2 950
2008	497 121	9,3	465 619	474 945	2 427	3 029
2009	516 050	9,6	470 530	480 517	2 546	3 160
2010	535 762	10,0	498 984	509 989	2 673	3 313
2011	560 243	10,4	552 042	562 929	2 761	3 415
2012	581 985	10,7	595 277	606 765	2 920	3 602
2013	603 085	11,1	610 419	622 072	3 043	3 747
2014	619 292	11,3	620 592	632 746	3 175	3 896
2015	635 358	11,6	665 822	678 402	3 484	4 361
2016	637 262	11,6	696 153	720 456	3 577	4 547
2017	553 666	10,0	604 660	623 803	2 809	3 560
2018	489 952	8,9	626 444	645 522	2 795	3 548
2019	495 035	8,9	653 167	672 560	2 894	3 680
2020	498 400	9,0	700 049	720 306	2 954	3 792
2021	501 653	9,0	740 205	760 815	3 021	3 952

Lower Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	828 191	15,8	237 409	339 464	4 558	6 423
2006	833 665	15,8	226 380	315 580	4 769	6 521
2007	835 283	15,8	229 353	318 920	4 958	6 689
2008	842 503	15,8	235 011	326 833	5 080	6 828
2009	850 307	15,9	230 585	323 452	5 223	7 000
2010	851 717	15,8	210 117	298 539	5 235	7 008
2011	853 920	15,8	230 141	327 432	5 285	7 125
2012	851 478	15,7	246 897	348 884	5 306	7 146
2013	849 208	15,6	233 749	357 237	5 174	6 892
2014	844 440	15,4	235 018	365 194	5 195	6 875
2015	840 877	15,3	243 565	377 463	5 482	7 526
2016	831 193	15,1	245 711	388 649	5 359	7 493
2017	941 101	17,0	305 560	482 557	6 389	9 113
2018	962 071	17,4	352 231	554 415	6 900	9 988
2019	975 518	17,6	376 243	592 235	7 260	10 647
2020	988 705	17,8	408 750	644 233	7 376	11 147
2021	993 098	17,9	431 474	679 845	7 471	11 608

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

**Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2021**

Hospital district	Recipients of reimbursement		Reimbursements		Total costs ¹		No. of dispensations ¹	
	Number of recipients	As a proportion of the population, %	EUR 1,000	EUR per recipient	EUR 1,000	EUR per recipient	In thousands	Per recipient
Whole country	2 956 849	53,2	1 711 055	579	2 249 581	761	48 390	16
Helsinki and Uusimaa	828 753	48,3	430 746	520	570 612	689	12 168	15
Southwest Finland	269 187	55,3	161 550	600	212 145	788	3 979	15
Satakunta	124 564	58,1	72 724	584	96 358	774	2 185	18
Kanta-Häme	96 417	56,5	61 055	633	79 375	823	1 695	18
Pirkanmaa	294 815	54,0	177 664	603	231 777	786	4 562	16
Päijät-Häme	116 865	55,9	68 637	587	90 631	776	2 043	18
Kymenlaakso	94 518	58,4	59 592	630	78 552	831	1 927	20
South Karelia	70 049	55,5	40 544	579	53 450	763	1 130	16
South Savo	58 626	60,6	35 902	612	47 761	815	1 063	18
Itä-Savo	24 765	62,4	14 442	583	19 282	779	456	18
North Karelia	94 645	57,9	58 367	617	76 738	811	1 859	20
North Savo	146 981	60,3	85 397	581	114 087	776	2 807	19
Central Finland	136 592	54,0	78 333	573	103 371	757	2 215	16
South Ostrobothnia	106 571	55,5	65 437	614	85 263	800	1 849	17
Vaasa	80 558	47,5	52 710	654	66 865	830	1 209	15
Central Ostrobothnia	41 106	53,3	24 290	591	31 865	775	748	18
North Ostrobothnia	214 006	51,8	129 582	606	168 106	786	3 789	18
Kainuu	42 211	59,2	25 181	597	33 100	784	815	19
Länsi-Pohja	33 001	56,1	18 923	573	24 990	757	579	18
Lapland	65 537	55,6	42 185	644	54 739	835	1 128	17
Åland	13 450	44,4	6 783	504	9 084	675	163	12

¹ The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Table 6.3. Payback payments for conditional reimbursements in 2019-2021

Year	Payback payments, euros
2019	13 146 860
2020	32 870 279
2021	38 040 324



Medicine costs and their reimbursement in diseases entitling patients to special refund

Table 6.4. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2021

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Anterior pituitary hypofunction (101)	4 870	3 436	1 434	375	489	108
Diabetes insipidus (102)	1 209	559	650	911	1 041	797
Diabetes, insulin-treated (103)	386 968	211 153	175 815	654	692	602
Thyroid insufficiency (104)	85 161	13 117	72 044	40	44	39
Adrenal cortical hypofunction (105)	1 555	571	984	147	157	141
Hypoparathyroidism (106)	2 244	393	1 851	274	369	251
Pernicious anaemia (107)	13 796	5 286	8 510	32	32	32
Myasthenia gravis (108)	1 688	776	912	453	420	482
Multiple sclerosis (109)	9 626	2 645	6 981	214	265	195
Parkinson's disease and comparable movement disorders (110)	19 873	10 919	8 954	1 318	1 336	1 296
Epilepsy and comparable convulsive disorders (111)	72 093	36 177	35 916	303	319	285
Severe psychotic and other severe mental disorders (112)	98 404	46 638	51 766	867	989	761
Anxiety disorders associated with mental retardation (113)	7 172	4 230	2 942	274	297	233
Glaucoma (114)	101 469	39 693	61 776	258	254	260
Breast cancer (115)	44 003	193	43 810	549	867	547
Prostate cancer (116)	28 194	28 194	0	1 620	1 620	0
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	24 343	12 466	11 877	1 318	1 417	1 228
Trigeminal neuralgia or glossopharyngeusneuralgia (119)	2 628	714	1 914	121	143	111

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Hypogammaglobulinaemia (120)	785	321	464	30 709	32 468	29 445
Severe hypofunction of sexual glands (121)	8 745	3 814	4 931	320	522	113
Aplastic anaemia (122)	429	238	191	1 364	1 431	1 278
Chronic disorders of vitamin D metabolism (123)	9 157	5 687	3 470	128	124	135
Inborn metabolic disorders (124)	355	187	168	6 883	4 632	8 882
Chronic coagulation defects (126)	1 133	578	555	74 650	111 353	4 846
Transplant complication (127)	7 006	4 095	2 911	3 596	3 721	3 411
Cancers of female genital organs (128)	5 080	0	5 080	1 871	0	1 871
Idiopathic thrombocytopaenia or granulocytopenia (129)	1 120	480	640	1 247	1 855	756
Malignant tumour (130)	32 018	18 331	13 687	2 937	2 767	3 137
Sarcoidosis (132)	3 578	1 763	1 815	24	24	24
Severe chronic pancreatic insufficiency (133)	6 556	3 944	2 612	876	891	855
General erythroderma (134)	2 141	1 404	737	308	321	284
Pemphigus (135)	275	98	177	48	51	46
Uraemia requiring dialysis (137)	2 582	1 583	999	21 621	21 678	21 537
Severe anaemia associated with chronic renal failure (138)	8 307	5 017	3 290	2 516	2 616	2 383
Dasatinib (150)	183	99	84	18 867	18 743	19 037
Palbociclib (1501)	1 684	14	1 670	23 912	27 892	23 870
Cabozantinib (1502)	569	379	190	43 943	45 398	41 342
Emicizumab (haemophilia A, with inhibitors) (1503)	12	12	0	146 964	146 964	0
Alectinib (1504)	86	22	64	51 920	48 285	53 131

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Ixazomib (1505)	208	104	104	44 278	48 352	40 001
The combination of trifluridine and tipiracil (1506)	452	262	190	11 367	13 168	9 678
Pomalidomide (1507)	358	174	184	82 403	77 488	86 677
Lenvatinib (1508)	153	100	53	28 134	30 374	23 654
Dabrafenib and trametinib (1509)	278	162	116	82 038	82 945	80 501
Eliglustat, imiglucerase and velaglucerase alfa (151)	13	4	9	234 499	200 619	249 557
Niraparib (1510)	243	0	243	56 228	0	56 228
Olaparib (1511)	116	0	116	61 141	0	61 141
Ibrutinib (1512)	465	303	162	68 947	68 055	70 838
Binimetinib and encorafenib (melanoma) (1513)	107	63	44	73 840	73 705	73 961
Ribociclib (1514)	30	0	30	20 409	0	20 409
Abemaciclib (1515)	171	0	171	24 631	0	24 631
Romiplostim (1516)	105	56	49	30 338	33 174	26 849
Eltrombopag (1517)	290	167	123	21 450	22 367	20 403
Venetoclax (1518)	184	119	65	62 942	61 901	65 224
Osimertinib (1519)	180	67	113	0	0	0
Nilotinib (152)	190	90	100	24 920	24 447	25 370
Emicizumab (haemophilia A, without inhibitors) (1520)	16	15	1	0	0	0
Brigatinib (1521)	7	2	5	0	0	0
Midostaurin (1522)	8	3	5	0	0	0
Enzalutamide (1523)	1 439	1 439	0	0	0	0

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Lenalidomid (153)	1 887	955	932	44 771	45 080	44 456
Afatinib and gefitinib (155)	233	78	155	15 953	17 614	15 372
Lapatinib (156)	87	0	87	23 241	0	23 241
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis) (157)	5 012	1 354	3 658	10 544	10 504	10 559
Everolimus (158)	197	120	77	21 128	22 734	19 879
Pazopanib (159)	320	172	148	23 205	22 223	24 111
Exenatide and liraglutide (160)	15 712	8 306	7 406	0	0	0
Preparation with von Willebrand's factor (161)	4	0	4	145 058	0	145 058
Liraglutide (162)	7 936	4 161	3 775	0	0	0
Abiraterone (163)	2 779	2 779	0	31 102	31 102	0
Cladribine and fingolimod (164)	1 360	323	1 037	21 504	21 133	21 625
Preservative-free combination product containing bimatoprost and timolol (165)	155	36	119	0	0	0
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1 747	805	942	2 190	2 281	2 115
Vemurafenib (167)	169	95	74	33 124	27 633	36 784
Axitinib (168)	134	86	48	25 562	29 962	20 184
Crizotinib (169)	80	29	51	43 740	50 390	40 159
Bosutinib (170)	51	25	26	23 847	29 090	15 983
Insulin degludec (171)	1 104	369	735	0	0	0
Blood coagulation factor VIII and von Willebrand factor for desensitisation treatment in inhibitor-positive patients with haemophilia A (172)	3	3	0	139 835	139 835	0
Trastuzumab injection (173)	13	0	13	0	0	0
Ruxolitinib (174)	274	127	147	36 053	34 704	37 685

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Deferasirox (175)	94	49	45	13 488	16 538	9 785
Regorafenib (176)	296	183	113	11 434	12 521	8 390
Insulin glargine 300 U/ml (177)	15 627	8 930	6 697	0	0	0
Combination product containing tegafur, gimeracil and oteracil (178)	174	108	66	1 600	1 506	1 787
Vismodegib (179)	23	13	10	49 882	47 256	68 259
Interferon alfa (180)	547	286	261	0	0	0
Retigabine and vigabatrin (181)	1 322	637	685	951	926	976
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide (182)	23 069	10 713	12 356	1 325	1 369	1 286
Lamotrigin and topiramate (183)	11 458	4 401	7 057	556	575	544
Paclitaxel (184)	2	0	2	0	0	0
Docetaxel (185)	2	0	2	0	0	0
Growth retardation associated with renal failure (growth hormone) (186)	1 264	808	456	6 668	6 880	6 240
Treatment-resistant psychosis (188)	6 989	3 410	3 579	0	0	0
Imatinib (189)	843	477	366	8 394	8 741	7 913
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	1 657	1 064	593	1 261	1 315	1 160
Erlotinib (191)	134	64	70	3 932	3 139	4 365
Fulvestrant (192)	1 044	5	1 039	3 872	3 705	3 873
Rasagiline (193)	3 143	1 723	1 420	102	104	100
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	53	26	27	127 408	187 687	101 574

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Agalsidase alfa, agalsidase beta and migalastat (195)	48	21	27	220 032	250 970	200 232
Paricalcitol and cinacalcet (196)	1 440	872	568	1 387	1 432	1 320
Sunitinib (197)	588	359	229	21 028	22 687	18 647
Sorafenib (198)	333	252	81	18 808	20 085	14 593
Rufinamide (199)	242	143	99	2 650	2 844	2 338
Chronic cardiac insufficiency (201)	29 737	18 037	11 700	135	129	144
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	126 233	44 441	81 792	319	337	311
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	290 503	118 727	171 776	365	375	359
Chronic hypertension (205)	387 630	188 254	199 376	127	125	129
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	182 637	118 144	64 493	121	119	124
Chronic arrhythmias (207)	168 467	85 155	83 312	74	73	75
Ulcerative colitis and Crohn's disease (208)	56 536	29 728	26 808	629	653	602
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	4 860	2 257	2 603	85	83	87
Gout (212)	9 604	7 454	2 150	42	42	41
Severe and chronic narcolepsy (214)	530	211	319	1 433	1 505	1 380
Diabetes, non-insulin-treated (215)	386 974	211 161	175 813	409	432	381
Dapagliflozin and empagliflozin (250)	1 174	863	311	0	0	0
Benralizumab (251)	137	62	75	0	0	0
Anakinra (252)	85	46	39	0	0	0
Vedolizumab (253)	569	313	256	0	0	0

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Clopidogrel (280)	88	48	40	0	0	0
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ixekizumab, sarilumab, secukinumab and tocilizumab (281)	18 232	7 356	10 876	8 991	9 048	8 949
Sodium oxybat (282)	430	170	260	4 353	4 767	4 069
Ivabradine (283)	59	40	19	0	0	0
Nintedanib and pirfenidone (284)	862	625	237	24 984	25 856	22 588
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (285)	47 649	25 176	22 473	1 449	1 448	1 450
Ciclosporin eye drop (286)	252	13	239	885	1 030	876
Ticagrelor 60 mg (287)	327	248	79	720	724	710
Febuxostat (288)	2 015	1 382	633	201	201	201
Combination product containing sacubitril and valsartan (289)	4 084	3 202	882	2 035	2 016	2 099
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	180 280	92 564	87 716	947	937	957
Tofacitinib (291)	1 091	294	797	9 862	10 307	9 695
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (292)	342	178	164	5 767	5 680	5 876
Baricitinib (293)	866	177	689	10 313	10 918	10 165
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	991	634	357	5 586	5 535	5 696
Liraglutide (type 2 diabetes, children and adolescents) (295)	13	5	8	501	501	0
Rivaroxaban for the treatment of coronary artery disease (296)	234	174	60	677	677	675
Mepolizumab (297)	299	133	166	13 954	13 809	14 060
Upadacitinib (298)	362	87	275	0	0	0
Apremilast (299)	464	237	227	0	0	0

When calculating the average costs, only those persons whose entitlement to special reimbursement for medicines has been in force throughout the year, and who have purchased such medicines, have been included.
Source: Dispensations reimbursable under the National Health Insurance Scheme register (includes purchases falling under the initial deductible) and Special Reimbursement Entitlement Register.



Table 6.5. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2021

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
All diseases under the Special Refund Categories	1 245 192	1 445 754	1 244 436
Anterior pituitary hypofunction (101)	3 354	1 251	1 102
Diabetes insipidus (102)	838	747	721
Diabetes, insulin-treated (103)	126 094	79 813	75 752
Thyroid insufficiency (104)	75 262	3 226	1 301
Adrenal cortical hypofunction (105)	1 334	194	139
Hypoparathyroidism (106)	1 431	386	333
Pernicious anaemia (107)	10 098	358	231
Myasthenia gravis (108)	1 304	573	516
Multiple sclerosis (109)	2 274	503	446
Parkinson's disease and comparable movement disorders (110)	16 876	20 149	19 250
Epilepsy and comparable convulsive disorders (111)	37 076	10 906	9 495
Severe psychotic and other severe mental disorders (112)	76 760	66 027	61 062
Anxiety disorders associated with mental retardation (113)	2 714	737	636
Glaucoma (114)	85 680	21 293	17 622
Breast cancer (115)	26 960	18 555	17 514
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 115)	469	405	397
Prostate cancer (116)	17 593	25 755	25 107
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 116)	207	177	174

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	10 835	14 540	14 134
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 117)	503	363	354
Trigeminal neuralgia or glossofaryngeusneuralgia (119)	691	83	66
Hypogammaglobulinaemia (120)	578	16 909	16 881
Severe hypofunction of sexual glands (121)	5 775	1 808	1 572
Aplastic anaemia (122)	181	239	231
Chronic disorders of vitamin D metabolism (123)	4 528	539	452
Inborn metabolic disorders (124)	186	1 180	1 175
Chronic coagulation defects (126)	426	35 621	35 605
Transplant complication (127)	5 553	19 355	18 992
Tacrolimus granules (an addendum to the prescription + 127)	25	148	147
Cancers of female genital organs (128)	1 931	3 191	3 118
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 128)	209	168	164
Idiopathic thrombocytopenia or granulocytopenia (129)	249	294	289
Malignant tumour (130)	14 565	26 183	25 553
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 130)	1 454	1 343	1 316
Sarcoidosis (132)	675	18	9
Severe chronic pancreatic insufficiency (133)	5 108	4 114	3 982

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
General erythroderma (134)	709	220	203
Pemphigus (135)	84	5	3
Uraemia requiring dialysis (137)	479	8 367	8 342
Severe anaemia associated with chronic renal failure (138)	3 973	8 837	8 730
Dasatinib (150)	132	2 234	2 228
Palbociclib (1501)	1 057	19 472	19 445
Cabozantinib (1502)	374	11 782	11 773
Emicizumab (haemophilia A, with inhibitors) (1503)	10	1 280	1 280
Alectinib (1504)	77	3 053	3 050
Ixazomib (1505)	106	3 465	3 463
The combination of trifluridine and tipiracil (1506)	268	2 019	2 016
Pomalidomide (1507)	240	12 652	12 648
Lenvatinib (1508)	113	1 981	1 977
Dabrafenib and trametinib (1509)	163	10 113	10 106
Eliglustat, imiglucerase and velaglucerase alfa (151)	13	3 048	3 048
Niraparib (1510)	180	5 956	5 954
Olaparib (1511)	89	4 158	4 155
Ibrutinib (1512)	330	17 830	17 817
Binimetinib and encorafenib (melanoma) (1513)	60	3 502	3 499
Ribociclib (1514)	16	123	122
Abemaciclib (1515)	137	1 501	1 500
Romiplostim (1516)	83	2 075	2 070

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Eltrombopag (1517)	223	4 270	4 262
Venetoclax (1518)	141	6 251	6 246
Osimertinib (1519)	150	5 792	5 790
Nilotinib (152)	144	3 262	3 256
Emicizumab (haemophilia A, without inhibitors) (1520)	12	2 167	2 167
Brigatinib (1521)	4	47	47
Midostaurin (1522)	4	329	329
Enzalutamide (1523)	1 155	7 889	7 886
Lenalidomid (153)	1 185	42 697	42 666
Afatinib and gefitinib (155)	155	1 726	1 721
Lapatinib (156)	43	524	523
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis) (157)	4 093	41 514	41 287
Everolimus (158)	72	796	795
Pazopanib (159)	125	1 910	1 907
Preparation with von Willebrand's factor (161)	1	145	145
Abiraterone (163)	2 128	52 668	52 605
Cladribine and fingolimod (164)	994	22 110	22 058
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1 046	1 561	1 535
Vemurafenib (167)	5	166	165
Axitinib (168)	73	1 195	1 193
Crizotinib (169)	38	1 121	1 119

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Bosutinib (170)	26	551	550
Blood coagulation factor VIII and von Willebrand factor for desensitisation treatment in inhibitor-positive patients with haemophilia A (172)	2	280	280
Ruxolitinib (174)	212	6 316	6 308
Deferasirox (175)	45	532	531
Regorafenib (176)	125	856	854
Combination product containing tegafur, gimeracil and oteracil (178)	53	68	66
Vismodegib (179)	13	588	588
Retigabine and vigabatrin (181)	112	88	86
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagablin and zonisamide (182)	17 876	21 970	21 270
Lamotrigin and topiramate (183)	7 041	3 794	3 489
Growth retardation associated with renal failure (growth hormone) (186)	985	6 149	6 128
Imatinib (189)	662	5 015	4 985
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	1 001	1 012	996
Erlotinib (191)	69	167	164
Fulvestrant (192)	580	1 625	1 594
Rasagiline (193)	1 587	157	123

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	21	2 550	2 549
Agalsidase alfa, agalsidase beta and migalastat (195)	44	9 235	9 232
Paricalcitol and cinacalcet (196)	704	865	845
Sunitinib (197)	238	3 888	3 881
Sorafenib (198)	156	1 690	1 686
Rufinamide (199)	125	305	301
Chronic cardiac insufficiency (201)	26 319	3 374	2 015
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	76 047	24 180	16 740
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	228 681	82 881	54 808
Chronic hypertension (205)	359 819	46 184	26 270
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	165 345	20 915	12 247
Ticagrelor 90mg (an addendum to the prescription + 206)	6 455	3 164	2 113
Rivaroxaban in the management of acute coronary syndrome (an addendum to the prescription + 206)	30	7	5
Prasugrel (an addendum to the prescription + 206)	265	95	63
Chronic arrhythmias (207)	88 722	6 177	3 699
Ulcerative colitis and Crohn's disease (208)	37 882	23 765	16 043

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	3 131	292	155
Gout (212)	4 634	192	110
Severe and chronic narcolepsy (214)	272	369	296
Diabetes, non-insulin-treated (215)	296 405	116 882	78 153
Dapagliflozin and empagliflozin (250)	578	113	88
Benralizumab (251)	113	732	730
Anakinra (252)	64	259	256
Vedolizumab (253)	253	320	319
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ixekizumab, sarilumab, secukinumab and tocilizumab (281)	14 394	122 591	115 402
Sodium oxybat (282)	131	556	500
Nintedanib and pirfenidone (284)	654	13 837	13 499
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (285)	37 712	49 184	39 006
Ciclosporin eye drop (286)	151	125	98
Ticagrelor 60 mg (287)	208	118	82
Febuxostat (288)	1 348	252	165
Combination product containing sacubitril and valsartan (289)	3 317	5 899	4 887

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	163 097	140 353	96 967
Tofacitinib (291)	617	5 381	5 109
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (292)	266	1 395	1 270
Baricitinib (293)	536	5 118	4 867
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	658	3 055	2 781
Liraglutide (type 2 diabetes, children and adolescents) (295)	8	4	2
Rivaroxaban for the treatment of coronary artery disease (296)	170	95	69
Mepolizumab (297)	267	3 134	3 017
Upadacitinib (298)	278	2 026	1 958
Apremilast (299)	349	1 935	1 904

1 The figures include purchases falling under the initial deductible.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.6. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2021**

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro	Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro
Chronic hypertension (205)		368 769	125	Sitagliptin	A10BH01	45 855	450
Bisoprolol	C07AB07	140 507	40	Linagliptin	A10BH05	29 859	445
Amlodipine	C08CA01	117 690	30	Dapagliflozin	A10BK01	29 413	466
Furosemide	C03CA01	64 568	42	Insulin degludec	A10AE06	27 903	482
Losartan	C09CA01	53 700	37	Semaglutide	A10BJ06	27 516	1 193
Candesartan	C09CA06	42 262	49	Metformin and sitagliptin	A10BD07	24 324	445
Lercanidipine	C08CA13	42 050	55	Insulin detemir	A10AE05	23 572	482
Metoprolol	C07AB02	41 138	65	Insulin lispro	A10AB04	8 659	299
Ramipril	C09AA05	35 193	26	Liraglutide	A10BJ02	7 503	1 296
Enalapril	C09AA02	28 467	43	Metformin and empagliflozin	A10BD20	7 225	474
Losartan and diuretics	C09DA01	28 256	73	Vildagliptin	A10BH02	5 840	388
Valsartan	C09CA03	21 477	67	Chronic asthma and similar chronic obstructive pulmonary diseases (203)		233 261	355
Spironolactone	C03DA01	21 314	47	Salbutamol	R03AC02	113 089	35
Candesartan and diuretics	C09DA06	20 905	120	Formoterol and budesonide	R03AK07	51 555	294
Felodipine	C08CA02	20 476	87	Montelukast	R03DC03	44 315	39
Enalapril and diuretics	C09BA02	17 607	52	Salmeterol and fluticasone	R03AK06	42 485	205
Diabetes (103, 215, 285, 295)		353 573	695	Fluticasone	R03BA05	29 710	163
Metformin	A10BA02	223 710	74	Prednisolone	H02AB06	28 814	14
Insulin glargine	A10AE04	69 356	475	Budesonide	R03BA02	26 008	145
Insulin aspart	A10AB05	59 172	288	Tiotropium bromide	R03BB04	24 217	383
Empagliflozin	A10BK03	57 956	493				

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Ciclesonide	R03BA08	22 841	166
Vilanterol and fluticasone furoate	R03AK10	18 293	424
Formoterol and beclometasone	R03AK08	16 005	379
Beclometasone	R03BA01	15 202	140
Terbutaline	R03AC03	14 566	37
Formoterol and fluticasone	R03AK11	7 015	388
Formoterol, glycopyrronium bromide and beclometasone	R03AL09	6 340	632
Chronic arrhythmias (207, 290)		178 719	820
Apixaban	B01AF02	84 577	840
Bisoprolol	C07AB07	68 090	39
Rivaroxaban	B01AF01	52 727	848
Dabigatran etexilate	B01AE07	17 870	895
Digoxin	C01AA05	15 212	60
Edoxaban	B01AF03	10 667	806
Flecainide	C01BC04	7 814	173
Metoprolol	C07AB02	7 670	57
Amiodarone	C01BD01	3 027	79
Propranolol	C07AA05	1 800	39
Atenolol	C07AB03	1 391	59
Verapamil	C08DA01	1 251	62
Diltiazem	C08DB01	947	116
Sotalol	C07AA07	853	79
Celiprolol	C07AB08	93	55

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic coronary heart disease (206, 294, 296, an addendum to the prescription + 206)		168 927	142
Atorvastatin	C10AA05	72 166	41
Bisoprolol	C07AB07	70 997	35
Rosuvastatin	C10AA07	44 502	46
Isosorbide dinitrate	C01DA08	38 529	25
Isosorbide mononitrate	C01DA14	38 220	73
Ezetimibe	C10AX09	35 262	34
Simvastatin	C10AA01	30 821	42
Amlodipine	C08CA01	22 789	27
Glyceryl trinitrate	C01DA02	22 122	24
Clopidogrel	B01AC04	20 074	33
Metoprolol	C07AB02	16 644	56
Ticagrelor	B01AC24	6 455	490
Pravastatin	C10AA03	2 839	113
Fluvastatin	C10AA04	2 318	117

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Propranolol	C07AA05	1 512	26
Glaucoma (114)		86 229	246
Timolol, combinations	S01ED51	50 901	194
Latanoprost	S01EE01	22 645	106
Brinzolamide	S01EC04	15 748	81
Tafluprost	S01EE05	13 919	230
Bimatoprost	S01EE03	8 338	157
Travoprost	S01EE04	5 157	178
Brinzolamide, combinations	S01EC54	4 580	168
Brimonidine	S01EA05	3 979	98
Timolol	S01ED01	3 573	113
Dorzolamide	S01EC03	1 877	91
Acetazolamide	S01EC01	1 728	217
Betaxolol	S01ED02	1 099	107

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Disseminated connective tissue diseases, rheumatoid arthritis and comparable conditions (202, 281, 284, 286, 291, 293, 298, 299)		84 152	2 082
Methotrexate	L04AX03	40 703	340
Hydroxychloroquine	P01BA02	25 364	88
Prednisolone	H02AB06	24 850	14
Sulfasalazine	A07EC01	21 235	184
Adalimumab	L04AB04	5 145	6 668
Leflunomide	L04AA13	4 435	206
Etanercept	L04AB01	4 247	6 545
Ursodeoxycholic acid	A05AA02	3 534	455
Azathioprine	L04AX01	2 717	109
Golimumab	L04AB06	2 374	11 201
Prednisone	H02AB07	1 502	9
Methylprednisolone	H02AB04	1 454	57
Methotrexate	L01BA01	956	153
Certolizumab pegol	L04AB05	881	9 071
Secukinumab	L04AC10	821	9 082

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Severe psychotic and other severe mental disorders (112)		78 565	836
Quetiapine	N05AH04	25 131	117
Olanzapine	N05AH03	22 570	580
Aripiprazole	N05AX12	13 056	750
Clozapine	N05AH02	11 135	456
Risperidone	N05AX08	10 999	669
Mirtazapine	N06AX11	10 362	80
Valproic acid	N03AG01	9 309	222
Lamotrigine	N03AX09	7 248	290
Venlafaxine	N06AX16	6 481	217
Escitalopram	N06AB10	5 365	40
Lithium	N05AN01	5 197	145
Sertraline	N06AB06	5 196	72
Citalopram	N06AB04	4 959	59
Perphenazine	N05AB03	4 364	154
Levomepromazine	N05AA02	3 844	68

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Cancers (115–117, 128, 130, 150, 152, 153, 155, 156, 158, 159, 163, 166–170, 173, 174, 176, 178–180, 189, 191, 192, 197, 198, 1501, 1502, 1504–1515, 1518, 1519, 1521–1523, an addendum to the prescription + 115–117, 128 or 130)		75 016	4 489
Letrozole	L02BG04	14 563	142
Oxycodone	N02AA05	13 327	117
Dexamethasone	H02AB02	11 799	125
Prednisolone	H02AB06	8 787	18
Leuprorelin	L02AE02	8 722	1 079
Denosumab	M05BX04	6 690	1 630
Tamoxifen	L02BA01	6 073	110
Palonosetron, combinations	A04AA55	4 427	358
Tramadol	N02AX02	4 160	41
Hydroxycarbamide	L01XX05	4 131	163
Pegfilgrastim	L03AA13	4 076	2 323
Capecitabine	L01BC06	3 976	294
Bicalutamide	L02BB03	3 953	865
Triptorelin	L02AE04	3 232	1 005
Filgrastim	L03AA02	2 834	710

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Epilepsy and comparable convulsive disorders (111, 181-183, 199)		49 775	742
Valproic acid	N03AG01	14 753	231
Levetiracetam	N03AX14	13 528	714
Oxcarbazepine	N03AF02	12 307	345
Carbamazepine	N03AF01	8 724	145
Lamotrigine	N03AX09	5 809	413
Lacosamide	N03AX18	3 723	1 728
Midazolam	N05CD08	3 164	279
Clobazam	N05BA09	2 747	79
Clonazepam	N03AE01	2 301	58
Topiramate	N03AX11	1 674	828
Brivaracetam	N03AX23	1 180	1 990
Pregabalin	N03AX16	1 074	225
Gabapentin	N03AX12	983	259
Zonisamide	N03AX15	737	1 473
Phenytoin	N03AB02	726	169

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Ulcerative colitis and Crohn's disease (208, 253)		38 569	624
Mesalazine	A07EC02	28 537	695
Azathioprine	L04AX01	8 164	134
Prednisolone	H02AB06	5 484	19
Budesonide	A07EA06	4 749	285
Mercaptopurine	L01BB02	3 096	121
Sulfasalazine	A07EC01	2 048	194
Metronidazole	P01AB01	1 614	35
Methotrexate	L04AX03	1 374	342
Vedolizumab	L04AA33	253	1 266
Methylprednisolone	H02AB04	226	42
Prednisone	H02AB07	142	12
Hydrocortisone	H02AB09	142	32
Olsalazine	A07EC03	60	337
Ciclosporin	L04AD01	54	658
Dexamethasone	H02AB02	39	89

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic cardiac insufficiency (201, 250, 289)		26 958	348
Bisoprolol	C07AB07	18 785	45
Furosemide	C03CA01	14 732	48
Ramipril	C09AA05	8 285	27
Spironolactone	C03DA01	7 859	41
Digoxin	C01AA05	3 352	60
Valsartan and sacubitril	C09DX04	3 317	1 778
Losartan	C09CA01	3 272	35
Isosorbide mononitrate	C01DA14	2 962	66
Isosorbide dinitrate	C01DA08	2 949	27
Metoprolol	C07AB02	2 681	65
Candesartan	C09CA06	2 170	47
Enalapril	C09AA02	1 968	41
Glyceryl trinitrate	C01DA02	1 875	33
Valsartan	C09CA03	1 270	63
Carvedilol	C07AG02	781	55

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Parkinson's disease and other comparable movement disorders (110, 193)		16 955	1 196
Levodopa and decarboxylase inhibitor	N04BA02	13 956	904
Pramipexole	N04BC05	3 908	240
Levodopa, decarboxylase inhibitor and comt inhibitor	N04BA03	3 403	1 276
Selegiline	N04BD01	2 348	189
Ropinirole	N04BC04	2 206	224
Rasagiline	N04BD02	1 604	98
Rotigotine	N04BC09	514	1 297
Amantadine	N04BB01	343	131
Entacapone	N04BX02	322	739
Biperiden	N04AA02	302	59
Orphenadrine (citrate)	M03BC01	216	19
Apomorphine	N04BC07	40	7 944
Cabergoline	N04BC06	6	56
Bromocriptine	G02CB01	1	573

1 The data covers all beneficiaries who in 2020 purchased medicines under the Special Refund Categories for any of the listed diseases, including purchases that did not clear the initial deductible limit.

2 One patient may use medicines from several medicine groups.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Medicinal products eligible for restricted basic refund

Table 6.7. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2021

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Medicinal products eligible for restricted basic refund, total	85 603	2 266	194 017
Ribociclib (3002)
Osimertinib (3004)	65	10 622	690
Tofacitinib (3005)	292	8 764	2 559
Baricitinib (3006)	23	3 830	88
Erenumab, fremanezumab and galcanezumab (3007)	4 792	5 452	26 124
Tolvaptan (3008)	18	15 325	276
Niraparib (3009)	85	17 237	1 465
Growth hormone (301)	864	5 865	5 067
Midodrine (3010)	72	821	59
Tafamidis (3011)	13	66 771	868
Cabozantinib (3012)	4	35 811	143
Rivaroxaban for the treatment of coronary artery disease and peripheral artery disease (3013)	146	409	60
Midostaurin (3014)	10	64 997	650
Alirocumab, evolocumab and inclisiran for the treatment of hypercholesterolaemia and dyslipidaemia (3015)	67	4 184	280
Brigatinib (3017)

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
The combination of trifluridine and tipiracil (3018)
Lenvatinib (3019)	5	14 137	71
Patiromer and sodium zirconium cyclosilicate (3020)	32	2 004	64
Allergen extract of birch pollen (adults) (3023)	1 568	936	1 468
Calcium carbonate (3025)	14	20	0
Lorlatinib (3026)	10	35 686	357
Benralizumab (3027)	104	7 861	818
Mepolizumab (3028)	19	2 547	48
Upadacitinib (3029)	65	2 225	145
Dimethyl fumarate, glatiramer acetate, interferon beta, ofatumumab, ponesimod and teriflunomid (Multiple sclerosis) (303)
Apalutamide (3031)	37	21 920	811
Budesonide tablet, orodispersible (3032)	35	1 010	35
Gilteritinib (3033)	10	103 064	1 031
Larotrectinib (3034)	4	74 160	297
Pitolisant and solriamfetol (3035)	72	3 171	228
Darolutamide (3036)	53	23 404	1 240

Table continued



Table 6.7. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Neratinib (3037)
Eltrombopag (3039)	5	23 796	119
Dornase alfa (304)	61	6 955	424
Burosumab (3040)	4	165 761	663
Vedolizumab (3042)	277	5 871	1 626
Combination product containing ivacaftor and lumacaftor (3043)	6	130 272	782
Combination therapy with ivacaftor and tezacaftor (3044)	5	43 086	215
Combination therapy with elexacaftor, ivacaftor and tezacaftor (3045)	36	165 705	5 965
Cannabidiol (3046)	48	10 186	489
Filgotinib (3048)	10	3 257	33
Encorafenib (colorectal cancer) (3049)	18	11 838	213
Liraglutide (obesity) (3051)	691	513	354
Anakinra (3053)	7	5 036	35
Enzalutamide (3054)
Combination product containing bupropion and naltrexone (3055)	42	146	6
Ataluren (3056)
Erythropoietin and darbepoetin (306)	22	6 558	144
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine (308)	2 686	170	457
Nalmefene and naltrexone (309)	310	155	48

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases) (313)	476	7 823	3 724
Imatinib (316)
Topical pimecrolimus and tacrolimus (317)	3 812	122	465
Teriparatide (318)	349	2 409	841
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis) (319)	2 475	12 126	30 013
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (320)
Paricalcitol and cinacalcet (321)	925	1 213	1 122
Adalimumab, golimumab, infliximab and ustekinumab (intestinal diseases) (326)	2 963	10 578	31 342
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine (331)	10 931	987	10 792
Treprostinil (334)	13	141 258	1 836
C1-esterase inhibitor, conestat alfa, icatibant and lanadelumab (338)	65	188 557	12 256
Product containing buprenorfine and naloxone (339)	279	965	269
Everolimus (340)	29	32 751	950
Dronedarone (342)	690	480	331
Omalizumab (344)	392	8 623	3 380

Table continued



Table 6.7. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (346)	292	723	211
Roflumilast (348)	448	526	236
Febuxostat (349)	5	150	1
Capsaicin (350)	26	1 444	38
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (351)	417	231	96
Cladribine and fingolimod (353)
Dienogest (355)	544	515	280
Nintedanib and pirfenidone (356)	7	6 127	43
Combination product containing naproxen and esomeprazole (366)	85	149	13
Combination product containing docusate sodium and sorbitol (368)	155	1 218	189
Idelalisib (372)	33	26 781	884
Ponatinib (373)	22	38 836	854
Cyanocobalamin (376)	4	84	0
Apremilast and dimethyl fumarate (psoriasis) (377)	559	4 763	2 663
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep vein thrombosis and pulmonary embolism (379)	14 758	833	12 296
Adalimumab (hidradenitis suppurativa) (380)	151	14 509	2 191
Combination product containing sacubitril and valsartan (381)	6	279	2

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Selexipag (383)	27	50 152	1 354
Levofloxacin nebuliser solution (385)
Ticagrelor 60 mg (386)
Asfotase alfa (387)
Alirocumab, evolocumab and inclisiran for the treatment of familial hypercholesterolaemia (388)
Ibrutinib (390)
Obeticholic acid (391)	14	23 099	323
Ferric maltol (392)
Pomalidomide (393)
Palbociclib (394)
Dupilumab (395)	471	13 765	6 483
Idebenone (396)	6	24 492	147
Venetoclax (399)	43	40 178	1 728
Apixaban, dabigatran, edoxaban and rivaroxaban (an addendum to the prescription)	19 607	211	4 138
Enoxaparin (an addendum to the prescription)
Fidaxomicin (an addendum to the prescription)	67	2 020	135
Granisetron (an addendum to the prescription)	54	736	40
Letermovir (an addendum to the prescription)	70	25 170	1 762
Prasugrel (an addendum to the prescription)	186	201	37
Tacrolimus (an addendum to the prescription)

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Clinical nutritional preparations

Table 6.8. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2021

Disease	No. of purchasers	Average cost per patient, euro	Total cost, EUR 1,000
Whole group	5 404	1 712	9 254
Inborn metabolic disorders (503)	231	3 168	732
Conditions requiring daily forced enteral nutrition (504)	2 533	2 352	5 957
Allergy to cow's milk in infants (505)	875	879	769
Allergy to cow's milk and hypersensitivity to conventional formula in infants (506)	226	3 496	790
Severe malabsorption of nutrients, mainly fats (601)	1 027	622	639
Children's severe malnutrition (602)	640	573	367

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Medicine costs and their reimbursement according to prescriber

Table 6.9. Medicine prescribers, 2015–2021


Doctor

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	27 845	1 576	69 937
2016	28 306	1 642	71 685
2017	28 163	1 720	71 091
2018	28 409	1 781	73 630
2019	29 313	1 811	74 858
2020	29 999	1 817	75 644
2021	30 843	1 854	75 969

Dentist

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	5 466	93	958
2016	5 447	91	928
2017	5 132	87	864
2018	5 058	86	840
2019	5 113	87	826
2020	5 038	74	731
2021	5 032	64	693

Figure 6.1. Percentages of medicine prescribers, 2021



Nurse

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	194	51	853
2016	229	53	914
2017	275	54	924
2018	315	49	751
2019	389	41	562
2020	413	33	486
2021	488	34	535

The figures only include prescriber-specific IDs.
The figures include purchases falling under the initial deductible.

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.10. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2021 (only those dispensations entitled to reimbursement are included)****Doctors**

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	13,995	2,272	65,099
Specialist emergency medicine	139	645	16,454
Specialist anaesthesiology and intensive care medicin	1,126	173	4,243
Specialist endocrinology	92	2,163	194,738
Specialist phoniatics	30	105	3,030
Specialist physiatrics	245	578	13,001
Specialist gastroenterology	170	1,433	252,743
Specialist surgery: gastroenterology	372	293	8,469
Specialist geriatrics	442	4,384	63,787
Specialist dermatology and allergology	316	1,505	160,180
Specialist infectious diseases	146	527	103,915
Specialist cardiology	370	1,559	83,815
Specialist respiratory medicine and allergology	322	1,276	143,660
Specialist clinical pharmacology	36	487	19,635
Specialist clinical physiology	89	211	10,058
Specialist clinical haematology	115	1,106	1,040,956

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist clinical chemistry	115	335	17,771
Specialist clinical microbiology	85	652	8,579
Specialist clinical neurophysiology	90	57	3,388
Specialist otorhinolaryngology	507	475	11,258
Specialist hand surgery	99	272	3,501
Specialist paediatric surgery	94	222	5,557
Specialist child neurology	141	425	35,532
Specialist child psychiatry	336	307	12,824
Specialist paediatrics	942	591	66,839
Specialist sports medicine	50	967	28,974
Specialist obstetrics and gynaecology	1,062	967	42,712
Specialist nephrology	123	1,970	236,125
Specialist neurosurgery	113	180	3,622
Specialist neurology	472	1,229	219,517
Specialist adolescent psychiatry	205	560	19,255
Specialist forensic medicine	49	305	8,387
Specialist surgery: orthopaedics and traumatology	711	499	8,500
Specialist pathology	209	58	1,434

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Table continued



Table 6.10. continued

Medical specialty	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist clinical genetics	39	57	1,284
Specialist plastic surgery	158	177	3,557
Specialist psychiatry	1,302	871	35,945
Specialist forensic psychiatry	72	308	12,063
Specialist diagnostic radiology	741	62	1,956
Specialist rheumatology	174	2,939	663,256
Specialist ophthalmology	767	822	35,567
Specialist internal medicine	751	1,300	97,643
Specialist oral and maxillofacial surgery	25	195	4,804
Specialist cardiothoracic surgery	47	176	5,762
Specialist oncology	284	1,326	427,836
Specialist public health	143	575	14,071
Specialist occupational health	1,294	1,192	29,761
Specialist urology	215	1,149	183,530
Specialist vascular surgery	182	155	3,884
Specialist general surgery	195	373	8,172
Specialist general practice	2,861	4,024	112,788
All	30,843	1,854	75,969

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Dentists

Medical specialty	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	4,462	58	631
Dental specialist dental diagnostics	7	22	387
Dental specialist orthodontics	72	5	66
Dental specialist clinical dentistry	362	46	631
Dental specialist oral and maxillofacial surgery	125	334	3,401
Dental specialist public health	44	13	170
All	5,032	64	693

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.11. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2021****All reimbursed medicines**

	2016	2017	2018	2019	2020	2021
Dispensations, million	47,0	48,9	51,1	53,5	54,9	57,5
Total cost, EUR million	2 034,5	2 006,9	2 096,3	2 198,8	2 273,2	2 346,9
Refunds, EUR million	1 405,3	1 360,0	1 454,7	1 558,5	1 639,0	1 707,1
Customers	3 817 051	3 805 016	3 842 848	3 861 862	3 730 259	3 771 318

Purchases of products eligible for generic substitution

	2016	2017	2018	2019	2020	2021
Dispensations, million	30,7	31,6	32,3	33,4	32,9	34,4
Cost, EUR million	1 100,0	972,1	963,6	962,5	954,8	1 130,4
Refunds, EUR million	673,6	538,1	544,2	558,5	572,1	714,2
Dispensations substituted, %	5,8	6,6	7,4	8,6	9,0	9,4
Number of patients who accepted substitution for at least one productn	1 712 795	1 814 073	1 929 821	2 074 350	2 110 178	2 159 097

Table continued

Table continued



Table 6.11. continued

Purchases in reference price system

	2016	2017	2018	2019	2020	2021
Dispensations, million	26,8	28,3	29,6	30,0	29,5	29,7
Cost, EUR million	628,2	685,7	696,5	647,7	646,8	640,4
Refunds, EUR million	290,6	337,1	347,6	322,0	336,4	342,1
Dispensations substituted, %	5,6	6,4	7,2	8,4	8,9	9,0
Number of patients who accepted substitution for at least one product	1 673 567	1 784 469	1 913 794	2 049 581	2 094 543	2 124 634

Savings generated through generic substitution


	2016	2017	2018	2019	2020	2021
Total, EUR million	78,2	70,1	77,8	75,5	75,1	78,2
Saving, EUR / each substitution	28,8	23,7	22,9	19,0	18,2	16,7

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.
Price and reference price information from the Pharmaceutical Database.

The statistics include additional refunds.

The statistics also cover purchases made prior to reaching the initial deductible.

7. Tables: Sales statistics according to medicine group





A Alimentary tract and metabolism

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day						
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021			
A Alimentary tract and metabolism	299,685	308,932	320,857	333,239	7	7	7	8	304.83	314.69	326.05	337.73	4	4	3	3
A01 Stomatological preparations	1,906	1,931	2,086	2,022	7	7	8	8	11.00	12.81	14.27	17.41	6	4	3	3
A02 Drugs for acid related disorders	34,802	32,364	30,560	29,845	4	3	3	4	69.19	71.01	72.92	74.66	3	3	3	3
A03 Drugs for functional gastrointestinal disorders	5,381	5,728	5,337	5,244	44	50	44	46	2.77	2.78	2.71	2.66	9	9	9	9
A04 Antiemetics and antinauseants	4,117	4,185	4,831	5,571	43	40	48	54	0.28	0.29	0.29	0.29	44	43	41	40
A05 Bile and liver therapy	2,067	2,198	1,393	1,595	1	2	2	1	0.82	0.93	0.92	1.02	1	2	2	2
A06 Drugs for constipation	25,559	27,108	29,103	30,234	13	12	11	10	46.81	48.02	51.29	53.33	10	9	8	7
A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents	28,852	29,633	28,943	29,588	5	5	5	5	13.42	13.58	13.55	13.62	2	2	2	2
A08 Antiobesity preparations, excl. diet products	558	638	602	608	0	0	0	0	0.09	0.08	0.07	0.07	1	0	0	0
A09 Digestives, incl. enzymes	2,613	3,219	3,146	3,339	4	4	4	3	1.04	1.28	1.25	1.32	4	4	4	3
A10 Drugs used in diabetes	154,837	161,244	170,838	180,726	2	2	2	2	95.75	99.88	101.72	109.08	2	2	1	1
A11 Vitamins	9,305	9,120	9,352	7,067	13	13	14	19	23.27	23.52	25.42	22.59	4	3	3	3
A12 Mineral supplements	15,792	15,838	16,449	16,546	5	5	4	4	40.35	40.48	41.60	41.64	4	3	3	3
A14 Anabolic agents for systemic use	17	12	12	13	22	17	22	16	0.02	0.02	0.02	0.02	22	17	22	16
A16 Other alimentary tract and metabolism products	13,880	15,712	18,204	20,842	40	34	39	45	0.02	0.02	0.03	0.03	34	29	37	36



A01 Stomatological preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A01	Stomatological preparations	1,906	1,931	2,086	2,022	7	7	8	8	11.00	12.81	14.27	17.41	6	4	3	3
A01A	Stomatological preparations	1,906	1,931	2,086	2,022	7	7	8	8	11.00	12.81	14.27	17.41	6	4	3	3
A01AA	Caries prophylactic agents	619	610	662	818	12	11	7	6	8.66	10.47	11.90	15.20	5	4	3	2
A01AA01	Sodium fluoride	497	557	610	790	15	12	8	7	8.66	10.47	11.90	15.20	5	4	3	2
A01AA03	Olafur (DDD 1.10 mg)	50	54	52	28	1	1	1	1					0	0	0	0
A01AA51	Sodium fluoride, combinations	71				1								0			
A01AB	Antiinfectives for local oral treatment	1,048	1,096	1,262	1,176	6	6	10	9	2.30	2.30	2.35	2.20	6	6	8	8
A01AB03	Chlorhexidine (DDD 30 mg)	821	880	927	907	7	7	6	6	2.08	2.09	2.02	1.93	7	7	6	6
A01AB11	Various	227	216	335	270	0	0	21	21	0.22	0.21	0.33	0.27	0	0	21	22
A01AB22	Doxycycline	0	0			100	100							0	0		
A01AC	Corticosteroids for local oral treatment	135	153	113		1	1	1						0	0	0	
A01AC01	Triamcinolone	135	153	113		1	1	1						0	0	0	
A01AD	Other agents for local oral treatment	104	72	49	28	0	0	0	0	0.04	0.03	0.02	0.02	0	0	0	0
A01AD02	Benzydamine (DDD 9 mg)	104	72	49	28	0	0	0	0	0.04	0.03	0.02	0.02	0	0	0	0



A02 Drugs for acid related disorders

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A02	Drugs for acid related disorders	34,802	32,364	30,560	29,845	4	3	3	4	69.19	71.01	72.92	74.66	3	3	3	3
A02A	Antacids	3,356	3,565	3,680	3,853	1	1	1	1	2.20	2.22	2.23	2.26	1	1	1	1
A02AA	Magnesium compounds	171	151	141	139	22	22	21	23	0.08	0.07	0.07	0.07	22	22	21	23
A02AA04	Magnesium hydroxide (DDD 3,g)	171	151	141	139	22	22	21	23	0.08	0.07	0.07	0.07	22	22	21	23
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	3,185	3,414	3,539	3,713	0	0	0	0	2.12	2.15	2.17	2.20	0	0	0	0
A02AD01	Ordinary salt combinations	3,185	3,414	3,539	3,713	0	0	0	0	2.12	2.15	2.17	2.20	0	0	0	0
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	31,446	28,799	26,880	25,992	4	3	4	4	66.99	68.79	70.68	72.40	3	3	3	3
A02BA	H2-receptor antagonists	949	733	504	473	1	1	1	1	1.08	0.73	0.16	0.15	2	2	1	1
A02BA02	Ranitidine (DDD 0.30,g)	616	393	1	0	2	2	1	0	0.98	0.62	0.00	0.00	2	2	1	0
A02BA03	Famotidine (DDD 40 mg)	333	339	503	473	0	1	1	1	0.10	0.10	0.15	0.15	0	1	1	1
A02BB	Prostaglandins	48	41	61	67	64	66	50	41	0.02	0.02	0.03	0.03	63	66	50	41
A02BB01	Misoprostol (DDD 0.80 mg)	48	41	61	67	64	66	50	41	0.02	0.02	0.03	0.03	63	66	50	41

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A02BC	Proton pump inhibitors	28,026	25,406	23,390	22,331	4	4	4	4	64.71	66.87	69.22	70.86	3	3	3	3
A02BC01	Omeprazole (DDD 20 mg)	2,677	2,499	2,370	2,116	2	1	1	1	9.27	8.82	8.59	8.15	2	2	1	1
A02BC02	Pantoprazole (DDD 40 mg)	11,336	9,516	8,047	7,931	8	6	8	9	33.31	35.98	37.89	39.80	5	4	4	4
A02BC03	Lansoprazole (DDD 30 mg)	2,655	2,077	1,205	892	0	0	1	1	5.82	5.66	5.47	5.20	0	0	0	0
A02BC04	Rabeprazole (DDD 20 mg)	760	852	922	953	0	0	0	0	1.37	1.48	1.59	1.67	0	0	0	0
A02BC05	Esomeprazole (DDD 30 mg)	10,598	10,462	10,847	10,439	2	2	2	2	14.95	14.91	15.67	16.04	2	2	2	2
A02BD	Combinations for eradication of helicobacter pylori	309	303	218	259	0	0	0	0	0.03	0.03	0.02	0.03	0	0	0	0
A02BD03	Lansoprazole, metronidazole and amoxicillin (DDD 9,ED)	72	74	23	58	0	0	0	0	0.01	0.01	0.00	0.01	0	0	0	0
A02BD07	Lansoprazole, amoxicillin and clarithromycin (DDD 8,ED)	238	229	196	202	0	0	0	0	0.02	0.02	0.02	0.02	0	0	0	0
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	2,113	2,317	2,706	2,861	3	3	3	2	1.14	1.15	1.25	1.33	3	3	3	2
A02BX02	Sucralfate (DDD 4,g)	328	380	455	519	0	0	0	0	0.20	0.23	0.28	0.32	0	0	0	0
A02BX13	Alginic acid	1,786	1,937	2,251	2,343	4	3	3	3	0.94	0.91	0.98	1.02	4	4	3	3

**A03 Drugs for functional gastrointestinal disorders**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A03	Drugs for functional gastrointestinal disorders	5,381	5,728	5,337	5,244	44	50	44	46	2.77	2.78	2.71	2.66	9	9	9	9
A03A	Drugs for functional gastrointestinal disorders	1,769	1,868	1,889	1,719	18	20	19	21	1.16	1.24	1.17	1.15	6	7	7	7
A03AB	Synthetic anticholinergics, quaternary ammonium compounds	307	381	370	381	92	88	86	84	0.04	0.05	0.05	0.05	92	88	87	84
A03AB02	Glycopyrronium bromide	307	381	370	381	92	88	86	84	0.04	0.05	0.05	0.05	92	88	87	84
A03AX	Other drugs for functional gastrointestinal disorders	1,462	1,486	1,519	1,338	2	2	2	3	1.12	1.18	1.12	1.09	3	3	3	3
A03AX13	Silicones (DDD 0.50,g)	1,462	1,468	1,385	1,149	2	2	2	3	1.12	1.18	1.12	1.09	3	3	3	3
A03AX15	Menthae piperitae aetheroleum		18	134	189		0	0	0		0.00	0.00	0.00		0	0	0
A03B	Belladonna and derivatives, plain	521	624	329	388	95	95	92	92	0.05	0.06	0.04	0.04	94	95	93	91
A03BA	Belladonna alkaloids, tertiary amines	435	541	272	321	94	94	92	92	0.05	0.06	0.04	0.04	94	94	93	91
A03BA01	Atropine (DDD 1.50 mg)	435	541	272	321	94	94	92	92	0.05	0.06	0.04	0.04	94	94	93	91
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds	86	82	57	66	99	99	95	93	0.00	0.00	0.00	0.00	99	99	97	94
A03BB01	Butylscopolamine (DDD 60 mg)	86	82	57	66	99	99	95	93	0.00	0.00	0.00	0.00	99	99	97	94

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A03C	Antispasmodics in combination with psycholeptics	194	222	195	179	1	1	1	1	0.20	0.21	0.18	0.17	1	1	0	1
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	194	222	195	179	1	1	1	1	0.20	0.21	0.18	0.17	1	1	0	1
A03CA02	Clidinium and psycholeptics (DDD 4,ED)	194	222	195	179	1	1	1	1	0.20	0.21	0.18	0.17	1	1	0	1
A03D	Antispasmodics in combination with analgesics	2,511	2,645	2,523	2,441	57	68	63	65	0.38	0.28	0.31	0.29	7	9	7	7
A03DA	Synthetic anticholinergic agents in combination with analgesics	2,511	2,645	2,523	2,441	57	68	63	65	0.38	0.28	0.31	0.29	7	9	7	7
A03DA02	Pitofenone and analgesics	2,511	2,645	2,523	2,441	57	68	63	65	0.38	0.28	0.31	0.29	7	9	7	7
A03F	Propulsives	386	369	401	518	31	34	31	25	0.98	1.00	1.00	1.02	10	10	10	9
A03FA	Propulsives	386	369	401	518	31	34	31	25	0.98	1.00	1.00	1.02	10	10	10	9
A03FA01	Metoclopramide (DDD 30 mg)	386	369	401	518	31	34	31	25	0.98	1.00	1.00	1.02	10	10	10	9

**A04 Antiemetics and antinauseants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A04	Antiemetics and antinauseants	4,117	4,185	4,831	5,571	43	40	48	54	0.28	0.29	0.29	0.29	44	43	41	40
A04A	Antiemetics and antinauseants	4,117	4,185	4,831	5,571	43	40	48	54	0.28	0.29	0.29	0.29	44	43	41	40
A04AA	Serotonin (5HT3) antagonists	3,172	3,337	4,102	4,704	42	38	48	55	0.22	0.23	0.23	0.23	48	47	44	44
A04AA01	Ondansetron (DDD 16 mg)	1,042	996	1,837	2,568	44	40	65	73	0.14	0.15	0.16	0.17	51	50	45	44
A04AA02	Granisetron	886	870	850	654	43	44	41	49	0.06	0.06	0.06	0.04	38	35	38	48
A04AA05	Palonosetron	313	294	257	227	100	99	99	100	0.01	0.01	0.01	0.00	100	100	100	100
A04AA55	Palonosetron, combinations (DDD 1,ED)	930	1,178	1,157	1,256	20	16	14	13	0.01	0.01	0.01	0.01	20	15	14	13
A04AD	Other antiemetics	946	848	729	867	44	49	49	46	0.07	0.06	0.06	0.06	28	29	28	27
A04AD01	Scopolamine (DDD 1,ED)	298	296	371	535	27	26	26	24	0.06	0.05	0.06	0.06	27	26	26	24
A04AD12	Aprepitant	633	528	359	333	52	62	73	81	0.01	0.01	0.01	0.01	41	47	51	61

A05 Sapeneritystä lisäävät valmisteet ja maksan suoja-aineet

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A04AD14	Rolapitant (DDD 0.18,g)	14	24			66	53			0.00	0.00			66	53		
A05	Bile and liver therapy	2,067	2,198	1,393	1,595	1	2	2	1	0.82	0.93	0.92	1.02	1	2	2	2
A05A	Bile therapy	2,067	2,198	1,393	1,595	1	2	2	1	0.82	0.93	0.92	1.02	1	2	2	2
A05AA	Bile acids and derivatives	2,067	2,198	1,393	1,595	1	2	2	1	0.82	0.93	0.92	1.02	1	2	2	2
A05AA02	Ursodeoxycholic acid (DDD 0.75,g)	2,067	2,164	1,321	1,331	1	2	2	2	0.82	0.93	0.92	1.02	1	2	2	2
A05AA04	Obeticholic acid (DDD 10 mg)		35	72	264		0	4	0		0.00	0.00	0.00		0	4	0

**A06 Drugs for constipation**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A06	Drugs for constipation	25,559	27,108	29,103	30,234	13	12	11	10	46.81	48.02	51.29	53.33	10	9	8	7
A06A	Drugs for constipation	25,559	27,108	29,103	30,234	13	12	11	10	46.81	48.02	51.29	53.33	10	9	8	7
A06AB	Contact laxatives	3,788	3,784	3,739	3,510	9	9	7	7	6.29	6.21	6.31	6.01	7	6	5	5
A06AB02	Bisacodyl (DDD 10 mg)	385	363	265	248	6	5	2	1	0.97	0.91	0.71	0.66	5	4	2	1
A06AB06	Senna glycosides	119	60	52	51	0	0	0	0	0.29	0.15	0.13	0.12	0	0	0	0
A06AB08	Sodium picosulfate (DDD 5 mg)	2,653	2,688	2,819	2,572	7	6	4	4	5.02	5.15	5.48	5.22	8	7	6	5
A06AB56	Senna glycosides, combinations	183	169	163	145	0	0	0	0					0	0	0	0
A06AB58	Sodium picosulfate, combinations (DDD 33,ED)	448	505	441	493	30	31	31	28	0.00	0.00	0.00	0.00	30	31	30	28
A06AC	Bulk-forming laxatives	4,878	5,287	5,843	6,260	2	2	2	2	9.95	10.75	11.98	12.85	0	0	0	0
A06AC01	Ispaghula (psylla seeds) (DDD 7,g)	4,635	5,050	5,613	6,040	2	2	2	2	9.33	10.15	11.39	12.29	0	0	0	0
A06AC51	Ispaghula, combinations (DDD 15,ED)	243	238	230	220	2	1	1	1	0.62	0.61	0.59	0.56	2	1	1	1
A06AD	Osmotically acting laxatives	13,664	14,745	16,135	17,040	15	14	12	11	29.03	29.55	31.51	32.99	13	12	11	10
A06AD11	Lactulose (DDD 6.70,g)	2,862	2,711	2,628	2,558	11	10	9	8	14.17	13.46	13.23	12.77	11	10	9	9
A06AD15	Macrogol (DDD 10,g)	8,939	10,211	11,750	12,806	15	14	12	11	13.43	14.85	17.20	19.29	16	14	12	11
A06AD17	Sodium phosphate (DDD 50,g)	51	55	41	26	17	16	18	26					0	0	0	0
A06AD65	Macrogol, combinations	1,813	1,768	1,716	1,651	21	20	21	22	1.43	1.24	1.08	0.93	2	3	3	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A06AG	Enemas	2,628	2,510	2,411	2,414	23	21	17	16	1.43	1.36	1.30	1.30	18	16	10	9
A06AG02	Bisacodyl (DDD 1,ED)	463	419	411	408	40	36	31	29	0.28	0.25	0.24	0.24	41	37	32	30
A06AG10	Docusate sodium, incl. combinations (DDD 1,ED)	609	588	551	563	51	48	45	45	0.06	0.06	0.05	0.06	54	51	48	49
A06AG11	Laurilsulfate, incl. combinations (DDD 1,ED)	1,556	1,504	1,449	1,443	7	7	2	2	1.09	1.06	1.01	1.00	10	9	3	2
A06AH	Peripheral opioid receptor antagonists	443	623	756	773	52	44	39	37	0.07	0.11	0.13	0.14	39	33	28	26
A06AH01	Methylnaltrexone bromide (DDD 6 mg)	119	118	133	137	93	95	97	97	0.00	0.00	0.00	0.00	93	95	97	97
A06AH03	Naloxegol (DDD 25 mg)	324	505	624	636	37	32	26	24	0.07	0.11	0.13	0.13	36	31	26	24
A06AX	Other drugs for constipation	158	159	218	236	5	4	5	3	0.04	0.04	0.05	0.06	4	4	4	2
A06AX04	Linaclotide (DDD 0.29 mg)	77	66	111	120	2	2	1	1	0.02	0.02	0.03	0.03	2	2	1	1
A06AX05	Prucalopride (DDD 2 mg)	81	93	107	116	7	6	9	4	0.02	0.02	0.02	0.02	6	5	8	4

**A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	28,852	29,633	28,943	29,588	5	5	5	5	13.42	13.58	13.55	13.62	2	2	2	2
A07A	Intestinal antiinfectives	1,737	2,397	2,666	3,060	45	40	33	32	0.08	0.14	0.17	0.20	28	25	21	19
A07AA	Antibiotics	1,737	2,397	2,666	3,060	45	40	33	32	0.08	0.14	0.17	0.20	28	25	21	19
A07AA02	Nystatin (DDD 1.50,MU)	292	668	679	648	27	22	18	18	0.03	0.07	0.07	0.07	26	21	18	18
A07AA09	Vancomycin (DDD 2,g)	670	702	687	722	57	59	53	47	0.01	0.01	0.01	0.01	57	59	53	47
A07AA11	Rifaximin (DDD 0.60,g)	545	735	1,026	1,293	25	24	20	18	0.05	0.07	0.09	0.12	25	24	20	18
A07AA12	Fidaxomicin (DDD 0.40,g)	231	292	274	397	77	78	73	72	0.00	0.00	0.00	0.00	77	78	73	72
A07B	Intestinal adsorbents	641	617	620	550	44	48	51	48	0.13	0.12	0.13	0.11	45	54	52	50
A07BA	Charcoal preparations	641	617	620	550	44	48	51	48	0.13	0.12	0.13	0.11	45	54	52	50
A07BA01	Medicinal charcoal (DDD 5,g)	641	617	620	550	44	48	51	48	0.13	0.12	0.13	0.11	45	54	52	50
A07C	Electrolytes with carbohydrates	269	228	138	143	6	5	5	5	0.01	0.01	0.01	0.01	6	5	5	5
A07CA	Oral rehydration salt formulations	539	456	275	287	11	9	9	11	0.03	0.02	0.01	0.02	11	9	9	11
A07D	Antipropulsives	4,290	4,426	3,787	3,919	1	1	1	1	1.31	1.37	1.20	1.22	2	2	2	2
A07DA	Antipropulsives	4,290	4,426	3,787	3,919	1	1	1	1	1.31	1.37	1.20	1.22	2	2	2	2
A07DA02	Opium				0				0				0.00				0
A07DA03	Loperamide (DDD 10 mg)	3,221	3,407	2,962	3,115	1	1	1	1	1.31	1.37	1.20	1.22	2	2	2	2
A07DA06	Eluxadolone (DDD 0.20,g)	19	0			1	0			0.00	0.00			1	0		
A07DA53	Loperamide, combinations	1,050	1,019	825	804	0	0	0	0					0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A07E	Intestinal antiinflammatory agents	17,121	17,944	18,961	19,282	1	1	1	1	10.39	10.75	11.23	11.29	1	1	1	1
A07EA	Corticosteroids acting locally	1,667	1,834	1,976	2,084	3	2	3	3	0.30	0.32	0.35	0.36	3	3	3	3
A07EA02	Hydrocortisone (DDD 0.10,g)	0				0				0.00				0			
A07EA06	Budesonide	1,667	1,834	1,976	2,084	3	2	3	3	0.30	0.32	0.35	0.36	3	3	3	3
A07EB	Antiallergic agents, excl.corticosteroids	-1				17				0.00				17			
A07EB01	Cromoglicic acid (DDD 0.80,g)	-1				17				0.00				17			
A07EC	Aminosalicylic acid and similar agents	15,455	16,110	16,985	17,197	1	1	1	1	10.09	10.42	10.88	10.93	1	1	1	1
A07EC01	Sulfasalazine (DDD 2,g)	2,900	2,883	2,926	2,841	1	1	1	1	3.23	3.21	3.25	3.15	1	1	1	1
A07EC02	Mesalazine (DDD 1.50,g)	12,534	13,207	14,046	14,341	1	1	1	1	6.85	7.20	7.63	7.77	1	1	1	1
A07EC03	Olsalazine (DDD 1,g)	21	20	14	16	1	0	0	0	0.01	0.01	0.01	0.01	1	0	0	0
A07F	Antidiarrheal microorganisms	4,371	3,568	2,472	2,374	6	4	4	4	1.48	1.19	0.82	0.79	6	4	4	4
A07FA	Antidiarrheal microorganisms	4,371	3,568	2,472	2,374	6	4	4	4	1.48	1.19	0.82	0.79	6	4	4	4
A07FA01	Lactic acid producing organisms (DDD 3,ED)	71	0			1	1991			0.05	0.00			1	499		
A07FA02	Saccharomyces boulardii (DDD 1,g)	4,300	3,568	2,472	2,374	6	4	4	4	1.43	1.19	0.82	0.79	6	4	4	4
A07X	Other antidiarrheals	422	454	299	261	4	5	7	7					0	0	0	0
A07XA	Other antidiarrheals	422	454	299	261	4	5	7	7					0	0	0	0
A07XA04	Racecadotril	422	454	299	261	4	5	7	7					0	0	0	0

**A08 Antiobesity preparations, excl. diet products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
		A08	Antiobesity preparations, excl. diet products	558	638	602	608	0	0	0	0	0.09	0.08	0.07	0.07	1	0
A08A	Antiobesity preparations, excl. diet products	558	638	602	608	0	0	0	0	0.09	0.08	0.07	0.07	1	0	0	0
A08AA	Centrally acting antiobesity products	266	355	334	337	0	0	0	0			0.00	0.00	0	0	0	0
A08AA62	Bupropion and naltrexone	266	355	334	337	0	0	0	0			0.00	0.00	0	0	0	0
A08AB	Peripherally acting antiobesity products	292	283	268	270	1	0	0	0	0.09	0.08	0.07	0.07	1	0	0	0
A08AB01	Orlistat (DDD 0.36,g)	292	283	268	270	1	0	0	0	0.09	0.08	0.07	0.07	1	0	0	0

A09 Digestives, incl. enzymes

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
		A09	Digestives, incl. enzymes	2,613	3,219	3,146	3,339	4	4	4	3	1.04	1.28	1.25	1.32	4	4
A09A	Digestives, incl. enzymes	2,613	3,219	3,146	3,339	4	4	4	3	1.04	1.28	1.25	1.32	4	4	4	3
A09AA	Enzyme preparations	2,613	3,219	3,146	3,339	4	4	4	3	1.04	1.28	1.25	1.32	4	4	4	3
A09AA02	Multienzymes (lipase, protease etc.)	2,613	3,219	3,146	3,339	4	4	4	3	1.04	1.28	1.25	1.32	4	4	4	3

**A10 Drugs used in diabetes**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A10	Drugs used in diabetes	154,837	161,244	170,838	180,726	2	2	2	2	95.75	99.88	101.72	109.08	2	2	1	1
A10A	Insulins and analogues	63,779	61,128	58,293	54,639	3	3	2	2	32.14	32.33	31.23	30.18	3	3	3	3
A10AB	Insulins and analogues for injection, fast-acting (DDD 40,U)	16,238	15,441	15,324	13,750	3	3	3	3	10.32	10.70	10.66	10.71	3	3	3	3
A10AB01	Insulin (human) (DDD 40,U)	107	81	70	58	36	38	40	36	0.09	0.07	0.06	0.05	36	38	40	37
A10AB04	Insulin lispro (DDD 40,U)	2,896	2,003	1,774	1,703	2	2	2	1	1.89	1.67	1.56	1.51	1	1	2	1
A10AB05	Insulin aspart (DDD 40,U)	12,413	12,590	12,730	11,264	3	3	3	3	7.82	8.45	8.53	8.66	3	3	3	3
A10AB06	Insulin glulisine (DDD 40,U)	823	767	750	725	2	2	2	2	0.51	0.51	0.49	0.49	2	2	2	2
A10AC	Insulins and analogues, intermediate-acting (DDD 40,U)	1,002	879	720	651	9	10	7	11	0.71	0.63	0.51	0.46	9	10	7	11
A10AC01	Insulin (human) (DDD 40,U)	1,002	879	720	651	9	10	7	11	0.71	0.63	0.51	0.46	9	10	7	11
A10AD	Insulins and analogues, intermediate-acting combined with fast-acting (DDD 40,U)	743	593	466	354	5	5	4	5	0.43	0.36	0.28	0.22	5	5	4	5
A10AD04	Insulin lispro (DDD 40,U)	49	34	26	19	4	3	3	3	0.03	0.02	0.02	0.01	4	3	3	3
A10AD05	Insulin aspart (DDD 40,U)	694	560	441	335	5	5	4	5	0.41	0.34	0.27	0.20	5	5	4	5
A10AE	Insulins and analogues, long-acting	45,796	44,215	41,782	39,884	2	2	2	2	20.68	20.64	19.78	18.79	2	2	2	2
A10AE04	Insulin glargine (DDD 40,U)	28,672	26,163	24,511	22,865	2	3	3	2	13.68	13.03	12.26	11.43	2	3	3	2
A10AE05	Insulin detemir (DDD 40,U)	15,962	13,167	9,760	7,930	2	2	2	3	6.60	5.59	4.39	3.56	2	2	2	3
A10AE06	Insulin degludec (DDD 40,U)	1,162	4,884	7,511	9,089	2	2	1	2	0.40	2.03	3.14	3.79	2	2	1	2
A10AE54	Insulin glargine and lixisenatide (DDD 40,U)	0	0			0	0			0.00	0.00			0	0		

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A10B	Blood glucose lowering drugs, excl. insulins	91,058	100,116	112,544	126,087	1	1	1	1	63.61	67.55	70.50	78.90	1	1	1	1
A10BA	Biguanides	11,327	11,666	11,386	11,229	1	1	1	1	32.43	33.50	33.60	34.41	1	1	1	1
A10BA02	Metformin (DDD 2,g)	11,327	11,666	11,386	11,229	1	1	1	1	32.43	33.50	33.60	34.41	1	1	1	1
A10BB	Sulfonylureas	138	110	87	69	1	2	2	2	1.41	1.12	0.88	0.69	1	1	1	1
A10BB12	Glimepiride (DDD 2 mg)	138	110	87	69	1	2	2	2	1.41	1.12	0.88	0.69	1	1	1	1
A10BD	Combinations of oral blood glucose lowering drugs	13,744	13,556	13,689	13,372	0	0	0	0	6.06	6.22	6.28	6.19	0	0	0	0
A10BD05	Metformin and pioglitazone (DDD 2,ED)	17	6			0	0			0.01	0.01			0	0		
A10BD07	Metformin and sitagliptin (DDD 2,ED)	9,669	8,930	8,464	7,670	1	1	1	1	4.36	4.25	4.08	3.79	1	0	1	0
A10BD08	Metformin and vildagliptin (DDD 2,ED)	1,477	1,311	1,221	1,085	0	0	0	0	0.63	0.59	0.55	0.49	0	0	0	0
A10BD09	Pioglitazone and alogliptin (DDD 1,ED)	22	20	18	20	0	0	0	1	0.01	0.01	0.01	0.01	0	0	0	1
A10BD10	Metformin and saxagliptin (DDD 2,ED)	45	37	34	28	0	0	0	0	0.02	0.02	0.02	0.01	0	0	0	0
A10BD11	Metformin and linagliptin (DDD 2,ED)	463	452	471	460	0	0	1	1	0.20	0.20	0.21	0.21	0	0	1	1
A10BD13	Metformin and alogliptin (DDD 2,ED)	31	22	12		0	0	0		0.01	0.01	0.01		0	0	0	
A10BD15	Metformin and dapagliflozin (DDD 2,ED)	776	983	1,156	1,377	0	0	0	0	0.33	0.43	0.50	0.60	0	0	0	0
A10BD19	Linagliptin and empagliflozin (DDD 1,ED)	141	249	292	299	0	0	0	0	0.03	0.06	0.07	0.07	0	0	0	0
A10BD20	Metformin and empagliflozin (DDD 2,ED)	1,083	1,505	1,976	2,371	0	0	0	0	0.45	0.64	0.84	1.01	0	0	0	0
A10BD21	Saxagliptin and dapagliflozin (DDD 1,ED)	20	37	38	44	0	0	0	0	0.00	0.01	0.01	0.01	0	0	0	0
A10BD23	Metformin and ertugliflozin (DDD 2,ED)		1	2	4		0	0	0		0.00	0.00	0.00		0	0	0
A10BD24	Sitagliptin and ertugliflozin (DDD 1,ED)	0	5	7	14	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
A10BG	Thiazolidinediones	810	710	707	667	1	1	1	1	0.56	0.53	0.51	0.47	1	1	1	1
A10BG03	Pioglitazone (DDD 30 mg)	810	710	707	667	1	1	1	1	0.56	0.53	0.51	0.47	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A10BH	Dipeptidyl peptidase 4,(DPP-4) inhibitors	30,050	28,602	27,074	26,638	2	2	2	2	13.47	13.43	12.70	12.52	2	2	2	2
A10BH01	Sitagliptin (DDD 0.10,g)	18,649	17,083	16,187	14,910	2	2	2	2	8.21	7.86	7.44	6.86	2	2	2	2
A10BH02	Vildagliptin (DDD 0.10,g)	2,317	1,999	1,792	1,558	2	2	2	2	1.08	0.98	0.87	0.76	2	2	2	2
A10BH03	Saxagliptin (DDD 5 mg)	144	120	108	95	1	2	1	2	0.06	0.05	0.05	0.04	1	1	1	1
A10BH04	Alogliptin (DDD 25 mg)	85	69	61	58	1	1	0	0	0.04	0.03	0.03	0.03	1	1	0	0
A10BH05	Linagliptin (DDD 5 mg)	8,855	9,331	8,926	10,019	4	3	3	3	4.08	4.51	4.31	4.84	3	3	3	3
A10BJ	Glucagon-like peptide-1,(GLP-1) analogues	18,060	23,934	32,819	41,474	1	1	1	1	2.83	3.80	5.42	11.10	1	1	1	1
A10BJ01	Exenatide	3,030	2,545	2,073	1,481	1	1	1	1	0.54	0.47	0.38	0.28	1	1	1	1
A10BJ02	Liraglutide (DDD 1.50 mg)	13,128	14,175	12,084	8,755	1	1	1	1	1.92	2.08	1.77	1.40	1	1	1	1
A10BJ03	Lixisenatide (DDD 20,mcg)	27	30	22	6	1	1	2	0	0.00	0.00	0.00	0.00	1	1	2	0
A10BJ05	Dulaglutide (DDD 0.16 mg)	1,876	3,080	3,761	3,429	1	1	1	1	0.37	0.64	0.79	0.75	1	1	1	1
A10BJ06	Semaglutide		4,104	14,879	27,804		0	1	1		0.61	2.49	8.67		0	0	0
A10BK	Sodium-glucose co-transporter 2,(SGLT2) inhibitors	16,878	21,470	26,698	32,563	1	1	1	1	6.67	8.79	10.96	13.39	1	1	1	1
A10BK01	Dapagliflozin (DDD 10 mg)	6,267	7,142	8,383	10,482	1	1	1	1	2.67	3.07	3.57	4.38	1	1	1	1
A10BK02	Canagliflozin (DDD 0.20,g)		46	572	1,057		0	0	1		0.01	0.19	0.36		0	0	0
A10BK03	Empagliflozin (DDD 17.50 mg)	10,609	14,258	17,711	20,981	1	1	1	1	4.00	5.71	7.19	8.63	1	1	1	1
A10BK04	Ertugliflozin (DDD 10 mg)	2	24	32	43	2	0	0	1	0.00	0.01	0.01	0.02	2	0	0	1
A10BX	Other blood glucose lowering drugs, excl. insulins	50	69	84	74	2	2	1	1	0.18	0.15	0.14	0.12	1	1	1	1
A10BX01	Guar gum	4				1								0			
A10BX02	Repaglinide (DDD 4 mg)	46	69	84	74	2	2	1	1	0.18	0.15	0.14	0.12	1	1	1	1

**A11 Vitamins**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A11	Vitamins	9,305	9,120	9,352	7,067	13	13	14	19	23.27	23.52	25.42	22.59	4	3	3	3
A11C	Vitamin a and d, incl. combinations of the two	932	918	1,043	1,608	4	3	2	1	2.77	4.20	6.10	10.22	2	1	1	1
A11CC	Vitamin d and analogues	932	918	1,043	1,608	4	3	2	1	2.77	4.20	6.10	10.22	2	1	1	1
A11CC01	Ergocalciferol (vitamin D2)	11	4			2	1							0	0		
A11CC02	Dihydrotachysterol (DDD 1 mg)	78	69	19		3	2	2		0.06	0.05	0.01		3	2	2	
A11CC03	Alfacalcidol (DDD 1,mcg)	409	396	433	476	8	5	4	3	0.42	0.42	0.46	0.50	5	5	3	3
A11CC05	Colecalciferol (vitamin D3) (DDD 20,mcg)	434	450	591	1,133	1	1	1	0	2.29	3.72	5.63	9.72	1	1	0	0
A11D	Vitamin b1. plain and in combination with vitamin b6,and b12	2,246	2,215	2,246	2,170	49	50	54	58	5.23	5.05	4.64	4.26	12	12	12	12
A11DA	Vitamin b1. plain	1,059	1,072	1,204	1,263	99	99	99	99	0.49	0.48	0.50	0.48	99	99	99	99
A11DA01	Thiamine (vitamin B1) (DDD 50 mg)	1,059	1,072	1,204	1,263	99	99	99	99	0.49	0.48	0.50	0.48	99	99	99	99
A11DB	Vitamin b1,in comb. with vitamin b6,and/or vitamin b12	2,375	2,287	2,085	1,813	8	8	5	3	9.49	9.13	8.29	7.57	6	6	4	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A11E	Vitamin b-complex, incl. combinations	5,744	5,667	5,697	2,978	1	1	1	1	12.81	12.41	12.41	6.57	1	1	1	2
A11EA	Vitamin b-complex (DDD 1,ED)	2,066	2,022	1,990	1,965	8	8	8	8	5.48	5.35	5.25	5.18	8	8	8	8
A11EX	Vitamin b-complex, other combinations	9,423	9,311	9,405	3,991	0	0	0	0	20.14	19.47	19.57	7.95	0	0	0	0
A11G	Ascorbic acid (VITAMIN C), INCL. COMBINATIONS	146	108	138	89	1	1	1	1	2.19	1.61	2.06	1.33	1	1	1	1
A11GA	Ascorbic acid (vitamin C), plain	146	108	138	89	1	1	1	1	2.19	1.61	2.06	1.33	1	1	1	1
A11GA01	Ascorbic acid (vitamin C) (DDD 0.20,g)	146	108	138	89	1	1	1	1	2.19	1.61	2.06	1.33	1	1	1	1
A11H	Other plain vitamin preparations	236	212	227	221	4	4	4	4	0.27	0.26	0.21	0.21	7	9	8	7
A11HA	Other plain vitamin preparations	236	212	227	221	4	4	4	4	0.27	0.26	0.21	0.21	7	9	8	7
A11HA02	Pyridoxine (vitamin B6) (DDD 0.16,g)	48	49	43	44	13	14	12	11	0.15	0.15	0.13	0.14	13	14	12	11
A11HA03	Tocopherol (vitamin E) (DDD 0.20,g)	27	23	18	17	1	1	2	1	0.12	0.11	0.08	0.07	1	1	2	1
A11HA08	Tocofersolan (DDD 0.20,g)			3	1			100	100			0.00	0.00			100	100
A11HA30	Dexpanthenol	161	140	164	160	1	1	1	1					0	0	0	0



A12 Mineral supplements

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A12	Mineral supplements	15,792	15,838	16,449	16,546	5	5	4	4	40.35	40.48	41.60	41.64	4	3	3	3
A12A	Calcium	10,806	10,841	11,382	11,312	3	2	2	2	34.55	34.58	35.49	35.38	3	2	2	2
A12AA	Calcium	815	816	852	846	2	2	1	1	1.10	1.09	1.13	1.13	2	2	1	1
A12AA04	Calcium carbonate (DDD 3,g)	809	801	846	846	2	2	1	1	1.10	1.08	1.13	1.13	2	2	1	1
A12AA06	Calcium lactate gluconate (DDD 3,g)	6	15	6		9	6	6		0.00	0.01	0.00		9	6	6	
A12AX	Calcium, combinations with vitamin d and/or other drugs	19,982	20,050	21,059	20,932	5	5	4	4	66.89	66.99	68.72	68.50	5	5	4	4
A12B	Potassium	4,909	4,906	4,982	5,190	9	9	9	8	5.70	5.78	6.00	6.21	8	7	7	7
A12BA	Potassium	4,909	4,906	4,982	5,190	9	9	9	8	5.70	5.78	6.00	6.21	8	7	7	7
A12BA01	Potassium chloride (DDD 3,g)	4,780	4,801	4,982	5,190	10	9	9	8	5.65	5.74	6.00	6.21	8	7	7	7
A12BA51	Potassium chloride, combinations (DDD 6,ED)	130	105			3	3			0.05	0.04			3	3		
A12C	Other mineral supplements	77	92	86	44	47	39	32	31	0.10	0.12	0.11	0.06	47	39	32	31
A12CA	Sodium	77	92	86	44	47	39	32	31	0.10	0.12	0.11	0.06	47	39	32	31
A12CA01	Sodium chloride (DDD 1,g)	77	92	86	44	47	39	32	31	0.10	0.12	0.11	0.06	47	39	32	31



A14 Anabolic agents for systemic use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A14	Anabolic agents for systemic use	17	12	12	13	22	17	22	16	0.02	0.02	0.02	0.02	22	17	22	16
A14A	Anabolic steroids	17	12	12	13	22	17	22	16	0.02	0.02	0.02	0.02	22	17	22	16
A14AB	Estren derivatives	17	12	12	13	22	17	22	16	0.02	0.02	0.02	0.02	22	17	22	16
A14AB01	Nandrolone (DDD 2 mg)	17	12	12	13	22	17	22	16	0.02	0.02	0.02	0.02	22	17	22	16

A16 Other alimentary tract and metabolism products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A16	Other alimentary tract and metabolism products	13,880	15,712	18,204	20,842	40	34	39	45	0.02	0.02	0.03	0.03	34	29	37	36
A16A	Other alimentary tract and metabolism products	13,880	15,712	18,204	20,842	40	34	39	45	0.02	0.02	0.03	0.03	34	29	37	36
A16AA	Amino acids and derivatives		4	162	211		100	83	87		0.00	0.00	0.00		100	63	67
A16AA04	Mercaptamine (DDD 2,g)			22	21			0	0			0.00	0.00			0	0
A16AA05	Carglumic acid (DDD 0.20,g)		4	135	183		100	100	100		0.00	0.00	0.00		100	100	100
A16AA06	Betaine (DDD 6,g)			6	8			0	6			0.00	0.00			0	6
A16AB	Enzymes	12,360	12,383	13,404	15,373	44	41	44	46	0.01	0.01	0.01	0.01	45	42	44	40
A16AB02	Imiglucerase (DDD 300,U)	1,253	904	662	758	17	12	15	42	0.00	0.00	0.00	0.00	17	12	15	42
A16AB03	Agalsidase alfa (DDD 1 mg)	1,837	1,847	1,670	1,372	60	48	47	31	0.00	0.00	0.00	0.00	60	48	47	31
A16AB04	Agalsidase beta (DDD 5 mg)	8,008	8,249	9,230	9,533	42	41	45	39	0.01	0.01	0.01	0.01	43	41	45	39

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A16AB05	Laronidase (DDD 1,TU)	311	259	258	263	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AB07	Alglucosidase alfa (DDD 0.10,g)	356	396	619	663	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AB09	Idursulfase	3			219	100			100					0			0
A16AB10	Velaglucerase alfa (DDD 300,U)	592	728	965	855	6	5	0	0	0.00	0.00	0.00	0.00	6	5	0	0
A16AB13	Asfotase alfa				202				0								0
A16AB14	Sebelipase alfa				1,509				100				0.00				100
A16AX	Various alimentary tract and metabolism products	1,519	3,326	4,638	5,258	8	8	25	37	0.01	0.01	0.01	0.01	11	11	24	26
A16AX03	Sodium phenylbutyrate (DDD 20,g)	272	223	220	238	4	3	1	4	0.00	0.00	0.00	0.00	4	3	1	4
A16AX04	Nitisinone (DDD 20 mg)	529	462	510	487	0	1	1	1	0.00	0.00	0.00	0.00	0	0	1	0
A16AX05	Zinc acetate (DDD 0.15,g)			1	2			67	100			0.00	0.00			67	100
A16AX06	Miglustat (DDD 0.30,g)	304	208	236	375	6	0	0	0	0.00	0.00	0.00	0.00	6	0	0	0
A16AX08	Teduglutide (DDD 5 mg)	38	152	616	1,283	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AX09	Glycerol phenylbutyrate (DDD 15,g)	28	142	175	196	26	1	0	1	0.00	0.00	0.00	0.00	26	1	0	1
A16AX10	Eliglustat (DDD 0.17,g)	208	1,058	1,114	1,211	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
A16AX12	Trientine (DDD 0.45,g)		15	488	657		100	100	100		0.00	0.00	0.00		100	100	100
A16AX14	Migalastat (DDD 61.50 mg)	100	1,002	1,217	793	0	1	0	0	0.00	0.00	0.00	0.00	0	1	0	0
A16AX15	Telotristat (DDD 0.75,g)	40	64	60	15	100	98	96	83	0.00	0.00	0.00	0.00	100	98	96	83
A16AX14	Migalastaatti (DDD 61.50 mg)		100	1,002	1,217			1			0.00	0.00	0.00			1	
A16AX15	Telotrastaatti (DDD 0.75,g)		40	64	60		100	98	96		0.00	0.00	0.00		100	98	96



B Blood and blood forming organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B	Blood and blood forming organs	237,138	267,916	284,633	295,792	29	28	27	25	135.53	136.61	140.78	146.10	4	4	4	4
B01	Antithrombotic agents	116,600	138,493	155,554	162,730	17	14	12	10	115.13	115.37	116.20	116.93	4	4	4	3
B02	Antihemorrhagics	58,371	56,157	55,131	54,554	28	28	27	27	0.30	0.29	0.34	0.38	24	24	21	20
B03	Antianemic preparations	25,806	35,208	35,604	36,814	26	39	41	45	20.11	20.95	24.25	28.78	6	6	5	5
B05	Blood substitutes and perfusion solutions	31,336	30,853	30,276	30,339	77	79	80	81								
B06	Other hematological agents	5,025	7,205	8,067	11,356	19	20	34	13	0.00	0.00	0.00	0.01	19	21	40	15

**B01 Antithrombotic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B01	Antithrombotic agents	116,600	138,493	155,554	162,730	17	14	12	10	115.13	115.37	116.20	116.93	4	4	4	3
B01A	Antithrombotic agents	116,600	138,493	155,554	162,730	17	14	12	10	115.13	115.37	116.20	116.93	4	4	4	3
B01AA	Vitamin k antagonists	2,896	2,313	1,877	1,547	2	1	1	1	12.64	10.09	8.18	6.76	2	1	1	1
B01AA03	Warfarin (DDD 7.50 mg)	2,896	2,313	1,877	1,547	2	1	1	1	12.64	10.09	8.18	6.76	2	1	1	1
B01AB	Heparin group	25,257	24,682	23,306	19,520	41	41	39	38	6.89	6.71	6.63	5.78	36	36	36	34
B01AB01	Heparin (DDD 10,TU)	804	757	814	729	99	99	99	99	0.08	0.08	0.08	0.07	99	99	99	99
B01AB02	Antithrombin (DDD 2.10,TU)	451	399	381	356	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB04	Dalteparin (DDD 2.50,TU)	1,387	1,221	1,272	1,611	3	5	8	18	0.55	0.47	0.48	0.63	3	5	7	16
B01AB05	Enoxaparin	16,427	15,840	14,592	7,945	42	43	41	42	5.32	5.11	5.01	3.52	40	41	40	41
B01AB09	Danaparoid (DDD 1.50,TU)	200	210	160	238	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB10	Tinzaparin (DDD 3.50,TU)	5,989	6,254	6,086	8,642	33	30	28	28	0.94	1.05	1.06	1.56	27	23	21	22
B01AC	Platelet aggregation inhibitors excl. heparin	20,059	19,744	20,398	19,719	7	7	5	5	81.55	78.84	77.47	77.53	2	2	1	1
B01AC04	Clopidogrel (DDD 75 mg)	1,372	1,394	1,565	1,569	22	19	21	19	8.38	9.49	10.34	10.84	4	3	3	3
B01AC06	Acetylsalicylic acid (DDD 1,ED)	7,731	7,317	7,323	7,383	1	1	1	1	67.13	63.89	62.32	62.22	1	1	1	1
B01AC07	Dipyridamole	391	320	156	92	2	2	2	2	0.45	0.37	0.18	0.11	2	2	2	2
B01AC11	Iloprost	304	297	256	176	42	42	47	45	0.00	0.00	0.00	0.00	68	68	72	66
B01AC13	Abciximab (DDD 25 mg)	69	90	-13		100	100	100		0.00	0.00	0.00		100	100	100	
B01AC16	Eptifibatide (DDD 0.20,g)	89	109	90	112	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC17	Tirofiban (DDD 10 mg)	51	34	27	23	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC21	Treprostinil (DDD 4.30 mg)	2,015	2,048	2,158	1,558	7	10	3	3	0.00	0.00	0.00	0.00	6	8	2	3
B01AC22	Prasugrel (DDD 10 mg)	82	74	119	146	24	19	15	11	0.02	0.02	0.03	0.04	24	18	14	11

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B01AC24	Ticagrelor (DDD 0.18,g)	3,301	3,480	3,538	3,343	5	5	4	4	0.80	0.84	0.85	0.81	4	4	4	4
B01AC25	Cangrelor (DDD 50 mg)	137	182	147	193	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC27	Selexipag (DDD 1.80 mg)	543	776	788	1,142	12	4	0	2	0.00	0.00	0.00	0.00	6	1	0	1
B01AC30	Combinations (DDD 2,ED)	3,975	3,623	4,245	3,982	2	2	1	2	4.75	4.23	3.74	3.51	2	2	1	2
B01AD	Enzymes	4,967	4,726	5,035	4,699	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD02	Alteplase (DDD 0.10,g)	4,046	4,036	4,075	4,206	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD07	Retepase (DDD 20,U)	252				100				0.00				100			
B01AD11	Tenecteplase (DDD 40 mg)	669	690	960	493	99	99	99	99	0.00	0.00	0.00	0.00	99	99	99	99
B01AE	Direct thrombin inhibitors	11,283	12,414	12,618	12,032	5	4	3	3	2.46	2.79	2.87	2.74	2	2	2	1
B01AE03	Argatroban (DDD 0.20,g)	52	54	83	78	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE06	Bivalirudin (DDD 0.25,g)	211	186	104	147	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE07	Dabigatran etexilate (DDD 0.30,g)	11,020	12,173	12,431	11,808	2	2	2	1	2.46	2.79	2.87	2.74	2	2	1	1
B01AF	Direct factor xa inhibitors	51,214	73,796	91,106	104,249	3	3	3	2	11.56	16.91	21.02	24.11	3	3	2	2
B01AF01	Rivaroxaban (DDD 20 mg)	25,299	32,952	37,647	40,303	3	2	2	2	5.99	7.95	9.11	9.72	2	2	2	2
B01AF02	Apixaban (DDD 10 mg)	24,362	36,986	47,651	56,798	4	4	3	3	5.25	8.13	10.67	12.86	3	3	3	2
B01AF03	Edoxaban (DDD 60 mg)	1,554	3,858	5,808	7,148	3	3	3	3	0.33	0.83	1.24	1.53	2	2	2	2
B01AX	Other antithrombotic agents	923	818	1,214	963	83	78	85	77	0.02	0.03	0.03	0.02	13	10	10	19
B01AX01	Defibrotide (DDD 1.75,g)	750	613	716	592	99	100	100	86	0.00	0.00	0.00	0.00	99	100	100	86
B01AX05	Fondaparinux (DDD 2.50 mg)	174	205	193	166	14	10	9	18	0.02	0.03	0.03	0.02	13	10	9	18
B01AX07	Caplacizumab (DDD 10 mg)			305	205			100	100			0.00	0.00			100	100

**B02 Antihemorrhagics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B02	Antihemorrhagics	58,371	56,157	55,131	54,554	28	28	27	27	0.30	0.29	0.34	0.38	24	24	21	20
B02A	Antifibrinolytics	1,787	1,915	2,264	2,009	73	76	75	69	0.25	0.23	0.27	0.31	20	21	18	17
B02AA	Amino acids	1,678	1,744	2,014	1,741	71	74	72	65	0.24	0.23	0.27	0.31	20	21	17	16
B02AA02	Tranexamic acid (DDD 2,g)	1,678	1,744	2,014	1,741	71	74	72	65	0.24	0.23	0.27	0.31	20	21	17	16
B02AB	Proteinase inhibitors	109	171	250	268	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB01	Aprotinin (DDD 500,TU)	40	118	190	217	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB02	Alfa1,antitrypsin (DDD 0.60,g)	69	54	61	51	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02B	Vitamin k and other hemostatics	56,584	54,242	52,867	52,544	26	26	25	26	0.05	0.06	0.07	0.07	41	36	32	35
B02BA	Vitamin k	141	134	107	106	88	88	87	86	0.02	0.02	0.02	0.02	88	88	89	88
B02BA01	Phytomenadione (DDD 20 mg)	141	134	107	106	88	88	87	86	0.02	0.02	0.02	0.02	88	88	89	88
B02BB	Fibrinogen	1,484	1,869	1,867	1,993	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BB01	Fibrinogen, human (DDD 5,g)	1,484	1,869	1,867	1,993	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BC	Local hemostatics	3,390	3,441	3,172	3,304	100	100	100	100	0.00	0.00	0.00	0.00	0	0	0	0
B02BC30	Combinations	3,390	3,441	3,172	3,304	100	100	100	100	0.00	0.00	0.00	0.00	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B02BD	Blood coagulation factors	47,523	43,110	40,028	38,247	20	20	19	19		0.00	0.00	0.00	0	0	0	0
B02BD01	Coagulation factor ix, ii, vii and x in combination	5,738	4,627	4,420	3,946	100	100	100	100					0	0	0	0
B02BD02	Coagulation factor viii	25,506	25,579	24,213	23,854	4	4	5	3		0.00	0.00	0.00	0	0	0	0
B02BD03	Factor viii inhibitor bypassing activity	1,307	1,949	831	602	22	48	37	100					0	0	0	0
B02BD04	Coagulation factor ix	6,533	5,806	5,447	5,437	6	11	7	8					0	0	0	0
B02BD06	Von willebrand factor and coagulation factor viii in combination	6,467	4,192	3,851	2,861	18	17	17	22			0.00	0.00	0	0	0	0
B02BD07	Coagulation factor xiii	739	611	730	779	33	40	37	35					0	0	0	0
B02BD08	Coagulation factor viia	464	347	483	488	84	82	79	72					0	0	0	0
B02BD10	Von willebrand factor	769		52	280	43		67	59					0		0	0
B02BX	Other systemic hemostatics	4,046	5,688	7,694	8,894	8	8	7	10	0.03	0.04	0.05	0.05	8	9	8	14
B02BX04	Romiplostim (DDD 30,mcg)	1,331	1,379	1,805	1,978	9	9	8	18	0.01	0.01	0.01	0.02	9	9	9	18
B02BX05	Eltrombopag (DDD 50 mg)	2,700	3,751	4,518	4,008	8	9	9	12	0.02	0.03	0.03	0.03	8	9	9	12
B02BX06	Emicizumab (DDD 15 mg)	16	559	1,371	2,907	0	0	2	1	0.00	0.00	0.00	0.00	0	0	2	1
B02BX08	Avatrombopag				1				100				0.00				100

**B03 Antianemic preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B03	Antianemic preparations	25,806	35,208	35,604	36,814	26	39	41	45	20.11	20.95	24.25	28.78	6	6	5	5
B03A	Iron preparations	8,915	16,696	16,411	18,096	52	69	77	83	5.74	6.07	5.94	5.59	6	5	5	6
B03AA	Iron bivalent, oral preparations	3,045	3,498	2,332	1,710	3	2	2	3	4.20	4.15	4.14	3.85	3	3	3	3
B03AA01	Ferrous glycine sulfate (DDD 0.20,g)	2,446	2,912	1,903	1,358	3	2	2	3	3.07	3.05	3.24	3.00	4	3	3	3
B03AA07	Ferrous sulfate (DDD 0.20,g)	599	586	428	352	3	3	2	2	1.12	1.10	0.90	0.85	3	3	2	2
B03AB	Iron trivalent, oral preparations	1,142	1,417	1,348	1,283	3	3	3	3	1.39	1.75	1.63	1.54	2	2	2	2
B03AB05	Ferric oxide polymaltose complexes (DDD 90 mg)	1,140	1,413	1,343	1,273	3	3	3	3	1.39	1.75	1.63	1.53	2	2	2	2
B03AB10	Ferric maltol (DDD 60 mg)	2	4	6	10	6	0	0	0	0.00	0.00	0.00	0.00	5	0	0	0
B03AC	Iron, parenteral preparations (DDD 0.10,g)	9,330	23,542	25,461	30,206	193	195	196	197	0.29	0.33	0.34	0.40	197	196	197	197
B03AD	Iron in combination with folic acid	64	10			2	2							0	0		
B03AD01	Ferrous amino acid complex	64	10			2	2							0	0		
B03B	Vitamin b12,and folic acid	1,937	2,009	2,161	2,573	5	5	5	4	13.31	13.70	17.08	21.92	6	6	5	4
B03BA	Vitamin b12,(cyanocobalamin and derivatives)	1,146	1,144	1,080	1,210	5	5	4	3	6.06	5.96	5.59	5.88	5	5	4	4
B03BA01	Cyanocobalamin	364	385	369	531	5	5	1	1	1.09	1.16	1.10	1.59	5	5	1	1
B03BA03	Hydroxocobalamin (DDD 20,mcg)	782	759	711	679	5	5	5	5	4.96	4.81	4.49	4.29	5	5	5	5
B03BB	Folic acid, combinations	791	865	1,082	1,363	6	5	6	6	7.26	7.74	11.49	16.05	6	6	6	5
B03BB01	Folic acid	791	865	1,082	1,363	6	5	6	6	7.26	7.74	11.49	16.05	6	6	6	5
B03X	Other antianemic preparations	14,954	16,503	17,032	16,145	13	12	11	10	1.06	1.18	1.23	1.27	13	12	11	10
B03XA	Other antianemic preparations	14,954	16,503	17,032	16,145	13	12	11	10	1.06	1.18	1.23	1.27	13	12	11	10
B03XA01	Erythropoietin (DDD 1,TU)	2,012	2,094	2,439	2,335	18	15	18	20	0.17	0.19	0.21	0.23	18	14	17	19
B03XA02	Darbepoetin alfa (DDD 4.50,mcg)	10,397	11,850	12,361	11,878	12	11	10	9	0.72	0.82	0.85	0.89	12	11	10	9
B03XA03	Methoxy polyethylene glycolepoetin beta (DDD 4,mcg)	2,546	2,559	2,232	1,933	10	12	9	7	0.17	0.18	0.17	0.16	10	12	9	7

**B05 Blood substitutes and perfusion solutions**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B05	Blood substitutes and perfusion solutions	31,336	30,853	30,276	30,339	77	79	80	81								
B05A	Blood and related products	3,628	5,175	5,765	5,953	100	100	100	100								
B05AA	Blood substitutes and plasma protein fractions	3,628	5,175	5,765	5,953	100	100	100	100								
B05AA01	Albumin	3,606	5,158	5,758	5,950	100	100	100	100								
B05AA05	Dextran	1				100											
B05AA06	Gelatin agents	9	12	7	3	96	96	95	95								
B05AA07	Hydroxyethylstarch	11	4			95	100										
B05B	I.v. solutions	18,812	17,452	16,960	16,992	99	99	99	99								
B05BA	Solutions for parenteral nutrition	5,193	5,102	5,403	5,297	100	100	100	100								
B05BA01	Amino acids	108	95	76	88	100	100	100	100								
B05BA02	Fat emulsions	47	39	37	48	97	95	95	99								
B05BA03	Carbohydrates	432	417	415	402	99	99	99	99								
B05BA10	Combinations	4,606	4,552	4,874	4,759	100	100	100	100								
B05BB	Solutions affecting the electrolyte balance	13,592	12,324	11,528	11,672	99	99	99	99								
B05BB01	Electrolytes	12,512	11,409	10,707	10,859	99	99	99	99								
B05BB02	Electrolytes with carbohydrates	1,081	915	821	812	100	100	100	100								
B05BC	Solutions producing osmotic diuresis	27	26	30	24	99	99	98	96								
B05BC01	Mannitol	27	26	30	24	99	99	98	96								
B05D	Peritoneal dialytics	7,458	6,774	6,108	5,954	7	7	6	6								
B05DA	Isotonic solutions	5,704	5,348	4,945	5,133	11	13	11	11								
B05DB	Hypertonic solutions	9,212	8,199	7,270	6,775	14	15	11	11								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B05X	I.v. solution additives	1,271	1,251	1,202	1,198	99	99	99	98								
B05XA	Electrolyte solutions	836	820	777	786	98	98	98	97								
B05XA01	Potassium chloride	289	275	225	225	100	99	99	98								
B05XA03	Sodium chloride	181	176	131	129	94	94	92	90								
B05XA05	Magnesium sulfate	74	81	107	99	100	99	100	100								
B05XA06	Potassium phosphate, incl. comb. with other potassium salts	34	31	33	29	98	98	99	99								
B05XA07	Calcium chloride			27	53			100	100								
B05XA14	Sodium glycerophosphate	68	65	58	57	97	94	96	95								
B05XA31	Electrolytes in combination with other drugs	190	191	197	195	100	100	100	100								
B05XB	Amino acids	41	31	27	21	100	100	100	100								
B05XB02	Alanyl glutamine	41	31	27	21	100	100	100	100								
B05XC	Vitamins	789	800	794	781	198	199	199	199								
B05Z	Hemodialytics and hemofiltrates	167	202	242	242	100	100	100	100								
B05ZB	Hemofiltrates	334	403	484	484	200	200	200	200								

**B06 Other hematological agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B06	Other hematological agents	5,025	7,205	8,067	11,356	19	20	34	13	0.00	0.00	0.00	0.01	19	21	40	15
B06A	Other hematological agents	5,025	7,205	8,067	11,356	19	20	34	13	0.00	0.00	0.00	0.01	19	21	40	15
B06AB	Heme products			15	43			100	100								
B06AB01	Hemin			15	43			100	100								
B06AC	Drugs used in hereditary angioedema	5,025	7,205	8,052	11,229	19	20	34	12	0.00	0.00	0.00	0.00	19	21	40	10
B06AC01	C1-inhibitor, plasma derived (DDD 1.40,TU)	2,745	3,952	4,425	3,712	17	20	20	16	0.00	0.00	0.00	0.00	17	19	20	16
B06AC02	Icatibant (DDD 30 mg)	1,977	2,837	2,025	2,661	13	12	11	9	0.00	0.00	0.00	0.00	13	12	11	6
B06AC04	Conestat alfa (DDD 3.50,TU)	303	273	96	100	75	69	100	100	0.00	0.00	0.00	0.00	75	69	100	100
B06AC05	Lanadelumab (DDD 21.40 mg)		143	1,506	4,756		100	100	9		0.00	0.00	0.00		100	100	8
B06AX	Other hematological agents				84				100				0.00				100
B06AX01	Crizanlizumab				84				100				0.00				100



C Cardiovascular system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C	Cardiovascular system	172,313	150,662	138,176	130,578	10	12	13	13	598.18	626.10	654.87	682.37	2	2	2	1
C01	Cardiac therapy	22,899	22,057	22,397	21,102	57	57	61	61	14.82	13.97	13.44	12.91	10	8	8	9
C02	Antihypertensives	6,978	7,864	9,119	9,156	8	7	7	7	3.00	3.23	3.18	3.32	3	3	3	3
C03	Diuretics	8,213	8,669	9,142	9,217	18	20	21	19	51.43	51.42	50.49	50.16	6	6	5	5
C04	Peripheral vasodilators	77	76	76	67	3	2	2	1	0.11	0.10	0.10	0.09	3	2	2	1
C05	Vasoprotectives	4,580	4,469	4,515	4,887	4	5	5	5								
C07	Beta blocking agents	21,649	20,279	19,267	18,397	5	4	4	4	65.09	64.37	65.65	63.93	2	2	2	2
C08	Calcium channel blockers	16,292	12,799	11,381	11,080	3	4	4	3	90.14	95.51	99.50	104.32	1	1	1	1
C09	Agents acting on the renin-angiotensin system	46,444	43,195	38,543	34,466	1	1	1	1	253.02	264.30	274.79	280.96	1	1	1	1
C10	Lipid modifying agents	45,180	31,255	23,735	22,207	1	1	1	1	120.58	133.20	147.71	166.68	1	1	1	1

**C01 Cardiac therapy**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C01	Cardiac therapy	22,899	22,057	22,397	21,102	57	57	61	61	14.82	13.97	13.44	12.91	10	8	8	9
C01A	Cardiac glycosides	1,127	1,106	1,052	1,051	12	14	15	19	2.26	2.08	1.91	1.79	4	4	4	4
C01AA	Digitalis glycosides	1,127	1,106	1,052	1,051	12	14	15	19	2.26	2.08	1.91	1.79	4	4	4	4
C01AA05	Digoxin (DDD 0.25 mg)	1,127	1,106	1,052	1,051	12	14	15	19	2.26	2.08	1.91	1.79	4	4	4	4
C01B	Antiarrhythmics, class i and iii	4,094	3,730	2,862	2,511	34	37	41	38	2.06	2.01	1.97	1.92	4	3	3	3
C01BB	Antiarrhythmics, class ib	181	360	283	164	97	97	97	98	0.00	0.00	0.00	0.00	97	97	97	98
C01BB01	Lidocaine (DDD 3,g)	181	360	283	164	97	97	97	98	0.00	0.00	0.00	0.00	97	97	97	98
C01BC	Antiarrhythmics, class ic	1,942	1,644	1,177	1,145	1	1	2	2	1.43	1.42	1.40	1.36	1	1	1	1
C01BC04	Flecainide (DDD 0.20,g)	1,942	1,644	1,177	1,145	1	1	2	2	1.43	1.42	1.40	1.36	1	1	1	1
C01BD	Antiarrhythmics, class iii	1,209	948	668	550	34	24	23	21	0.63	0.58	0.57	0.56	12	9	10	10
C01BD01	Amiodarone (DDD 0.20,g)	516	307	260	255	61	37	28	26	0.49	0.46	0.46	0.45	15	11	12	12
C01BD05	Ibutilide (DDD 1 mg)	87	109	77	48	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BD07	Dronedarone (DDD 0.80,g)	607	532	331	247	1	1	1	1	0.14	0.12	0.11	0.11	1	1	1	1
C01BG	Other antiarrhythmics, class i and iii	762	778	733	652	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BG11	Vernakalant (DDD 0.20,g)	762	778	733	652	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01C	Cardiac stimulants excl. cardiac glycosides	12,103	11,743	13,209	11,956	84	84	85	83	0.91	0.61	0.69	0.77	87	83	83	87
C01CA	Adrenergic and dopaminergic agents	7,304	6,568	8,062	7,417	73	70	75	73	0.90	0.61	0.68	0.77	87	83	83	87
C01CA01	Etilefrine (DDD 50 mg)	392	417	259	301	76	77	62	73	0.06	0.06	0.06	0.05	26	23	23	25
C01CA02	Isoprenaline (DDD 90 mg)			138	416			100	100			0.00	0.00			100	100
C01CA03	Norepinephrine (DDD 6 mg)	1,503	1,359	2,294	1,291	99	99	100	99	0.06	0.06	0.08	0.05	99	99	99	99
C01CA04	Dopamine (DDD 0.50,g)	33	70	120	21	84	89	91	62	0.00	0.00	0.00	0.00	83	89	91	64

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day				
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	
C01CA06	Phenylephrine (DDD 4 mg)	504	595	675	635	100	99	99	100	0.01	0.02	0.02	0.02	99	100	99	100
C01CA07	Dobutamine (DDD 0.50,g)	79	51	84	36	99	99	100	100	0.00	0.00	0.00	0.00	99	99	100	100
C01CA17	Midodrine (DDD 30 mg)		41	65	84		14	17	18		0.00	0.01	0.01		11	15	16
C01CA24	Epinephrine (DDD 0.50 mg)	4,495	3,730	4,140	4,350	59	52	56	58	0.77	0.47	0.52	0.65	91	88	88	91
C01CA26	Ephedrine	298	304	288	283	99	99	98	98								
C01CE	Phosphodiesterase inhibitors	338	738	819	633	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CE02	Milrinone (DDD 50 mg)	338	738	819	633	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX	Other cardiac stimulants	4,461	4,438	4,328	3,906	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX08	Levosimendan (DDD 11 mg)	4,461	4,438	4,328	3,906	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01D	Vasodilators used in cardiac diseases	4,764	4,599	4,561	4,631	12	10	12	16	9.56	9.23	8.85	8.38	4	4	4	4
C01DA	Organic nitrates	4,764	4,599	4,561	4,630	12	10	12	16	9.56	9.23	8.85	8.38	4	4	4	4
C01DA02	Glyceryl trinitrate	1,031	989	1,018	1,176	32	30	40	53	0.70	0.69	0.65	0.60	17	16	22	24
C01DA08	Isosorbide dinitrate	1,082	1,043	991	927	13	10	8	7	1.63	1.57	1.49	1.41	6	6	5	6
C01DA14	Isosorbide mononitrate (DDD 40 mg)	2,652	2,566	2,553	2,527	3	3	2	2	7.23	6.96	6.71	6.37	3	3	2	2
C01DX	Other vasodilators used in cardiac diseases				0				0				0.00				0
C01DX22	Vericiguat				0				0				0.00				0
C01E	Other cardiac preparations	812	879	714	954	94	95	95	96	0.03	0.03	0.03	0.04	61	60	49	59
C01EA	Prostaglandins	276	329	287	331	98	100	100	100	0.00	0.00	0.00	0.00	98	100	100	100
C01EA01	Alprostadil (DDD 0.50 mg)	276	329	287	331	98	100	100	100	0.00	0.00	0.00	0.00	98	100	100	100
C01EB	Other cardiac preparations	536	550	427	622	92	91	92	94	0.03	0.03	0.03	0.04	60	60	48	58
C01EB10	Adenosine (DDD 15 mg)	363	363	222	364	98	96	98	98	0.02	0.02	0.01	0.02	100	96	99	98
C01EB16	Ibuprofen (DDD 30 mg)			9	12			100	100			0.00	0.00		100	100	
C01EB17	Ivabradine (DDD 10 mg)	38	36	33	34	4	3	4	4	0.01	0.01	0.02	0.02	4	2	3	3
C01EB21	Regadenoson (DDD 0.40 mg)	134	151	162	212	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

**C02 Antihypertensives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C02	Antihypertensives	6,978	7,864	9,119	9,156	8	7	7	7	3.00	3.23	3.18	3.32	3	3	3	3
C02A	Antiadrenergic agents, centrally acting	1,246	1,419	1,523	1,571	30	26	31	25	2.52	2.70	2.61	2.70	3	3	3	2
C02AC	Imidazoline receptor agonists	1,246	1,419	1,523	1,571	30	26	31	25	2.52	2.70	2.61	2.70	3	3	3	2
C02AC01	Clonidine (DDD 0.45 mg)	373	363	460	355	87	86	89	87	0.06	0.07	0.06	0.06	36	36	35	34
C02AC02	Guanfacine (DDD 3 mg)	235	310	439	606	18	14	13	11	0.03	0.04	0.07	0.09	17	15	14	12
C02AC05	Moxonidine (DDD 0.30 mg)	638	745	624	610	2	2	1	1	2.43	2.59	2.48	2.55	2	2	1	1
C02C	Antiadrenergic agents, peripherally acting	341	379	403	462	4	4	4	4	0.43	0.48	0.51	0.55	4	4	3	4
C02CA	Alpha-adrenoceptor blocking agents	341	379	403	462	4	4	4	4	0.43	0.48	0.51	0.55	4	4	3	4
C02CA01	Prazosin (DDD 5 mg)	341	379	403	462	4	4	4	4	0.43	0.48	0.51	0.55	4	4	3	4
C02D	Arteriolar smooth muscle, agents acting on				67				100				0.00				100
C02DD	Nitroferricyanide derivatives				67				100				0.00				100
C02DD01	Nitroprusside				67				100				0.00				100
C02K	Other antihypertensives	5,391	6,066	7,193	7,056	3	3	2	2	0.05	0.05	0.06	0.06	2	2	2	2
C02KX	Antihypertensives for pulmonary arterial hypertension	5,391	6,066	7,193	7,056	3	3	2	2	0.05	0.05	0.06	0.06	2	2	2	2
C02KX01	Bosentan (DDD 0.25.g)	1,010	810	1,317	1,297	3	4	3	4	0.02	0.01	0.01	0.01	2	4	3	3
C02KX02	Ambrisentan (DDD 7.50 mg)	816	783	797	343	3	2	1	2	0.01	0.01	0.01	0.00	2	1	1	1
C02KX04	Macitentan (DDD 10 mg)	2,450	3,094	3,416	3,586	3	3	2	1	0.02	0.02	0.02	0.03	3	3	2	1
C02KX05	Riociguat (DDD 4.50 mg)	1,115	1,378	1,664	1,830	1	1	2	1	0.01	0.01	0.02	0.02	1	1	1	1



C03 Diuretics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C03	Diuretics	8,213	8,669	9,142	9,217	18	20	21	19	51.43	51.42	50.49	50.16	6	6	5	5
C03A	Low-ceiling diuretics, thiazides	1,223	1,301	1,429	1,497	2	2	2	2	6.67	6.68	7.11	7.18	2	2	2	2
C03AA	Thiazides, plain	1,223	1,301	1,429	1,497	2	2	2	2	6.67	6.68	7.11	7.18	2	2	2	2
C03AA03	Hydrochlorothiazide (DDD 25 mg)	1,223	1,301	1,429	1,497	2	2	2	2	6.67	6.68	7.11	7.18	2	2	2	2
C03B	Low-ceiling diuretics, excl. thiazides	183	185	235	306	1	1	14	21	0.48	0.48	0.49	0.49	1	1	3	5
C03BA	Sulfonamides, plain	183	185	235	306	1	1	14	21	0.48	0.48	0.49	0.49	1	1	3	5
C03BA08	Metolazone (DDD 5 mg)			52	130			60	48			0.01	0.04			60	48
C03BA11	Indapamide (DDD 2.50 mg)	183	185	183	176	1	1	1	1	0.48	0.48	0.48	0.46	1	1	1	1
C03C	High-ceiling diuretics	4,691	5,055	5,238	5,026	29	33	35	32	34.98	35.24	34.93	34.61	8	8	7	6
C03CA	Sulfonamides, plain	4,691	5,055	5,238	5,026	29	33	35	32	34.98	35.24	34.93	34.61	8	8	7	6
C03CA01	Furosemide (DDD 40 mg)	4,691	5,055	5,238	5,026	29	33	35	32	34.98	35.24	34.93	34.61	8	8	7	6
C03D	Aldosterone antagonists and other potassium-sparing agents	1,303	1,374	1,496	1,594	3	3	3	2	2.56	2.70	2.92	3.11	3	3	2	2
C03DA	Aldosterone antagonists	1,303	1,374	1,496	1,594	3	3	3	2	2.56	2.70	2.92	3.11	3	3	2	2
C03DA01	Spironolactone (DDD 75 mg)	1,231	1,300	1,412	1,498	3	3	3	2	2.55	2.69	2.90	3.09	3	3	2	2
C03DA04	Eplerenone (DDD 50 mg)	71	74	84	95	3	3	2	3	0.01	0.01	0.01	0.02	3	3	2	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C03E	Diuretics and potassium-sparing agents in combination	770	722	609	535	2	2	1	1	6.75	6.32	5.03	4.76	1	2	1	1
C03EA	Low-ceiling diuretics and potassium-sparing agents	615	585	487	426	1	1	1	1	5.89	5.57	4.37	4.16	1	1	1	1
C03EA01	Hydrochlorothiazide and potassium-sparing agents (DDD 1,ED)	615	585	487	426	1	1	1	1	5.89	5.57	4.37	4.16	1	1	1	1
C03EB	High-ceiling diuretics and potassium-sparing agents	155	137	122	109	5	5	4	5	0.85	0.75	0.67	0.60	5	5	4	5
C03EB01	Furosemide and potassium-sparing agents (DDD 1,ED)	155	137	122	109	5	5	4	5	0.85	0.75	0.67	0.60	5	5	4	5
C03X	Other diuretics	42	31	135	260	93	68	20	10	0.00	0.00	0.00	0.01	93	32	1	1
C03XA	Vasopressin antagonists	42	31	135	260	93	68	20	10	0.00	0.00	0.00	0.01	93	32	1	1
C03XA01	Tolvaptan (DDD 30 mg)	42	31	135	260	93	68	20	10	0.00	0.00	0.00	0.01	93	32	1	1

C04 Peripheral vasodilators

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C04	Peripheral vasodilators	77	76	76	67	3	2	2	1	0.11	0.10	0.10	0.09	3	2	2	1
C04A	Peripheral vasodilators	77	76	76	67	3	2	2	1	0.11	0.10	0.10	0.09	3	2	2	1
C04AD	Purine derivatives	77	76	76	67	3	2	2	1	0.11	0.10	0.10	0.09	3	2	2	1
C04AD03	Pentoxifylline	77	76	76	67	3	2	2	1	0.11	0.10	0.10	0.09	3	2	2	1

**C05 Vasoprotectives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C05	Vasoprotectives	4,580	4,469	4,515	4,887	4	5	5	5								
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use	2,895	2,785	2,786	3,096	2	2	2	2								
C05AA	Corticosteroids	2,646	2,559	2,648	2,969	2	2	2	2								
C05AA01	Hydrocortisone	57	59	79	58	28	27	29	36								
C05AA04	Prednisolone	2,188	2,049	2,131	2,449	1	1	1	1								
C05AA08	Fluocortolone	400	451	437	462	2	2	1	1								
C05AE	Muscle relaxants	125	134	139	128	4	1	1	3								
C05AE01	Glyceryl trinitrate	125	134	139	128	4	1	1	3								
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use	124	92			0	0										
C05AX03	Other preparations, combinations	124	92			0	0										
C05B	Antivaricose therapy	1,685	1,684	1,729	1,790	8	11	11	11								
C05BA	Heparins or heparinoids for topical use	1,570	1,515	1,537	1,593	2	2	2	2								
C05BA01	Organo-heparinoid	1,570	1,515	1,537	1,593	2	2	2	2								
C05BB	Sclerosing agents for local injection	115	169	192	197	89	90	87	87								
C05BB02	Polidocanol	115	169	192	197	89	90	87	87								

**C07 Beta blocking agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C07	Beta blocking agents	21,649	20,279	19,267	18,397	5	4	4	4	65.09	64.37	65.65	63.93	2	2	2	2
C07A	Beta blocking agents	18,883	17,820	17,205	16,601	5	5	5	4	59.87	59.56	61.27	60.10	2	2	2	2
C07AA	Beta blocking agents, non-selective	1,083	1,387	1,443	1,501	2	2	2	2	2.44	2.73	2.68	2.68	2	2	2	1
C07AA05	Propranolol (DDD 0.16,g)	995	1,240	1,307	1,370	2	2	2	2	2.14	2.23	2.22	2.24	2	2	2	1
C07AA07	Sotalol (DDD 0.16,g)	88	147	136	131	2	1	1	2	0.30	0.49	0.46	0.44	2	1	1	2
C07AB	Beta blocking agents, selective	16,510	15,259	14,716	14,205	3	3	3	3	55.16	54.69	56.57	55.49	2	2	2	2
C07AB02	Metoprolol (DDD 0.15,g)	5,374	4,663	3,881	3,560	5	5	5	4	10.30	10.03	9.70	8.99	2	2	2	1
C07AB03	Atenolol (DDD 75 mg)	408	365	383	335	2	2	2	2	2.05	1.83	1.91	1.69	2	2	2	2
C07AB04	Acebutolol (DDD 0.40,g)	80	73	59	58	3	3	2	3	0.15	0.14	0.11	0.11	3	3	2	3
C07AB05	Betaxolol (DDD 20 mg)	247	227	90		1	1	1		0.68	0.63	0.25		1	1	1	
C07AB07	Bisoprolol (DDD 10 mg)	9,697	9,244	9,665	9,681	2	2	2	2	39.44	39.56	42.15	42.25	2	2	2	2
C07AB08	Celiprolol (DDD 0.20,g)	193	175	148	146	2	2	1	1	0.85	0.77	0.65	0.64	2	2	1	1
C07AB09	Esmolol (DDD 2.50,g)	25	26	26	38	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C07AB12	Nebivolol (DDD 5 mg)	488	484	463	385	1	1	1	1	1.69	1.74	1.79	1.81	1	1	1	1
C07AB14	Landiolol		2	1	1		100	100	100								
C07AG	Alpha and beta blocking agents	1,290	1,174	1,047	896	35	37	41	36	2.27	2.14	2.03	1.93	2	2	2	2
C07AG01	Labetalol (DDD 0.60,g)	592	593	503	442	74	73	83	71	0.09	0.09	0.05	0.07	8	7	13	7
C07AG02	Carvedilol (DDD 37.50 mg)	698	581	543	454	2	1	1	1	2.18	2.05	1.98	1.86	2	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C07B	Beta blocking agents and thiazides	1,320	1,194	1,048	873	0	0	0	0	3.72	3.40	3.06	2.61	0	0	0	0
C07BB	Beta blocking agents, selective, and thiazides	1,320	1,194	1,048	873	0	0	0	0	3.72	3.40	3.06	2.61	0	0	0	0
C07BB02	Metoprolol and thiazides (DDD 1,ED)	290	227	142	50	0	0	0	0	0.62	0.49	0.32	0.11	0	0	0	0
C07BB07	Bisoprolol and thiazides (DDD 1,ED)	982	923	867	784	0	0	0	0	3.09	2.91	2.74	2.50	0	0	0	0
C07BB12	Nebivolol and thiazides	48	44	38	38	0	0	0	0								
C07F	Beta blocking agents, other combinations	1,446	1,264	1,014	922	0	0	0	0	1.50	1.41	1.32	1.21	0	0	0	0
C07FB	Beta blocking agent and calcium channel blockers	1,446	1,264	1,014	922	0	0	0	0	1.50	1.41	1.32	1.21	0	0	0	0
C07FB02	Metoprolol and felodipine (DDD 1,ED)	1,446	1,264	1,014	922	0	0	0	0	1.50	1.41	1.32	1.21	0	0	0	0

**C08 Calcium channel blockers**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C08	Calcium channel blockers	16,292	12,799	11,381	11,080	3	4	4	3	90.14	95.51	99.50	104.32	1	1	1	1
C08C	Selective calcium channel blockers with mainly vascular effects	15,288	11,820	10,496	10,254	3	4	4	3	88.60	94.05	98.04	102.94	1	1	1	1
C08CA	Dihydropyridine derivatives	15,288	11,820	10,496	10,254	3	4	4	3	88.60	94.05	98.04	102.94	1	1	1	1
C08CA01	Amlodipine (DDD 5 mg)	4,786	4,208	4,357	4,632	1	1	1	1	61.62	66.49	69.36	72.79	1	1	1	1
C08CA02	Felodipine (DDD 5 mg)	3,345	2,712	2,250	1,878	1	1	1	1	7.46	7.58	7.56	7.92	1	1	1	1
C08CA03	Isradipine (DDD 5 mg)	139	13			1	1			0.22	0.02			1	1		
C08CA05	Nifedipine (DDD 30 mg)	911	735	506	407	3	2	2	2	1.69	1.02	0.68	0.54	2	2	2	2
C08CA06	Nimodipine	274	286	305	247	95	95	95	95	0.01	0.01	0.00	0.00	84	84	81	83
C08CA07	Nisoldipine (DDD 20 mg)	38	3			3	6			0.03	0.00			3	6		
C08CA10	Nilvadipine (DDD 8 mg)	463	434	427	440	1	1	2	1	0.77	0.72	0.71	0.73	1	1	1	1
C08CA13	Lercanidipine (DDD 10 mg)	5,332	3,430	2,652	2,650	1	1	1	1	16.81	18.21	19.73	20.96	1	1	1	1
C08D	Selective calcium channel blockers with direct cardiac effects	1,004	979	885	826	6	10	2	2	1.54	1.46	1.45	1.38	2	2	2	2
C08DA	Phenylalkylamine derivatives	285	309	243	244	16	25	1	2	0.73	0.72	0.75	0.74	2	3	2	2
C08DA01	Verapamil (DDD 0.24,g)	285	309	243	244	16	25	1	2	0.73	0.72	0.75	0.74	2	3	2	2
C08DB	Benzothiazepine derivatives	720	670	641	582	2	2	3	3	0.81	0.75	0.71	0.64	2	2	2	2
C08DB01	Diltiazem (DDD 0.24,g)	720	670	641	582	2	2	3	3	0.81	0.75	0.71	0.64	2	2	2	2

**C09 Agents acting on the renin-angiotensin system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C09	Agents acting on the renin-angiotensin system	46,444	43,195	38,543	34,466	1	1	1	1	253.02	264.30	274.79	280.96	1	1	1	1
C09A	Ace inhibitors, plain	9,221	8,175	6,223	5,212	2	1	1	1	104.81	103.84	103.85	101.22	2	1	1	1
C09AA	Ace inhibitors, plain	9,221	8,175	6,223	5,212	2	1	1	1	104.81	103.84	103.85	101.22	2	1	1	1
C09AA02	Enalapril (DDD 10 mg)	2,156	2,049	2,003	1,829	2	1	1	1	22.90	22.02	21.93	20.86	1	1	1	1
C09AA03	Lisinopril (DDD 10 mg)	731	680	557	310	2	2	1	2	3.69	3.63	3.48	3.31	1	1	1	1
C09AA04	Perindopril (DDD 4 mg)	1,734	1,711	1,575	1,138	1	1	1	1	4.60	4.69	4.59	4.45	1	1	1	1
C09AA05	Ramipril (DDD 2.50 mg)	4,570	3,736	2,079	1,930	2	2	1	1	73.52	73.49	73.82	72.59	2	1	1	1
C09AA06	Quinapril (DDD 15 mg)	30		8	4	1		2	0	0.10		0.03	0.01	1		2	0
C09AA15	Zofenopril (DDD 30 mg)		0				0				0.00				0		
C09B	Ace inhibitors, combinations	4,786	4,028	3,519	3,080	0	0	0	0	11.92	11.55	11.24	10.79	0	0	0	0
C09BA	Ace inhibitors and diuretics	3,503	2,990	2,433	1,976	0	0	0	0	10.10	9.53	9.09	8.61	0	0	0	0
C09BA02	Enalapril and diuretics (DDD 1,ED)	2,085	1,664	1,223	870	0	0	0	0	6.71	6.34	6.02	5.73	0	0	0	0
C09BA03	Lisinopril and diuretics (DDD 1,ED)	676	634	529	470	0	0	0	0	1.32	1.24	1.13	1.04	0	0	0	0
C09BA04	Perindopril and diuretics (DDD 1,ED)	537	523	505	473	0	0	0	0	1.01	1.00	0.97	0.93	1	0	0	0
C09BA05	Ramipril and diuretics (DDD 1,ED)	172	168	165	157	0	0	0	0	0.98	0.96	0.94	0.89	0	0	0	0
C09BA06	Quinapril and diuretics (DDD 1,ED)	33		11	6	0		1	0	0.08		0.03	0.02	0		1	0
C09BA15	Zofenopril and diuretics	0				0								0			
C09BB	Ace inhibitors and calcium channel blockers	935	747	777	799	0	0	0	0	1.47	1.60	1.67	1.72	0	0	0	0
C09BB02	Enalapril and lercanidipine (DDD 1,ED)	124	126	123	121	0	0	0	0	0.35	0.36	0.36	0.35	0	0	0	0
C09BB04	Perindopril and amlodipine (DDD 1,ED)	811	621	654	677	0	0	0	0	1.12	1.24	1.32	1.36	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C09BX	Ace inhibitors, other combinations	348	291	309	305	0	0	0	0	0.35	0.41	0.47	0.46	0	0	0	0
C09BX01	Perindopril, amlodipine and indapamide (DDD 1,ED)	334	275	293	299	0	0	0	0	0.33	0.38	0.43	0.44	0	0	0	0
C09BX02	Perindopril and bisoprolol (DDD 1,ED)	14	16	17	6	0	0	0	0	0.02	0.04	0.04	0.02	0	0	0	0
C09C	Angiotensin ii receptor blockers (ARBs), PLAIN	15,483	14,030	13,100	11,377	1	1	1	1	103.89	115.66	125.67	134.63	1	1	1	1
C09CA	Angiotensin ii receptor blockers (ARBs), plain	15,483	14,030	13,100	11,377	1	1	1	1	103.89	115.66	125.67	134.63	1	1	1	1
C09CA01	Losartan (DDD 50 mg)	7,571	6,533	5,458	3,486	1	1	1	1	42.26	47.21	49.44	52.12	1	1	1	1
C09CA02	Eprosartan (DDD 0.60,g)	321	288	202	75	2	1	2	2	0.37	0.35	0.27	0.11	2	1	2	2
C09CA03	Valsartan (DDD 80 mg)	2,249	1,940	2,146	2,094	2	1	1	1	15.12	14.79	16.00	16.68	1	1	1	1
C09CA06	Candesartan (DDD 8 mg)	4,083	4,199	3,927	3,915	1	1	1	1	36.71	43.16	49.04	54.38	1	1	1	1
C09CA07	Telmisartan (DDD 40 mg)	1,047	886	986	1,369	2	2	1	1	8.36	9.06	9.80	10.30	1	1	1	1
C09CA08	Olmesartan medoxomil (DDD 20 mg)	210	185	381	438	1	1	1	1	1.07	1.09	1.12	1.04	0	1	0	0
C09D	Angiotensin ii receptor blockers (ARBs), COMBINATIONS	16,954	16,962	15,700	14,798	1	1	1	1	32.40	33.26	34.03	34.32	0	0	0	0
C09DA	Angiotensin ii receptor blockers (ARBs) and diuretics	9,744	9,564	9,391	8,170	0	0	0	0	28.12	28.70	29.11	29.03	0	0	0	0
C09DA01	Losartan and diuretics (DDD 1,ED)	3,536	3,837	3,748	2,970	0	0	0	0	12.08	12.77	12.51	12.44	0	0	0	0
C09DA02	Eprosartan and diuretics (DDD 1,ED)	347	291	240	215	0	0	0	0	0.38	0.35	0.32	0.30	0	0	0	0
C09DA03	Valsartan and diuretics (DDD 1,ED)	1,256	1,137	1,103	1,035	0	0	0	0	4.76	4.42	4.53	4.50	0	0	0	0
C09DA06	Candesartan and diuretics (DDD 1,ED)	3,432	3,380	3,352	2,980	0	0	0	0	6.96	7.21	7.52	7.62	0	0	0	0
C09DA07	Telmisartan and diuretics (DDD 1,ED)	1,013	775	785	820	0	0	0	0	3.59	3.60	3.89	3.84	0	0	0	0
C09DA08	Olmesartan medoxomil and diuretics (DDD 1,ED)	159	145	164	149	0	0	0	0	0.35	0.35	0.35	0.32	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C09DB	Angiotensin ii receptor blockers (ARBs) and calcium channel blockers	3,295	2,452	1,369	935	0	0	0	0	2.59	2.67	2.81	2.99	0	0	0	0
C09DB01	Valsartan and amlodipine (DDD 1,ED)	3,173	2,384	1,284	864	0	0	0	0	2.47	2.56	2.68	2.86	0	0	0	0
C09DB02	Olmesartan medoxomil and amlodipine (DDD 1,ED)	122	68	85	71	0	0	1	0	0.12	0.11	0.14	0.12	0	0	1	0
C09DX	Angiotensin ii receptor blockers (ARBs), other combinations	3,915	4,946	4,941	5,693	2	2	2	2	1.69	1.89	2.11	2.30	1	1	1	1
C09DX01	Valsartan, amlodipine and hydrochlorothiazide (DDD 1,ED)	2,181	2,193	1,183	1,056	0	0	0	0	1.49	1.58	1.68	1.77	0	0	0	0
C09DX04	Valsartan and sacubitril (DDD 2,ED)	1,735	2,753	3,758	4,637	4	3	3	2	0.20	0.31	0.42	0.53	4	3	3	2

**C10 Lipid modifying agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C10	Lipid modifying agents	45,180	31,255	23,735	22,207	1	1	1	1	120.58	133.20	147.71	166.68	1	1	1	1
C10A	Lipid modifying agents, plain	44,808	31,136	23,544	21,825	2	2	1	1	120.42	133.10	147.59	166.53	1	1	1	1
C10AA	Hmg coa reductase inhibitors	38,828	27,758	19,190	15,960	1	1	1	1	114.75	125.96	138.43	153.84	1	1	1	1
C10AA01	Simvastatin (DDD 30 mg)	17,003	11,269	6,678	4,589	1	1	1	1	36.94	35.62	33.39	31.30	1	1	1	1
C10AA02	Lovastatin (DDD 45 mg)	240	211	229	70	1	1	1	1	0.31	0.30	0.31	0.09	1	1	1	1
C10AA03	Pravastatin (DDD 30 mg)	1,295	1,205	1,029	942	2	2	2	2	2.24	2.17	1.83	1.78	2	2	2	1
C10AA04	Fluvastatin (DDD 60 mg)	837	737	600	730	1	2	2	1	1.90	1.85	1.76	1.64	1	1	1	1
C10AA05	Atorvastatin (DDD 20 mg)	11,291	8,406	6,166	5,478	2	2	1	1	49.20	56.15	63.09	70.99	2	1	1	1
C10AA07	Rosuvastatin (DDD 10 mg)	8,162	5,929	4,488	4,150	1	1	1	1	24.16	29.86	38.06	48.05	1	1	1	1
C10AB	Fibrates	447	398	417	413	2	2	1	1	0.53	0.49	0.52	0.52	2	2	1	1
C10AB02	Bezafibrate (DDD 0.60,g)	77	86	88	98	1	1	1	1	0.06	0.07	0.07	0.08	1	1	1	1
C10AB04	Gemfibrozil (DDD 1.20,g)	20	22	17		1	2	3		0.02	0.03	0.02		1	2	3	
C10AB05	Fenofibrate (DDD 0.20,g)	350	290	311	315	2	2	1	2	0.44	0.39	0.42	0.44	2	2	1	2
C10AC	Bile acid sequestrants	173	244	15	142	2	3	0	2	0.06	0.09	0.00	0.05	2	3	0	2
C10AC01	Colestyramine (DDD 14,g)	159	232		135	2	3		2	0.06	0.09		0.05	2	3		2
C10AC04	Colesevelam (DDD 3.75,g)	14	12	15	7	0	0	0	2	0.00	0.00	0.00	0.00	0	0	0	2
C10AX	Other lipid modifying agents	5,360	2,736	3,922	5,310	2	3	1	1	5.08	6.56	8.64	12.12	1	1	1	1
C10AX09	Ezetimibe (DDD 10 mg)	4,874	1,831	1,561	1,388	2	3	2	1	5.06	6.53	8.54	11.96	1	1	1	1
C10AX13	Evolocumab (DDD 10 mg)	432	687	1,790	3,078	5	3	1	1	0.02	0.03	0.07	0.11	5	3	1	1
C10AX14	Alirocumab (DDD 5.40 mg)	54	218	571	823	0	0	1	0	0.00	0.01	0.03	0.05	0	0	1	0
C10AX16	Inclisiran				22				41				0.00				0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C10B	Lipid modifying agents, combinations	372	120	191	382	0	0	0	0	0.16	0.10	0.13	0.15	0	0	0	0
C10BA	Combinations of various lipid modifying agents	253	12	58	232	1	1	0	0	0.10	0.00	0.00	0.00	0	1	0	0
C10BA02	Simvastatin and ezetimibe (DDD 1,ED)	253	12			1	1			0.10	0.00			0	1		
C10BA06	Rosuvastatin and ezetimibe (DDD 1,ED)			58	232			0	0			0.00	0.00			0	0
C10BX	Lipid modifying agents in combination with other drugs	119	108	134	149	0	0	0	0	0.06	0.09	0.13	0.15	0	0	0	0
C10BX11	Atorvastatin, amlodipine and perindopril (DDD 1,ED)	119	105	117	139	0	0	0	0	0.06	0.09	0.13	0.15	0	0	0	0
C10BX15	Atorvastatin and perindopril (DDD 1,ED)		2	17	10			0	0			0.00	0.00			0	0



D Dermatologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D	Dermatologicals	41,751	43,205	43,110	47,210	4	4	4	5	2.85	2.97	2.89	3.04	1	1	1	1
D01	Antifungals for dermatological use	5,815	5,919	5,939	5,923	3	3	3	3	1.55	1.58	1.43	1.49	1	1	1	1
D02	Emollients and protectives	2,232	2,376	49	53	1	1	0	0								
D03	Preparations for treatment of wounds and ulcers	6,547	6,688	6,809	7,128	3	3	2	2								
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	330	425	379	644	0	0	0	0								
D05	Antipsoriatics	2,172	2,151	2,215	2,038	3	2	2	2	0.15	0.15	0.17	0.16	2	2	2	1
D06	Antibiotics and chemotherapeutics for dermatological use	5,072	4,980	4,719	4,737	4	3	3	3								
D07	Corticosteroids, dermatological preparations	11,526	11,804	12,266	12,537	3	3	3	3								
D08	Antiseptics and disinfectants	919	980	967	1,039	58	66	67	71								
D09	Medicated dressings	139	141	132	134	24	22	18	21								
D10	Anti-acne preparations	3,562	3,531	3,672	3,746	1	1	1	1	1.07	1.15	1.19	1.24	1	1	1	1
D11	Other dermatological preparations	3,436	4,210	5,964	9,231	4	1	5	6	0.08	0.09	0.11	0.15	1	0	3	4



D01 Antifungals for dermatological use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D01	Antifungals for dermatological use	5,815	5,919	5,939	5,923	3	3	3	3	1.55	1.58	1.43	1.49	1	1	1	1
D01A	Antifungals for topical use	4,667	4,752	4,885	4,871	4	4	3	3								
D01AA	Antibiotics	44	44	47	44	4	2	2	2								
D01AA02	Natamycin	44	44	47	44	4	2	2	2								
D01AC	Imidazole and triazole derivatives	3,022	3,139	3,292	3,288	5	5	4	4								
D01AC01	Clotrimazole	256	250	224	214	1	1	1	1								
D01AC02	Miconazole	977	982	993	999	8	8	7	7								
D01AC07	Tioconazole	29	20	43	40	2	1	0	0								
D01AC08	Ketoconazole	960	1,062	1,159	1,168	2	2	1	1								
D01AC10	Bifonazole			39	29				0								
D01AC20	Imidazoles/triazoles in combination with corticosteroids	800	825	834	837	7	7	6	6								
D01AE	Other antifungals for topical use	1,601	1,568	1,546	1,539	1	1	1	1								
D01AE14	Ciclopirox	70	61	47	49	0	0	0	0								
D01AE15	Terbinafine	1,335	1,303	1,311	1,282	2	1	1	1								
D01AE16	Amorolfine	196	204	188	208	0	0	1	1								
D01B	Antifungals for systemic use	1,148	1,168	1,054	1,052	1	1	1	1	1.55	1.58	1.43	1.49	1	1	1	1
D01BA	Antifungals for systemic use	1,148	1,168	1,054	1,052	1	1	1	1	1.55	1.58	1.43	1.49	1	1	1	1
D01BA02	Terbinafine (DDD 0.25,g)	1,148	1,168	1,054	1,052	1	1	1	1	1.55	1.58	1.43	1.49	1	1	1	1

**D02 Emollients and protectives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D02	Emollients and protectives	2,232	2,376	49	53	1	1	0	0								
D02A	Emollients and protectives	2,232	2,376	49	53	1	1	0	0								
D02AE	Carbamide products	1,198	1,287	29	32	1	1	0	1								
D02AE01	Carbamide	1,198	1,287	29	32	1	1	0	1								
D02AX	Other emollients and protectives	2,068	2,178	40	42	1	1	0	0								

D03 Preparations for treatment of wounds and ulcers

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D03	Preparations for treatment of wounds and ulcers	6,547	6,688	6,809	7,128	3	3	2	2								
D03A	Cicatrizants	6,492	6,688	6,809	7,128	3	3	2	2								
D03AX	Other cicatrizants	6,492	6,688	6,809	7,128	3	3	2	2								
D03AX03	Dexpanthenol	6,492	6,688	6,809	7,128	3	3	2	2								
D03B	Enzymes	55								68							
D03BA	Proteolytic enzymes	55								68							
D03BA02	Collagenase	55								68							

**D04 Antipruritics, incl. antihistamines, anesthetics, etc.**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	330	425	379	644	0	0	0	0								
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.	330	425	379	644	0	0	0	0								
D04AA	Antihistamines for topical use	330	425	379	644	0	0	0	0								
D04AA04	Tripelennamine	330	425	379	644	0	0	0	0								

D05 Antipsoriatics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D05	Antipsoriatics	2,172	2,151	2,215	2,038	3	2	2	2	0.15	0.15	0.17	0.16	2	2	2	1
D05A	Antipsoriatics for topical use	1,777	1,860	1,908	1,739	3	3	2	2								
D05AX	Other antipsoriatics for topical use	1,777	1,860	1,908	1,739	3	3	2	2								
D05AX02	Calcipotriol	38	42	44	43	3	3	2	2								
D05AX03	Calcitriol	42	38	29	26	3	3	2	1								
D05AX52	Calcipotriol, combinations	1,696	1,779	1,836	1,670	3	3	2	2								
D05B	Antipsoriatics for systemic use	395	291	306	300	2	2	2	1	0.15	0.15	0.17	0.16	2	2	2	1
D05BB	Retinoids for treatment of psoriasis	395	291	306	300	2	2	2	1	0.15	0.15	0.17	0.16	2	2	2	1
D05BB02	Acitretin (DDD 35 mg)	395	291	306	300	2	2	2	1	0.15	0.15	0.17	0.16	2	2	2	1

**D06 Antibiotics and chemotherapeutics for dermatological use**

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day				
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	
D06 Antibiotics and chemotherapeutics for dermatological use	5,072	4,980	4,719	4,737	4	3	3	3						
D06A Antibiotics for topical use	2,250	2,289	2,221	2,311	6	5	5	5						
D06AX Other antibiotics for topical use	2,250	2,289	2,221	2,311	6	5	5	5						
D06AX01 Fusidic acid	968	1,046	1,016	996	11	9	9	9						
D06AX04 Neomycin	1,258	1,216	1,180	1,293	1	1	1	1						
D06AX09 Mupirocin	24	26	26	23	15	16	16	18						
D06B Chemotherapeutics for topical use	2,822	2,691	2,498	2,425	2	1	1	1						
D06BA Sulfonamides	74				56									
D06BA01 Silver sulfadiazine	74				56									
D06BB Antivirals	2,246	2,182	2,151	2,099	1	1	1	1						
D06BB03 Aciclovir	1,173	1,158	1,129	1,136	1	1	1	1						
D06BB04 Podophyllotoxin	66				3									
D06BB06 Penciclovir	202	245	195	190	0	0	0	0						
D06BB10 Imiquimod	495	516	631	590	1	1	1	1						
D06BB53 Aciclovir, combinations	310	262	196	183	0	0	0	0						
D06BX Other chemotherapeutics	502	509	347	326	0	0	0	0						
D06BX01 Metronidazole	349	353	342	326	0	0	0	0						
D06BX02 Ingenol mebutate	153	156	5		1	0	0							

**D07 Corticosteroids, dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D07	Corticosteroids, dermatological preparations	11,526	11,804	12,266	12,537	3	3	3	3								
D07A	Corticosteroids, plain	7,894	8,137	8,632	8,905	3	3	3	3								
D07AA	Corticosteroids, weak (group I)	3,527	3,589	3,724	3,995	2	2	1	1								
D07AA02	Hydrocortisone	3,527	3,589	3,724	3,995	2	2	1	1								
D07AB	Corticosteroids, moderately potent (group II)	1,359	1,305	1,508	1,509	4	3	3	3								
D07AB01	Clobetasone	8	9	9	1	1	0	0	0								
D07AB02	Hydrocortisone butyrate	714	861	929	872	3	2	2	2								
D07AB08	Desonide	637	435	570	636	5	5	4	4								
D07AC	Corticosteroids, potent (group III)	2,377	2,626	2,624	2,594	5	5	4	4								
D07AC01	Betamethasone	1,431	1,622	1,666	1,813	6	6	5	5								
D07AC03	Desoximetasone	70	81	32		11	6	10									
D07AC13	Mometasone	839	884	890	749	2	2	2	2								
D07AC14	Methylprednisolone aceponate	38	40	36	32	0	0	0	0								
D07AD	Corticosteroids, very potent (group IV)	630	617	776	806	4	4	3	3								
D07AD01	Clobetasol	630	617	776	806	4	4	3	3								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D07B	Corticosteroids, combinations with antiseptics	1,262	1,232	1,247	1,237	3	3	3	3								
D07BA	Corticosteroids, weak, combinations with antiseptics	765	748	727	714	3	2	2	2								
D07BA04	Hydrocortisone and antiseptics	765	748	727	714	3	2	2	2								
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	307	349	349	349	3	3	3	3								
D07BB04	Hydrocortisone butyrate and antiseptics	307	349	349	349	3	3	3	3								
D07BC	Corticosteroids, potent, combinations with antiseptics	190	135	171	174	5	6	5	5								
D07BC01	Betamethasone and antiseptics	190	135	171	174	5	6	5	5								
D07C	Corticosteroids, combinations with antibiotics	1,569	1,625	1,591	1,608	4	4	4	4								
D07CA	Corticosteroids, weak, combinations with antibiotics	921	949	925	933	4	4	4	4								
D07CA01	Hydrocortisone and antibiotics	921	949	925	933	4	4	4	4								
D07CC	Corticosteroids, potent, combinations with antibiotics	648	676	666	675	4	4	4	4								
D07CC01	Betamethasone and antibiotics	648	676	666	675	4	4	4	4								
D07X	Corticosteroids, other combinations	802	809	796	787	2	2	2	2								
D07XA	Corticosteroids, weak, other combinations	294	300	272	274	0	0	0	0								
D07XA01	Hydrocortisone	294	300	272	274	0	0	0	0								
D07XC	Corticosteroids, potent, other combinations	508	509	524	512	3	3	3	3								
D07XC01	Betamethasone, combinations	508	509	524	512	3	3	3	3								



D08 Antiseptics and disinfectants

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D08	Antiseptics and disinfectants	919	980	967	1,039	58	66	67	71								
D08A	Antiseptics and disinfectants	919	980	967	1,039	58	66	67	71								
D08AC	Biguanides and amidines	549	655	635	721	92	96	99	99								
D08AC02	Chlorhexidine	167	64	41	40	72	55	90	89								
D08AC52	Chlorhexidine, combinations	382	591	593	680	100	100	100	100								
D08AG	Iodine products	370	326	332	318	7	7	6	7								
D08AG02	Povidone-iodine	370	326	332	318	7	7	6	7								

D09 Medicated dressings

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D09	Medicated dressings	139	141	132	134	24	22	18	21								
D09A	Medicated dressings	139	141	132	134	24	22	18	21								
D09AA	Ointment dressings with antiinfectives	13				36											
D09AA02	Fusidic acid	13				36											
D09AB	Zinc bandages	126	141	132	134	22	22	18	21								
D09AB01	Zinc bandage without supplements	126	141	132	134	22	22	18	21								

**D10 Anti-acne preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D10	Anti-acne preparations	3,562	3,531	3,672	3,746	1	1	1	1	1.07	1.15	1.19	1.24	1	1	1	1
D10A	Anti-acne preparations for topical use	2,162	2,144	2,317	2,378	1	1	1	1								
D10AD	Retinoids for topical use in acne	840	908	882	919	2	2	2	2								
D10AD01	Tretinoin	174	206	235	223	0	0	1	0								
D10AD03	Adapalene	179	190	167	155	1	1	1	1								
D10AD53	Adapalene, combinations	487	512	480	542	3	3	3	3								
D10AE	Peroxides	474	452	461	461	1	0	0	0								
D10AE01	Benzoyl peroxide	474	452	461	461	1	0	0	0								
D10AF	Antiinfectives for treatment of acne	669	606	790	805	1	1	1	1								
D10AF01	Clindamycin	138	219	221	216	2	2	1	1								
D10AF51	Clindamycin, combinations	532	387	570	589	1	1	1	1								
D10AX	Other anti-acne preparations for topical use	179	177	183	193	0	0	1	0								
D10AX03	Azelaic acid	179	177	183	193	0	0	1	0								
D10B	Anti-acne preparations for systemic use	1,400	1,387	1,356	1,367	1	1	1	1	1.07	1.15	1.19	1.24	1	1	1	1
D10BA	Retinoids for treatment of acne	1,400	1,387	1,356	1,367	1	1	1	1	1.07	1.15	1.19	1.24	1	1	1	1
D10BA01	Isotretinoin (DDD 30 mg)	1,400	1,387	1,356	1,367	1	1	1	1	1.07	1.15	1.19	1.24	1	1	1	1

**D11 Other dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D11	Other dermatological preparations	3,436	4,210	5,964	9,231	4	1	5	6	0.08	0.09	0.11	0.15	1	0	3	4
D11A	Other dermatological preparations	3,436	4,210	5,964	9,231	4	1	5	6	0.08	0.09	0.11	0.15	1	0	3	4
D11AC	Medicated shampoos	96	107	113	107	0	0	0	0								
D11AC03	Selenium compounds	96	107	113	107	0	0	0	0								
D11AH	Agents for dermatitis, excluding corticosteroids	2,033	2,679	4,318	7,487	6	2	7	8	0.02	0.03	0.05	0.09	6	1	7	7
D11AH01	Tacrolimus	1,234	884	993	979	3	2	2	2								
D11AH02	Pimecrolimus	365	579	438	447	2	1	1	1					0	0	0	0
D11AH04	Alitretinoin (DDD 20 mg)	321	316	340	187	1	0	0	0	0.02	0.02	0.02	0.02	1	0	0	0
D11AH05	Dupilumab (DDD 21.40 mg)	112	899	2,548	5,874	71	2	11	10	0.00	0.01	0.03	0.07	70	2	11	10
D11AX	Other dermatologicals	1,308	1,424	1,532	1,637	0	0	0	0	0.07	0.06	0.06	0.06	0	0	0	0
D11AX01	Minoxidil	725	780	887	971	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
D11AX10	Finasteride (DDD 1 mg)	223	212	205	217	0	0	0	0	0.07	0.06	0.06	0.06	0	0	0	0
D11AX16	Eflornithine	33	56	44	39	0	0	0	0								
D11AX18	Diclofenac	5	5	5	3	5	3	0	0								
D11AX21	Brimonidine	106	112	95	97	0	0	0	1								
D11AX22	Ivermectin	208	251	295	305	0	0	0	0								
D11AX24	Deoxycholic acid	8	8	2	5	20	33	0	0								
D11AX16	Eflornitiini	41	33	56	44	0	0		0								
D11AX18	Diklofenaakki	5	5	5	5	2	5	3									
D11AX21	Brimonidiini	119	106	112	95	0	0	0	1								
D11AX22	Ivermektiini	187	208	251	295	0	0	0	1								
D11AX24	Deoksikoolihappo	13	8	8	2	20	20	33									



G Genito urinary system and sex hormones

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G	Genito urinary system and sex hormones	110,634	112,664	104,274	91,992	6	6	6	7	134.39	138.42	138.08	139.31	6	8	8	8
G01	Gynecological antiinfectives and antiseptics	3,266	3,425	3,223	3,162	1	1	1	1	0.80	0.81	0.75	0.75	1	1	1	1
G02	Other gynecologicals	7,882	8,154	7,702	7,594	34	37	39	39	2.90	2.77	2.38	2.18	9	12	12	11
G03	Sex hormones and modulators of the genital system	57,759	59,593	56,738	50,332	5	6	5	6	80.43	83.16	81.49	81.18	9	12	12	12
G04	Urologicals	41,727	41,493	36,611	30,904	2	2	2	2	50.27	51.68	53.46	55.19	2	2	2	2

**G01 Gynecological antiinfectives and antiseptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G01	Gynecological antiinfectives and antiseptics	3,266	3,425	3,223	3,162	1	1	1	1	0.80	0.81	0.75	0.75	1	1	1	1
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	3,266	3,425	3,223	3,162	1	1	1	1	0.80	0.81	0.75	0.75	1	1	1	1
G01AA	Antibiotics	395	408	426	391	1	0	0	0	0.06	0.06	0.07	0.06	1	0	1	0
G01AA10	Clindamycin (DDD 0.10,g)	395	408	426	391	1	0	0	0	0.06	0.06	0.07	0.06	1	0	1	0
G01AC	Quinoline derivatives	153	216	229	229	0	0	0	0	0.01	0.01	0.02	0.02	0	0	0	0
G01AC05	Dequalinium (DDD 20 mg)	153	216	229	229	0	0	0	0	0.01	0.01	0.02	0.02	0	0	0	0
G01AF	Imidazole derivatives	2,718	2,801	2,567	2,543	1	1	1	1	0.72	0.73	0.67	0.67	1	1	1	1
G01AF01	Metronidazole	855	831	769	723	1	1	1	1	0.17	0.17	0.16	0.15	1	1	1	1
G01AF02	Clotrimazole (DDD 0.10,g)	1,670	1,790	1,674	1,716	1	0	1	1	0.41	0.42	0.42	0.43	1	0	1	1
G01AF04	Miconazole (DDD 0.10,g)	193	180	124	104	2	2	2	2	0.15	0.14	0.10	0.08	2	2	2	2

**G02 Other gynecologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G02	Other gynecologicals	7,882	8,154	7,702	7,594	34	37	39	39	2.90	2.77	2.38	2.18	9	12	12	11
G02A	Uterotonics	87	75	72	121	99	100	100	100	0.00	0.00	0.00	0.00	43	100	100	100
G02AB	Ergot alkaloids	1				31				0.00				31			
G02AB01	Methylergometrine (DDD 0.20 mg)	1				31				0.00				31			
G02AD	Prostaglandins	86	75	72	121	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02AD02	Dinoprostone (DDD 0.50 mg)		7	12	10		100	100	100		0.00	0.00	0.00		100	100	100
G02AD06	Misoprostol (DDD 0.20 mg)	86	69	60	111	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02B	Contraceptives for topical use	7,370	7,702	7,195	7,136	31	34	35	36	2.86	2.74	2.35	2.16	9	12	12	11
G02BA	Intrauterine contraceptives	5,540	6,074	5,914	6,000	39	41	42	42								
G02BA03	Plastic iud with progestogens	5,540	6,074	5,914	6,000	39	41	42	42								
G02BB	Intravaginal contraceptives	1,830	1,627	1,280	1,137	4	7	5	5	2.86	2.74	2.35	2.16	9	12	12	11
G02BB01	Vaginal ring with progestogen and estrogen (DDD 0.04,ED)	1,830	1,627	1,280	1,137	4	7	5	5	2.86	2.74	2.35	2.16	9	12	12	11
G02C	Other gynecologicals	425	377	435	336	84	87	87	85	0.03	0.03	0.03	0.02	10	10	10	12
G02CB	Prolactin inhibitors	75	54	60	55	11	10	9	10	0.03	0.02	0.03	0.02	9	8	9	11
G02CB01	Bromocriptine (DDD 5 mg)	24	18	20	15	9	7	9	11	0.03	0.02	0.02	0.02	9	7	9	11
G02CB03	Cabergoline (DDD 0.50 mg)	45	35	40	40	13	11	9	10	0.01	0.01	0.01	0.01	13	11	9	10
G02CB04	Quinagolide (DDD 75,mcg)	6				0				0.00				0			
G02CX	Other gynecologicals	350	323	376	282	100	100	99	99	0.00	0.00	0.00	0.00	100	100	99	99
G02CX01	Atosiban (DDD 165 mg)	350	323	376	282	100	100	99	99	0.00	0.00	0.00	0.00	100	100	99	99

**G03 Sex hormones and modulators of the genital system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G03	Sex hormones and modulators of the genital system	57,759	59,593	56,738	50,332	5	6	5	6	80.43	83.16	81.49	81.18	9	12	12	12
G03A	Hormonal contraceptives for systemic use	18,883	18,635	17,760	17,871	14	16	15	15	43.77	45.38	43.66	43.25	16	21	21	22
G03AA	Progestogens and estrogens, fixed combinations	11,321	10,467	9,633	9,221	12	15	13	14	26.00	25.62	24.51	24.17	14	19	19	21
G03AA07	Levonorgestrel and ethinylestradiol	160	170	227	233	3	4	12	17	0.59	0.60	0.81	0.94	5	5	20	24
G03AA09	Desogestrel and ethinylestradiol	984	886	779	694	8	7	4	5	3.43	3.08	2.90	2.75	9	10	15	18
G03AA10	Gestodene and ethinylestradiol	1,370	1,327	1,173	1,023	3	5	4	5	5.08	5.25	4.62	4.11	9	15	15	16
G03AA11	Norgestimate and ethinylestradiol	13	7	0		1	1	0		0.03	0.02	0.00		1	1	0	
G03AA12	Drospirenone and ethinylestradiol	6,534	6,506	5,762	5,264	15	18	15	16	12.78	13.14	12.10	11.45	17	21	20	21
G03AA13	Norelgestromin and ethinylestradiol (DDD 0.11,ED)	289	265	253	238	5	8	10	12	0.48	0.44	0.42	0.40	5	8	10	12
G03AA14	Nomegestrol and estradiol (DDD 1,ED)	1,847	860	770	960	12	20	14	13	3.13	1.51	1.30	1.62	12	23	14	13
G03AA16	Dienogest and ethinylestradiol	125	446	669	810	24	20	15	14	0.47	1.58	2.37	2.90	45	37	31	31
G03AB	Progestogens and estrogens, sequential preparations	918	1,097	996	881	6	8	9	7	1.50	1.75	1.58	1.39	6	8	9	7
G03AB03	Levonorgestrel and ethinylestradiol (DDD 0.75,ED)	40	0			0	0			0.09	0.00			0	0		
G03AB05	Desogestrel and ethinylestradiol	6	2			0	0			0.01	0.00			0	0		
G03AB06	Gestodene and ethinylestradiol (DDD 0.75,ED)	20	2			0	0			0.04	0.00			0	0		
G03AB08	Dienogest and estradiol (DDD 1,ED)	851	1,092	996	881	6	8	9	7	1.36	1.74	1.58	1.39	6	8	9	7
G03AC	Progestogens	5,547	5,995	6,173	6,900	20	22	21	21	16.22	17.96	17.53	17.64	21	25	26	26
G03AC01	Norethisterone	240	228	165	60	2	2	3	4	0.85	0.89	0.71	0.26	2	2	3	4
G03AC03	Levonorgestrel (DDD 1,ED)	272	274	267	247	23	18	22	15	0.45	0.46	0.41	0.41	11	8	8	6

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G03AC08	Etonogestrel (DDD 67,mcg)	925	1,031	985	1,059	49	56	59	58	3.99	4.69	4.50	4.91	48	55	59	58
G03AC09	Desogestrel (DDD 1,ED)	4,111	4,462	4,100	3,586	14	16	12	12	10.93	11.92	11.91	12.07	13	16	15	14
G03AC10	Drospirenone			656	1,948			22	18			0.00	0.00			0	0
G03AD	Emergency contraceptives	1,098	1,077	958	869	2	2	2	2	0.05	0.05	0.04	0.04	2	2	2	2
G03AD01	Levonorgestrel	554	521	464	428	2	3	2	2	0.03	0.03	0.02	0.02	2	3	2	3
G03AD02	Ulipristal (DDD 30 mg)	544	556	494	441	1	1	2	2	0.02	0.02	0.02	0.02	1	1	1	1
G03B	Androgens	4,943	5,809	5,915	5,971	0	0	0	0	1.99	2.31	2.43	2.50	0	0	0	0
G03BA	3-oxoandrostens (4) derivatives	4,943	5,809	5,915	5,971	0	0	0	0	1.99	2.31	2.43	2.50	0	0	0	0
G03BA03	Testosterone	4,943	5,809	5,915	5,971	0	0	0	0	1.99	2.31	2.43	2.50	0	0	0	0
G03C	Estrogens	22,319	23,582	22,134	14,885	1	1	1	1	18.99	20.08	20.84	21.13	1	1	1	1
G03CA	Natural and semisynthetic estrogens, plain	21,997	23,348	21,922	14,704	1	1	1	1	18.28	19.44	20.22	20.59	1	1	1	1
G03CA03	Estradiol	20,136	20,944	18,980	12,042	1	1	1	0	12.77	13.63	14.61	15.45	0	0	0	0
G03CA04	Estriol	1,861	2,404	2,942	2,662	1	1	1	1	5.52	5.81	5.62	5.14	1	1	2	2
G03CC	Estrogens, combinations with other drugs		15	7													
G03CC07	Conjugated estrogens and bazedoxifene		15	7													
G03CX	Other estrogens	322	219	205	180	0	0	0	0	0.70	0.65	0.62	0.54	0	0	0	0
G03CX01	Tibolone (DDD 2.50 mg)	322	219	205	180	0	0	0	0	0.70	0.65	0.62	0.54	0	0	0	0
G03D	Progestogens	1,473	1,462	1,490	1,503	0	0	0	0	2.32	2.30	2.23	2.38	1	0	0	0
G03DA	Pregnen (4) derivatives	533	449	427	449	0	0	0	0	0.43	0.46	0.54	0.59	1	1	0	0
G03DA02	Medroxyprogesterone	40	55	69	64	1	1	0	1	0.21	0.29	0.37	0.34	1	1	0	1
G03DA04	Progesterone	493	393	357	385	0	0	0	0	0.22	0.17	0.17	0.24	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G03DB	Pregnadien derivatives	428	490	619	611	0	0	0	0	0.47	0.54	0.71	0.72	0	0	0	0
G03DB01	Dydrogesterone (DDD 10 mg)	206	240	317	311	0	0	0	0	0.38	0.44	0.58	0.57	0	0	0	0
G03DB08	Dienogest (DDD 2 mg)	222	250	302	300	0	0	0	0	0.09	0.10	0.13	0.15	0	0	0	0
G03DC	Estren derivatives	512	524	445	443	1	0	1	1	1.42	1.30	0.98	1.08	1	0	1	1
G03DC02	Norethisterone (DDD 5 mg)	456	478	445	397	0	0	1	1	1.18	1.11	0.98	0.88	0	0	1	0
G03DC03	Lynestrenol (DDD 5 mg)	57	47		46	2	1		1	0.24	0.20		0.20	2	1		1
G03F	Progestogens and estrogens in combination	4,154	4,236	3,935	4,192	0	0	0	0	9.72	9.79	9.45	9.53	0	0	0	0
G03FA	Progestogens and estrogens, combinations	3,351	3,458	3,249	3,458	0	0	0	0	7.60	7.78	7.59	7.68	0	0	0	0
G03FA01	Norethisterone and estrogen	1,268	1,366	1,085	1,422	0	0	0	0	2.94	3.07	2.63	3.03	0	0	0	0
G03FA12	Medroxyprogesterone and estrogen (DDD 1,ED)	548	527	515	500	0	0	0	0	1.23	1.18	1.15	1.12	0	0	0	0
G03FA14	Dydrogesterone and estrogen (DDD 1,ED)	1,188	1,250	1,403	1,297	0	0	0	0	2.96	3.11	3.48	3.22	0	0	0	0
G03FA17	Drospirenone and estrogen (DDD 1,ED)	347	315	246	238	0	0	0	0	0.47	0.42	0.33	0.32	0	0	0	0
G03FB	Progestogens and estrogens, sequential preparations	803	778	686	735	0	0	0	0	2.12	2.01	1.86	1.85	0	0	0	0
G03FB05	Norethisterone and estrogen	291	287	185	266	0	0	0	0	0.70	0.66	0.51	0.58	0	0	0	0
G03FB06	Medroxyprogesterone and estrogen	33	28	21	16	0	0	0	0	0.15	0.13	0.09	0.08	0	0	0	0
G03FB08	Dydrogesterone and estrogen (DDD 1,ED)	478	464	479	452	0	0	0	0	1.27	1.22	1.26	1.19	0	0	0	0
G03G	Gonadotrophins and other ovulation stimulants	4,401	4,392	4,302	4,832	0	0	1	1	0.22	0.17	0.24	0.28	0	0	0	0
G03GA	Gonadotrophins	4,401	4,392	4,302	4,832	0	0	1	1	0.22	0.17	0.24	0.28	0	0	0	0
G03GA01	Chorionic gonadotrophin (DDD 250,U)	143	59	109	125	0	0	0	0	0.13	0.08	0.16	0.18	0	0	0	0
G03GA02	Human menopausal gonadotrophin (DDD 75,U)	1,138	1,214	1,327	1,667	0	0	0	0	0.03	0.03	0.03	0.05	0	0	0	0
G03GA04	Urofollitropin (DDD 75,U)	56	26	38	24	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G03GA05 Follitropin alfa (DDD 75,U)	1,769	1,860	1,783	1,962	0	0	1	2	0.05	0.05	0.05	0.05	0	0	1	2
G03GA06 Follitropin beta (DDD 75,U)	216	43	13		0	0	0		0.01	0.00	0.00		0	0	0	
G03GA07 Lutropin alfa (DDD 75,U)	1	1	1		8	0	0		0.00	0.00	0.00		8	0	0	
G03GA08 Choriogonadotropin alfa (DDD 0.25 mg)	178	235	191	206	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
G03GA09 Corifollitropin alfa (DDD 0.15 mg)	290	249	177	176	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
G03GA30 Combinations	610	706	662	672	0	0	0	0					0	0	0	0
G03H Antiandrogens	1,261	1,152	938	592	1	1	1	1	3.39	3.10	2.56	1.95	3	3	3	3
G03HA Antiandrogens, plain preparations	135	121	103	90	7	5	5	6	0.05	0.05	0.04	0.04	6	5	5	6
G03HA01 Cyproterone (DDD 0.10,g)	135	121	103	90	7	5	5	6	0.05	0.05	0.04	0.04	6	5	5	6
G03HB Antiandrogens and estrogens	1,126	1,031	835	503	1	1	1	1	3.34	3.05	2.51	1.92	3	3	3	3
G03HB01 Cyproterone and estrogen (DDD 0.75,ED)	1,126	1,031	835	503	1	1	1	1	3.34	3.05	2.51	1.92	3	3	3	3
G03X Other sex hormones and modulators of the genital system	325	323	264	485	47	48	73	64	0.03	0.03	0.06	0.15	23	19	9	4
G03XB Progesterone receptor modulators	325	311	203	323	47	50	95	97	0.03	0.02	0.01	0.01	23	25	84	87
G03XB01 Mifepristone (DDD 0.20,g)	152	155	194	316	100	99	99	99	0.01	0.01	0.01	0.01	100	99	99	99
G03XB02 Ulipristal (DDD 5 mg)	172	156	9	7	0	0	-3	0	0.02	0.02	0.00	0.00	0	0	-3	0
G03XX Other sex hormones and modulators of the genital system		12	61	162		0	0	0		0.01	0.05	0.14		0	0	0
G03XX01 Prasterone (DDD 6.50 mg)		12	61	162		0	0	0		0.01	0.05	0.14		0	0	0

**G04 Urologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G04	Urologicals	41,727	41,493	36,611	30,904	2	2	2	2	50.27	51.68	53.46	55.19	2	2	2	2
G04B	Urologicals	20,940	20,964	19,732	18,728	2	2	2	2	18.22	18.67	19.26	20.03	1	1	2	1
G04BD	Drugs for urinary frequency and incontinence	12,375	12,301	11,975	12,478	2	2	2	2	6.79	7.15	7.30	7.66	2	2	2	2
G04BD04	Oxybutynin	217	211	202	134	2	2	2	2	0.14	0.13	0.13	0.09	2	2	2	2
G04BD07	Tolterodine (DDD 4 mg)	405	310	289	229	4	3	3	3	0.31	0.25	0.24	0.21	3	3	2	3
G04BD08	Solifenacin (DDD 5 mg)	2,340	1,463	670	548	2	3	3	2	1.51	1.49	1.35	1.37	2	1	2	2
G04BD09	Tropium (DDD 40 mg)	229	205	194	189	1	1	1	1	0.21	0.19	0.18	0.18	2	1	1	1
G04BD10	Darifenacin (DDD 7.50 mg)	84	51	38	39	4	3	2	2	0.06	0.04	0.03	0.03	3	2	2	2
G04BD11	Fesoterodine (DDD 4 mg)	841	718	611	559	2	2	2	2	0.55	0.49	0.44	0.41	2	2	1	2
G04BD12	Mirabegron (DDD 50 mg)	8,259	9,343	9,971	10,781	2	2	2	2	4.02	4.56	4.94	5.38	2	2	2	2
G04BE	Drugs used in erectile dysfunction	7,449	7,613	6,668	5,184	1	1	1	1	8.11	8.39	8.68	9.16	0	0	0	0
G04BE01	Alprostadil	825	666	419	560	1	0	0	0	0.06	0.04	0.04	0.03	0	0	0	0
G04BE03	Sildenafil (DDD 50 mg)	1,744	2,161	2,285	2,238	3	2	2	1	7.38	7.56	7.63	7.73	0	0	0	0
G04BE08	Tadalafil (DDD 10 mg)	4,620	4,516	3,678	2,153	0	0	0	0	0.65	0.77	0.99	1.38	0	0	0	0
G04BE09	Vardenafil (DDD 10 mg)	128	105	76	66	0	0	0	0	0.01	0.02	0.01	0.01	0	0	0	0
G04BE10	Avanafil (DDD 0.10,g)	69	60	56	51	0	0	0	0	0.01	0.01	0.01	0.01	0	0	0	0
G04BE30	Combinations (DDD 1,ED)	62	105	155	115	2	2	0	1	0.00	0.00	0.00	0.00	2	2	0	1
G04BX	Other urologicals	1,115	1,051	1,089	1,066	2	2	4	4	3.32	3.13	3.28	3.22	3	2	4	4
G04BX01	Magnesium hydroxide (DDD 0.50,g)	1,071	1,007	1,042	1,023	3	2	4	4	3.31	3.12	3.27	3.21	3	2	4	4
G04BX14	Dapoxetine (DDD 30 mg)	45	44	47	43					0.01	0.01	0.01	0.01				

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G04C	Drugs used in benign prostatic hypertrophy	20,787	20,528	16,880	12,176	2	2	2	2	32.05	33.01	34.20	35.15	2	2	2	2
G04CA	Alpha-adrenoreceptor antagonists	14,689	14,681	11,227	7,141	2	1	1	2	22.80	23.73	24.79	26.05	2	2	2	1
G04CA01	Alfuzosin (DDD 7.50 mg)	2,527	1,981	1,901	1,371	1	1	1	1	5.60	5.79	6.08	6.27	1	1	1	1
G04CA02	Tamsulosin (DDD 0.40 mg)	3,449	3,494	3,489	3,473	2	2	2	2	11.27	11.69	12.07	12.70	2	2	2	2
G04CA52	Tamsulosin and dutasteride (DDD 1,ED)	8,631	9,126	5,773	2,229	1	1	1	2	5.89	6.22	6.62	7.05	1	1	1	1
G04CA53	Tamsulosin and solifenacin (DDD 1,ED)	82	81	64	68	1	0	0	0	0.03	0.03	0.03	0.03	1	0	0	0
G04CB	Testosterone-5-alpha reductase inhibitors	5,480	5,353	5,231	4,674	2	2	2	2	8.40	8.64	8.85	8.60	2	2	2	2
G04CB01	Finasteride (DDD 5 mg)	4,778	4,865	4,787	4,255	2	2	2	2	6.35	6.18	6.05	5.71	2	2	2	2
G04CB02	Dutasteride (DDD 0.50 mg)	702	487	444	419	3	2	2	2	2.05	2.46	2.79	2.89	3	2	2	2
G04CX	Other drugs used in benign prostatic hypertrophy	618	495	421	361	0	0	0	0	0.85	0.64	0.56	0.51	0	0	0	0
G04CX02	Sabalis serrulatae fructus (DDD 0.32,g)	618	495	421	361	0	0	0	0	0.85	0.64	0.56	0.51	0	0	0	0
G04CB02	Dutasteridi (DDD 0.50 mg)	1,312	702	487	444	3	3	2	2	1.90	2.05	2.46	2.79	3	3	2	2
G04CX	Muut hyvänlaatuisen eturauhasen liikakasvun lääkkeet	547	618	495	421					0.74	0.85	0.64	0.56				
G04CX02	Sabalis serrulatae fructus (DDD 0.32,g)	547	618	495	421					0.74	0.85	0.64	0.56				



H Systemic hormonal preparations, excl. sex hormones and insulins

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H	Systemic hormonal preparations, excl. sex hormones and insulins	46,820	48,209	49,488	45,877	19	18	18	19	55.81	55.96	55.49	55.06	6	6	6	5
H01	Pituitary, hypothalamic hormones and analogues	26,788	28,230	29,255	25,358	10	9	9	10	1.16	1.30	1.40	1.46	4	3	3	2
H02	Corticosteroids for systemic use	10,354	10,082	10,251	10,872	57	56	54	52	18.81	18.69	17.61	17.07	15	14	15	14
H03	Thyroid therapy	6,848	6,888	6,959	6,927	1	1	1	1	35.59	35.72	36.22	36.27	1	1	1	1
H04	Pancreatic hormones	251	264	225	302	65	61	60	47	0.01	0.01	0.01	0.01	69	64	65	57
H05	Calcium homeostasis	2,580	2,745	2,797	2,419	13	12	11	13	0.23	0.24	0.25	0.25	11	10	9	10

**H01 Pituitary, hypothalamic hormones and analogues**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H01	Pituitary, hypothalamic hormones and analogues	26,788	28,230	29,255	25,358	10	9	9	10	1.16	1.30	1.40	1.46	4	3	3	2
H01A	Anterior pituitary lobe hormones and analogues	8,914	9,637	9,957	9,905	14	13	11	10	0.27	0.29	0.32	0.33	1	1	0	0
H01AB	Thyrotrophin	1,238	1,220	1,103	992	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AB01	Thyrotrophin alfa (DDD 0.90 mg)	1,238	1,220	1,103	992	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AC	Somatropin and somatropin agonists	7,235	7,936	8,324	8,395	0	0	0	0	0.26	0.29	0.31	0.33	0	0	0	0
H01AC01	Somatropin (DDD 2,U)	7,235	7,936	8,324	8,395	0	0	0	0	0.26	0.29	0.31	0.33	0	0	0	0
H01AX	Other anterior pituitary hormones and analogues	441	480	530	518	1	0	0	1	0.00	0.00	0.00	0.00	1	0	0	1
H01AX01	Pegvisomant (DDD 10 mg)	441	480	530	518	1	0	0	1	0.00	0.00	0.00	0.00	1	0	0	1
H01B	Posterior pituitary lobe hormones	2,440	2,667	2,608	2,715	25	28	33	36	0.62	0.72	0.77	0.80	6	5	5	3
H01BA	Vasopressin and analogues	2,250	2,491	2,399	2,460	19	23	27	30	0.60	0.70	0.75	0.79	2	2	2	1
H01BA01	Vasopressin (argipressin) (DDD 40,U)		85	137	128		100	100	100		0.00	0.00	0.00		100	100	100
H01BA02	Desmopressin	1,932	2,036	1,872	1,811	5	6	6	5	0.60	0.70	0.75	0.78	2	2	2	1
H01BA04	Terlipressin (DDD 12 mg)	318	370	391	521	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01BB	Oxytocin and analogues	190	176	209	255	100	100	100	100	0.02	0.02	0.02	0.02	100	100	100	100
H01BB02	Oxytocin	177	125	99	55	100	100	100	100	0.02	0.02	0.02	0.01	100	100	100	100
H01BB03	Carbetocin (DDD 0.10 mg)	13	51	110	201	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H01C	Hypothalamic hormones	15,434	15,926	16,689	12,738	4	4	4	4	0.27	0.29	0.31	0.32	3	2	3	2
H01CA	Gonadotrophin-releasing hormones	232	215	245	298	0	0	0	0	0.04	0.04	0.04	0.05	0	0	0	0
H01CA02	Nafarelin (DDD 0.40 mg)	232	215	245	298	0	0	0	0	0.04	0.04	0.04	0.05	0	0	0	0
H01CB	Somatostatin and analogues	14,763	15,404	16,152	12,102	5	4	5	5	0.22	0.24	0.25	0.26	3	3	3	3
H01CB02	Octreotide (DDD 0.70 mg)	7,797	7,507	7,430	3,873	8	8	9	13	0.12	0.12	0.12	0.12	6	5	6	5
H01CB03	Lanreotide (DDD 3 mg)	6,921	7,853	8,697	8,176	1	1	1	1	0.10	0.12	0.13	0.14	1	1	1	1
H01CB05	Pasireotide (DDD 1.20 mg)	45	45	25	53	0	0	40	32	0.00	0.00	0.00	0.00	0	0	40	30
H01CC	Anti gonadotropin releasing hormones	439	306	292	338	0	0	1	2	0.01	0.01	0.01	0.01	0	0	1	2
H01CC01	Ganirelix (DDD 0.25 mg)	376	287	278	329	0	0	1	2	0.01	0.01	0.01	0.01	0	0	1	2
H01CC02	Cetrorelix (DDD 0.25 mg)	62	19	13	9	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0

**H02 Corticosteroids for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H01CC54	Relugolix, estradiol and norethisterone				0				0				0.00				0
H02	Corticosteroids for systemic use	10,354	10,082	10,251	10,872	57	56	54	52	18.81	18.69	17.61	17.07	15	14	15	14
H02A	Corticosteroids for systemic use, plain	8,119	7,721	8,181	8,692	54	53	51	49	18.72	18.59	17.52	16.98	15	14	14	14
H02AA	Mineralocorticoids	153	151	147	129	6	6	6	5	0.68	0.67	0.65	0.57	6	6	6	5
H02AA02	Fludrocortisone (DDD 0.10 mg)	153	151	147	129	6	6	6	5	0.68	0.67	0.65	0.57	6	6	6	5
H02AB	Glucocorticoids	7,967	7,570	8,034	8,563	55	54	52	50	18.04	17.92	16.87	16.41	15	14	15	15
H02AB01	Betamethasone	152	171	170	160	81	82	83	82	0.29	0.28	0.27	0.26	73	71	72	71
H02AB02	Dexamethasone (DDD 1.50 mg)	1,535	1,514	2,429	2,891	78	77	58	56	2.15	2.18	2.32	2.37	39	37	39	40
H02AB04	Methylprednisolone	1,929	1,752	1,720	1,712	75	72	74	69	1.14	1.09	1.08	1.01	39	36	38	36
H02AB06	Prednisolone (DDD 10 mg)	1,511	1,571	1,314	1,430	19	19	12	12	12.15	12.42	11.39	11.00	8	7	6	6
H02AB07	Prednisone (DDD 10 mg)	126	88	82	92	3	2	2	2	0.82	0.57	0.54	0.49	3	2	2	2
H02AB08	Triamcinolone (DDD 7.50 mg)	859	833	874	827	76	76	71	70	0.09	0.09	0.09	0.09	76	76	71	69
H02AB09	Hydrocortisone (DDD 30 mg)	1,854	1,640	1,446	1,452	34	37	39	38	1.40	1.29	1.17	1.20	15	15	16	15
H02B	Corticosteroids for systemic use, combinations	2,235	2,361	2,070	2,179	70	65	64	62	0.09	0.10	0.09	0.09	70	65	64	62
H02BX	Corticosteroids for systemic use, combinations	2,235	2,361	2,070	2,179	70	65	64	62	0.09	0.10	0.09	0.09	70	65	64	62
H02BX01	Methylprednisolone, combinations (DDD 0.50,ED)	2,235	2,361	2,070	2,179	70	65	64	62	0.09	0.10	0.09	0.09	70	65	64	62



H03 Thyroid therapy

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H03	Thyroid therapy	6,848	6,888	6,959	6,927	1	1	1	1	35.59	35.72	36.22	36.27	1	1	1	1
H03A	Thyroid preparations	6,157	6,229	6,317	6,318	1	1	1	1	35.02	35.17	35.70	35.77	1	1	1	1
H03AA	Thyroid hormones	6,157	6,229	6,317	6,318	1	1	1	1	35.02	35.17	35.70	35.77	1	1	1	1
H03AA01	Levothyroxine sodium (DDD 0.15 mg)	6,157	6,229	6,317	6,318	1	1	1	1	35.02	35.17	35.70	35.77	1	1	1	1
H03B	Antithyroid preparations	690	658	642	609	3	3	3	3	0.57	0.54	0.53	0.50	3	3	3	3
H03BB	Sulphur-containing imidazole derivatives	690	658	642	609	3	3	3	3	0.57	0.54	0.53	0.50	3	3	3	3
H03BB01	Carbimazole (DDD 15 mg)	690	658	642	609	3	3	3	3	0.57	0.54	0.53	0.50	3	3	3	3

H04 Haiman hormonit

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H04	Pancreatic hormones	251	264	225	302	65	61	60	47	0.01	0.01	0.01	0.01	69	64	65	57
H04A	Glycogenolytic hormones	251	264	225	302	65	61	60	47	0.01	0.01	0.01	0.01	69	64	65	57
H04AA	Glycogenolytic hormones	251	264	225	302	65	61	60	47	0.01	0.01	0.01	0.01	69	64	65	57
H04AA01	Glucagon	251	264	225	302	65	61	60	47	0.01	0.01	0.01	0.01	69	64	65	57



H05 Calcium homeostasis

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H05	Calcium homeostasis	2,580	2,745	2,797	2,419	13	12	11	13	0.23	0.24	0.25	0.25	11	10	9	10
H05A	Parathyroid hormones and analogues	1,343	1,225	817	721	5	7	7	11	0.06	0.06	0.05	0.05	5	7	7	11
H05AA	Parathyroid hormones and analogues	1,343	1,225	817	721	5	7	7	11	0.06	0.06	0.05	0.05	5	7	7	11
H05AA02	Teriparatide (DDD 20,mcg)	1,343	1,225	817	721	5	7	7	11	0.06	0.06	0.05	0.05	5	7	7	11
H05B	Anti-parathyroid agents	1,236	1,519	1,981	1,698	22	16	12	14	0.17	0.19	0.19	0.20	13	11	10	9
H05BA	Calcitonin preparations	99	55	28	38	98	97	98	97	0.00	0.00	0.00	0.00	98	97	98	97
H05BA01	Calcitonin (salmon synthetic)	99	55	28	38	98	97	98	97	0.00	0.00	0.00	0.00	98	97	98	97
H05BX	Other anti-parathyroid agents	1,137	1,464	1,953	1,660	16	13	11	12	0.17	0.19	0.19	0.20	12	11	10	9
H05BX01	Cinacalcet (DDD 60 mg)	983	1,310	1,779	1,502	10	9	6	6	0.15	0.16	0.17	0.18	8	7	6	6
H05BX02	Paricalcitol (DDD 2,mcg)	144	136	155	124	49	50	59	62	0.02	0.02	0.02	0.01	45	46	46	49
H05BX04	Etelcalcetide (DDD 2.10 mg)	10	18	18	34	100	98	100	100	0.00	0.00	0.00	0.00	100	98	100	100



J Antiinfectives for systemic use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J	Antiinfectives for systemic use	246,317	267,787	256,588	244,852	74	77	77	77	17.61	16.79	13.91	13.33	19	19	21	21
J01	Antibacterials for systemic use	49,450	44,542	41,360	38,760	50	49	57	56	15.39	14.63	11.86	11.27	14	14	16	16
J02	Antimycotics for systemic use	16,788	17,942	13,200	12,508	76	81	76	75	0.40	0.38	0.35	0.35	16	16	15	14
J04	Antimycobacterials	1,063	977	759	735	90	85	87	89	0.18	0.16	0.16	0.13	86	85	86	86
J05	Antivirals for systemic use	113,135	140,120	127,743	127,767	93	94	94	93	1.65	1.62	1.54	1.58	59	56	53	53
J06	Immune sera and immunoglobulins	40,633	43,065	51,949	49,823	81	80	80	73								

**J01 Antibacterials for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J01	Antibacterials for systemic use	49,450	44,542	41,360	38,760	50	49	57	56	15.39	14.63	11.86	11.27	14	14	16	16
J01A	Tetracyclines	2,390	2,276	1,724	1,572	32	30	25	19	3.17	3.11	2.48	2.30	4	5	5	4
J01AA	Tetracyclines	2,390	2,276	1,724	1,572	32	30	25	19	3.17	3.11	2.48	2.30	4	5	5	4
J01AA02	Doxycycline (DDD 0.10,g)	1,189	1,124	709	645	17	16	8	7	2.00	1.93	1.29	1.17	6	6	8	8
J01AA04	Lymecycline (DDD 0.60,g)	463	453	469	482	1	1	1	1	0.77	0.79	0.82	0.84	1	1	1	1
J01AA07	Tetracycline (DDD 1,g)	189	189	185	204	2	2	2	2	0.40	0.39	0.36	0.29	2	2	2	2
J01AA12	Tigecycline (DDD 0.10,g)	550	510	362	241	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01C	Beta-lactam antibacterials, penicillins	16,881	16,832	16,560	16,176	44	47	63	60	4.97	4.95	3.64	3.52	11	12	15	15
J01CA	Penicillins with extended spectrum	7,068	6,691	4,774	4,762	17	15	22	24	2.67	2.64	1.81	1.77	8	8	10	9
J01CA01	Ampicillin	812	612	712	838	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01CA04	Amoxicillin	4,689	4,437	2,612	2,689	6	7	9	9	2.01	1.95	1.20	1.19	7	8	10	9
J01CA08	Pivmecillinam (DDD 0.60,g)	1,567	1,642	1,450	1,235	7	6	6	7	0.66	0.68	0.61	0.58	9	7	7	8
J01CE	Beta-lactamase sensitive penicillins	2,121	2,038	1,562	1,672	55	53	46	40	1.29	1.25	1.01	0.90	8	9	10	11
J01CE01	Benzympenicillin (DDD 3.60,g)	1,141	1,055	722	646	100	100	94	95	0.06	0.06	0.05	0.05	99	99	94	94
J01CE02	Phenoxymethylpenicillin (DDD 2,g)	981	983	840	1,025	3	3	5	5	1.23	1.19	0.96	0.85	4	4	5	5
J01CF	Beta-lactamase resistant penicillins	826	1,028	993	1,282	62	61	59	58	0.16	0.20	0.19	0.24	56	54	51	50
J01CF02	Cloxacillin (DDD 2,g)	479	574	534	744	100	100	100	91	0.08	0.10	0.08	0.12	100	100	100	91
J01CF05	Flucloxacillin (DDD 2,g)	347	454	459	538	10	11	12	11	0.08	0.10	0.10	0.12	10	11	12	11
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	6,866	7,074	9,230	8,460	66	74	88	84	0.85	0.87	0.62	0.61	15	20	27	25
J01CR02	Amoxicillin and beta-lactamase inhibitor	2,483	2,004	1,288	1,451	7	9	13	10	0.78	0.78	0.53	0.52	8	11	15	12
J01CR05	Piperacillin and beta-lactamase inhibitor (DDD 14,g)	4,382	5,071	7,942	7,008	100	100	100	100	0.07	0.09	0.09	0.09	100	100	100	99

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J01D	Other beta-lactam antibacterials	14,665	12,633	11,170	10,308	62	60	62	62	2.85	2.62	2.27	2.19	33	33	35	35
J01DB	First-generation cephalosporins	5,773	5,190	4,369	4,043	5	6	6	7	2.00	1.86	1.56	1.51	6	6	7	7
J01DB01	Cefalexin (DDD 2,g)	5,770	5,188	4,364	4,037	5	6	6	7	2.00	1.85	1.56	1.51	6	6	7	7
J01DB04	Cefazolin (DDD 3,g)	3	2	5	6	100	100	100	91	0.00	0.00	0.00	0.00	100	100	100	97
J01DC	Second-generation cephalosporins	4,470	3,880	3,155	2,828	98	98	98	98	0.72	0.65	0.57	0.56	96	96	97	97
J01DC02	Cefuroxime	4,468	3,880	3,155	2,828	98	98	98	98	0.72	0.65	0.57	0.56	96	96	97	97
J01DC04	Cefaclor (DDD 1,g)	2				0				0.00				0			
J01DD	Third-generation cephalosporins	1,319	1,246	1,391	1,350	95	95	95	93	0.07	0.08	0.09	0.07	97	98	98	97
J01DD01	Cefotaxime (DDD 4,g)	3	2	2	2	92	100	100	100	0.00	0.00	0.00	0.00	99	100	100	100
J01DD02	Ceftazidime (DDD 4,g)	186	108	68	63	100	100	100	100	0.01	0.01	0.01	0.00	100	100	100	100
J01DD04	Ceftriaxone (DDD 2,g)	1,009	958	1,121	1,009	93	94	94	93	0.07	0.07	0.08	0.06	97	97	98	97
J01DD52	Ceftazidime and beta-lactamase inhibitor (DDD 6,g)	121	178	200	276	100	100	99	93	0.00	0.00	0.00	0.00	100	100	99	93
J01DE	Fourth-generation cephalosporins	4	4	6	32	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DE01	Cefepime (DDD 4,g)	4	4	6	32	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DF	Monobactams	43	41	32	49	100	100	95	100	0.00	0.00	0.00	0.00	100	100	95	100
J01DF01	Aztreonam	43	41	32	49	100	100	95	100	0.00	0.00	0.00	0.00	100	100	95	100
J01DH	Carbapenems	2,750	2,059	1,921	1,922	100	100	100	99	0.05	0.04	0.04	0.04	100	100	100	100
J01DH02	Meropenem (DDD 3,g)	1,640	1,049	910	816	100	100	100	100	0.04	0.03	0.03	0.03	100	100	100	100
J01DH03	Ertapenem (DDD 1,g)	1,111	1,010	1,011	1,007	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01DH51	Imipenem and cilastatin (DDD 4,ED)				38				100				0.00				100
J01DH52	Meropenem and vaborbactam				3				100				0.00				0
J01DH56	Imipenem, cilastatin and relebactam				58				86				0.00				0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J01DI	Other cephalosporins and penems	306	214	297	85	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI02	Ceftaroline fosamil (DDD 1.20,g)	77	83	127	119	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI54	Ceftolozane and beta-lactamase inhibitor (DDD 3,ED)	229	131	170	-34	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01E	Sulfonamides and trimethoprim	1,466	1,525	1,352	1,373	9	6	7	7	1.08	1.14	1.02	1.01	7	7	8	8
J01EA	Trimethoprim and derivatives	817	879	817	807	6	6	6	7	0.74	0.77	0.70	0.68	6	6	7	7
J01EA01	Trimethoprim (DDD 0.40,g)	817	879	817	807	6	6	6	7	0.74	0.77	0.70	0.68	6	6	7	7
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	649	646	535	565	13	7	8	8	0.34	0.36	0.33	0.34	10	9	9	10
J01EE01	Sulfamethoxazole and trimethoprim	159	175	203	227	39	14	11	10	0.13	0.15	0.16	0.17	14	12	11	10
J01EE02	Sulfadiazine and trimethoprim	490	471	332	338	5	5	7	7	0.21	0.21	0.17	0.17	7	8	8	9
J01F	Macrolides, lincosamides and streptogramins	3,745	3,060	2,488	2,259	35	35	47	52	0.83	0.75	0.55	0.49	16	17	21	22
J01FA	Macrolides	1,654	1,502	1,095	1,025	23	29	44	48	0.55	0.49	0.31	0.26	12	14	21	21
J01FA01	Erythromycin	79	77	93	96	99	100	100	100	0.00	0.00	0.00	0.00	99	100	100	100
J01FA06	Roxithromycin (DDD 0.30,g)	153	165	100	70	8	12	11	12	0.10	0.07	0.04	0.03	9	10	11	12
J01FA09	Clarithromycin	444	365	209	173	18	18	28	32	0.11	0.10	0.06	0.04	14	16	22	23
J01FA10	Azithromycin	978	895	693	687	21	30	46	49	0.33	0.31	0.21	0.19	11	13	22	22
J01FF	Lincosamides	2,091	1,558	1,393	1,234	45	42	49	55	0.28	0.26	0.24	0.23	23	22	22	22
J01FF01	Clindamycin	2,091	1,558	1,393	1,234	45	42	49	55	0.28	0.26	0.24	0.23	23	22	22	22
J01G	Aminoglycoside antibacterials	1,192	1,193	1,074	837	51	49	49	47	0.02	0.02	0.02	0.01	50	49	48	49
J01GB	Other aminoglycosides	1,192	1,193	1,074	837	51	49	49	47	0.02	0.02	0.02	0.01	50	49	48	49
J01GB01	Tobramycin	794	848	725	595	27	28	25	26	0.01	0.01	0.01	0.01	40	41	37	38
J01GB03	Gentamicin (DDD 0.24,g)	210	155	118	120	99	98	97	93	0.00	0.00	0.00	0.00	97	97	95	95
J01GB06	Amikacin (DDD 1,g)	188	190	230	123	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J01M	Quinolone antibacterials	3,472	2,604	2,441	1,814	43	45	52	42	0.82	0.63	0.55	0.49	25	25	29	25
J01MA	Fluoroquinolones	3,472	2,604	2,441	1,814	43	45	52	42	0.82	0.63	0.55	0.49	25	25	29	25
J01MA02	Ciprofloxacin	1,760	1,442	1,235	1,087	29	35	37	30	0.48	0.38	0.32	0.32	17	17	18	18
J01MA12	Levofloxacin	1,175	778	808	547	52	52	59	53	0.25	0.18	0.18	0.14	36	35	44	39
J01MA14	Moxifloxacin (DDD 0.40,g)	538	385	398	180	70	70	86	81	0.09	0.07	0.05	0.03	37	35	47	43
J01X	Other antibacterials	5,638	4,421	4,552	4,421	66	63	64	63	1.65	1.42	1.35	1.26	10	9	10	10
J01XA	Glycopeptide antibacterials	1,497	1,083	1,051	1,031	100	100	98	97	0.03	0.02	0.03	0.03	100	99	98	97
J01XA01	Vancomycin (DDD 2,g)	1,175	799	749	768	100	100	97	96	0.03	0.02	0.03	0.03	100	99	98	97
J01XA02	Teicoplanin (DDD 0.40,g)	279	193	188	42	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XA04	Dalbavancin (DDD 1.50,g)	43	90	115	220	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XB	Polymyxins	119	160	177	147	0	22	8	3	0.00	0.00	0.00	0.00	0	22	8	3
J01XB01	Colistin	119	160	177	147	0	22	8	3	0.00	0.00	0.00	0.00	0	22	8	3
J01XC	Steroid antibacterials	12	12	1		13	13	10		0.00	0.00	0.00		13	13	10	
J01XC01	Fusidic acid (DDD 1.50,g)	12	12	1		13	13	10		0.00	0.00	0.00		13	13	10	
J01XD	Imidazole derivatives	979	689	1,031	916	100	100	100	100	0.06	0.04	0.05	0.05	100	100	100	100
J01XD01	Metronidazole (DDD 1.50,g)	979	689	1,031	916	100	100	100	100	0.06	0.04	0.05	0.05	100	100	100	100
J01XE	Nitrofurantoin derivatives	605	471	558	558	3	4	3	3	0.35	0.27	0.31	0.32	4	6	5	4
J01XE01	Nitrofurantoin (DDD 0.20,g)	605	471	558	558	3	4	3	3	0.35	0.27	0.31	0.32	4	6	5	4
J01XX	Other antibacterials	2,426	2,006	1,734	1,769	51	47	47	49	1.21	1.08	0.96	0.87	5	4	4	4
J01XX01	Fosfomicin	10	11	9	9	100	100	100	98	0.00	0.00	0.00	0.00	100	100	100	98
J01XX05	Methenamine	1,030	931	840	849	5	4	3	3	1.19	1.07	0.94	0.86	4	4	3	3
J01XX08	Linezolid (DDD 1.20,g)	816	552	434	359	74	70	74	79	0.01	0.01	0.01	0.01	68	61	57	60
J01XX09	Daptomycin (DDD 0.28,g)	568	511	450	552	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XX11	Tedizolid (DDD 0.20,g)	2				0				0.00				0			

**J02 Antimycotics for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J02	Antimycotics for systemic use	16,788	17,942	13,200	12,508	76	81	76	75	0.40	0.38	0.35	0.35	16	16	15	14
J02A	Antimycotics for systemic use	16,788	17,942	13,200	12,508	76	81	76	75	0.40	0.38	0.35	0.35	16	16	15	14
J02AA	Antibiotics	2,358	2,691	1,778	1,925	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AA01	Amphotericin (DDD 35 mg)	2,358	2,691	1,778	1,925	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AB	Imidazole derivatives	1	1	9	1	100	100	0	100	0.00	0.00	0.00	0.00	100	100	0	100
J02AB02	Ketoconazole (DDD 0.20,g)	1	1	9	1	100	100	0	100	0.00	0.00	0.00	0.00	100	100	0	100
J02AC	Triazole and tetrazole derivatives	5,224	4,694	4,095	3,816	24	29	24	19	0.38	0.36	0.34	0.33	12	11	11	10
J02AC01	Fluconazole (DDD 0.20,g)	2,837	2,506	2,080	1,883	12	12	14	11	0.27	0.26	0.23	0.22	14	14	13	12
J02AC02	Itraconazole (DDD 0.20,g)	385	373	378	385	1	1	1	1	0.09	0.09	0.08	0.08	1	1	1	1
J02AC03	Voriconazole (DDD 0.40,g)	788	661	235	234	51	71	54	40	0.01	0.01	0.01	0.01	26	25	22	20
J02AC04	Posaconazole (DDD 0.30,g)	873	688	718	534	48	47	45	44	0.00	0.00	0.01	0.01	48	48	39	33
J02AC05	Isavuconazole (DDD 0.20,g)	341	466	684	779	27	51	38	24	0.00	0.00	0.00	0.00	19	36	25	19
J02AX	Other antimycotics for systemic use	9,205	10,555	7,318	6,766	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AX04	Caspofungin (DDD 50 mg)	3,458	4,377	1,848	1,108	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02AX05	Micafungin (DDD 0.10,g)	3,934	4,388	2,587	2,521	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02AX06	Anidulafungin (DDD 0.10,g)	1,814	1,790	2,883	3,137	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100



J04 Antimycobacterials

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J04	Antimycobacterials	1,063	977	759	735	90	85	87	89	0.18	0.16	0.16	0.13	86	85	86	86
J04A	Drugs for treatment of tuberculosis	1,063	977	759	735	90	85	87	89	0.18	0.16	0.16	0.13	86	85	86	86
J04AA	Aminosalicylic acid and derivatives	22	-3	2		100	100	100		0.00	0.00	0.00		100	100	100	
J04AA01	Aminosalicylic acid (DDD 12,g)	22	-3	2		100	100	100		0.00	0.00	0.00		100	100	100	
J04AB	Antibiotics	439	387	362	354	77	75	74	78	0.09	0.08	0.07	0.07	74	71	71	74
J04AB02	Rifampicin (DDD 0.60,g)	371	294	298	253	73	68	70	70	0.09	0.07	0.07	0.06	73	68	70	70
J04AB04	Rifabutin (DDD 0.15,g)	68	93	64	101	97	96	94	98	0.01	0.01	0.01	0.01	97	96	94	98
J04AC	Hydrazides	84	98	109	86	98	98	98	97	0.04	0.05	0.05	0.03	98	98	98	97
J04AC01	Isoniazid	84	98	109	86	98	98	98	97	0.04	0.05	0.05	0.03	98	98	98	97
J04AK	Other drugs for treatment of tuberculosis	518	496	285	296	100	90	100	100	0.04	0.04	0.04	0.03	100	98	99	100
J04AK01	Pyrazinamide (DDD 1.50,g)	72	61	85	62	100	98	100	99	0.02	0.01	0.01	0.01	100	98	100	99
J04AK02	Ethambutol (DDD 1.20,g)	191	179	154	165	100	99	99	100	0.03	0.03	0.02	0.02	100	99	99	100
J04AK05	Bedaquiline (DDD 86 mg)	255	255	46	70	100	82	100	100	0.00	0.00	0.00	0.00	100	82	100	100

**J05 Antivirals for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J05	Antivirals for systemic use	113,135	140,120	127,743	127,767	93	94	94	93	1.65	1.62	1.54	1.58	59	56	53	53
J05A	Direct acting antivirals	113,135	140,120	127,743	127,767	93	94	94	93	1.65	1.62	1.54	1.58	59	56	53	53
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	10,637	11,151	10,486	10,688	38	35	37	36	0.63	0.70	0.72	0.76	8	7	7	7
J05AB01	Aciclovir (DDD 4,g)	2,703	2,729	2,873	2,605	24	20	28	21	0.27	0.31	0.32	0.33	4	3	4	3
J05AB06	Ganciclovir	168	251	174	143	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AB09	Famciclovir (DDD 0.75,g)	131	131	126	108	0	1	2	1	0.01	0.01	0.01	0.01	0	1	2	1
J05AB11	Valaciclovir (DDD 3,g)	4,542	5,059	4,511	4,784	3	3	3	2	0.32	0.35	0.36	0.39	3	3	3	3
J05AB14	Valganciclovir (DDD 0.90,g)	3,094	2,980	2,802	3,048	100	99	100	100	0.03	0.03	0.03	0.03	100	99	100	100
J05AE	Protease inhibitors	2,652	1,878	496	298	100	100	100	100	0.06	0.05	0.03	0.03	100	100	100	100
J05AE01	Saquinavir (DDD 1.80,g)	12	8			100	100			0.00	0.00			100	100		
J05AE03	Ritonavir (DDD 1.20,g)	198	141	104	88	100	100	99	100	0.01	0.00	0.00	0.00	100	100	99	100
J05AE07	Fosamprenavir (DDD 1.40,g)	6				100				0.00				100			
J05AE08	Atazanavir (DDD 0.30,g)	669	451	142	69	100	100	100	100	0.02	0.02	0.01	0.01	100	100	100	100
J05AE10	Darunavir (DDD 1.20,g)	1,767	1,277	250	141	100	100	100	100	0.03	0.03	0.02	0.02	100	100	100	100
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	1,181	1,277	1,142	1,219	99	100	100	100	0.07	0.07	0.07	0.08	99	100	100	99
J05AF01	Zidovudine (DDD 0.60,g)	14	4		2	100	100		100	0.00	0.00		0.00	100	100		100
J05AF05	Lamivudine (DDD 0.30,g)	77	65	50	38	98	97	100	100	0.01	0.01	0.00	0.00	98	97	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J05AF06	Abacavir (DDD 0.60,g)	81	69	45	39	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF07	Tenofovir disoproxil (DDD 0.25,g)	639	695	655	768	100	100	100	100	0.04	0.05	0.05	0.06	100	100	100	100
J05AF08	Adefovir dipivoxil (DDD 10 mg)	32	38	31	30	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF09	Emtricitabine (DDD 0.20,g)	9	11	8	8	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF10	Entecavir (DDD 0.50 mg)	118	167	117	106	96	100	99	97	0.00	0.01	0.01	0.01	95	100	99	96
J05AF13	Tenofovir alafenamide (DDD 25 mg)	211	229	235	226	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG	Non-nucleoside reverse transcriptase inhibitors	963	885	761	959	100	100	100	100	0.05	0.04	0.04	0.05	100	100	100	100
J05AG01	Nevirapine (DDD 0.40,g)	496	475	207	180	100	100	100	100	0.02	0.02	0.02	0.02	100	100	100	100
J05AG03	Efavirenz (DDD 0.60,g)	115	81	115	111	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG04	Etravirine (DDD 0.40,g)	202	160	83	53	100	100	100	100	0.01	0.01	0.00	0.00	100	100	100	100
J05AG05	Rilpivirine	151	117	133	210	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG06	Doravirine (DDD 0.10,g)		52	223	405		100	100	100		0.00	0.01	0.01		100	100	100
J05AH	Neuraminidase inhibitors	1,409	783	358	16	33	37	14	42	0.14	0.08	0.04	0.00	33	37	15	35
J05AH02	Oseltamivir (DDD 0.15,g)	1,409	783	358	16	33	37	14	42	0.14	0.08	0.04	0.00	33	37	15	35
J05AJ	Integrase inhibitors	7,207	7,179	7,045	7,516	100	100	100	100	0.18	0.19	0.19	0.20	100	100	100	100
J05AJ01	Raltegravir (DDD 0.80,g)	2,195	2,232	2,179	2,094	100	100	100	100	0.07	0.07	0.07	0.07	100	100	100	100
J05AJ03	Dolutegravir (DDD 50 mg)	5,012	4,946	4,866	5,295	100	100	100	100	0.12	0.12	0.12	0.13	100	100	100	100
J05AJ04	Cabotegravir				127				100				0.00				100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J05AP	Antivirals for treatment of hcv infections	64,610	90,287	84,527	82,773	100	100	100	100	0.07	0.08	0.08	0.07	100	100	100	100
J05AP01	Ribavirin	545	281	42	6	100	100	99	100	0.01	0.01	0.00	0.00	100	100	99	100
J05AP08	Sofosbuvir (DDD 0.40,g)	42	42	126		100	100	100		0.00	0.00	0.00		100	100	100	
J05AP09	Dasabuvir (DDD 0.50,g)	1				100				0.00				100			
J05AP51	Sofosbuvir and ledipasvir (DDD 1,ED)	312	49	361	148	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP53	Ombitasvir, paritaprevir and ritonavir (DDD 2,ED)	14				100				0.00				100			
J05AP54	Elbasvir and grazoprevir (DDD 1,ED)	22,937	17,130	4,388	2,023	100	100	100	100	0.02	0.02	0.01	0.00	100	100	100	100
J05AP55	Sofosbuvir and velpatasvir (DDD 1,ED)	40,246	63,353	58,351	50,135	100	100	100	100	0.03	0.05	0.05	0.04	100	100	100	100
J05AP56	Sofosbuvir, velpatasvir and voxilaprevir (DDD 1,ED)	108	216	1,205	1,582	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP57	Glecaprevir and pibrentasvir (DDD 3,ED)	406	9,215	20,054	28,879	100	100	100	100	0.00	0.01	0.02	0.03	100	100	100	100
J05AR	Antivirals for treatment of hiv infections, combinations	24,398	26,192	21,672	22,149	100	100	100	100	0.45	0.41	0.37	0.39	100	98	94	94
J05AR01	Zidovudine and lamivudine (DDD 2,ED)	23	30	12		97	100	100		0.00	0.00	0.00		96	100	100	
J05AR02	Lamivudine and abacavir (DDD 1,ED)	792	401	155	131	100	99	99	100	0.04	0.03	0.03	0.03	100	99	99	100
J05AR03	Tenofovir disoproxil and emtricitabine (DDD 1,ED)	2,757	2,281	1,215	1,499	100	99	94	95	0.06	0.09	0.13	0.18	100	92	82	86
J05AR04	Zidovudine, lamivudine and abacavir (DDD 2,ED)	11	4			100	100			0.00	0.00			100	100		
J05AR06	Emtricitabine, tenofovir disoproxil and efavirenz (DDD 1,ED)	1,249	736	194	123	100	100	97	100	0.02	0.01	0.01	0.01	100	100	96	100
J05AR08	Emtricitabine, tenofovir disoproxil and rilpivirine (DDD 1,ED)	203	198	137	112	97	98	100	93	0.00	0.00	0.00	0.00	97	98	100	93
J05AR09	Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat (DDD 1,ED)	205	156	96	60	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J05AR10	Lopinavir and ritonavir (DDD 0.80,g)	138	79	27	3	100	100	98	100	0.00	0.00	0.00	0.00	100	100	98	100
J05AR13	Lamivudine, abacavir and dolutegravir (DDD 1,ED)	6,992	7,385	6,124	5,220	100	100	100	100	0.09	0.10	0.08	0.07	100	100	100	100
J05AR14	Darunavir and cobicistat (DDD 1,ED)	177	218	242	153	100	100	100	100	0.00	0.01	0.01	0.00	100	100	100	100
J05AR17	Emtricitabine and tenofovir alafenamide (DDD 1,ED)	5,171	3,810	2,651	2,331	100	100	100	100	0.13	0.10	0.07	0.06	100	100	100	100
J05AR18	Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat (DDD 1,ED)	3,136	1,416	1,092	859	100	100	100	100	0.04	0.02	0.01	0.01	100	100	100	100
J05AR19	Emtricitabine, tenofovir alafenamide and rilpivirine (DDD 1,ED)	2,050	1,896	1,420	1,057	100	100	100	100	0.03	0.03	0.02	0.02	100	100	100	100
J05AR20	Emtricitabine, tenofovir alafenamide and bictegravir	942	5,411	4,632	4,889	100	100	100	100								
J05AR21	Dolutegravir and rilpivirine	59	182	215	195	100	100	100	100								
J05AR22	Emtricitabine, tenofovir alafenamide, darunavir and cobicistat (DDD 1,ED)	495	1,458	1,010	892	100	100	100	100	0.01	0.02	0.02	0.02	100	100	100	100
J05AR24	Lamivudine, tenofovir disoproxil and doravirine		456	1,901	3,013		100	100	100								
J05AR25	Lamivudine and dolutegravir		74	549	1,612		100	100	100								
J05AX	Other antivirals	77	488	1,256	2,150	100	100	65	32	0.00	0.00	0.00	0.00	100	100	74	46
J05AX07	Enfuvirtide (DDD 0.18,g)	2				100				0.00				100			
J05AX09	Maraviroc (DDD 0.60,g)	75	83	82	87	100	100	97	100	0.00	0.00	0.00	0.00	100	100	98	100
J05AX18	Letermovir (DDD 0.48,g)		405	1,173	2,062		100	62	29		0.00	0.00	0.00		100	61	29
J05AX25	Baloxavir marboxil				1				0				0.00				0

**J06 Immune sera and immunoglobulins**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J06	Immune sera and immunoglobulins	40,633	43,065	51,949	49,823	81	80	80	73								
J06B	Immunoglobulins	40,633	43,065	51,949	49,823	81	80	80	73								
J06BA	Immunoglobulins, normal human	39,068	41,450	50,568	48,282	80	79	80	72								
J06BA01	Immunoglobulins, normal human, for extravascular adm.	7,852	8,816	10,595	13,884	3	3	3	3								
J06BA02	Immunoglobulins, normal human, for intravascular adm.	31,217	32,634	39,972	34,397	100	100	100	100								
J06BB	Specific immunoglobulins	618	617	645	691	100	100	100	100								
J06BB01	Anti-d (rh) immunoglobulin	618	617	645	691	100	100	100	100								
J06BC	Antibacterial monoclonal antibodies	153	204	186	313	100	100	100	100								
J06BC03	Bezlotoxumab	153	204	186	313	100	100	100	100								
J06BD	Antiviral monoclonal antibodies	793	794	550	537	100	100	100	100								
J06BD01	Palivizumab	793	794	550	537	100	100	100	100								



J07 Vaccines

ATC classification		Doses per year			
		2018	2019	2020	2021
J07	Vaccines	4,241,400	4,054,300	6,015,500	16,312,400
J07A	Bacterial vaccines	682,800	585,800	626,200	559,700
J07AE	Cholera vaccines	7,000	5,700	2,200	2,000
J07AG	Haemophilus influenzae B vaccines	200	900	900	900
J07AH	Meningococcal vaccines	46,600	56,100	55,000	40,100
J07AJ	Pertussis vaccines	148,400	118,500	108,800	115,900
J07AL	Pneumococcal vaccines	226,700	196,200	275,600	167,000
J07AM	Tetanus vaccines	196,200	162,000	153,200	211,400
J07AN	Tuberculosis vaccines	35,700	25,400	24,800	18,300
J07AP	Typhoid vaccines	22,200	20,900	5,700	4,000
J07B	Viral vaccines	3,199,900	3,088,000	5,060,600	15,552,100
J07BA	Encephalitis vaccines	268,700	241,100	232,300	254,400
J07BB	Influenza vaccines	2,024,300	2,082,100	4,050,800	4,322,400
J07BC	Hepatitis vaccines	319,500	264,400	138,000	93,700
J07BD	Measles vaccines	186,200	190,700	153,400	170,000
J07BF	Poliomyelitis vaccines	19,400	13,400	11,700	7,600
J07BH	Rota virus diarrhea vaccines	153,300	132,800	135,300	145,000
J07BK	Varicella zoster vaccines	154,300	77,000	75,000	68,100
J07BL	Yellow fever vaccines	10,300	8,800	3,100	2,300
J07BM	Papillomavirus vaccines	63,700	77,700	215,000	144,700
J07BX	Other viral vaccines	0	0	45,800	10,344,000
J07BX03	covid-19,vaccines	0	0	45,800	10,344,000
J07C	Bacterial and viral vaccines, combined	358,800	380,500	328,700	200,700
J07CA	Bacterial and viral vaccines, combined	358,800	380,500	328,700	200,700



L Antineoplastic and immunomodulating agents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L	Antineoplastic and immunomodulating agents	690,175	782,967	813,257	895,552	44	44	42	44	22.54	23.86	24.63	26.00	10	11	12	13
L01	Antineoplastic agents	259,554	308,365	328,298	381,940	75	70	68	68	0.32	0.41	0.44	0.48	3	3	3	3
L02	Endocrine therapy	55,958	65,173	70,383	72,991	3	3	2	2	7.60	7.87	7.75	7.78	3	3	3	3
L03	Immunostimulants	37,862	31,836	31,137	27,498	14	13	16	16	0.77	0.70	0.68	0.66	5	5	7	7
L04	Immunosuppressants	336,801	377,594	383,439	413,122	31	32	30	31	13.85	14.88	15.76	17.09	15	16	17	17

**L01 Antineoplastic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01	Antineoplastic agents	259,554	308,365	328,298	381,940	75	70	68	68	0.32	0.41	0.44	0.48	3	3	3	3
L01A	Alkylating agents	4,912	6,108	6,213	6,388	65	69	73	75								
L01AA	Nitrogen mustard analogues	2,536	2,665	2,803	2,605	94	94	95	97								
L01AA01	Cyclophosphamide	816	752	710	705	96	96	96	95								
L01AA02	Chlorambucil	113	112	96	33	15	14	14	12								
L01AA03	Melphalan	63	65	457	400	38	40	93	96								
L01AA05	Chlormethine			10				100									
L01AA06	Ifosfamide	407	501	451	361	100	100	100	100								
L01AA09	Bendamustine	1,138	1,235	1,080	1,105	100	100	100	100								
L01AB	Alkyl sulphonates	119	224	646	721	100	100	100	100								
L01AB01	Busulfan	119	108	120	197	100	100	100	100								
L01AB02	Treosulfan		116	525	523		100	100	100								
L01AC	Ethylene imines	407	537	460	743	100	100	100	100								
L01AC01	Thiotepa	407	537	460	743	100	100	100	100								
L01AD	Nitrosoureas	38	784	633	616	99	100	99	100								
L01AD01	Carmustine	13	716	547	533	100	100	100	100								
L01AD02	Lomustine	26	18	28	30	99	93	85	94								
L01AD04	Streptozocin		51	57	54		100	100	100								
L01AX	Other alkylating agents	1,812	1,899	1,672	1,704	13	10	8	10								
L01AX03	Temozolomide	1,693	1,802	1,603	1,622	7	5	4	5								
L01AX04	Dacarbazine	118	97	69	82	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01B	Antimetabolites	16,623	17,659	17,391	16,331	87	84	82	82								
L01BA	Folic acid analogues	6,942	6,420	6,349	6,887	98	98	98	99								
L01BA01	Methotrexate	636	475	421	444	73	69	70	82								
L01BA04	Pemetrexed	6,306	5,944	5,928	6,443	100	100	100	100								
L01BB	Purine analogues	475	646	537	616	69	47	39	37								
L01BB02	Mercaptopurine	90	250	299	371	18	5	6	4								
L01BB04	Cladribine	101	62	94	64	98	90	100	100								
L01BB05	Fludarabine	176	179	103	114	60	44	57	71								
L01BB06	Clofarabine	107	119	38	14	100	100	100	100								
L01BB07	Nelarabine		35	4	53		100	100	100								
L01BC	Pyrimidine analogues	9,205	10,594	10,505	8,829	80	78	74	72								
L01BC01	Cytarabine	212	98	156	151	100	100	100	100								
L01BC02	Fluorouracil	374	359	403	320	100	100	100	99								
L01BC05	Gemcitabine	1,147	997	531	651	100	100	100	100								
L01BC06	Capecitabine	1,221	1,145	955	800	2	2	2	2								
L01BC07	Azacitidine	5,330	6,353	6,417	4,922	100	100	100	100								
L01BC08	Decitabine	231	386	216	257	100	100	100	100								
L01BC52	Fluorouracil, combinations	1	2	6	5	0	0	0	0								
L01BC53	Tegafur, combinations	144	127	100	96	6	8	9	8								
L01BC59	Trifluridine, combinations	545	1,126	1,720	1,627	1	0	1	0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01C	Plant alkaloids and other natural products	13,672	14,740	13,967	14,652	90	90	94	95								
L01CA	Vinca alkaloids and analogues	1,821	1,843	1,183	1,060	37	36	52	58								
L01CA01	Vinblastine	27	26	34	54	100	100	95	100								
L01CA02	Vincristine	138	103	174	243	100	99	99	100								
L01CA03	Vindesine	5				100											
L01CA04	Vinorelbine	1,520	1,570	810	661	25	25	30	33								
L01CA05	Vinflunine	132	145	165	103	100	100	100	100								
L01CB	Podophyllotoxin derivatives	336	350	452	402	72	72	76	72								
L01CB01	Etoposide	336	350	452	402	72	72	76	72								
L01CD	Taxanes	10,062	11,010	11,102	11,772	100	100	100	100								
L01CD01	Paclitaxel	5,789	5,410	6,198	6,689	100	100	100	100								
L01CD02	Docetaxel	890	922	739	726	100	100	100	100								
L01CD04	Cabazitaxel	3,383	4,679	4,165	4,357	100	100	100	100								
L01CE	Topoisomerase 1,(TOP1) inhibitors	809	951	700	871	88	84	85	85								
L01CE01	Topotecan	156	238	185	175	37	35	45	30								
L01CE02	Irinotecan	653	713	515	697	100	100	100	99								
L01CX	Other plant alkaloids and other natural products	644	585	530	546	100	100	100	100								
L01CX01	Trabectedin	644	585	530	546	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01D	Cytotoxic antibiotics and related substances	4,302	3,244	2,561	2,581	99	99	99	100								
L01DB	Anthracyclines and related substances	3,843	2,680	2,173	2,070	100	100	100	100								
L01DB01	Doxorubicin	1,932	1,769	1,487	1,420	100	100	100	100								
L01DB03	Epirubicin	1,342	490	274	229	100	100	100	100								
L01DB06	Idarubicin	329	257	268	299	100	100	100	100								
L01DB07	Mitoxantrone	158	97	111	113	100	100	100	99								
L01DB11	Pixantrone	82	67	32	8	100	100	100	100								
L01DC	Other cytotoxic antibiotics	459	564	389	511	96	97	98	98								
L01DC01	Bleomycin	72	81	101	151	100	100	100	100								
L01DC03	Mitomycin	387	482	287	360	95	96	97	97								
L01E	Protein kinase inhibitors	60,088	82,710	91,282	101,910	5	4	4	4	0.32	0.41	0.44	0.48	3	3	3	3
L01EA	Bcr-abl tyrosine kinase inhibitors	12,257	11,942	10,865	9,764	3	2	3	2	0.12	0.12	0.12	0.12	2	1	2	2
L01EA01	Imatinib (DDD 0.40,g)	5,977	5,501	4,913	4,031	1	1	0	0	0.09	0.09	0.09	0.09	1	1	1	1
L01EA02	Dasatinib (DDD 0.10,g)	2,621	2,752	2,174	1,885	5	3	6	4	0.01	0.01	0.01	0.01	5	2	5	4
L01EA03	Nilotinib (DDD 0.60,g)	2,505	2,548	2,576	2,668	1	0	1	1	0.02	0.02	0.02	0.02	1	0	1	1
L01EA04	Bosutinib (DDD 0.40,g)	436	293	342	444	2	0	0	0	0.00	0.00	0.00	0.00	2	0	0	0
L01EA05	Ponatinib (DDD 45 mg)	718	849	860	735	18	8	20	4	0.00	0.00	0.00	0.00	19	7	20	5
L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	3,927	4,873	5,257	6,926	9	1	1	1	0.03	0.03	0.03	0.03	5	1	1	1
L01EB01	Gefitinib (DDD 0.25,g)	904	618	232	65	4	2	1	2	0.01	0.01	0.01	0.00	4	2	1	2
L01EB02	Erlotinib (DDD 0.15,g)	1,521	992	553	144	3	1	3	1	0.01	0.01	0.01	0.00	3	1	2	1
L01EB03	Afatinib (DDD 40 mg)	1,106	1,729	1,806	1,341	2	1	0	1	0.01	0.01	0.01	0.01	2	1	0	1
L01EB04	Osimertinib (DDD 80 mg)	396	1,533	2,666	5,375	62	2	1	1	0.00	0.00	0.01	0.02	62	2	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01EC	B-raf serine-threonine kinase (BRAF) inhibitors	5,778	6,324	5,820	6,799	1	2	1	1	0.01	0.02	0.01	0.02	1	2	1	1
L01EC01	Vemurafenib (DDD 1.92,g)	631	400	225	138	2	1	1	2	0.00	0.00	0.00	0.00	2	1	1	2
L01EC02	Dabrafenib (DDD 0.30,g)	5,147	5,675	4,694	5,006	1	2	1	1	0.01	0.01	0.01	0.01	1	2	1	1
L01EC03	Encorafenib (DDD 0.45,g)		249	900	1,656		8	0	1		0.00	0.00	0.00		8	0	1
L01ED	Anaplastic lymphoma kinase (ALK) inhibitors	1,581	2,690	3,592	3,964	5	3	7	5	0.00	0.01	0.01	0.01	5	3	6	5
L01ED01	Crizotinib (DDD 0.50,g)	1,540	1,468	1,169	966	5	2	4	5	0.00	0.00	0.00	0.00	5	2	4	5
L01ED03	Alectinib (DDD 1.20,g)	41	1,174	2,061	2,532	28	2	2	2	0.00	0.00	0.01	0.01	25	2	2	2
L01ED04	Brigatinib (DDD 0.18,g)		48	223	163		56	68	62		0.00	0.00	0.00		58	67	63
L01ED05	Lorlatinib (DDD 0.10,g)			139	302			0	0			0.00	0.00			0	0
L01EE	Mitogen-activated protein kinase (MEK) inhibitors	1,976	3,168	3,695	4,831	2	3	1	2	0.01	0.01	0.01	0.02	2	2	1	2
L01EE01	Trametinib (DDD 2 mg)	1,976	2,939	2,892	3,418	2	2	1	3	0.01	0.01	0.01	0.01	2	2	1	3
L01EE03	Binimetinib (DDD 90 mg)		229	803	1,413		9	1	1		0.00	0.00	0.00		8	1	1
L01EF	Cyclin-dependent kinase (CDK) inhibitors	1,141	11,040	14,586	17,321	1	0	0	0	0.01	0.06	0.08	0.09	1	0	0	0
L01EF01	Palbociclib (DDD 94 mg)	1,141	11,002	14,439	15,952	1	0	0	0	0.01	0.06	0.08	0.09	1	0	0	0
L01EF02	Ribociclib (DDD 0.45,g)		38	76	103		0	0	0		0.00	0.00	0.00		0	0	0
L01EF03	Abemaciclib (DDD 0.30,g)			72	1,266			0	0			0.00	0.01			0	0
L01EG	Mammalian target of rapamycin (mTOR) kinase inhibitors	2,010	1,613	1,609	1,495	8	9	8	2	0.01	0.01	0.01	0.01	9	8	9	2
L01EG01	Temsirolimus (DDD 3.57 mg)	34	59	61	25	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L01EG02	Everolimus (DDD 10 mg)	1,976	1,554	1,548	1,469	6	5	5	1	0.01	0.01	0.01	0.01	7	5	5	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01EH	Human epidermal growth factor receptor 2,(HER2) tyrosine kinase inhibitors	618	541	436	477	1	0	3	9	0.00	0.00	0.00	0.00	1	0	3	6
L01EH01	Lapatinib (DDD 1.25,g)	618	541	436	417	1	0	3	1	0.00	0.00	0.00	0.00	1	0	3	1
L01EH02	Neratinib				60				69				0.00				69
L01EJ	Janus-associated kinase (JAK) inhibitors	3,818	4,720	5,631	6,561	12	17	17	21	0.02	0.02	0.03	0.03	11	14	15	18
L01EJ01	Ruxolitinib (DDD 30 mg)	3,818	4,720	5,631	6,561	12	17	17	21	0.02	0.02	0.03	0.03	11	14	15	18
L01EK	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	1,661	1,102	911	970	0	0	0	0	0.01	0.00	0.00	0.00	0	0	0	0
L01EK01	Axitinib (DDD 10 mg)	1,661	1,102	911	970	0	0	0	0	0.01	0.00	0.00	0.00	0	0	0	0
L01EL	Bruton's tyrosine kinase (BTK) inhibitors	4,413	10,349	12,908	14,833	5	1	1	1	0.01	0.03	0.04	0.04	5	1	1	1
L01EL01	Ibrutinib (DDD 0.42,g)	4,413	10,349	12,908	14,833	5	1	1	1	0.01	0.03	0.04	0.04	5	1	1	1
L01EM	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	2,351	1,490	1,024	821	4	2	1	10	0.01	0.01	0.00	0.00	4	2	1	8
L01EM01	Idelalisib (DDD 0.30,g)	2,351	1,490	1,024	729	4	2	1	1	0.01	0.01	0.00	0.00	4	2	1	1
L01EM03	Alpelisib				92				79				0.00				73
L01EX	Other protein kinase inhibitors	18,556	22,859	24,947	27,149	6	7	6	6	0.08	0.09	0.09	0.10	3	4	3	4
L01EX01	Sunitinib (DDD 33 mg)	5,886	5,547	3,792	3,203	2	1	1	2	0.03	0.03	0.02	0.02	2	1	1	2
L01EX02	Sorafenib (DDD 0.80,g)	2,217	1,882	1,880	1,578	13	15	14	13	0.01	0.01	0.01	0.01	12	14	14	13
L01EX03	Pazopanib (DDD 0.80,g)	2,889	2,411	2,045	1,613	1	2	2	2	0.01	0.01	0.01	0.01	1	2	2	2
L01EX04	Vandetanib (DDD 0.30,g)	145	108	30	44	100	100	100	67	0.00	0.00	0.00	0.00	100	100	100	67
L01EX05	Regorafenib (DDD 0.12,g)	1,369	1,145	926	708	0	1	0	2	0.01	0.01	0.01	0.00	0	1	0	2
L01EX07	Cabozantinib (DDD 60 mg)	1,827	6,350	8,588	10,078	1	4	2	2	0.00	0.01	0.02	0.02	1	4	1	3
L01EX08	Lenvatinib (DDD 18 mg)	375	543	1,106	1,667	0	3	4	0	0.00	0.00	0.00	0.01	0	3	5	0
L01EX09	Nintedanib (DDD 0.38,g)	3,238	3,841	4,562	5,298	1	1	1	1	0.02	0.02	0.03	0.03	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01EX10	Midostaurin (DDD 0.10,g)	610	1,031	1,813	1,723	100	77	44	53	0.00	0.00	0.00	0.00	100	76	44	53
L01EX12	Larotrectinib (DDD 0.20,g)			86	253			85	4			0.00	0.00			85	4
L01EX13	Gilteritinib (DDD 0.12,g)			119	952			14	11			0.00	0.00			14	11
L01EX22	Selpercatinib				32				100				0.00				100
L01F	Monoclonal antibodies and antibody drug conjugates	131,780	153,457	162,695	188,799	100	100	100	100								
L01FA	Cd20,(Clusters of Differentiation 20) inhibitors	36,723	37,411	30,374	34,449	100	100	100	100								
L01FA01	Rituximab	35,153	35,693	28,912	32,063	100	100	100	100								
L01FA02	Ofatumumab	222	13			100	100										
L01FA03	Obinutuzumab	1,349	1,705	1,461	2,386	100	100	100	100								
L01FB	Cd22,(Clusters of Differentiation 22) inhibitors	339	309	399	229	100	100	100	100								
L01FB01	Inotuzumab ozogamicin	339	309	399	229	100	100	100	100								
L01FC	Cd38,(Clusters of Differentiation 38) inhibitors	5,383	5,670	6,187	11,053	100	100	100	100								
L01FC01	Daratumumab	5,383	5,670	6,187	10,535	100	100	100	100								
L01FC02	Isatuximab				518				100								
L01FD	Her2,(Human Epidermal Growth Factor Receptor 2) inhibitors	39,538	43,521	48,908	43,841	100	100	100	100								
L01FD01	Trastuzumab	26,036	27,840	30,979	27,361	100	100	100	100								
L01FD02	Pertuzumab	9,767	10,894	12,253	9,934	100	100	100	100								
L01FD03	Trastuzumab emtansine	3,734	4,787	5,676	6,396	100	100	100	100								
L01FD04	Trastuzumab deruxtecan				151				100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01FE	Egfr (Epidermal Growth Factor Receptor) inhibitors	6,988	7,667	6,879	7,053	100	100	100	100								
L01FE01	Cetuximab	2,580	3,053	2,104	2,143	100	100	100	100								
L01FE02	Panitumumab	4,403	4,613	4,775	4,910	100	100	100	100								
L01FE03	Necitumumab	6				100											
L01FF	Pd-1/pdL-1,(Programmed cell death protein 1/death ligand 1) inhibitors	15,378	28,765	39,612	54,923	100	100	100	100								
L01FF01	Nivolumab	8,200	10,989	12,347	15,351	100	100	100	100								
L01FF02	Pembrolizumab	6,365	14,753	22,396	33,503	100	100	100	100								
L01FF03	Durvalumab		346	863	1,622		100	100	99								
L01FF04	Avelumab		63	2	219		100	0	100								
L01FF05	Atezolizumab	813	2,591	3,894	4,094	100	100	100	100								
L01FF06	Cemiplimab		23	109	121		100	100	100								
L01FF07	Dostarlimab				14				100								
L01FG	Vegf/vegfr (Vascular Endothelial Growth Factor) inhibitors	24,592	25,763	26,535	30,352	100	100	100	100								
L01FG01	Bevacizumab	24,275	25,352	25,984	29,801	100	100	100	100								
L01FG02	Ramucirumab	317	411	551	551	100	100	100	100								
L01FX	Other monoclonal antibodies and antibody drug conjugates	2,839	4,352	3,801	6,899	100	100	100	100								
L01FX02	Gemtuzumab ozogamicin	14	101	137	43	100	100	100	100								
L01FX04	Ipilimumab	170	840	1,240	2,328	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01FX05	Brentuximab vedotin	921	1,063	1,160	1,926	100	100	100	100								
L01FX07	Blinatumomab	363	2,050	1,156	1,652	100	100	100	100								
L01FX08	Elotuzumab	63	199	42	125	100	100	100	100								
L01FX09	Mogamulizumab				33				100								
L01FX10	Olaratumab	1,308	99			100	100										
L01FX14	Polatuzumab vedotin			66	792			100	100								
L01X	Other antineoplastic agents	28,178	30,446	34,189	51,279	91	77	67	60								
L01XA	Platinum compounds	1,221	1,086	1,317	1,313	100	100	100	100								
L01XA01	Cisplatin	234	249	273	254	100	100	100	100								
L01XA02	Carboplatin	325	334	467	501	99	100	100	100								
L01XA03	Oxaliplatin	662	503	577	558	100	100	100	100								
L01XD	Sensitizers used in photodynamic/radiation therapy	935	1,005	1,051	947	100	99	99	99								
L01XD03	Methyl aminolevulinate	698	751	820	730	100	99	99	99								
L01XD04	Aminolevulinic acid	237	254	231	217	100	100	100	100								
L01XF	Retinoids for cancer treatment	411	385	391	336	100	100	100	100								
L01XF01	Tretinoin	49	31	32	46	99	100	99	100								
L01XF03	Bexarotene	362	354	359	290	100	100	100	100								
L01XG	Proteasome inhibitors	20,535	19,761	17,723	17,968	99	90	88	84								
L01XG01	Bortezomib	11,412	10,295	8,001	7,003	100	100	100	100								
L01XG02	Carfilzomib	8,673	7,348	7,531	8,051	100	100	100	100								
L01XG03	Ixazomib	450	2,119	2,190	2,914	71	5	3	3								
L01XJ	Hedgehog pathway inhibitors	258	293	319	499	5	10	4	3								
L01XJ01	Vismodegib	258	293	319	499	5	10	4	3								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L01XK	Poly (ADP-ribose) polymerase (PARP) inhibitors	713	1,813	4,683	9,588	1	0	0	0								
L01XK01	Olaparib	713	1,513	2,249	3,504	1	0	1	1								
L01XK02	Niraparib		300	2,433	6,084		0	0	0								
L01XX	Other antineoplastic agents	4,106	5,890	8,339	12,645	64	52	52	41								
L01XX05	Hydroxycarbamide	468	493	533	476	2	2	2	2								
L01XX11	Estramustine	6	3	1	1	2	8	19	13								
L01XX23	Mitotane	256	178	197	196	4	5	4	6								
L01XX24	Pegaspargase	630	486	622	486	100	96	100	100								
L01XX27	Arsenic trioxide	172	341	298	357	100	100	100	100								
L01XX35	Anagrelide	677	395	351	221	1	1	1	1								
L01XX41	Eribulin	1,182	1,078	1,358	1,612	100	99	100	100								
L01XX44	Aflibercept	509	380	295	350	100	100	100	100								
L01XX51	Talimogene laherparepvec		55	347	552		100	100	100								
L01XX52	Venetoclax	207	2,482	4,338	8,394	49	28	32	22								
L01XY	Combinations of antineoplastic agents		213	366	7,982		100	100	100								
L01XY01	Cytarabine and daunorubicin		213	366	284		100	100	100								
L01XY02	Pertuzumab and trastuzumab				7,698				100								

**L02 Endocrine therapy**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L02	Endocrine therapy	55,958	65,173	70,383	72,991	3	3	2	2	7.60	7.87	7.75	7.78	3	3	3	3
L02A	Hormones and related agents	11,781	12,182	12,168	11,772	5	5	5	4	1.72	1.81	1.85	1.90	5	5	4	4
L02AB	Progestogens	101	94	89	92	7	6	8	9	0.01	0.01	0.01	0.01	7	6	8	9
L02AB02	Medroxyprogesterone (DDD 1,g)	101	94	89	92	7	6	8	9	0.01	0.01	0.01	0.01	7	6	8	9
L02AE	Gonadotrophin releasing hormone analogues	11,680	12,089	12,079	11,680	5	5	5	4	1.70	1.80	1.84	1.88	4	5	4	4
L02AE01	Buserelin	28	16			0	0			0.00	0.00			0	0		
L02AE02	Leuprorelin	9,074	8,835	8,531	7,994	5	5	5	5	1.33	1.32	1.31	1.30	5	5	5	5
L02AE03	Goserelin (DDD 0.13 mg)	1,409	1,342	1,213	991	5	6	4	4	0.20	0.19	0.18	0.16	5	6	4	4
L02AE04	Triptorelin	1,170	1,896	2,335	2,695	3	2	2	1	0.17	0.28	0.35	0.43	3	2	2	1
L02B	Hormone antagonists and related agents	44,178	52,991	58,215	61,219	2	2	2	2	5.89	6.06	5.90	5.88	3	3	3	3
L02BA	Anti-estrogens	2,946	3,543	3,661	2,032	5	6	6	8	1.20	1.23	1.20	1.10	2	2	2	2
L02BA01	Tamoxifen (DDD 20 mg)	551	549	515	453	1	1	1	1	1.07	1.06	1.02	0.93	1	1	1	1
L02BA02	Toremifene (DDD 60 mg)	11	11	7	8	0	0	0	0	0.01	0.01	0.00	0.00	0	0	0	0
L02BA03	Fulvestrant (DDD 8.30 mg)	2,384	2,983	3,138	1,570	6	7	7	10	0.13	0.17	0.17	0.17	6	6	7	5
L02BB	Anti-androgens	27,317	32,374	34,846	40,221	1	1	1	1	1.73	1.68	1.56	1.48	2	2	2	2
L02BB01	Flutamide (DDD 0.75,g)	36	27	16	14	5	5	4	2	0.01	0.00	0.00	0.00	5	5	4	2
L02BB03	Bicalutamide (DDD 50 mg)	1,373	1,308	1,949	2,676	2	2	3	3	1.59	1.53	1.39	1.29	2	2	2	2
L02BB04	Enzalutamide (DDD 0.16,g)	25,909	31,039	32,729	35,784	1	1	1	1	0.13	0.15	0.16	0.18	1	1	1	1
L02BB05	Apalutamid (DDD 0.24,g)			114	681			2	1			0.00	0.00			2	1
L02BB06	Darolutamide (DDD 1.20,g)			38	1,065			0	0			0.00	0.01			0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L02BG	Aromatase inhibitors	1,166	2,758	2,882	2,379	2	2	2	2	2.65	2.83	2.78	2.92	2	2	1	1
L02BG03	Anastrozole (DDD 1 mg)	173	330	278	243	2	3	3	3	0.27	0.29	0.24	0.22	2	3	2	1
L02BG04	Letrozole (DDD 2.50 mg)	828	1,983	2,031	1,551	1	1	1	2	2.15	2.28	2.26	2.40	2	1	1	1
L02BG06	Exemestane (DDD 25 mg)	165	445	573	584	3	3	3	2	0.24	0.26	0.28	0.30	3	2	2	2
L02BX	Other hormone antagonists and related agents	12,748	14,316	16,825	16,587	4	4	3	4	0.31	0.32	0.36	0.39	19	21	21	24
L02BX02	Degarelix (DDD 2.70 mg)	1,969	1,938	2,138	2,162	17	19	19	22	0.26	0.25	0.29	0.32	23	25	26	29
L02BX03	Abiraterone (DDD 1,g)	10,779	12,378	14,688	14,425	1	1	1	1	0.05	0.06	0.07	0.07	1	1	1	1

**L03 Immunostimulants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L03	Immunostimulants	37,862	31,836	31,137	27,498	14	13	16	16	0.77	0.70	0.68	0.66	5	5	7	7
L03A	Immunostimulants	37,862	31,836	31,137	27,498	14	13	16	16	0.77	0.70	0.68	0.66	5	5	7	7
L03AA	Colony stimulating factors	19,383	15,703	16,115	14,053	16	16	15	12	0.23	0.24	0.29	0.31	15	15	13	11
L03AA02	Filgrastim (DDD 0.35 mg)	3,247	2,606	2,704	2,176	39	37	33	29	0.03	0.04	0.04	0.05	34	31	25	23
L03AA10	Lenograstim (DDD 0.35 mg)	28	18	29	21	34	49	23	29	0.00	0.00	0.00	0.00	34	49	23	29
L03AA13	Pegfilgrastim (DDD 0.30 mg)	9,330	9,299	9,916	8,429	15	17	15	12	0.11	0.15	0.18	0.19	15	16	14	13
L03AA14	Lipegfilgrastim (DDD 0.30 mg)	6,777	3,780	3,467	3,427	7	1	1	1	0.09	0.06	0.07	0.07	7	1	1	1
L03AB	Interferons	10,496	8,998	7,863	7,080	2	2	8	13	0.43	0.36	0.29	0.26	1	1	3	4
L03AB04	Interferon alfa-2a (DDD 2,MU)	204	669			1	1			0.01	0.03			1	1		
L03AB05	Interferon alfa-2b (DDD 2,MU)	778	57			1	1			0.03	0.00			1	1		
L03AB07	Interferon beta-1a (DDD 4.30,mcg)	6,762	5,684	4,793	4,084	0	0	0	0	0.32	0.27	0.22	0.20	0	0	0	0
L03AB08	Interferon beta-1b (DDD 4,MU)	1,050	790	713	482	0	0	0	0	0.03	0.02	0.02	0.02	0	0	0	0
L03AB10	Peginterferon alfa-2b (DDD 7.50,mcg)	21				100				0.00				100			
L03AB11	Peginterferon alfa-2a (DDD 26,mcg)	140	145	607	776	100	97	99	99	0.00	0.00	0.01	0.01	100	97	99	99
L03AB13	Peginterferon beta-1a (DDD 8.90,mcg)	1,540	1,653	1,712	1,621	0	0	0	0	0.03	0.03	0.04	0.04	0	0	0	0
L03AB15	Ropeginterferon alfa-2b			37	117			100	100			0.00	0.00			0	0
L03AX	Other immunostimulants	7,983	7,135	7,159	6,365	24	20	27	29	0.11	0.10	0.10	0.09	0	0	0	0
L03AX03	Bcg vaccine (DDD 1.80 mg)	714	627	918	977	99	100	100	100					0	0	0	0
L03AX13	Glatiramer acetate (DDD 20 mg)	6,105	5,684	5,213	4,508	0	0	0	0	0.11	0.10	0.10	0.09	0	0	0	0
L03AX16	Plerixafor (DDD 16.80 mg)	1,165	824	1,028	880	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

**L04 Immunosuppressants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L04	Immunosuppressants	336,801	377,594	383,439	413,122	31	32	30	31	13.85	14.88	15.76	17.09	15	16	17	17
L04A	Immunosuppressants	336,801	377,594	383,439	413,122	31	32	30	31	13.85	14.88	15.76	17.09	15	16	17	17
L04AA	Selective immunosuppressants	65,739	82,246	89,486	100,388	42	44	44	46	1.60	1.88	2.04	2.17	17	18	19	19
L04AA04	Antithymocyte immunoglobulin (DDD 0.10,g)	249	166	104	148	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L04AA06	Mycophenolic acid (DDD 2,g)	4,577	4,743	4,839	4,847	5	5	4	5	0.44	0.47	0.49	0.50	3	3	3	3
L04AA10	Sirolimus (DDD 3 mg)	159	191	193	255	18	16	15	16	0.01	0.01	0.01	0.01	18	16	15	16
L04AA13	Leflunomide (DDD 20 mg)	379	416	611	632	2	2	1	2	0.49	0.54	0.56	0.53	2	2	1	2
L04AA18	Everolimus (DDD 1.50 mg)	89	157	172	149	98	97	97	97	0.00	0.00	0.00	0.00	98	97	97	97
L04AA23	Natalizumab (DDD 10 mg)	7,168	7,444	7,027	7,902	100	100	100	100	0.05	0.05	0.05	0.05	100	100	100	100
L04AA24	Abatacept (DDD 27 mg)	7,914	7,430	7,512	8,065	36	37	34	32	0.08	0.08	0.09	0.10	42	41	36	33
L04AA25	Eculizumab				557				100				0.00				100
L04AA26	Belimumab (DDD 25 mg)	379	412	478	562	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100
L04AA27	Fingolimod (DDD 0.50 mg)	14,370	13,974	12,807	11,654	0	0	0	0	0.14	0.13	0.12	0.12	0	0	0	0
L04AA28	Belatacept (DDD 12.50 mg)			5				100				0.00				100	
L04AA29	Tofacitinib (DDD 10 mg)	2,357	5,226	5,574	6,438	3	4	1	2	0.04	0.09	0.10	0.13	3	4	1	2
L04AA31	Teriflunomide (DDD 14 mg)	6,544	7,417	7,721	7,699	0	0	0	0	0.12	0.13	0.15	0.15	0	0	0	0
L04AA32	Apremilast (DDD 60 mg)	2,061	2,847	3,601	3,660	0	0	0	1	0.04	0.06	0.07	0.08	0	0	0	1
L04AA33	Vedolizumab (DDD 5.40 mg)	13,688	19,173	20,271	22,508	100	100	100	93	0.13	0.18	0.21	0.26	100	100	100	85
L04AA34	Alemtuzumab (DDD 0.13 mg)	985	427	83	69	97	100	100	100	0.01	0.00	0.00	0.00	97	100	100	100
L04AA36	Ocrelizumab (DDD 3.29 mg)	1,700	5,118	8,537	11,186	100	100	100	100	0.01	0.04	0.06	0.08	100	100	100	100
L04AA37	Baricitinib (DDD 4 mg)	2,208	4,049	4,477	4,154	2	1	1	1	0.03	0.07	0.07	0.07	2	1	1	1

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day								
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021					
L04AA40	Cladribine (DDD 0.34 mg)				913	3,057	5,240	6,396	5	0	0	0	0.01	0.02	0.04	0.05	4	0	0	0	
L04AA43	Ravulizumab							1,721				100				0.00				100	
L04AA44	Upadacitinib (DDD 15 mg)						235	1,751			0	0			0.00	0.03			0	0	
L04AA45	Filgotinib							14				0				0.00				0	
L04AA52	Ofatumumab							20				100				0.00				0	
L04AB	Tumor necrosis factor alpha (TNF-a) inhibitors				172,902	177,797	163,610	161,533	39	43	39	40	3.41	3.85	4.20	4.68	46	45	47	46	
L04AB01	Etanercept (DDD 7 mg)				26,327	23,508	24,182	22,092	0	0	0	0	0.56	0.53	0.55	0.58	0	0	0	0	
L04AB02	Infliximab (DDD 3.75 mg)				66,381	75,481	63,663	64,429	100	100	100	100	1.53	1.70	1.94	2.14	100	100	100	99	
L04AB04	Adalimumab (DDD 2.90 mg)				51,988	50,241	47,071	44,756	2	1	1	1	0.77	1.00	1.07	1.22	2	1	1	1	
L04AB05	Certolizumab pegol (DDD 14 mg)				6,206	6,895	6,606	6,523	2	1	0	0	0.10	0.13	0.12	0.13	2	1	0	0	
L04AB06	Golimumab (DDD 1.66 mg)				22,001	21,672	22,088	23,732	1	1	1	1	0.45	0.50	0.53	0.61	1	1	1	1	
L04AC	Interleukin inhibitors				34,078	40,641	48,846	62,048	21	19	18	21	0.65	0.82	1.04	1.39	23	20	22	23	
L04AC01	Daclizumab (DDD 5 mg)				14				0				0.00				0				
L04AC02	Basiliximab (DDD 40 mg)				256	349	386	513	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100	
L04AC03	Anakinra (DDD 0.10,g)				466	465	539	587	11	9	9	12	0.01	0.01	0.01	0.01	11	9	9	12	
L04AC05	Ustekinumab (DDD 0.54 mg)				12,005	13,522	17,729	22,212	17	18	24	25	0.33	0.40	0.56	0.74	24	24	31	29	
L04AC07	Tocilizumab (DDD 20 mg)				9,001	9,065	7,892	10,710	54	54	47	59	0.14	0.15	0.14	0.18	49	47	38	49	
L04AC08	Canakinumab (DDD 2.70 mg)						156	312				100	100			0.00	0.00			100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
L04AC10	Secukinumab (DDD 10 mg)	9,818	9,863	9,749	9,883	0	0	0	0	0.14	0.15	0.15	0.16	0	0	0	0
L04AC11	Siltuximab (DDD 37 mg)		3		38		100		100		0.00		0.00		100		100
L04AC12	Brodalumab (DDD 15 mg)	14	134	205	262	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
L04AC13	Ixekizumab (DDD 2.90 mg)	1,923	3,785	4,870	6,710	0	0	1	0	0.03	0.06	0.08	0.11	0	0	1	0
L04AC14	Sarilumab (DDD 14.30 mg)	197	731	1,081	1,639	0	0	0	6	0.00	0.01	0.02	0.03	0	0	0	6
L04AC16	Guselkumab (DDD 1.79 mg)	382	2,715	4,655	5,914	0	0	0	0	0.01	0.04	0.07	0.09	0	0	0	0
L04AC18	Risankizumab (DDD 1.67 mg)		8	1,584	3,237		0	0	0		0.00	0.03	0.06		0	0	0
L04AC19	Satralizumab				31				100				0.00				0
L04AD	Calcineurin inhibitors	11,653	12,122	11,798	11,371	5	5	5	5	0.74	0.78	0.79	0.79	5	5	4	4
L04AD01	Ciclosporin (DDD 0.25,g)	4,932	4,744	4,418	3,899	4	4	4	3	0.40	0.39	0.36	0.33	4	4	4	3
L04AD02	Tacrolimus (DDD 5 mg)	6,721	7,378	7,380	7,472	6	6	5	6	0.34	0.39	0.42	0.46	5	6	5	5
L04AX	Other immunosuppressants	52,429	64,788	69,698	77,783	4	2	2	2	7.45	7.56	7.69	8.04	1	1	1	1
L04AX01	Azathioprine (DDD 0.15,g)	1,078	861	919	1,018	1	1	0	1	1.48	1.17	1.22	1.36	1	1	0	1
L04AX02	Thalidomide (DDD 0.10,g)	94	78	72	71	23	39	25	15	0.00	0.00	0.00	0.00	23	39	25	15
L04AX03	Methotrexate (DDD 2.50 mg)	7,411	8,337	9,582	10,317	0	0	0	0	5.67	6.04	6.09	6.25	1	1	1	1
L04AX04	Lenalidomide (DDD 10 mg)	24,332	30,185	31,671	35,168	6	4	3	4	0.08	0.10	0.10	0.11	6	3	3	4
L04AX05	Pirfenidone (DDD 2.40,g)	4,277	5,643	6,083	6,100	2	1	1	1	0.03	0.04	0.04	0.04	2	1	1	1
L04AX06	Pomalidomide (DDD 3 mg)	1,623	6,451	8,259	10,598	22	4	1	2	0.00	0.01	0.01	0.02	23	3	1	2
L04AX07	Dimethyl fumarate (DDD 0.48,g)	13,614	13,233	13,112	14,511	0	0	0	0	0.19	0.20	0.22	0.26	0	0	0	0



M Musculo-skeletal system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M	Musculo-skeletal system	101,896	102,349	97,706	99,580	23	22	20	20	99.34	101.80	98.58	99.85	2	2	2	2
M01	Antiinflammatory and antirheumatic products	45,537	46,056	42,895	42,294	2	2	2	2	79.56	80.89	77.43	78.32	1	1	1	1
M02	Topical products for joint and muscular pain	12,941	12,952	14,131	14,572	1	1	1	1								
M03	Muscle relaxants	14,322	15,236	14,648	15,953	63	64	62	59	4.67	5.26	5.14	5.09	3	3	2	2
M04	Antigout preparations	1,935	1,940	1,791	1,490	3	2	2	2	3.99	4.19	4.46	4.46	2	2	2	2
M05	Drugs for treatment of bone diseases	16,113	16,516	16,915	18,001	14	12	15	14	11.05	11.41	11.52	11.97	5	5	5	4
M09	Other drugs for disorders of the musculo-skeletal system	11,048	9,650	7,325	7,270	98	98	98	99	0.07	0.05	0.02	0.02	77	72	42	53

**M01 Antiinflammatory and antirheumatic products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M01	Antiinflammatory and antirheumatic products	45,537	46,056	42,895	42,294	2	2	2	2	79.56	80.89	77.43	78.32	1	1	1	1
M01A	Antiinflammatory and antirheumatic products, non-steroids	45,459	45,917	42,686	42,058	2	2	2	2	79.44	80.84	77.43	78.32	1	1	1	1
M01AB	Acetic acid derivatives and related substances	2,293	2,246	2,120	2,012	6	6	6	6	4.04	3.93	3.75	3.58	2	2	2	2
M01AB01	Indometacin (DDD 0.10,g)	136	128	138	122	1	1	1	1	0.19	0.17	0.18	0.15	1	1	1	1
M01AB05	Diclofenac (DDD 0.10,g)	2,004	1,982	1,862	1,781	5	5	4	4	3.77	3.68	3.51	3.37	2	2	2	2
M01AB15	Ketorolac (DDD 30 mg)	61	53	49	49	81	82	84	84	0.02	0.02	0.02	0.02	81	82	84	85
M01AB55	Diclofenac, combinations (DDD 2,ED)	92	83	71	61	1	1	0	0	0.07	0.06	0.05	0.05	1	1	0	0
M01AC	Oxicams	413	363	336	285	1	1	1	1	1.25	1.11	1.02	0.93	1	1	1	1
M01AC06	Meloxicam (DDD 15 mg)	413	363	336	285	1	1	1	1	1.25	1.11	1.02	0.93	1	1	1	1
M01AE	Propionic acid derivatives	33,737	34,732	32,547	32,690	1	1	1	1	60.10	61.53	58.18	58.63	1	1	1	1
M01AE01	Ibuprofen (DDD 1.20,g)	29,508	30,661	28,990	29,338	1	1	1	1	51.50	52.78	49.97	50.86	1	1	1	1
M01AE02	Naproxen (DDD 0.50,g)	1,882	1,649	1,405	1,433	2	2	2	2	5.81	5.95	5.59	5.32	2	2	2	1
M01AE03	Ketoprofen (DDD 0.15,g)	494	462	421	391	1	1	0	0	0.74	0.67	0.60	0.55	1	1	1	1
M01AE17	Dexketoprofen (DDD 75 mg)	192	201	162	172	83	84	82	81	0.04	0.05	0.05	0.06	88	76	63	63
M01AE51	Ibuprofen, combinations (DDD 3,ED)	776	867	691	456	0	0	0	0	0.51	0.56	0.46	0.31	0	0	0	0
M01AE52	Naproxen and esomeprazole (DDD 0.50,g)	884	892	878	901	0	0	0	0	1.51	1.52	1.49	1.53	0	0	0	0
M01AG	Fenamates	90	90	81	70	0	0	0	0	0.21	0.21	0.19	0.16	0	0	0	0
M01AG01	Mefenamic acid (DDD 1,g)	15	15	13	3	0	1	1	1	0.04	0.03	0.03	0.01	0	1	0	1
M01AG02	Tolfenamic acid (DDD 0.30,g)	75	75	68	67	0	0	0	0	0.18	0.18	0.16	0.16	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M01AH	Coxibs	4,012	3,743	3,238	2,651	3	3	3	3	9.55	10.72	11.43	12.24	1	1	1	1
M01AH01	Celecoxib (DDD 0.20,g)	240	214	178	155	2	2	2	2	0.67	0.65	0.61	0.61	2	3	3	3
M01AH04	Parecoxib (DDD 40 mg)	50	50	51	53	99	98	99	98	0.00	0.00	0.00	0.00	99	98	99	98
M01AH05	Etoricoxib (DDD 60 mg)	3,722	3,480	3,008	2,442	2	2	1	1	8.88	10.07	10.82	11.63	1	1	1	1
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	4,915	4,743	4,364	4,350	1	1	0	0	4.28	3.34	2.86	2.77	1	1	1	1
M01AX01	Nabumetone (DDD 1,g)	18	14	8	1	1	1	1	3	0.04	0.03	0.02	0.00	1	1	1	3
M01AX05	Glucosamine (DDD 1.50,g)	2,452	2,048	1,788	1,758	1	1	0	1	4.25	3.31	2.85	2.76	1	1	1	1
M01AX25	Chondroitin sulfate	2,445	2,681	2,568	2,591	0	0	0	0					0	0	0	0
M01C	Specific antirheumatic agents	78	139	209	236	1	0	0	0	0.12	0.05			1	1	0	0
M01CB	Gold preparations	78	33			1	1			0.12	0.05			1	1		
M01CB01	Sodium aurothiomalate (DDD 2.40 mg)	78	33			1	1			0.12	0.05			1	1		
M01CX	Other specific antirheumatic agents		210	418	472		1	0	0						0	0	0

**M02 Topical products for joint and muscular pain**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M02	Topical products for joint and muscular pain	12,941	12,952	14,131	14,572	1	1	1	1								
M02A	Topical products for joint and muscular pain	12,941	12,952	14,131	14,572	1	1	1	1								
M02AA	Antiinflammatory preparations, non-steroids for topical use	11,955	12,045	13,258	13,762	1	1	1	1								
M02AA07	Piroxicam	897	864	880	846	3	3	2	1								
M02AA10	Ketoprofen	94	98	96	96	26	25	23	24								
M02AA13	Ibuprofen	616	1,116	760	1,039	0	0	0	0								
M02AA15	Diclofenac	10,348	9,968	11,522	11,782	0	0	0	0								
M02AC	Preparations with salicylic acid derivatives	1,973	1,813	1,747	1,619	11	11	9	10								

**M03 Muscle relaxants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M03	Muscle relaxants	14,322	15,236	14,648	15,953	63	64	62	59	4.67	5.26	5.14	5.09	3	3	2	2
M03A	Muscle relaxants, peripherally acting agents	10,226	10,167	9,751	10,726	81	79	76	72								
M03AB	Choline derivatives	637	500	639	561	99	99	99	99								
M03AB01	Suxamethonium	637	500	639	561	99	99	99	99								
M03AC	Other quaternary ammonium compounds	1,910	1,860	1,083	847	99	99	99	98								
M03AC09	Rocuronium bromide	1,798	1,759	914	726	99	99	99	98								
M03AC10	Mivacurium chloride	22	22	14	15	93	89	87	83								
M03AC11	Cisatracurium	89	80	154	105	100	100	100	100								
M03AX	Other muscle relaxants, peripherally acting agents	7,679	7,807	8,029	9,318	75	73	72	69								
M03AX01	Botulinum toxin	7,679	7,807	8,029	9,318	75	73	72	69								
M03B	Muscle relaxants, centrally acting agents	4,097	5,068	4,897	5,227	20	33	32	31	4.67	5.26	5.14	5.09	3	3	2	2
M03BC	Ethers, chemically close to antihistamines	1,076	1,244	1,143	1,461	43	39	37	28	2.25	2.82	2.76	2.75	2	1	1	1
M03BC01	Orphenadrine (citrate) (DDD 0.12,g)	951	1,097	1,025	1,295	49	44	42	31	1.99	2.51	2.52	2.52	2	2	1	1
M03BC51	Orphenadrine, combinations (DDD 4,ED)	125	147	117	166	1	0	0	0	0.26	0.31	0.24	0.22	1	0	0	0
M03BX	Other centrally acting agents	3,020	3,825	3,755	3,766	12	31	31	33	2.42	2.43	2.39	2.34	3	4	3	3
M03BX01	Baclofen	818	1,652	1,617	1,716	38	68	69	70	0.51	0.54	0.53	0.55	8	11	9	9
M03BX02	Tizanidine (DDD 12 mg)	2,202	2,172	2,137	2,050	2	2	2	1	1.91	1.89	1.86	1.78	2	2	1	1



M04 Antigout preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M04	Antigout preparations	1,935	1,940	1,791	1,490	3	2	2	2	3.99	4.19	4.46	4.46	2	2	2	2
M04A	Antigout preparations	1,935	1,940	1,791	1,490	3	2	2	2	3.99	4.19	4.46	4.46	2	2	2	2
M04AA	Preparations inhibiting uric acid production	1,898	1,897	1,739	1,474	3	2	2	2	3.97	4.18	4.44	4.45	2	2	2	2
M04AA01	Allopurinol (DDD 0.40,g)	1,501	1,567	1,493	1,208	2	2	2	2	3.75	3.92	4.15	4.12	2	2	2	2
M04AA03	Febuxostat (DDD 80 mg)	397	330	246	266	4	3	3	3	0.22	0.26	0.29	0.32	4	3	3	3
M04AC	Preparations with no effect on uric acid metabolism	37	43	52	16	16	17	11	22	0.02	0.02	0.02	0.01	16	17	11	22
M04AC01	Colchicine (DDD 1 mg)	37	43	52	16	16	17	11	22	0.02	0.02	0.02	0.01	16	17	11	22



M05 Drugs for treatment of bone diseases

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M05	Drugs for treatment of bone diseases	16,113	16,516	16,915	18,001	14	12	15	14	11.05	11.41	11.52	11.97	5	5	5	4
M05B	Drugs affecting bone structure and mineralization	16,113	16,516	16,915	18,001	14	12	15	14	11.05	11.41	11.52	11.97	5	5	5	4
M05BA	Bisphosphonates	3,082	2,709	3,199	2,870	44	41	54	57	3.58	3.41	3.26	3.17	3	2	2	2
M05BA02	Clodronic acid	167	126	86	78	1	2	2	2	0.02	0.01	0.01	0.01	1	2	1	1
M05BA03	Pamidronic acid (DDD 60 mg)	91	51	43	42	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
M05BA04	Alendronic acid (DDD 10 mg)	946	953	895	700	2	2	2	1	2.31	2.31	2.27	2.28	2	2	2	1
M05BA06	Ibandronic acid	261	204	168	138	9	6	3	2	0.59	0.48	0.43	0.38	2	2	2	2
M05BA07	Risedronic acid (DDD 5 mg)	389	355	335	317	4	3	3	3	0.66	0.59	0.54	0.49	3	3	3	2
M05BA08	Zoledronic acid (DDD 4 mg)	1,229	1,020	1,672	1,596	99	99	99	99	0.01	0.00	0.00	0.01	99	99	99	99
M05BB	Bisphosphonates, combinations	264	139	121	110	1	1	1	1	0.26	0.23	0.20	0.18	1	1	1	1
M05BB03	Alendronic acid and colecalciferol (DDD 10 mg)	264	139	121	110	1	1	1	1	0.26	0.23	0.20	0.18	1	1	1	1
M05BC	Bone morphogenetic proteins	40	55	46	67	100	100	100	100								
M05BC01	Dibotermin alfa	40	55	46	67	100	100	100	100								
M05BX	Other drugs affecting mineralization	12,727	13,613	13,550	14,953	6	6	6	5	7.21	7.77	8.06	8.62	7	6	6	5
M05BX03	Strontium ranelate (DDD 2,g)	0				100				0.00				100			
M05BX04	Denosumab (DDD 0.33 mg)	12,727	13,613	13,550	14,398	6	6	6	5	7.21	7.77	8.06	8.62	7	6	6	5
M05BX05	Burosumab				555				2				0.00				0

**M09 Other drugs for disorders of the musculo-skeletal system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M09	Other drugs for disorders of the musculo-skeletal system	11,048	9,650	7,325	7,270	98	98	98	99	0.07	0.05	0.02	0.02	77	72	42	53
M09A	Other drugs for disorders of the musculo-skeletal system	11,048	9,650	7,325	7,270	98	98	98	99	0.07	0.05	0.02	0.02	77	72	42	53
M09AB	Enzymes	1,021	1,230	9		97	96	100		0.00	0.00	0.00		97	96	100	
M09AB02	Collagenase clostridium histolyticum (DDD 0.90 mg)	1,021	1,230	9		97	96	100		0.00	0.00	0.00		97	96	100	
M09AX	Other drugs for disorders of the musculo-skeletal system	10,026	8,420	7,316	7,270	98	98	98	99	0.07	0.05	0.02	0.02	77	71	42	53
M09AX01	Hyaluronic acid (DDD 3.60 mg)	610	420	150	104	74	68	24	32	0.07	0.05	0.02	0.01	74	68	24	32
M09AX07	Nusinersen (DDD 0.10 mg)	9,416	7,999	7,166	7,166	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
M09AX07	Nusinerseeni (DDD 0.10 mg)	750	9,416	7,999	7,166	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100



N Nervous system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N	Nervous system	293,906	306,269	320,435	328,013	16	16	16	17	270.53	278.90	288.20	294.15	5	4	4	4
N01	Anesthetics	19,516	18,946	17,422	17,188	89	88	88	86								
N02	Analgesics	64,023	74,533	82,196	81,418	16	13	11	11	55.08	56.75	59.06	58.15	6	6	5	5
N03	Antiepileptics	54,697	52,622	47,894	47,280	9	9	8	8	22.25	23.26	24.26	25.14	4	4	4	3
N04	Anti-parkinson drugs	18,743	17,289	16,860	16,351	4	4	4	4	5.21	5.27	5.06	5.21	4	4	4	4
N05	Psycholeptics	69,863	70,388	72,917	74,063	14	14	14	14	83.89	84.99	86.24	86.92	5	5	5	5
N06	Psychoanaleptics	49,986	53,905	58,436	64,554	3	3	3	3	96.89	101.15	105.63	111.04	2	2	2	2
N07	Other nervous system drugs	17,078	18,586	24,710	27,159	19	24	40	51	7.22	7.48	7.95	7.68	14	17	19	22

**N01 Anesthetics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N01	Anesthetics	19,516	18,946	17,422	17,188	89	88	88	86								
N01A	Anesthetics, general	10,324	9,673	8,496	7,288	96	97	96	96								
N01AB	Halogenated hydrocarbons	3,016	2,622	2,314	1,959	98	97	98	97								
N01AB06	Isoflurane	10	11	12	11	100	100	100	88								
N01AB07	Desflurane	698	588	390	285	100	100	100	100								
N01AB08	Sevoflurane	2,308	2,023	1,912	1,664	97	97	97	96								
N01AF	Barbiturates, plain	107	27	50	27	99	99	99	98								
N01AF03	Thiopental	107	27	50	27	99	99	99	98								
N01AH	Opioid anesthetics	1,702	1,558	1,698	1,783	95	95	94	94								
N01AH01	Fentanyl	216	228	225	235	98	98	99	99								
N01AH02	Alfentanil	167	165	138	123	93	92	87	85								
N01AH03	Sufentanil	37	36	30	30	100	100	100	100								
N01AH06	Remifentanil	1,282	1,128	1,304	1,395	94	95	94	94								
N01AX	Other general anesthetics	5,499	5,466	4,434	3,519	96	97	96	95								
N01AX03	Ketamine	52	53	26	47	88	91	89	93								
N01AX10	Propofol	4,200	4,000	3,319	2,719	96	96	96	95								
N01AX14	Esketamine	1,247	1,413	1,089	753	97	98	99	98								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N01B	Anesthetics, local	9,192	9,273	8,926	9,900	80	80	79	79								
N01BB	Amides	8,773	8,797	8,467	9,369	80	79	79	79								
N01BB01	Bupivacaine	846	747	565	549	89	87	96	98								
N01BB02	Lidocaine	1,770	1,769	1,757	2,269	80	79	77	79								
N01BB03	Mepivacaine	5	5	5	4	13	10	10	13								
N01BB04	Prilocaine			1	7			82	98								
N01BB09	Ropivacaine	1,446	1,537	1,546	1,768	96	97	97	97								
N01BB10	Levobupivacaine	983	1,010	975	867	99	99	98	96								
N01BB20	Combinations	1,098	1,097	1,034	1,057	51	48	45	44								
N01BB51	Bupivacaine, combinations	39	44	24	37	89	80	92	88								
N01BB52	Lidocaine, combinations	1,077	1,117	1,214	1,311	82	81	81	80								
N01BB54	Prilocaine, combinations	145	118	149	146	61	62	62	60								
N01BB58	Articaine, combinations	1,364	1,355	1,196	1,355	67	68	66	66								
N01BX	Other local anesthetics	419	476	459	531	90	88	83	83								
N01BX04	Capsaicin	419	476	459	531	90	88	83	83								

**N02 Analgesics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N02	Analgesics	64,023	74,533	82,196	81,418	16	13	11	11	55.08	56.75	59.06	58.15	6	6	5	5
N02A	Opioids	27,595	25,790	24,778	24,028	24	25	24	25	14.02	13.75	13.30	12.95	9	9	9	8
N02AA	Natural opium alkaloids	10,422	10,188	10,337	10,771	50	50	49	47	2.33	2.37	2.36	2.29	34	35	35	33
N02AA01	Morphine	1,640	1,397	1,642	1,385	86	87	87	85	0.28	0.29	0.31	0.26	84	90	91	90
N02AA03	Hydromorphone	511	618	544	581	63	71	70	73	0.09	0.11	0.09	0.10	55	63	63	67
N02AA05	Oxycodone	4,922	5,089	4,955	5,179	48	48	45	45	1.68	1.68	1.68	1.65	25	25	24	23
N02AA55	Oxycodone and naloxone (DDD 75 mg)	3,349	3,083	3,196	3,627	34	32	30	32	0.28	0.29	0.28	0.29	35	33	32	31
N02AB	Phenylpiperidine derivatives	3,826	3,209	3,061	2,996	20	21	17	15	0.82	0.75	0.67	0.62	19	17	14	13
N02AB03	Fentanyl	3,826	3,209	3,061	2,996	20	21	17	15	0.82	0.75	0.67	0.62	19	17	14	13
N02AE	Oripavine derivatives	5,482	5,124	5,084	4,698	8	7	7	6	1.45	1.48	1.48	1.52	7	6	5	5
N02AE01	Buprenorphine (DDD 1.20 mg)	5,482	5,124	5,084	4,698	8	7	7	6	1.45	1.48	1.48	1.52	7	6	5	5
N02AJ	Opioids in combination with non-opioid analgesics	3,904	3,663	3,230	3,024	1	1	1	1	6.75	6.51	6.26	5.97	1	1	1	1
N02AJ06	Codeine and paracetamol	3,307	3,073	2,749	2,522	1	1	1	1	6.32	5.97	5.69	5.41	2	2	1	1
N02AJ08	Codeine and ibuprofen (DDD 4,ED)	341	294	265	254	0	0	0	0	0.14	0.11	0.11	0.10	0	0	0	0
N02AJ13	Tramadol and paracetamol (DDD 3,ED)	251	289	208	239	1	1	1	0	0.29	0.43	0.46	0.46	1	1	1	1
N02AJ14	Taramadol and dexketoprofen	4	8	9	9	0	0	0	0								
N02AX	Other opioids	3,961	3,605	3,066	2,539	4	4	4	4	2.67	2.64	2.54	2.54	2	2	2	2
N02AX02	Tramadol (DDD 0.30,g)	3,961	3,605	3,066	2,539	4	4	4	4	2.67	2.64	2.54	2.54	2	2	2	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N02B	Other analgesics and antipyretics	29,917	28,412	31,517	29,309	11	11	9	11	38.75	40.19	42.62	41.71	5	5	4	4
N02BA	Salicylic acid and derivatives	4,569	1,506	3,388	2,714	0	1	0	0	1.68	1.02	1.33	1.12	0	1	0	0
N02BA01	Acetylsalicylic acid	1,142	997	1,033	966	1	1	1	1	0.83	0.77	0.73	0.67	1	1	1	1
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	3,427	509	2,355	1,749	0	0	0	0	0.85	0.25	0.59	0.45	0	0	0	0
N02BE	Anilides	25,225	26,725	27,940	26,347	12	11	10	12	37.07	39.16	41.29	40.58	6	6	5	5
N02BE01	Paracetamol (DDD 3,g)	24,745	25,861	27,341	25,989	13	11	10	12	36.90	38.87	41.09	40.46	6	6	5	5
N02BE51	Paracetamol, combinations excl. psycholeptics (DDD 6,ED)	480	864	600	358	0	0	0	0	0.17	0.28	0.20	0.13	0	0	0	0
N02BG	Other analgesics and antipyretics	123	181	189	247	17	47	52	57	0.00	0.00	0.00	0.00	16	10	17	15
N02BG09	Methoxyflurane	2	75	88	131	100	99	94	95	0.00	0.00	0.00	0.00	0	0	0	0
N02BG10	Cannabinoids (DDD 8,ED)	121	105	101	116	16	10	17	15	0.00	0.00	0.00	0.00	16	10	17	15
N02C	Antimigraine preparations	6,511	20,332	25,900	28,081	7	2	0	0	2.31	2.82	3.14	3.50	1	1	0	0
N02CC	Selective 5ht1-receptor agonists	6,004	8,056	7,876	7,700	1	1	1	1	2.29	2.40	2.34	2.51	1	1	1	1
N02CC01	Sumatriptan	2,793	4,820	4,717	4,557	2	2	1	2	1.49	1.55	1.46	1.59	1	1	1	1
N02CC02	Naratriptan (DDD 2.50 mg)	152	94	79	76	0	0	0	0	0.02	0.03	0.03	0.03	0	0	0	0
N02CC03	Zolmitriptan (DDD 2.50 mg)	817	909	865	793	1	1	1	1	0.19	0.19	0.19	0.19	1	1	1	1
N02CC04	Rizatriptan (DDD 10 mg)	645	669	700	769	0	0	0	0	0.13	0.14	0.14	0.16	0	0	0	0
N02CC05	Almotriptan (DDD 12.50 mg)	437	448	440	502	0	0	0	0	0.10	0.11	0.11	0.11	0	0	0	0
N02CC06	Eletriptan (DDD 40 mg)	592	543	479	419	0	0	0	0	0.20	0.23	0.24	0.26	0	0	0	0
N02CC07	Frovatriptan (DDD 2.50 mg)	567	574	595	583	0	0	0	0	0.15	0.16	0.17	0.17	0	0	0	0
N02CD	Calcitonin gene-related peptide (CGRP) antagonists	507	12,276	18,024	20,381	79	3	0	0	0.02	0.41	0.80	0.98	79	3	0	0
N02CD01	Erenumab (DDD 2.50 mg)	507	12,247	13,284	10,209	79	3	0	0	0.02	0.41	0.63	0.62	79	3	0	0
N02CD02	Galcanezumab (DDD 4 mg)			288	2,633			0	0			0.01	0.10			0	0
N02CD03	Fremanezumab (DDD 7.50 mg)		29	4,452	7,539		0	0	0		0.00	0.16	0.27		0	0	0

**N03 Antiepileptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N03	Antiepileptics	54,697	52,622	47,894	47,280	9	9	8	8	22.25	23.26	24.26	25.14	4	4	4	3
N03A	Antiepileptics	54,697	52,622	47,894	47,280	9	9	8	8	22.25	23.26	24.26	25.14	4	4	4	3
N03AB	Hydantoin derivatives	907	1,046	723	657	86	89	86	86	0.19	0.17	0.15	0.13	10	12	8	9
N03AB02	Phenytoin (DDD 0.30,g)	138	127	107	96	7	8	5	6	0.18	0.17	0.14	0.13	7	8	5	6
N03AB05	Fosphenytoin (DDD 0.45,g)	769	919	616	561	100	100	100	100	0.01	0.01	0.01	0.00	100	100	100	100
N03AE	Benzodiazepine derivatives	533	501	471	434	3	3	2	2	0.74	0.69	0.64	0.59	2	2	2	2
N03AE01	Clonazepam (DDD 8 mg)	533	501	471	434	3	3	2	2	0.74	0.69	0.64	0.59	2	2	2	2
N03AF	Carboxamide derivatives	4,912	4,942	4,993	4,900	4	4	3	2	3.66	3.62	3.58	3.50	3	2	2	2
N03AF01	Carbamazepine (DDD 1,g)	1,246	1,159	1,097	1,007	9	7	6	3	1.40	1.32	1.26	1.18	3	3	2	2
N03AF02	Oxcarbazepine (DDD 1,g)	3,073	3,117	3,180	3,165	3	3	2	2	2.20	2.22	2.25	2.23	3	2	2	2
N03AF03	Rufinamide (DDD 1.40,g)	204	220	235	251	6	6	5	3	0.01	0.02	0.02	0.02	5	6	5	3
N03AF04	Eslicarbazepine (DDD 0.80,g)	389	447	481	477	3	2	2	1	0.05	0.06	0.06	0.06	3	2	2	1
N03AG	Fatty acid derivatives	4,795	4,717	4,700	4,552	11	10	9	9	3.62	3.60	3.57	3.50	6	6	6	5
N03AG01	Valproic acid (DDD 1.50,g)	4,707	4,634	4,617	4,474	11	10	9	9	3.60	3.58	3.55	3.48	6	6	6	5
N03AG04	Vigabatrin (DDD 2,g)	89	83	83	78	10	9	9	10	0.02	0.02	0.02	0.02	10	9	9	10

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N03AX	Other antiepileptics	43,549	41,417	37,008	36,738	7	8	8	7	14.05	15.19	16.32	17.42	4	4	4	3
N03AX09	Lamotrigine (DDD 0.30,g)	4,830	4,749	4,559	4,517	3	3	3	2	2.12	2.23	2.32	2.41	3	3	2	2
N03AX11	Topiramate (DDD 0.30,g)	1,635	1,567	1,504	1,423	5	4	4	3	0.37	0.36	0.36	0.34	5	5	5	4
N03AX12	Gabapentin (DDD 1.80,g)	5,964	6,107	6,487	6,773	4	4	4	4	3.09	3.54	4.20	4.69	4	4	4	4
N03AX14	Levetiracetam (DDD 1.50,g)	8,220	8,623	8,689	8,156	12	10	8	9	2.53	2.70	2.77	2.83	7	6	5	5
N03AX15	Zonisamide (DDD 0.20,g)	920	857	833	801	3	3	2	2	0.20	0.19	0.19	0.19	2	3	2	2
N03AX16	Pregabalin (DDD 0.30,g)	16,541	12,512	6,563	5,241	4	4	3	4	5.19	5.43	5.57	5.89	3	3	3	2
N03AX17	Stiripentol (DDD 1,g)	293	319	341	338	3	1	3	2	0.01	0.01	0.01	0.01	3	1	3	2
N03AX18	Lacosamide (DDD 0.30,g)	4,183	4,839	5,561	6,050	23	22	21	19	0.45	0.52	0.61	0.67	8	7	7	5
N03AX22	Perampanel (DDD 8 mg)	737	884	958	1,021	7	7	6	7	0.06	0.08	0.09	0.10	5	5	5	5
N03AX23	Brivaracetam (DDD 0.10,g)	226	960	1,513	1,968	29	16	14	9	0.03	0.11	0.20	0.28	9	6	5	3
N03AX24	Cannabidiol				448				6				0.00				6

**N04 Anti-parkinson drugs**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N04	Anti-parkinson drugs	18,743	17,289	16,860	16,351	4	4	4	4	5.21	5.27	5.06	5.21	4	4	4	4
N04A	Anticholinergic agents	102	94	91	87	5	4	5	5	0.18	0.17	0.16	0.16	5	4	5	5
N04AA	Tertiary amines	102	94	91	87	5	4	5	5	0.18	0.17	0.16	0.16	5	4	5	5
N04AA02	Biperiden (DDD 10 mg)	102	94	91	87	5	4	5	5	0.18	0.17	0.16	0.16	5	4	5	5
N04B	Dopaminergic agents	18,641	17,195	16,770	16,264	4	4	4	4	5.02	5.10	4.90	5.06	4	4	4	4
N04BA	Dopa and dopa derivatives	13,417	13,120	13,127	13,076	5	5	4	4	2.39	2.47	2.31	2.53	6	6	5	5
N04BA02	Levodopa and decarboxylase inhibitor (DDD 0.60,g)	11,295	11,210	10,853	9,853	5	5	4	3	1.65	1.75	1.60	1.84	6	6	5	5
N04BA03	Levodopa, decarboxylase inhibitor and comt inhibitor (DDD 0.45,g)	2,122	1,910	2,274	3,223	6	5	5	5	0.74	0.72	0.71	0.69	6	6	5	5
N04BC	Dopamine agonists	4,428	3,362	2,974	2,524	3	3	3	3	1.48	1.45	1.46	1.43	2	2	2	2
N04BC01	Bromocriptine (DDD 40 mg)	8	6	6	0	19	12	18	27	0.00	0.00	0.00	0.00	19	12	18	27
N04BC04	Ropinirole (DDD 6 mg)	821	589	464	331	2	2	2	2	0.69	0.70	0.68	0.64	2	2	2	2
N04BC05	Pramipexole (DDD 2.50 mg)	2,694	1,802	1,514	1,347	2	2	2	2	0.67	0.64	0.67	0.69	2	2	2	2
N04BC06	Cabergoline (DDD 3 mg)	68	71	74	73	5	4	6	6	0.01	0.01	0.01	0.01	5	4	6	6
N04BC07	Apomorphine (DDD 20 mg)	229	329	348	250	3	3	2	3	0.01	0.01	0.01	0.01	3	3	2	3
N04BC09	Rotigotine (DDD 6 mg)	609	566	568	521	4	4	3	3	0.09	0.08	0.09	0.08	4	3	3	3
N04BD	Monoamine oxidase type b inhibitors	614	557	499	459	4	3	3	2	1.13	1.15	1.10	1.06	3	2	4	3
N04BD01	Selegiline (DDD 5 mg)	355	367	341	324	2	2	2	2	0.75	0.78	0.73	0.71	2	2	2	2
N04BD02	Rasagiline (DDD 1 mg)	257	190	158	134	5	5	6	3	0.38	0.37	0.37	0.35	3	3	6	4
N04BD03	Safinamide (DDD 75 mg)	2	0	1	1	8	0	20	0	0.00	0.00	0.00	0.00	6	0	19	0
N04BX	Other dopaminergic agents	182	155	169	205	7	9	6	5	0.03	0.02	0.03	0.03	7	9	6	5
N04BX02	Entacapone (DDD 1,g)	182	155	169	174	7	9	6	5	0.03	0.02	0.03	0.03	7	9	6	5
N04BX04	Opicapone				31				4				0.00				4



N05 Psycholeptics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N05	Psycholeptics	69,863	70,388	72,917	74,063	14	14	14	14	83.89	84.99	86.24	86.92	5	5	5	5
N05A	Antipsychotics	49,941	50,472	51,762	52,700	11	11	11	10	21.85	22.16	22.94	23.13	7	7	7	7
N05AA	Phenothiazines with aliphatic side chain	361	362	347	337	7	6	6	6	0.34	0.33	0.31	0.28	7	6	6	6
N05AA02	Levomepromazine	361	362	347	337	7	6	6	6	0.34	0.33	0.31	0.28	7	6	6	6
N05AB	Phenothiazines with piperazine structure	573	571	568	551	5	5	5	5	0.45	0.45	0.44	0.42	5	5	5	5
N05AB03	Perphenazine	550	551	549	530	6	5	5	5	0.44	0.43	0.43	0.41	5	5	5	5
N05AB04	Prochlorperazine	22	21	19	20	2	2	2	2	0.01	0.01	0.01	0.01	2	2	2	2
N05AC	Phenothiazines with piperidine structure	8				5				0.01				4			
N05AC01	Periciazine	8				5				0.01				4			
N05AD	Butyrophenone derivatives	523	502	499	420	47	49	50	43	0.44	0.41	0.42	0.39	23	23	27	24
N05AD01	Haloperidol	371	346	360	336	27	26	32	29	0.42	0.39	0.40	0.38	20	20	24	22
N05AD08	Droperidol (DDD 2.50 mg)	152	157	139	84	98	98	97	97	0.02	0.02	0.02	0.01	98	98	97	97
N05AE	Indole derivatives	1,304	1,480	1,551	1,643	8	7	7	6	0.29	0.32	0.33	0.35	7	6	6	5
N05AE03	Sertindole (DDD 16 mg)	431	412	387	363	6	6	4	5	0.07	0.07	0.06	0.06	6	5	4	4
N05AE04	Ziprasidone	611	603	592	580	5	4	4	3	0.17	0.17	0.16	0.16	4	3	3	3
N05AE05	Lurasidone (DDD 60 mg)	262	465	572	700	17	13	12	9	0.05	0.08	0.10	0.13	18	12	11	9
N05AF	Thioxanthene derivatives	621	594	579	553	12	12	13	14	0.70	0.67	0.65	0.60	8	8	9	9
N05AF01	Flupentixol	71	70	69	69	4	3	3	3	0.06	0.06	0.05	0.05	5	4	3	2
N05AF03	Chlorprothixene	267	262	247	230	3	4	3	3	0.26	0.26	0.24	0.22	3	4	3	3
N05AF05	Zuclopenthixol	283	263	263	254	23	22	24	27	0.38	0.36	0.35	0.33	12	12	14	14

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N05AH	Diazepines, oxazepines, thiazepines and oxepines	20,745	19,820	20,079	20,494	12	12	12	11	13.82	13.92	14.52	14.53	7	7	7	6
N05AH01	Loxapine	5				100				0.00				100			
N05AH02	Clozapine (DDD 0.30,g)	4,953	3,874	3,884	3,530	9	9	9	9	2.30	2.25	2.36	2.32	9	9	9	10
N05AH03	Olanzapine (DDD 10 mg)	11,605	11,991	12,282	12,562	16	16	16	15	6.22	6.30	6.66	6.70	9	9	8	8
N05AH04	Quetiapine (DDD 0.40,g)	4,058	3,833	3,798	4,294	4	3	3	3	5.28	5.36	5.48	5.50	4	4	4	3
N05AH05	Asenapine (DDD 20 mg)	125	122	114	107	15	16	15	13	0.02	0.02	0.02	0.02	13	13	12	10
N05AL	Benzamides	109	100	102	93	9	7	8	7	0.05	0.04	0.04	0.04	9	7	9	7
N05AL01	Sulpiride (DDD 0.80,g)	109	100	102	93	9	7	8	7	0.05	0.04	0.04	0.04	9	7	9	7
N05AN	Lithium	607	615	621	626	6	6	6	6	0.97	0.98	0.99	0.99	6	6	6	6
N05AN01	Lithium (DDD 168 mg)	607	615	621	626	6	6	6	6	0.97	0.98	0.99	0.99	6	6	6	6
N05AX	Other antipsychotics	25,094	26,426	27,415	27,985	10	10	9	9	4.79	5.04	5.25	5.52	7	7	7	7
N05AX08	Risperidone	10,159	9,332	8,669	7,928	6	5	5	5	1.91	1.83	1.84	1.80	7	6	6	6
N05AX12	Aripiprazole	6,946	7,587	8,269	8,563	13	11	10	10	2.39	2.62	2.75	2.87	7	6	6	6
N05AX13	Paliperidone	7,987	9,436	10,257	10,560	12	13	12	11	0.48	0.58	0.64	0.67	13	13	12	11
N05AX15	Cariprazine (DDD 3 mg)	1	61	143	524	50	56	56	22	0.00	0.01	0.03	0.11	64	54	53	25
N05AX16	Brexpiprazole (DDD 3 mg)		10	77	410		23	23	16		0.00	0.01	0.06		23	24	17
N05B	Anxiolytics	6,329	5,989	6,916	7,078	11	11	25	30	17.43	16.22	15.48	14.50	6	6	6	6
N05BA	Benzodiazepine derivatives	5,013	4,676	5,588	5,744	12	13	30	35	15.95	14.76	14.03	13.09	6	6	6	6
N05BA01	Diazepam (DDD 10 mg)	1,599	1,411	1,295	1,133	32	28	27	22	4.69	4.30	3.98	3.60	9	9	9	8
N05BA02	Chlordiazepoxide	54				13				0.19				14			
N05BA04	Oxazepam (DDD 50 mg)	1,767	1,753	1,698	1,646	3	4	4	4	4.92	4.84	4.70	4.52	4	4	4	4

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N05BA06 Lorazepam (DDD 2.50 mg)	401	446	1,578	2,065	8	25	78	82	1.90	1.81	1.79	1.73	10	10	13	14
N05BA09 Clobazam (DDD 20 mg)	121	113	129	133	4	4	4	4	0.36	0.33	0.38	0.39	4	4	4	4
N05BA12 Alprazolam (DDD 1 mg)	1,071	953	887	767	1	1	1	1	3.88	3.47	3.19	2.86	1	1	1	1
N05BB Diphenylmethane derivatives	751	727	725	681	5	5	4	4	1.25	1.22	1.19	1.14	6	5	5	4
N05BB01 Hydroxyzine (DDD 75 mg)	751	727	725	681	5	5	4	4	1.25	1.22	1.19	1.14	6	5	5	4
N05BE Azaspirodecanedione derivatives	565	586	604	653	9	11	12	11	0.23	0.24	0.25	0.27	9	11	12	11
N05BE01 Buspirone (DDD 30 mg)	565	586	604	653	9	11	12	11	0.23	0.24	0.25	0.27	9	11	12	11
N05C Hypnotics and sedatives	13,593	13,927	14,239	14,285	26	25	21	21	44.61	46.61	47.82	49.30	4	4	4	4
N05CD Benzodiazepine derivatives	3,321	3,330	3,472	3,298	12	13	15	15	6.77	5.84	5.29	4.82	5	5	6	6
N05CD02 Nitrazepam (DDD 5 mg)	106	112	102	53	2	3	2	1	0.33	0.31	0.26	0.14	3	3	2	1
N05CD05 Triazolam	38	40	33	29	1	0	0	1	0.03	0.03	0.03	0.03	1	0	0	1
N05CD07 Temazepam (DDD 20 mg)	1,863	1,798	1,800	1,832	3	3	3	3	6.20	5.30	4.78	4.45	4	4	4	4
N05CD08 Midazolam	1,315	1,380	1,536	1,385	25	27	30	32	0.21	0.20	0.22	0.20	40	45	55	56
N05CF Benzodiazepine related drugs	2,674	2,510	2,505	2,328	2	2	2	2	17.83	16.73	16.02	14.80	2	2	2	2
N05CF01 Zopiclone (DDD 7.50 mg)	2,017	1,912	1,886	1,720	2	2	2	2	12.97	12.13	11.43	10.56	3	3	3	3
N05CF02 Zolpidem (DDD 10 mg)	657	598	619	608	1	1	1	1	4.86	4.60	4.59	4.24	1	1	1	1
N05CH Melatonin receptor agonists	4,467	5,131	5,662	6,045	6	5	4	4	19.79	23.93	26.29	29.48	5	5	4	4
N05CH01 Melatonin (DDD 2 mg)	4,467	5,131	5,662	6,045	6	5	4	4	19.79	23.93	26.29	29.48	5	5	4	4
N05CM Other hypnotics and sedatives	3,131	2,956	2,600	2,614	90	95	83	84	0.23	0.11	0.22	0.21	6	12	6	6
N05CM09 Valerianae radix	309	147	451	416	0	0	0	0	0.21	0.09	0.21	0.19	0	0	0	0
N05CM18 Dexmedetomidine (DDD 1 mg)	2,822	2,809	2,149	2,198	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100

**N06 Psychoanaleptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N06	Psychoanaleptics	49,986	53,905	58,436	64,554	3	3	3	3	96.89	101.15	105.63	111.04	2	2	2	2
N06A	Antidepressants	31,382	33,491	36,009	38,181	2	2	2	3	74.87	78.29	81.51	85.23	2	2	2	2
N06AA	Non-selective monoamine reuptake inhibitors	3,308	3,300	3,419	3,599	2	2	2	1	4.35	4.12	3.92	3.94	2	2	2	2
N06AA04	Clomipramine (DDD 0.10,g)	147	148	161	158	3	3	4	4	0.20	0.20	0.22	0.21	3	3	4	4
N06AA06	Trimipramine (DDD 0.15,g)	73	61	65	58	4	3	2	2	0.10	0.09	0.09	0.08	4	3	2	2
N06AA09	Amitriptyline (DDD 75 mg)	2,364	2,492	2,758	2,890	2	2	2	1	3.01	2.89	3.01	3.00	2	2	2	1
N06AA10	Nortriptyline	392	422	436	493	2	2	2	2	0.55	0.58	0.60	0.65	3	2	2	2
N06AA12	Doxepin (DDD 0.10,g)	332	176			3	2			0.48	0.36			3	2		
N06AB	Selective serotonin reuptake inhibitors	6,655	6,618	6,819	7,162	2	2	2	2	41.39	43.40	44.57	46.44	2	1	1	1
N06AB03	Fluoxetine (DDD 20 mg)	989	1,035	1,089	1,208	2	2	2	2	4.27	4.41	4.50	4.91	2	2	1	1
N06AB04	Citalopram (DDD 20 mg)	1,580	1,463	1,343	1,287	2	2	2	2	9.60	9.11	8.50	8.08	2	1	1	1
N06AB05	Paroxetine (DDD 20 mg)	716	701	652	570	1	1	1	1	2.32	2.32	2.33	2.31	1	1	1	1
N06AB06	Sertraline (DDD 50 mg)	1,573	1,413	1,610	1,676	2	2	2	2	8.58	9.70	10.87	11.93	2	2	2	2
N06AB08	Fluvoxamine (DDD 0.10,g)	83	78	76	73	1	1	1	1	0.15	0.14	0.14	0.13	1	1	1	1
N06AB10	Escitalopram (DDD 10 mg)	1,714	1,929	2,048	2,348	3	2	2	2	16.47	17.72	18.23	19.08	2	1	1	1
N06AG	Monoamine oxidase type a inhibitors	271	267	268	260	1	1	1	2	0.35	0.34	0.34	0.33	1	1	1	1
N06AG02	Moclobemide (DDD 0.30,g)	271	267	268	260	1	1	1	2	0.35	0.34	0.34	0.33	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N06AX	Other antidepressants	21,148	23,306	25,502	27,160	3	2	2	3	28.79	30.43	32.68	34.52	3	2	2	2
N06AX03	Mianserin (DDD 60 mg)	273	241	190	180	2	2	2	2	0.30	0.26	0.20	0.20	2	2	2	2
N06AX05	Trazodone (DDD 0.30,g)	139	169	179	187	3	3	3	2	0.16	0.19	0.20	0.21	3	3	3	2
N06AX11	Mirtazapine (DDD 30 mg)	4,230	4,612	5,077	5,275	5	4	4	3	8.07	8.24	8.47	8.54	4	4	3	3
N06AX12	Bupropion (DDD 0.30,g)	3,670	4,088	4,057	3,204	1	1	1	1	2.08	2.32	2.53	2.69	1	1	1	1
N06AX16	Venlafaxine (DDD 0.10,g)	6,299	6,478	6,982	7,016	2	2	2	2	11.19	11.04	11.67	11.90	2	2	2	2
N06AX17	Milnacipran (DDD 0.10,g)	68	51	23		2	2	1		0.05	0.04	0.02		2	2	1	
N06AX18	Reboxetin (DDD 8 mg)	33	34	30		1	2	2		0.03	0.03	0.03		1	2	2	
N06AX21	Duloxetine (DDD 60 mg)	1,147	1,228	1,308	2,049	3	2	4	3	3.61	3.93	4.14	4.49	2	2	2	2
N06AX22	Agomelatine (DDD 25 mg)	1,240	860	778	727	3	3	2	3	0.77	0.91	1.04	1.10	3	2	2	2
N06AX26	Vortioxetine (DDD 10 mg)	4,049	5,547	6,834	8,279	3	3	2	2	2.53	3.47	4.39	5.40	3	2	2	2
N06AX27	Esketamine (DDD 8 mg)			45	243			73	91			0.00	0.00			73	91
N06B	Psychostimulants, agents used for adhd and nootropics	11,432	13,732	16,115	20,090	4	3	3	2	4.60	5.56	6.70	8.61	1	1	1	1
N06BA	Centrally acting sympathomimetics	11,106	13,332	15,562	19,620	1	1	1	1	4.55	5.51	6.65	8.56	1	1	1	1
N06BA02	Dexamfetamine (DDD 15 mg)	540	646	739	817	0	0	0	1	0.11	0.13	0.15	0.17	0	0	0	1
N06BA04	Methylphenidate (DDD 30 mg)	6,086	7,201	8,107	9,931	1	1	1	0	3.69	4.28	4.95	6.21	1	1	1	0
N06BA07	Modafinil (DDD 0.30,g)	712	773	765	771	1	0	1	1	0.08	0.08	0.08	0.09	0	0	1	1
N06BA09	Atomoxetine (DDD 80 mg)	1,588	1,280	876	836	5	4	5	4	0.16	0.17	0.20	0.24	5	4	4	3
N06BA12	Lisdexamfetamine (DDD 30 mg)	2,179	3,432	5,075	7,253	1	1	1	1	0.52	0.84	1.27	1.85	1	1	1	1
N06BA14	Solriamfetol				13				0				0.00				0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N06BC	Xanthine derivatives	275	274	253	277	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BC01	Caffeine (DDD 0.40,g)	275	274	253	277	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BX	Other psychostimulants and nootropics	52	126	300	192	4	5	0	6	0.05	0.05	0.05	0.05	4	3	2	1
N06BX03	Piracetam	52	54	52	52	4	3	2	1	0.05	0.05	0.05	0.05	4	3	2	1
N06BX13	Idebenone (DDD 0.90,g)		73	248	140		6	0	8		0.00	0.00	0.00		6	0	8
N06C	Psycholeptics and psychoanaleptics in combination	468	457	439	421	1	1	1	1	0.78	0.75	0.71	0.68	1	1	1	1
N06CA	Antidepressants in combination with psycholeptics	468	457	439	421	1	1	1	1	0.78	0.75	0.71	0.68	1	1	1	1
N06CA01	Amitriptyline and psycholeptics	468	457	439	421	1	1	1	1	0.78	0.75	0.71	0.68	1	1	1	1
N06D	Anti-dementia drugs	6,703	6,225	5,874	5,862	6	5	5	5	16.65	16.57	16.70	16.52	5	4	4	4
N06DA	Anticholinesterases	5,156	4,362	4,451	4,516	6	5	5	4	10.06	9.84	9.83	9.58	4	4	4	3
N06DA02	Donepezil (DDD 7.50 mg)	411	467	649	733	3	4	3	3	6.27	6.02	5.93	5.52	4	3	3	3
N06DA03	Rivastigmine	3,490	2,643	2,470	2,538	7	7	6	6	2.23	2.23	2.23	2.31	5	5	5	4
N06DA04	Galantamine (DDD 16 mg)	1,255	1,252	1,332	1,245	4	3	4	3	1.56	1.59	1.66	1.75	4	3	4	3
N06DX	Other anti-dementia drugs	1,547	1,863	1,423	1,347	6	5	6	5	6.59	6.73	6.87	6.94	6	5	5	4
N06DX01	Memantine (DDD 20 mg)	1,547	1,863	1,423	1,347	6	5	6	5	6.59	6.73	6.87	6.94	6	5	5	4

**N07 Other nervous system drugs**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N07	Other nervous system drugs	17,078	18,586	24,710	27,159	19	24	40	51	7.22	7.48	7.95	7.68	14	17	19	22
N07A	Parasympathomimetics	471	460	489	448	44	38	43	36	0.25	0.27	0.27	0.27	6	5	5	5
N07AA	Anticholinesterases	459	445	477	437	45	39	44	37	0.25	0.27	0.27	0.27	6	5	5	5
N07AA02	Pyridostigmine	255	277	271	279	3	3	2	3	0.24	0.26	0.26	0.27	3	3	2	3
N07AA51	Neostigmine, combinations (DDD 1,ED)	204	168	206	158	98	98	99	98	0.01	0.01	0.01	0.01	98	98	99	98
N07AX	Other parasympathomimetics	13	15	12	11	4	1	1	5	0.00	0.00	0.00	0.00	4	1	1	5
N07AX01	Pilocarpine	13	15	12	11	4	1	1	5	0.00	0.00	0.00	0.00	4	1	1	5
N07B	Drugs used in addictive disorders	14,307	15,374	21,262	24,008	21	28	44	57	4.20	4.39	4.82	4.51	22	27	31	36
N07BA	Drugs used in nicotine dependence	10,360	10,366	11,083	8,934	4	4	4	5	2.56	2.47	2.67	2.23	5	6	6	7
N07BA01	Nicotine ¹	7,373	7,014	7,666	7,666	5	6	6	6	1.99	1.83	2.02	1.99	7	7	7	7
N07BA03	Varenicline (DDD 2 mg)	2,987	3,352	3,418	1,268	0	1	1	1	0.57	0.64	0.65	0.24	0	1	1	1
N07BB	Drugs used in alcohol dependence	658	642	604	567	5	6	6	5	0.66	0.65	0.63	0.58	6	6	7	6
N07BB01	Disulfiram (DDD 0.20,g)	417	410	396	366	6	7	7	6	0.56	0.55	0.53	0.49	6	7	7	6
N07BB04	Naltrexone (DDD 50 mg)	150	157	156	156	5	5	5	5	0.09	0.09	0.09	0.09	5	5	5	5
N07BB05	Nalmefene (DDD 18 mg)	91	75	52	44	3	1	2	0	0.01	0.01	0.01	0.01	3	1	2	0
N07BC	Drugs used in opioid dependence	3,289	4,366	9,575	14,507	80	86	93	91	0.98	1.27	1.52	1.69	77	81	86	86
N07BC01	Buprenorphine	17	1,739	7,415	10,512	95	98	97	95	0.00	0.12	0.53	0.78	95	98	97	95
N07BC02	Methadone (DDD 25 mg)	1,427	1,610	1,586	1,350	91	90	90	87	0.56	0.62	0.61	0.51	86	86	86	82
N07BC05	Levomethadone (DDD 15 mg)			74	321			73	67			0.02	0.08			73	66
N07BC51	Buprenorphine, combinations	1,846	1,017	500	2,323	71	61	52	75	0.42	0.52	0.36	0.32	67	71	71	72

¹ Includes nicotine replacement products sold to pharmacies and institutional customers. See also Nicotine replacement therapy page 236.

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N07C	Antivertigo preparations	699	701	706	666	1	1	1	1	2.71	2.76	2.80	2.82	1	1	1	1
N07CA	Antivertigo preparations	699	701	706	666	1	1	1	1	2.71	2.76	2.80	2.82	1	1	1	1
N07CA01	Betahistine (DDD 24 mg)	699	700	705	666	1	1	1	1	2.71	2.76	2.80	2.82	1	1	1	1
N07CA52	Cinnarizine, combinations (DDD 90 mg)	0	1	1	0	0	6	0	0	0.00	0.00	0.00	0.00	0	6	0	0
N07X	Other nervous system drugs	1,601	2,051	2,253	2,037	2	6	7	5	0.05	0.05	0.06	0.07	4	4	4	3
N07XX	Other nervous system drugs	1,601	2,051	2,253	2,037	2	6	7	5	0.05	0.05	0.06	0.07	4	4	4	3
N07XX02	Riluzole (DDD 0.10,g)	208	179	210	255	6	8	8	8	0.02	0.02	0.02	0.02	6	8	8	8
N07XX04	Sodium oxybate (DDD 7.50,g)	1,231	1,367	1,100	605	1	0	0	0	0.02	0.03	0.03	0.03	1	0	0	0
N07XX06	Tetrabenazine (DDD 0.10,g)	83	80	63	56	10	8	11	3	0.01	0.01	0.00	0.00	10	8	11	3
N07XX07	Fampridine (DDD 20 mg)	79	74	106	106	8	10	6	5	0.00	0.00	0.01	0.01	5	6	4	3
N07XX08	Tafamidis (DDD 20 mg)		285	654	807		31	20	9		0.00	0.00	0.00		31	20	5
N07XX11	Pitolisant (DDD 18 mg)		68	120	209		1	0	0		0.00	0.00	0.01		0	0	0



P Antiparasitic products, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
P	Antiparasitic products, insecticides and repellents	6,205	6,296	5,749	6,329	3	3	3	4	2.34	2.42	2.51	2.41	2	2	2	1
P01	Antiprotozoals	3,296	3,064	2,668	2,468	4	3	4	3	2.10	2.12	2.24	2.16	2	2	3	2
P02	Anthelmintics	1,428	1,679	1,515	1,927	0	0	0	4	0.25	0.29	0.27	0.25	0	0	0	0
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,481	1,553	1,566	1,933	4	4	4	4								

**P01 Antiprotozoals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
P01	Antiprotozoals	3,296	3,064	2,668	2,468	4	3	4	3	2.10	2.12	2.24	2.16	2	2	3	2
P01A	Agents against amoebiasis and other protozoal diseases	810	743	659	604	7	7	7	6	0.31	0.30	0.26	0.26	10	9	8	7
P01AB	Nitroimidazole derivatives	810	743	659	604	7	7	7	6	0.31	0.30	0.26	0.26	10	9	8	7
P01AB01	Metronidazole (DDD 2,g)	810	743	659	604	7	7	7	6	0.31	0.30	0.26	0.26	10	9	8	7
P01B	Antimalarials	2,487	2,320	2,009	1,864	3	2	4	2	1.79	1.83	1.98	1.91	1	1	2	1
P01BA	Aminoquinolines	1,555	1,594	1,754	1,691	1	1	2	1	1.75	1.79	1.97	1.90	1	1	2	1
P01BA02	Hydroxychloroquine (DDD 0.52,g)	1,555	1,594	1,754	1,691	1	1	2	1	1.75	1.79	1.97	1.90	1	1	2	1
P01BB	Biguanides	798	623	217	136	7	5	20	23	0.03	0.03	0.01	0.01	6	4	19	23
P01BB51	Proguanil and atovaquone (DDD 4,ED)	798	623	217	136	7	5	20	23	0.03	0.03	0.01	0.01	6	4	19	23
P01BC	Quinine alkaloids	134	104	37	37	0	0	4	1	0.01	0.00	0.00	0.00	0	0	4	1
P01BC02	Mefloquine (DDD 1,g)	134	104	37	37	0	0	4	1	0.01	0.00	0.00	0.00	0	0	4	1



P02 Anthelmintics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
P02	Anthelmintics	1,428	1,679	1,515	1,927	0	0	0	4	0.25	0.29	0.27	0.25	0	0	0	0
P02C	Antinematodal agents	1,428	1,679	1,515	1,927	0	0	0	4	0.25	0.29	0.27	0.25	0	0	0	0
P02CF	Avermectines				557				15				0.01				15
P02CF01	Ivermectin				557				15				0.01				15
P02CX	Other antinematodals	1,428	1,679	1,515	1,370	0	0	0	0	0.25	0.29	0.27	0.24	0	0	0	0
P02CX01	Pyviniium (DDD 0.35,g)	1,428	1,679	1,515	1,370	0	0	0	0	0.25	0.29	0.27	0.24	0	0	0	0

P03 Ectoparasiticides, incl. scabicides, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,481	1,553	1,566	1,933	4	4	4	4								
P03A	Ectoparasiticides, incl. scabicides	1,481	1,553	1,566	1,933	4	4	4	4								
P03AC	Pyrethrines, incl. synthetic compounds	1,481	1,553	1,566	1,933	4	4	4	4								
P03AC04	Permethrin	1,481	1,553	1,566	1,933	4	4	4	4								



R Respiratory system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R	Respiratory system	154,205	152,760	148,602	150,912	6	6	6	4	182.98	189.21	194.01	197.99	2	2	2	2
R01	Nasal preparations	24,823	26,971	23,802	24,113	1	1	1	1	35.48	37.03	33.25	33.71	1	1	1	1
R02	Throat preparations	7,938	7,555	5,708	5,375	0	0	0	0	3.68	3.28	2.51	2.28	0	0	0	0
R03	Drugs for obstructive airway diseases	93,537	91,012	93,802	90,249	8	9	8	5	78.39	79.91	83.82	80.99	3	3	3	3
R05	Cough and cold preparations	12,032	10,667	7,100	6,175	2	2	2	2	5.38	4.73	3.13	2.65	2	2	2	2
R06	Antihistamines for systemic use	14,992	15,862	17,165	18,344	1	0	1	0	60.06	64.26	71.31	78.35	1	1	1	1
R07	Other respiratory system products	884	693	1,027	6,656	100	100	83	13	0.00	0.00	0.00	0.00	100	100	87	21



R01 Nasal preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R01	Nasal preparations	24,823	26,971	23,802	24,113	1	1	1	1	35.48	37.03	33.25	33.71	1	1	1	1
R01A	Decongestants and other nasal preparations for topical use	19,047	20,916	19,755	19,940	1	1	1	1	33.52	35.12	31.97	32.61	1	1	1	1
R01AA	Sympathomimetics, plain	4,874	5,853	5,294	5,349	1	1	1	1	10.74	11.11	9.17	9.57	1	1	1	1
R01AA05	Oxymetazoline (DDD 0.40 mg)	267	284	260	253	0	0	0	0	0.78	0.82	0.75	0.73	0	0	0	0
R01AA07	Xylometazoline (DDD 0.80 mg)	4,607	5,569	5,034	5,096	1	1	1	1	9.96	10.29	8.42	8.84	1	1	1	1
R01AB	Sympathomimetics, combinations excl. corticosteroids	540	612	492	517	0	0	0	0	0.80	0.83	0.64	0.69	0	0	0	0
R01AB06	Xylometazoline (DDD 0.80,ml)	540	612	492	517	0	0	0	0	0.80	0.83	0.64	0.69	0	0	0	0
R01AC	Antiallergic agents, excl. corticosteroids	314	303	246	351	0	1	0	0	0.35	0.33	0.22	0.29	1	1	0	0
R01AC01	Cromoglicic acid (DDD 40 mg)	144	133	21		1	1	0		0.20	0.19	0.03		1	1	0	
R01AC02	Levocabastine (DDD 0.60 mg)	104	98	137	212	0	0	0	0	0.07	0.07	0.09	0.14	0	0	0	0
R01AC03	Azelastine (DDD 0.56 mg)	67	71	87	138	0	0	0	0	0.07	0.08	0.09	0.15	0	0	0	0
R01AD	Corticosteroids	12,887	13,708	13,275	13,264	1	1	1	1	21.26	22.50	21.63	21.74	1	1	1	1
R01AD01	Beclometasone (DDD 0.40 mg)	549	506	535	527	0	0	0	0	1.13	1.07	1.04	0.99	0	0	0	0
R01AD05	Budesonide (DDD 0.20 mg)	225	186	92		0	0	0		0.52	0.47	0.23		0	0	0	
R01AD08	Fluticasone (DDD 0.20 mg)	2,223	2,368	2,361	2,369	2	2	1	1	4.18	4.48	4.43	4.39	2	2	1	1
R01AD09	Mometasone (DDD 0.20 mg)	2,531	2,290	1,866	1,891	1	1	1	1	6.35	6.34	5.86	6.10	1	1	1	1
R01AD11	Triamcinolone (DDD 0.22 mg)	479	506	537	548	0	0	0	0	0.60	0.63	0.67	0.68	0	0	0	0
R01AD12	Fluticasone furoate (DDD 0.11 mg)	2,841	3,016	2,836	2,763	0	0	1	1	4.67	4.95	4.65	4.61	0	0	1	1
R01AD58	Fluticasone, combinations (DDD 4,ED)	4,039	4,837	5,048	5,166	1	1	0	0	3.81	4.56	4.75	4.95	1	1	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R01AX	Other nasal preparations	432	440	449	459	8	10	16	15	0.38	0.35	0.31	0.32	4	4	4	4
R01AX03	Ipratropium bromide (DDD 0.24 mg)	159	164	186	183	7	8	7	8	0.11	0.12	0.13	0.11	7	7	7	6
R01AX06	Mupirocin	130	149	163	162	16	20	35	33					0	0	0	0
R01AX10	Various (DDD 2,ml)	143	127	100	114	2	2	3	3	0.26	0.23	0.18	0.21	2	2	3	3
R01B	Nasal decongestants for systemic use	5,775	6,054	4,047	4,174	1	1	1	1	1.97	1.91	1.28	1.11	1	1	1	1
R01BA	Sympathomimetics	5,775	6,054	4,047	4,174	1	1	1	1	1.97	1.91	1.28	1.11	1	1	1	1
R01BA01	Phenylpropanolamine (DDD 0.10,g)	52	52	48	46	1	1	1	0	0.13	0.13	0.12	0.12	1	1	1	0
R01BA52	Pseudoephedrine, combinations	5,724	6,003	3,999	4,127	1	1	1	1	1.83	1.78	1.15	0.99	1	1	1	1



R02 Throat preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R02	Throat preparations	7,938	7,555	5,708	5,375	0	0	0	0	3.68	3.28	2.51	2.28	0	0	0	0
R02A	Throat preparations	7,938	7,555	5,708	5,375	0	0	0	0	3.68	3.28	2.51	2.28	0	0	0	0
R02AA	Antiseptics	4,241	4,259	2,976	3,012	0	0	0	0	1.61	1.52	1.06	1.12	0	0	0	0
R02AA03	Dichlorobenzyl alcohol (DDD 6,ED)	3,567	3,636	2,626	2,781	0	0	0	0	1.57	1.51	1.05	1.11	0	0	0	0
R02AA05	Chlorhexidine	47	28	12	4	3	9	5	0	0.03	0.02	0.01	0.00	3	9	5	0
R02AA20	Various	626	594	338	227	0	1	2	2			0.00	0.00	0	0	0	0
R02AB	Antibiotics	2,456	2,232	2,065	1,854	1	1	1	1	1.38	1.18	1.06	0.88	1	1	1	1
R02AB30	Gramicidin (DDD 6,ED)	2,456	2,232	2,065	1,854	1	1	1	1	1.38	1.18	1.06	0.88	1	1	1	1
R02AX	Other throat preparations	1,242	1,065	667	508	0	0	0	0	0.70	0.58	0.38	0.29	0	0	0	0
R02AX01	Flurbiprofen (DDD 44 mg)	285	275	169	132	0	0	0	0	0.06	0.06	0.04	0.03	0	0	0	0
R02AX03	Benzydamine (DDD 9 mg)	956	790	498	376	0	0	0	0	0.64	0.52	0.35	0.26	0	0	0	0

**R03 Drugs for obstructive airway diseases**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R03	Drugs for obstructive airway diseases	93,537	91,012	93,802	90,249	8	9	8	5	78.39	79.91	83.82	80.99	3	3	3	3
R03A	Adrenergics, inhalants	56,600	53,769	55,920	54,498	3	3	3	3	43.72	45.44	48.11	47.11	3	3	3	3
R03AC	Selective beta-2-adrenoceptor agonists	8,071	7,754	7,567	6,976	2	2	3	3	14.77	14.94	14.87	14.13	3	3	4	4
R03AC02	Salbutamol	5,634	5,515	5,334	4,968	3	3	3	3	12.27	12.60	12.53	12.03	4	3	5	4
R03AC03	Terbutaline	555	507	519	457	1	1	1	1	1.20	1.14	1.16	1.03	1	1	1	1
R03AC12	Salmeterol (DDD 0.10 mg)	520	482	481	433	1	1	1	1	0.36	0.34	0.34	0.31	1	1	1	1
R03AC13	Formoterol (DDD 24,mcg)	1,001	945	966	883	1	1	1	1	0.68	0.65	0.66	0.60	1	1	1	1
R03AC18	Indacaterol (DDD 0.15 mg)	229	183	160	130	3	2	3	2	0.17	0.14	0.12	0.10	2	2	3	2
R03AC19	Olodaterol (DDD 5,mcg)	132	122	107	105	3	3	3	3	0.08	0.07	0.07	0.06	3	3	3	3
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	42,950	37,912	38,253	36,196	3	2	2	2	26.71	27.67	29.87	29.31	2	2	2	2
R03AK06	Salmeterol and fluticasone	17,977	12,393	9,864	7,489	4	4	4	4	7.50	7.11	7.21	6.66	4	4	3	3
R03AK07	Formoterol and budesonide (DDD 2,ED)	14,932	14,420	15,132	14,353	1	1	1	1	13.53	13.71	14.41	13.76	1	1	1	1
R03AK08	Formoterol and beclometasone (DDD 2,ED)	3,164	3,688	4,497	5,034	2	2	2	2	2.46	3.08	3.81	4.27	2	2	2	2
R03AK10	Vilanterol and fluticasone furoate (DDD 1,ED)	4,710	5,262	6,389	7,136	1	1	1	1	1.91	2.37	2.90	3.17	1	1	1	1
R03AK11	Formoterol and fluticasone	2,168	2,148	2,369	2,181	2	2	2	2	1.30	1.41	1.54	1.46	2	2	2	2
R03AK14	Indacaterol and mometasone			1	3			0	0			0.00	0.00			0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	5,578	8,102	10,101	11,326	10	7	6	6	2.24	2.83	3.37	3.67	11	9	10	9
R03AL01	Fenoterol and ipratropium bromide	294	277	306	286	18	14	27	23	0.48	0.46	0.56	0.54	6	5	24	21
R03AL02	Salbutamol and ipratropium bromide (DDD 3,ED)	627	411	281	182	51	51	41	38	0.31	0.30	0.24	0.19	50	50	41	38
R03AL03	Vilanterol and umeclidinium bromide (DDD 1,ED)	1,049	1,120	1,170	1,165	3	2	2	3	0.35	0.37	0.40	0.39	3	2	2	3
R03AL04	Indacaterol and glycopyrronium bromide (DDD 1,ED)	523	448	369	339	3	3	2	3	0.18	0.15	0.13	0.12	3	3	2	3
R03AL05	Formoterol and aclidinium bromide (DDD 2,ED)	205	169	142	122	2	2	2	2	0.07	0.06	0.05	0.04	2	2	2	2
R03AL06	Olodaterol and tiotropium bromide (DDD 2,ED)	1,759	2,165	2,342	2,243	5	5	5	5	0.60	0.74	0.82	0.79	5	5	5	5
R03AL07	Formoterol and glycopyrronium bromide (DDD 4,ED)		7	21	33		2	3	6		0.00	0.01	0.01		2	3	6
R03AL08	Vilanterol, umeclidinium bromide and fluticasone furoate (DDD 1,ED)	507	1,688	2,585	2,874	3	2	3	3	0.13	0.44	0.67	0.78	3	2	3	3
R03AL09	Formoterol, glycopyrronium bromide and beclometasone (DDD 4,ED)	615	1,818	2,884	3,969	4	6	7	7	0.11	0.31	0.51	0.80	6	9	10	9
R03AL11	Formoterol, glycopyrronium bromide and budesonide				87				2				0.00				0
R03AL12	Indacaterol, glycopyrronium bromide and mometasone (DDD 1,ED)			1	26			0	0			0.00	0.01			0	0
R03B	Other drugs for obstructive airway diseases, inhalants	29,646	28,302	28,235	25,483	4	4	3	3	26.03	25.66	26.56	24.68	4	4	3	3
R03BA	Glucocorticoids	18,004	16,936	17,154	15,279	3	3	3	2	19.26	19.16	20.13	18.83	2	2	2	2
R03BA01	Beclometasone	2,487	2,370	2,426	2,125	2	2	2	2	2.54	2.49	2.53	2.28	2	2	2	2
R03BA02	Budesonide	4,684	4,567	4,728	4,114	6	6	4	4	4.67	4.43	4.55	4.08	3	3	3	3
R03BA05	Fluticasone	7,435	6,512	6,200	5,412	3	3	2	2	5.52	5.39	5.59	5.06	3	3	3	2
R03BA07	Mometasone (DDD 0.40 mg)	190	160	150	124	1	1	1	1	0.20	0.17	0.16	0.13	1	1	1	1
R03BA08	Ciclesonide (DDD 0.16 mg)	3,208	3,328	3,650	3,505	1	1	1	1	6.34	6.68	7.31	7.27	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R03BB	Anticholinergics	11,642	11,366	11,081	10,204	5	4	4	4	6.77	6.49	6.43	5.85	8	7	7	6
R03BB01	Ipratropium bromide	276	263	281	239	41	40	45	39	0.62	0.59	0.54	0.46	48	47	47	43
R03BB04	Tiotropium bromide	10,503	10,326	10,072	9,297	4	4	3	3	5.75	5.54	5.53	5.07	4	3	3	3
R03BB05	Acclidinium bromide (DDD 0.64 mg)	98	85	74	61	2	2	2	3	0.05	0.04	0.04	0.03	2	2	2	3
R03BB06	Glycopyrronium bromide (DDD 44,mcg)	232	186	154	133	3	2	1	2	0.11	0.09	0.08	0.07	3	2	1	2
R03BB07	Umeclidinium bromide (DDD 55,mcg)	532	505	501	474	2	2	2	2	0.25	0.24	0.24	0.23	2	2	2	2
R03C	Adrenergics for systemic use	98	104	74	80	2	2	3	1	0.04	0.03	0.03	0.03	3	3	3	1
R03CC	Selective beta-2-adrenoceptor agonists	98	104	74	80	2	2	3	1	0.04	0.03	0.03	0.03	3	3	3	1
R03CC02	Salbutamol (DDD 12 mg)	98	104	74	80	2	2	3	1	0.04	0.03	0.03	0.03	3	3	3	1
R03D	Other systemic drugs for obstructive airway diseases	7,193	8,837	9,572	10,188	68	67	48	20	8.60	8.77	9.12	9.16	2	2	2	2
R03DA	Xanthines	288	260	195	144	3	3	3	3	0.76	0.70	0.64	0.59	3	3	3	3
R03DA04	Theophylline (DDD 0.40,g)	211	194	192	144	3	3	3	3	0.73	0.68	0.64	0.59	3	3	3	3
R03DA05	Aminophylline (DDD 0.60,g)	3	3	1		4	2	4		0.01	0.01	0.00		4	2	4	
R03DA54	Theophylline, combinations excl. psycholeptics (DDD 12,ED)	74	63	2		1	1	4		0.02	0.02	0.00		1	1	4	

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R03DC	Leukotriene receptor antagonists	1,383	1,327	1,301	1,336	1	1	1	1	7.67	7.89	8.29	8.37	1	1	1	1
R03DC01	Zafirlukast (DDD 40 mg)	30	1			2	5			0.02	0.00			2	5		
R03DC03	Montelukast (DDD 10 mg)	1,352	1,326	1,301	1,336	1	1	1	1	7.65	7.89	8.29	8.37	1	1	1	1
R03DX	Other systemic drugs for obstructive airway diseases	5,523	7,251	8,077	8,708	88	81	56	23	0.16	0.18	0.19	0.20	42	43	32	16
R03DX05	Omalizumab (DDD 16 mg)	2,875	3,304	3,347	3,741	85	65	40	30	0.04	0.05	0.05	0.06	85	65	40	30
R03DX07	Roflumilast (DDD 0.50 mg)	236	221	217	197	7	5	5	4	0.09	0.09	0.09	0.08	7	5	4	4
R03DX08	Reslizumab (DDD 7.10 mg)	424	363	179	102	100	100	100	100	0.01	0.00	0.00	0.00	100	100	100	100
R03DX09	Mepolizumab (DDD 3.60 mg)	1,881	2,593	2,756	3,043	100	100	68	14	0.02	0.03	0.03	0.04	100	100	63	14
R03DX10	Benralizumab (DDD 0.54 mg)	106	771	1,577	1,626	100	100	74	21	0.00	0.01	0.02	0.02	100	100	71	21



R05 Cough and cold preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R05	Cough and cold preparations	12,032	10,667	7,100	6,175	2	2	2	2	5.38	4.73	3.13	2.65	2	2	2	2
R05C	Expectorants, excl. combinations with cough suppressants	4,460	4,251	3,077	2,604	4	4	5	5	2.79	2.64	1.89	1.58	3	3	3	3
R05CA	Expectorants	248	157	112	111	0	0	0	0	0.17	0.09	0.06	0.06	0	0	0	0
R05CA03	Guaifenesin (DDD 0.90,g)	81	14			0	0			0.06	0.01			0	0		
R05CA10	Combinations	167	144	112	111	0	0	0	0	0.11	0.08	0.06	0.06	0	0	0	0
R05CB	Mucolytics	4,211	4,093	2,965	2,494	4	4	5	5	2.62	2.54	1.83	1.52	3	3	3	3
R05CB01	Acetylcysteine	763	774	562	452	4	4	3	4	0.67	0.68	0.50	0.40	3	2	1	1
R05CB02	Bromhexine (DDD 24 mg)	1,513	1,357	968	785	0	0	0	0	1.14	1.02	0.72	0.59	0	0	0	0
R05CB03	Carbocisteine (DDD 1.50,g)	108	95	58	49	0	0	1	1	0.06	0.06	0.03	0.03	0	0	1	1
R05CB06	Ambroxol (DDD 0.12,g)	607	676	429	335	3	3	4	4	0.24	0.28	0.18	0.14	3	3	4	4
R05CB13	Dornase alfa (desoxyribonuclease) (DDD 2.50 mg)	305	360	388	380	7	10	11	10	0.01	0.01	0.01	0.01	7	10	11	10
R05CB15	Erdosteine (DDD 0.60,g)	914	830	561	492	10	10	11	11	0.50	0.50	0.37	0.35	11	10	11	11

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R05D	Cough suppressants, excl. combinations with expectorants	2,322	2,329	1,561	1,336	1	0	1	1	1.15	1.08	0.69	0.59	1	1	1	0
R05DA	Opium alkaloids and derivatives	1,742	1,839	1,202	1,123	1	1	1	1	0.96	0.91	0.57	0.52	1	1	1	1
R05DA01	Ethylmorphine (DDD 50 mg)	655	867	579	495	1	0	1	1	0.23	0.27	0.16	0.11	1	0	1	1
R05DA09	Dextromethorphan (DDD 90 mg)	1,087	972	622	628	1	1	1	0	0.73	0.65	0.42	0.42	1	1	1	0
R05DB	Other cough suppressants	580	490	359	213	0	0	0	0	0.19	0.16	0.12	0.07	0	0	0	0
R05DB05	Pentoxyverine (DDD 0.10,g)	580	490	359	213	0	0	0	0	0.19	0.16	0.12	0.07	0	0	0	0
R05F	Cough suppressants and expectorants, combinations	4,541	3,484	1,968	1,660	1	1	0	0	1.44	1.02	0.55	0.47	1	1	0	0
R05FA	Opium derivatives and expectorants	2,565	1,715	589	547	1	1	0	0	0.88	0.58	0.22	0.21	1	1	0	0
R05FA02	Opium derivatives and expectorants	2,565	1,715	589	547	1	1	0	0	0.88	0.58	0.22	0.21	1	1	0	0
R05FB	Other cough suppressants and expectorants	1,976	1,769	1,380	1,113	0	0	0	0	0.56	0.43	0.33	0.27	0	0	0	0
R05FB02	Cough suppressants and expectorants	1,976	1,769	1,380	1,113	0	0	0	0	0.56	0.43	0.33	0.27	0	0	0	0
R05X	Other cold preparations	1,419	1,206	988	1,150	0	0	0	0					0	0	0	0

**R06 Antihistamines for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R06	Antihistamines for systemic use	14,992	15,862	17,165	18,344	1	0	1	0	60.06	64.26	71.31	78.35	1	1	1	1
R06A	Antihistamines for systemic use	14,992	15,862	17,165	18,344	1	0	1	0	60.06	64.26	71.31	78.35	1	1	1	1
R06AA	Aminoalkyl ethers	81	108	137	159	2	1	1	2	0.06	0.08	0.10	0.12	1	1	1	2
R06AA09	Doxylamine (DDD 25 mg)	81	108	137	159	2	1	1	2	0.06	0.08	0.10	0.12	1	1	1	2
R06AE	Piperazine derivatives	8,064	8,494	9,335	9,910	1	1	1	1	33.05	35.07	37.91	40.61	1	1	1	1
R06AE03	Cyclizine	94		14	35	0		0	0	0.05		0.00	0.01	0		0	0
R06AE05	Meclozine (DDD 50 mg)	320	439	234	235	0	0	0	1	0.14	0.19	0.09	0.08	0	0	0	1
R06AE07	Cetirizine (DDD 10 mg)	6,183	6,591	7,583	8,199	1	1	1	1	28.13	30.16	32.81	35.39	2	1	1	1
R06AE09	Levocetirizine (DDD 5 mg)	1,468	1,464	1,505	1,441	0	0	0	0	4.74	4.72	5.01	5.14	0	0	0	0
R06AX	Other antihistamines for systemic use	6,846	7,259	7,693	8,275	0	0	0	0	26.94	29.11	33.29	37.62	0	0	0	0
R06AX13	Loratadine (DDD 10 mg)	687	635	751	725	1	1	0	0	3.26	3.07	3.53	3.39	1	1	0	0
R06AX18	Acrivastine (DDD 24 mg)	157	144	144	153	0	0	0	0	0.13	0.08	0.08	0.08	0	0	0	0
R06AX22	Ebastine (DDD 10 mg)	2,272	2,335	2,541	2,676	0	0	0	0	7.48	7.66	9.16	10.10	0	0	0	0
R06AX26	Fexofenadine (DDD 0.12,g)	1,431	1,664	1,733	1,863	0	0	0	0	3.10	3.86	4.20	4.94	0	0	0	0
R06AX27	Desloratadine (DDD 5 mg)	2,143	2,307	2,337	2,658	1	1	1	0	12.63	14.05	15.91	18.67	0	0	1	0
R06AX28	Rupatadine (DDD 10 mg)	0				0				0.00				0			
R06AX29	Bilastine (DDD 20 mg)	155	174	187	200	0	0	0	0	0.35	0.39	0.41	0.44	0	0	0	0



R07 Other respiratory system products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R07	Other respiratory system products	884	693	1,027	6,656	100	100	83	13	0.00	0.00	0.00	0.00	100	100	87	21
R07A	Other respiratory system products	884	693	1,027	6,656	100	100	83	13	0.00	0.00	0.00	0.00	100	100	87	21
R07AA	Lung surfactants	884	693	857	864	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AA02	Natural phospholipids (DDD 0.16,g)	884	693	857	864	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AX	Other respiratory system products			170	5,792			0	0			0.00	0.00			0	0
R07AX02	Ivacaftor (DDD 0.30,g)			85	2,014			0	0			0.00	0.00			0	0
R07AX30	Ivacaftor and lumacaftor				644				0				0.00				0
R07AX31	Ivacaftor and tezacaftor			85	71			0	0			0.00	0.00			0	0
R07AX32	Ivacaftor, tezacaftor and elexacaftor				3,064				0				0.00				0



S Sensory organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S	Sensory organs	63,145	67,362	67,879	70,730	40	41	44	44	28.34	30.03	31.28	31.79	2	2	2	2
S01	Ophthalmologicals	61,128	65,277	65,916	68,670	41	43	46	46	28.34	30.03	31.28	31.79	2	2	2	2
S02	Otologicals	1,774	1,887	1,784	1,884	2	2	2	2								
S03	Ophthalmological and otological preparations	243	197	180	176	10	8	10	8								

**S01 Ophthalmologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S01	Ophthalmologicals	61,128	65,277	65,916	68,670	41	43	46	46	28.34	30.03	31.28	31.79	2	2	2	2
S01A	Antiinfectives	4,284	4,434	3,501	3,334	9	9	11	11								
S01AA	Antibiotics	3,622	3,774	2,840	2,707	9	9	11	12								
S01AA01	Chloramphenicol	3,037	3,195	2,426	2,338	8	7	9	9								
S01AA12	Tobramycin	8	13	12	13	14	7	8	7								
S01AA13	Fusidic acid	453	415	270	202	4	4	6	4								
S01AA26	Azithromycin	58	60	30	28	0	0	1	1								
S01AA27	Cefuroxime	66	90	103	126	91	92	87	84								
S01AD	Antivirals	35	4	34	49	8	11	11	7								
S01AD03	Aciclovir	35	4	34	49	8	11	11	7								
S01AE	Fluoroquinolones	628	655	627	578	8	8	8	9								
S01AE01	Ofloxacin	105	94	54	47	2	3	4	4								
S01AE05	Levofloxacin	510	549	563	518	10	9	8	9								
S01AE07	Moxifloxacin	13	12	11	12	10	19	19	33								
S01B	Antiinflammatory agents	3,408	3,622	3,789	3,978	42	37	38	37								
S01BA	Corticosteroids, plain	2,782	2,864	2,993	2,986	50	46	48	49								
S01BA01	Dexamethasone	1,416	1,475	1,558	1,582	78	74	73	70								
S01BA02	Hydrocortisone	57	91	113	130	0	0	0	0								
S01BA04	Prednisolone	799	856	838	766	2	2	2	2								

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day				
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	
S01BA05	Triamcinolone	278	225	283	277	100	100	100	99								
S01BA07	Fluorometholone	232	217	201	177	1	1	1	1								
S01BA15	Fluocinolone acetonide				55				100								
S01BC	Antiinflammatory agents, non-steroids	626	758	796	992	4	1	1	1								
S01BC03	Diclofenac	87	82	87	80	24	5	6	5								
S01BC05	Ketorolac	6				14											
S01BC10	Nepafenac	497	621	645	827	1	1	1	1								
S01BC11	Bromfenac	37	55	64	85	0	0	0	0								
S01C	Antiinflammatory agents and antiinfectives in combination	958	1,022	978	1,274	10	9	10	8								
S01CA	Corticosteroids and antiinfectives in combination	958	1,022	978	1,274	10	9	10	8								
S01CA01	Dexamethasone and antiinfectives	701	743	708	1,026	11	10	10	8								
S01CA03	Hydrocortisone and antiinfectives	257	279	270	247	7	7	8	9								
S01E	Antiglaucoma preparations and miotics	14,553	14,565	14,581	14,395	3	3	3	3	28.34	30.03	31.28	31.79	2	2	2	2
S01EA	Sympathomimetics in glaucoma therapy	449	452	422	446	26	30	30	37	0.67	0.63	0.58	0.55	8	9	8	10
S01EA03	Apraclonidine (DDD 0.30,ml)	133	155	148	189	78	79	77	80	0.04	0.04	0.04	0.05	64	64	60	62
S01EA05	Brimonidine (DDD 0.20,ml)	315	297	274	256	5	5	4	5	0.62	0.59	0.54	0.51	5	5	4	5
S01EB	Parasympathomimetics	45	37	41	41	56	49	57	54	0.11	0.11	0.10	0.09	12	13	12	15
S01EB01	Pilocarpine	19	18	16	16	12	13	12	15	0.11	0.11	0.10	0.09	12	13	12	15
S01EB09	Acetylcholine	26	19	25	25	87	83	86	79								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S01EC	Carbonic anhydrase inhibitors	1,262	1,353	1,386	1,402	3	2	2	2	2.62	2.80	2.88	2.92	3	2	3	2
S01EC03	Dorzolamide (DDD 0.30,ml)	133	126	121	111	4	3	3	3	0.19	0.18	0.18	0.17	4	3	3	3
S01EC04	Brinzolamide (DDD 0.20,ml)	680	734	759	768	3	2	3	2	1.90	2.05	2.12	2.15	3	2	3	2
S01EC54	Brinzolamide, combinations (DDD 0.20,ml)	450	492	506	523	2	2	2	2	0.52	0.57	0.58	0.60	2	2	2	2
S01ED	Beta blocking agents	7,159	7,130	6,928	7,068	2	2	2	2	13.96	15.12	15.95	16.45	2	1	1	1
S01ED01	Timolol (DDD 0.20,ml)	282	281	286	275	3	2	2	2	0.64	0.58	0.51	0.22	3	3	3	5
S01ED02	Betaxolol (DDD 0.20,ml)	79	80	78	75	3	3	3	3	0.30	0.30	0.30	0.29	3	3	3	3
S01ED51	Timolol, combinations	6,798	6,769	6,565	6,718	2	2	2	2	13.02	14.24	15.15	15.94	1	1	1	1
S01EE	Prostaglandin analogues	5,638	5,593	5,804	5,438	2	2	2	2	10.98	11.36	11.78	11.77	2	2	2	2
S01EE01	Latanoprost (DDD 0.10,ml)	1,801	1,817	1,984	1,640	2	2	2	2	4.83	5.00	5.10	5.15	2	2	2	2
S01EE03	Bimatoprost (DDD 0.10,ml)	1,023	915	907	884	2	2	2	2	3.38	3.54	3.86	3.84	1	1	1	1
S01EE04	Travoprost (DDD 0.10,ml)	912	789	686	622	2	2	2	2	0.95	0.88	0.79	0.72	3	3	3	3
S01EE05	Tafluprost (DDD 0.30,ml)	1,902	2,072	2,227	2,293	1	1	1	1	1.82	1.93	2.03	2.06	1	1	1	1
S01F	Mydriatics and cycloplegics	615	610	635	799	64	61	58	59								
S01FA	Anticholinergics	545	533	552	716	63	60	56	58								
S01FA01	Atropine	17	20	28	30	19	18	15	16								
S01FA02	Scopolamine	59	39			16	17										
S01FA04	Cyclopentolate	97	98	113	125	60	50	41	41								
S01FA06	Tropicamide	215	241	272	283	56	54	51	50								
S01FA56	Tropicamide, combinations	157	134	139	279	97	96	87	78								
S01FB	Sympathomimetics excl. antiglaucoma preparations	70	76	82	83	73	72	71	69								
S01FB01	Phenylephrine	70	76	82	83	73	72	71	69								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S01G	Decongestants and antiallergics	3,733	3,810	3,310	3,970	1	1	1	1								
S01GA	Sympathomimetics used as decongestants	247	252	201	212	0	0	0	0								
S01GA02	Tetryzoline	247	252	201	212	0	0	0	0								
S01GX	Other antiallergics	3,486	3,559	3,109	3,758	1	1	1	1								
S01GX01	Cromoglicic acid	2,527	2,618	2,304	2,660	1	1	1	1								
S01GX02	Levocabastine	206	122	176	257	0	0	0	0								
S01GX05	Lodoxamide	36	56	35	44	0	0	0	0								
S01GX06	Emedastine	30	34	27	34	0	0	0	0								
S01GX07	Azelastine	24	26			0	0										
S01GX08	Ketotifen	611	640	516	696	0	0	1	1								
S01GX09	Olopatadine	52	63	52	68	0	0	0	0								
S01H	Local anesthetics	195	221	228	215	81	80	78	71								
S01HA	Local anesthetics	195	221	228	215	81	80	78	71								
S01HA02	Oxybuprocaine	195	221	228	215	81	80	78	71								
S01J	Diagnostic agents	190	187	200	203	58	56	58	57								
S01JA	Colouring agents	190	187	200	203	58	56	58	57								
S01JA01	Fluorescein	19	14	17	18	99	98	97	98								
S01JA51	Fluorescein, combinations	171	173	183	186	54	53	54	53								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S01L	Ocular vascular disorder agents	21,798	24,651	26,776	28,022	100	100	100	100								
S01LA	Antineovascularisation agents	21,798	24,651	26,776	28,022	100	100	100	100								
S01LA01	Verteporfin	203	167	161		100	100	100									
S01LA04	Ranibizumab	319	327	299	250	100	100	100	100								
S01LA05	Aflibercept	21,277	24,157	26,263	27,721	100	100	100	100								
S01LA06	Brolucizumab			54	50			100	100								
S01X	Other ophthalmologicals	11,393	12,156	11,918	12,481	3	3	2	2								
S01XA	Other ophthalmologicals	11,393	12,156	11,918	12,481	3	3	2	2								
S01XA02	Retinol	407	519	526	505	3	3	3	3								
S01XA18	Ciclosporin	442	600	660	740	1	0	1	1								
S01XA20	Artificial tears and other indifferent preparations	10,540	11,036	10,681	11,152	3	3	2	2								
S01XA21	Mercaptamine			51	84			0	5								
S01XA22	Ocriplasmin	3						100									



S02 Otologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S02	Otologicals	1,774	1,887	1,784	1,884	2	2	2	2								
S02A	Antiinfectives	691	715	735	724	2	2	2	1								
S02AA	Antiinfectives	691	715	735	724	2	2	2	1								
S02AA03	Boric acid	661	691	718	704	2	2	2	1								
S02AA15	Ciprofloxacin	30	24	17	20	2	2	2	2								
S02B	Corticosteroids		10	16	26		0	0	0								
S02BA	Corticosteroids		10	16	26		0	0	0								
S02BA08	Fluocinolone acetonide		10	16	26		0	0	0								
S02C	Corticosteroids and antiinfectives in combination	861	958	919	1,021	3	3	3	3								
S02CA	Corticosteroids and antiinfectives in combination	861	958	919	1,021	3	3	3	3								
S02CA02	Flumetasone and antiinfectives	1	180	224	94	8	3	3	2								
S02CA03	Hydrocortisone and antiinfectives	624	486	378	427	4	4	4	3								
S02CA05	Fluocinolone acetonide and antiinfectives	236	292	317	500	2	2	2	2								
S02D	Other otologicals	222	204	114	114	1	0	1	0								
S02DA	Analgesics and anesthetics	222	204	114	114	1	0	1	0								
S02DA04	Cinchocaine	222	204	114	114	1	0	1	0								

**S03 Ophthalmological and otological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S03	Ophthalmological and otological preparations	243	197	180	176	10	8	10	8								
S03C	Corticosteroids and antiinfectives in combination	243	197	180	176	10	8	10	8								
S03CA	Corticosteroids and antiinfectives in combination	243	197	180	176	10	8	10	8								
S03CA04	Hydrocortisone and antiinfectives	243	197	180	176	10	8	10	8								



V Various

ATC classification

Wholesale price (VAT excluded), thousand euros

Sales to hospitals and other health care units as a proportion (%) of wholesale value

Consumption, DDD/1.000 inhabitants/day

Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day

		2018				2019				2020				2021			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V	Various	35,576	38,868	39,673	41,348	90	89	86	85	0.19	0.19	0.19	0.18	39	41	42	44
V01	Allergens	2,369	3,248	4,979	6,244	56	59	46	45								
V03	All other therapeutic products	8,749	9,764	9,319	8,670	76	77	75	76	0.19	0.19	0.19	0.18	39	41	42	44
V04	Diagnostic agents	991	963	897	868	87	87	89	92								
V06	General nutrients	0				29											
V07	All other non-therapeutic products	3,222	3,232	3,045	2,873	95	95	94	92								
V08	Contrast media	20,121	21,476	21,382	22,681	99	99	99	98								

**V01 Allergens**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V01	Allergens	2,369	3,248	4,979	6,244	56	59	46	45								
V01A	Allergens	2,369	3,248	4,979	6,244	56	59	46	45								
V01AA	Allergen extracts	2,369	3,248	4,979	6,244	56	59	46	45								
V01AA02	Grass pollen	704	704	846	1,067	0	0	0	0								
V01AA03	House dust mites	27	43	50	52	21	24	22	24								
V01AA05	Tree pollen	1,443	2,205	3,736	4,645	79	74	53	51								
V01AA07	Insects	126	194	215	267	98	99	99	100								
V01AA11	Animals	69	101	131	212	77	78	78	77								
V01AA20	Various	1	1	1	1	57	92	84	100								



V03 All other therapeutic products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V03	All other therapeutic products	8,749	9,764	9,319	8,670	76	77	75	76	0.19	0.19	0.19	0.18	39	41	42	44
V03A	All other therapeutic products	8,749	9,764	9,319	8,670	76	77	75	76	0.19	0.19	0.19	0.18	39	41	42	44
V03AB	Antidotes	4,703	5,355	5,439	4,884	97	96	94	97								
V03AB14	Protamine	305	311	251	317	100	100	100	100								
V03AB15	Naloxone	82	177	252	59	90	89	92	89								
V03AB17	Methylthioninium chloride	94	133	108	112	100	99	99	99								
V03AB21	Potassium iodide	177	257	455	130	45	41	44	22								
V03AB25	Flumazenil	86	67	77	37	98	99	99	96								
V03AB33	Hydroxocobalamin	149	152	159	197	98	95	97	99								
V03AB34	Fomepizole	122	140	85	79	100	100	100	99								
V03AB35	Sugammadex	3,382	3,379	3,431	3,395	99	99	99	99								
V03AB37	Idarucizumab	308	278	198	225	100	100	100	100								
V03AB38	Andexanet alfa		461	422	333		100	100	100								
V03AC	Iron chelating agents	906	1,038	1,011	1,035	4	6	6	7								
V03AC01	Deferoxamine	10	20	19	20	87	88	85	100								
V03AC02	Deferiprone	8	6		9	20	4		31								
V03AC03	Deferasirox	888	1,013	992	1,006	3	4	5	5								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	1,227	1,210	1,232	1,062	18	18	17	17	0.14	0.13	0.13	0.12	19	19	18	17
V03AE01	Polystyrene sulphonate (DDD 45,g)	119	114	105	106	25	22	23	23	0.03	0.03	0.03	0.03	25	22	23	23
V03AE02	Sevelamer (DDD 6.40,g)	390	381	401	405	17	17	16	16	0.04	0.04	0.04	0.04	17	17	16	15
V03AE03	Lanthanum carbonate (DDD 2.25,g)	718	706	686	458	17	17	15	16	0.06	0.06	0.06	0.04	16	16	15	15
V03AE05	Sucroferric oxyhydroxide (DDD 1.50,g)	0	5	14	25	100	90	11	4	0.00	0.00	0.00	0.00	100	90	11	4
V03AE09	Patiromer calcium (DDD 8.40,g)		4	26	68		100	45	25		0.00	0.00	0.01		100	45	24
V03AF	Detoxifying agents for cytostatic treatment	1,913	2,160	1,636	1,690	95	96	94	93	0.05	0.06	0.06	0.06	95	95	95	94
V03AF01	Mesna	487	534	448	459	100	100	100	100			0.00	0.00	0	0	0	0
V03AF02	Dexrazoxane (DDD 1.50,g)	307	365	133	216	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AF03	Calcium folinate (DDD 60 mg)	745	781	625	517	88	89	84	76	0.05	0.05	0.06	0.06	95	95	95	94
V03AF07	Rasburicase (DDD 14 mg)	318	426	413	469	100	100	100	99	0.00	0.00	0.00	0.00	100	100	100	100
V03AF08	Palifermin (DDD 4.20 mg)	25	15			100	100			0.00	0.00			100	100		
V03AF10	Sodium levofolinate (DDD 30 mg)	31	39	18	29	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AX	Other therapeutic products		0				100				0.00				100		
V03AX03	Cobicistat (DDD 0.15,g)		0				100				0.00				100		



V04 Diagnostic agents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V04	Diagnostic agents	991	963	897	868	87	87	89	92								
V04C	Other diagnostic agents	991	963	897	868	87	87	89	92								
V04CD	Tests for pituitary function	102	108	108	77	38	25	29	32								
V04CD01	Metyrapone	102	108	108	77	38	25	29	32								
V04CF	Tuberculosis diagnostics	2	6	6	3	70	80	80	77								
V04CF01	Tuberculin	2	6	6	3	70	80	80	77								
V04CL	Tests for allergic diseases	399	296	180	179	151	158	163	155								
V04CX	Other diagnostic agents	688	701	694	699	97	98	100	100								
V04CX05	13c-urea	24	18	2		36	13	2									
V04CX06	Hexaminolevulinate	664	683	692	699	100	100	100	100								

**V06 General nutrients**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V06	General nutrients	0				29											
V06D	Other nutrients	0				29											
V06DD	Amino acids, incl. combinations with polypeptides	1				57											

V07 All other non-therapeutic products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V07	All other non-therapeutic products	3,222	3,232	3,045	2,873	95	95	94	92								
V07A	All other non-therapeutic products	3,222	3,232	3,045	2,873	95	95	94	92								
V07AB	Solvents and diluting agents, incl. irrigating solutions	6,444	6,464	6,089	5,745	190	190	188	185								

**V08 Contrast media**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a pro- portion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V08	Contrast media	20,121	21,476	21,382	22,681	99	99	99	98								
V08A	X-ray contrast media, iodinated	15,082	16,339	17,031	17,503	100	100	99	99								
V08AA	Watersoluble, nephrotropic, high osmolar x-ray contrast media	95	101	116	123	99	100	100	100								
V08AA01	Diatrizoic acid	95	101	116	123	99	100	100	100								
V08AB	Watersoluble, nephrotropic, low osmolar x-ray contrast media	14,987	16,238	16,915	17,380	100	100	99	99								
V08AB02	Iohexol	12,088	12,970	13,409	14,099	100	100	100	99								
V08AB03	Ioxaglic acid	94				100											
V08AB07	Ioversol	102	11	2		100	100	100									
V08AB09	Iodixanol	1,190	1,193	1,060	1,102	98	98	98	97								
V08AB10	Iomeprol	1,514	2,064	2,445	2,180	99	100	100	99								
V08B	X-ray contrast media, non-iodinated	22	0			100	100										
V08BA	Barium sulfate containing x-ray contrast media	22	0			100	100										
V08BA01	Barium sulfate with suspending agents	22	0			100	100										

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1.000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1.000 inhabitants/day			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V08C	Magnetic resonance imaging contrast media	4,919	5,050	4,281	5,106	97	96	98	96								
V08CA	Paramagnetic contrast media	4,919	5,050	4,281	5,106	97	96	98	96								
V08CA02	Gadoteric acid	4,595	4,812	4,045	4,906	97	96	97	95								
V08CA04	Gadoteridol	128	48	13	4	99	95	78	83								
V08CA08	Gadobenic acid	3	0	0		100	100	100									
V08CA09	Gadobutrol	26	20	16		100	100	100									
V08CA10	Gadoxetic acid	167	170	207	196	99	100	100	100								
V08D	Ultrasound contrast media	98	88	70	72	100	100	100	99								
V08DA	Ultrasound contrast media	98	88	70	72	100	100	100	99								
V08DA01	Microspheres of human albumin	2	2	2	1	100	100	100	100								
V08DA05	Sulphur hexafluoride	96	87	68	72	100	100	100	99								
V08DA01	Ihmisen albumiinin mikropartikkelit	1	2	2	2	100	100	100	100								
V08DA05	Rikkiheksafluoridi	112	96	87	68	94	100	100	100								



Nicotine replacement therapy

Total

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	57,716	61,368	71,691	75,207	13.80	14.78	17.86	18.83

Pharmacies

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	6,986	6,609	7,228	7,217	1.83	1.65	1.88	1.85
Medicated chewing gums (DDD 30 mg)	2,375	2,044	1,919	1,759	0.77	0.64	0.60	0.56
Losenzes and sublingual tablets (DDD 30 mg)	876	791	727	733	0.16	0.15	0.13	0.14
Transdermal patches (DDD 14 mg)	1,086	1,092	1,146	1,034	0.38	0.39	0.40	0.36
Other formulations	2,649	2,681	3,436	3,691	0.52	0.48	0.74	0.78

Table continued



Other

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	50,344	54,354	64,025	67,541	11.83	13.00	15.84	16.84
Medicated chewing gums (DDD 30 mg)	32,040	32,020	34,644	34,385	8.14	8.22	9.01	8.99
Losenzes and sublingual tablets (DDD 30 mg)	11,022	11,996	13,307	13,410	1.77	1.95	2.17	2.20
Transdermal patches (DDD 14 mg)	127	221	282	303	0.05	0.08	0.10	0.11
Other formulations	7,154	10,117	11,229	19,442	1.87	2.74	4.55	5.54

Hospital

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	387	406	438	449	0.13	0.13	0.14	0.14



OTC medicines in outpatient care

ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A	Alimentary tract and metabolism	82.37	81.61	84.60	83.18	59,326	60,805	61,457	60,152	100,887	103,447	104,109	101,845
A01	Stomatological preparations	2.61	2.19	2.18	5.35	1,340	1,258	1,299	1,273	2,390	2,241	2,288	2,242
A01A	Stomatological preparations	2.61	2.19	2.18	5.35	1,340	1,258	1,299	1,273	2,390	2,241	2,288	2,242
A01AA	Caries prophylactic agents	0.40			3.30	112			179	194			308
A01AA01	Sodium fluoride	0.40			3.30	41			179	70			308
A01AA51	Sodium fluoride, combinations					71				124			
A01AB	Antiinfectives for local oral treatment	2.16	2.16	2.16	2.03	991	1,034	1,138	1,066	1,766	1,853	2,011	1,884
A01AB03	Chlorhexidine	1.93	1.95	1.90	1.82	765	819	872	853	1,372	1,477	1,547	1,514
A01AB11	Various	0.22	0.21	0.26	0.21	226	215	266	213	394	376	463	370
A01AC	Corticosteroids for local oral treatment					133	152	112		231	261	193	
A01AC01	Triamcinolone					133	152	112		231	261	193	
A01AD	Other agents for local oral treatment	0.04	0.03	0.02	0.02	104	72	49	28	198	127	84	49
A01AD02	Benzydamine	0.04	0.03	0.02	0.02	104	72	49	28	198	127	84	49
A02	Drugs for acid related disorders	7.10	7.10	6.99	7.18	10,469	11,007	11,405	11,785	18,448	19,390	20,009	20,641
A02A	Antacids	2.18	2.20	2.22	2.25	3,318	3,530	3,648	3,819	5,955	6,330	6,523	6,797
A02AA	Magnesium compounds	0.06	0.06	0.05	0.05	135	118	111	108	235	206	194	188
A02AA04	Magnesium hydroxide	0.06	0.06	0.05	0.05	135	118	111	108	235	206	194	188
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	2.12	2.15	2.17	2.20	3,183	3,412	3,537	3,711	5,720	6,124	6,330	6,608
A02AD01	Ordinary salt combinations	2.12	2.15	2.17	2.20	3,183	3,412	3,537	3,711	5,720	6,124	6,330	6,608

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)	4.92	4.90	4.77	4.93	7,151	7,477	7,757	7,965	12,493	13,060	13,486	13,845
A02BA	H2-receptor antagonists	0.36	0.27	0.15	0.14	603	514	497	468	1,063	906	862	811
A02BA02	Ranitidine	0.26	0.17			270	177			485	318		
A02BA03	Famotidine	0.10	0.10	0.15	0.14	333	338	497	468	578	588	862	811
A02BC	Proton pump inhibitors	3.45	3.52	3.39	3.49	4,501	4,712	4,627	4,706	7,904	8,282	8,102	8,242
A02BC01	Omeprazole	1.20	1.08	0.99	0.91	1,220	1,137	1,044	962	2,123	1,979	1,812	1,669
A02BC02	Pantoprazole	0.97	1.02	0.99	1.08	2,216	2,260	2,230	2,426	3,831	3,924	3,851	4,203
A02BC03	Lansoprazole	0.13	0.14	0.13	0.12	227	227	214	194	407	406	389	345
A02BC04	Rabeprazole	0.03	0.05	0.05	0.04	37	77	79	69	65	137	139	120
A02BC05	Esomeprazole	1.13	1.23	1.24	1.33	801	1,011	1,061	1,055	1,478	1,836	1,912	1,905
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)	1.10	1.11	1.22	1.30	2,047	2,251	2,633	2,791	3,526	3,872	4,522	4,792
A02BX02	Sucralfate	0.20	0.23	0.27	0.31	326	378	453	517	560	648	774	884
A02BX13	Alginic acid	0.90	0.88	0.95	0.98	1,721	1,873	2,180	2,274	2,966	3,224	3,747	3,908
A03	Drugs for functional gastrointestinal disorders	1.08	1.15	1.09	1.06	1,427	1,452	1,488	1,304	2,432	2,480	2,531	2,221
A03A	Drugs for functional gastrointestinal disorders	1.08	1.15	1.09	1.06	1,427	1,452	1,488	1,304	2,432	2,480	2,531	2,221
A03AX	Other drugs for functional gastrointestinal disorders	1.08	1.15	1.09	1.06	1,427	1,452	1,488	1,304	2,432	2,480	2,531	2,221
A03AX13	Silicones	1.08	1.15	1.09	1.06	1,427	1,434	1,354	1,115	2,432	2,449	2,307	1,908
A03AX15	Menthae piperitae aetheroleum						18	134	188		31	224	313

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A06	Drugs for constipation	36.01	36.73	39.48	40.90	19,669	20,852	22,601	23,473	33,109	35,099	37,923	39,372
A06A	Drugs for constipation	36.01	36.73	39.48	40.90	19,669	20,852	22,601	23,473	33,109	35,099	37,923	39,372
A06AB	Contact laxatives	5.83	5.82	5.96	5.68	3,441	3,446	3,468	3,246	5,906	5,899	5,927	5,563
A06AB02	Bisacodyl	0.92	0.87	0.70	0.65	361	344	260	246	631	601	455	431
A06AB06	Senna glycosides	0.29	0.15	0.13	0.12	118	60	52	51	207	104	91	89
A06AB08	Sodium picosulfate	4.62	4.80	5.14	4.90	2,464	2,523	2,688	2,450	4,250	4,342	4,612	4,225
A06AB56	Senna glycosides, combinations					182	168	162	145	304	280	270	241
A06AB58	Sodium picosulfate, combinations	0.00	0.00	0.00	0.00	315	351	306	353	513	572	499	576
A06AC	Bulk-forming laxatives	3.73	3.79	4.21	4.31	2,575	2,716	2,982	3,122	4,308	4,542	4,983	5,220
A06AC01	Ispaghula (psylla seeds)	3.11	3.19	3.63	3.76	2,336	2,481	2,754	2,905	3,901	4,143	4,597	4,850
A06AC51	Ispaghula, combinations	0.61	0.60	0.58	0.56	239	235	228	218	406	399	386	369
A06AD	Osmotically acting laxatives	25.28	25.99	28.13	29.73	11,631	12,719	14,147	15,087	19,490	21,343	23,647	25,198
A06AD11	Lactulose	12.58	12.06	11.99	11.65	2,546	2,439	2,395	2,346	4,392	4,192	4,118	4,042
A06AD15	Macrogol	11.31	12.72	15.09	17.18	7,602	8,820	10,367	11,426	12,614	14,705	17,212	18,950
A06AD17	Sodium phosphate					42	46	34	19	69	76	55	31
A06AD65	Macrogol, combinations	1.39	1.20	1.05	0.90	1,441	1,414	1,351	1,296	2,416	2,371	2,261	2,175
A06AG	Enemas	1.17	1.14	1.17	1.18	2,023	1,971	2,004	2,018	3,405	3,315	3,366	3,391
A06AG02	Bisacodyl	0.16	0.16	0.16	0.17	278	266	283	288	455	435	463	474
A06AG10	Docusate sodium, incl. combinations	0.03	0.03	0.03	0.03	300	307	303	310	474	485	480	492
A06AG11	Laurilsulfate, incl. combinations	0.98	0.96	0.98	0.98	1,444	1,399	1,418	1,420	2,477	2,395	2,423	2,426

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	2.39	2.15	1.62	1.59	8,910	8,307	6,331	6,298	15,453	14,471	11,009	10,953
A07B	Intestinal adsorbents	0.07	0.05	0.06	0.06	360	318	305	285	610	540	515	481
A07BA	Charcoal preparations	0.07	0.05	0.06	0.06	360	318	305	285	610	540	515	481
A07BA01	Medicinal charcoal	0.07	0.05	0.06	0.06	360	318	305	285	610	540	515	481
A07C	Electrolytes with carbohydrates	0.01	0.01	0.01	0.01	254	218	131	136	434	372	224	232
A07CA	Oral rehydration salt formulations	0.03	0.02	0.01	0.01	508	435	263	271	868	744	449	464
A07D	Antipropulsives	0.90	0.94	0.76	0.77	3,806	3,922	3,254	3,361	6,834	7,047	5,820	5,993
A07DA	Antipropulsives	0.90	0.94	0.76	0.77	3,806	3,922	3,254	3,361	6,834	7,047	5,820	5,993
A07DA03	Loperamide	0.90	0.94	0.76	0.77	2,756	2,903	2,429	2,557	4,956	5,225	4,355	4,564
A07DA53	Loperamide, combinations					1,050	1,019	825	804	1,878	1,823	1,466	1,429
A07F	Antidiarrheal microorganisms	1.40	1.15	0.79	0.76	4,129	3,430	2,374	2,284	6,943	5,781	3,983	3,842
A07FA	Antidiarrheal microorganisms	1.40	1.15	0.79	0.76	4,129	3,430	2,374	2,284	6,943	5,781	3,983	3,842
A07FA02	Saccharomyces boulardii	1.35	1.15	0.79	0.76	4,058	3,430	2,374	2,284	6,822	5,781	3,983	3,842
A07X	Other antidiarrheals					361	418	267	232	632	731	467	405
A07XA	Other antidiarrheals					361	418	267	232	632	731	467	405
A07XA04	Racecadotril					361	418	267	232	632	731	467	405
A08	Antiobesity preparations, excl. diet products	0.06	0.04	0.04	0.04	209	192	182	183	333	303	288	289
A08A	Antiobesity preparations, excl. diet products	0.06	0.04	0.04	0.04	209	192	182	183	333	303	288	289
A08AB	Peripherally acting antiobesity products	0.06	0.04	0.04	0.04	209	192	182	183	333	303	288	289
A08AB01	Orlistat	0.06	0.04	0.04	0.04	209	192	182	183	333	303	288	289

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A09	Digestives, incl. enzymes	0.99	1.23	1.20	1.28	2,501	3,090	3,036	3,229	3,984	4,923	4,845	5,153
A09A	Digestives, incl. enzymes	0.99	1.23	1.20	1.28	2,501	3,090	3,036	3,229	3,984	4,923	4,845	5,153
A09AA	Enzyme preparations	0.99	1.23	1.20	1.28	2,501	3,090	3,036	3,229	3,984	4,923	4,845	5,153
A09AA02	Multienzymes (lipase, protease etc.)	0.99	1.23	1.20	1.28	2,501	3,090	3,036	3,229	3,984	4,923	4,845	5,153
A11	Vitamins	18.02	16.99	17.11	10.48	6,315	6,159	6,173	3,319	10,723	10,458	10,451	5,625
A11C	Vitamin a and d, incl. combinations of the two	1.07	1.12	1.11	1.33	128	127	122	147	232	231	222	267
A11CC	Vitamin d and analogues	1.07	1.12	1.11	1.33	128	127	122	147	232	231	222	267
A11CC01	Ergocalciferol (vitamin d2)					10	4			19	8		
A11CC05	Colecalciferol (vitamin d3)	1.07	1.12	1.11	1.33	117	123	122	147	213	223	222	267
A11D	Vitamin b1. plain and in combination with vitamin b6, and b12	4.59	4.42	4.06	3.73	1,135	1,094	1,015	894	1,913	1,842	1,708	1,508
A11DB	Vitamin b1, in comb. with vitamin b6, and/or vitamin b12	9.18	8.84	8.12	7.46	2,271	2,189	2,031	1,787	3,826	3,683	3,417	3,017
A11E	Vitamin b-complex, incl. combinations	10.06	9.73	9.78	3.97	4,706	4,652	4,699	1,993	7,967	7,881	7,927	3,347
A11EX	Vitamin b-complex, other combinations	20.13	19.47	19.57	7.95	9,411	9,303	9,398	3,986	15,934	15,762	15,855	6,695
A11G	Ascorbic acid (vitamin c), incl. combinations	2.17	1.59	2.05	1.32	145	106	137	89	258	189	245	158
A11GA	Ascorbic acid (vit c), plain	2.17	1.59	2.05	1.32	145	106	137	89	258	189	245	158
A11GA01	Ascorbic acid (vit c)	2.17	1.59	2.05	1.32	145	106	137	89	258	189	245	158
A11H	Other plain vitamin preparations	0.13	0.13	0.12	0.12	201	180	200	197	353	316	349	344
A11HA	Other plain vitamin preparations	0.13	0.13	0.12	0.12	201	180	200	197	353	316	349	344
A11HA02	Pyridoxine (vit b6)	0.13	0.13	0.12	0.12	42	42	38	39	71	72	64	66
A11HA30	Dexpanthenol					159	138	162	158	282	244	285	277

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
A12	Mineral supplements	14.12	14.03	14.89	15.31	8,482	8,488	8,942	9,289	14,009	14,081	14,765	15,349
A12A	Calcium	8.86	8.67	9.30	9.52	4,033	4,020	4,391	4,529	6,821	6,860	7,415	7,664
A12AA	Calcium	1.08	1.07	1.12	1.12	798	802	843	837	1,378	1,388	1,456	1,448
A12AA04	Calcium carbonate	1.08	1.06	1.12	1.12	793	788	837	837	1,368	1,362	1,445	1,448
A12AA06	Calcium lactate gluconate	0.00	0.01	0.00		5	14	6		9	26	10	
A12AX	Calcium, combinations with vitamin d and/or other drugs	15.55	15.20	16.37	16.80	6,471	6,436	7,096	7,384	10,887	10,944	11,918	12,432
A12B	Potassium	5.27	5.36	5.59	5.80	4,449	4,468	4,551	4,760	7,188	7,221	7,350	7,685
A12BA	Potassium	5.27	5.36	5.59	5.80	4,449	4,468	4,551	4,760	7,188	7,221	7,350	7,685
A12BA01	Potassium chloride	5.22	5.32	5.59	5.80	4,324	4,366	4,551	4,760	6,985	7,057	7,350	7,685
A12BA51	Potassium chloride, combinations	0.05	0.04			125	102			203	164		



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
B	Blood and blood forming organs	72.30	68.78	67.19	66.73	11,983	12,084	10,890	10,277	20,611	20,797	18,697	17,748
B01	Antithrombotic agents	66.20	63.05	61.57	61.48	7,625	7,221	7,239	7,300	13,312	12,595	12,623	12,695
B01A	Antithrombotic agents	66.20	63.05	61.57	61.48	7,625	7,221	7,239	7,300	13,312	12,595	12,623	12,695
B01AC	Platelet aggregation inhibitors excl. heparin	66.20	63.05	61.57	61.48	7,625	7,221	7,239	7,300	13,312	12,595	12,623	12,695
B01AC06	Acetylsalicylic acid	66.20	63.05	61.57	61.48	7,625	7,221	7,239	7,300	13,312	12,595	12,623	12,695
B03	Antianemic preparations	6.10	5.73	5.62	5.25	4,297	4,796	3,584	2,903	7,198	8,093	5,964	4,932
B03A	Iron preparations	5.42	5.73	5.62	5.25	4,069	4,796	3,584	2,903	6,867	8,093	5,964	4,932
B03AA	Iron bivalent, oral preparations	4.05	4.01	4.02	3.75	2,964	3,421	2,277	1,666	5,048	5,829	3,814	2,898
B03AA01	Ferrous glycine sulfate	2.96	2.95	3.15	2.91	2,383	2,851	1,859	1,321	4,058	4,859	3,103	2,303
B03AA07	Ferrous sulfate	1.09	1.07	0.88	0.84	582	570	418	345	990	970	710	596
B03AB	Iron trivalent, oral preparations	1.36	1.72	1.60	1.50	1,105	1,375	1,306	1,237	1,819	2,264	2,151	2,034
B03AB05	Ferric oxide polymaltose complexes	1.36	1.72	1.60	1.50	1,105	1,375	1,306	1,237	1,819	2,264	2,151	2,034
B03B	Vitamin b12,and folic acid	0.69				228				332			
B03BA	Vitamin b12,(cyanocobalamin and derivatives)	0.69				228				332			
B03BA01	Cyanocobalamin	0.69				228				332			
B05	Blood substitutes and perfusion solutions					62	67	67	74	101	109	110	121
B05B	I.v. solutions					62	67	67	74	101	109	110	121
B05BB	Solutions affecting the electrolyte balance					62	67	67	74	101	109	110	121
B05BB01	Electrolytes					62	67	67	74	101	109	110	121



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
C	Cardiovascular system	0.10	0.10	0.10	0.09	3,896	3,678	3,691	4,058	6,635	6,244	6,257	6,861
C04	Peripheral vasodilators	0.10	0.10	0.10	0.09	75	74	75	66	124	123	123	108
C04A	Peripheral vasodilators	0.10	0.10	0.10	0.09	75	74	75	66	124	123	123	108
C04AD	Purine derivatives	0.10	0.10	0.10	0.09	75	74	75	66	124	123	123	108
C04AD03	Pentoxifylline	0.10	0.10	0.10	0.09	75	74	75	66	124	123	123	108
C05	Vasoprotectives					3,821	3,604	3,616	3,992	6,511	6,122	6,134	6,753
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use					2,282	2,116	2,109	2,430	3,928	3,625	3,605	4,142
C05AA	Corticosteroids					2,157	2,024	2,109	2,430	3,707	3,462	3,605	4,142
C05AA04	Prednisolone					2,157	2,024	2,109	2,430	3,707	3,462	3,605	4,142
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use					124	92			220	163		
C05AX03	Other preparations, combinations					124	92			220	163		
C05B	Antivaricose therapy					1,540	1,488	1,507	1,562	2,584	2,497	2,529	2,610
C05BA	Heparins or heparinoids for topical use					1,540	1,488	1,507	1,562	2,584	2,497	2,529	2,610
C05BA01	Organo-heparinoid					1,540	1,488	1,507	1,562	2,584	2,497	2,529	2,610



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D	Dermatologicals					22,838	23,360	21,348	22,322	39,600	40,414	36,980	38,588
D01	Antifungals for dermatological use					3,958	4,038	4,209	4,166	6,823	6,931	7,216	7,138
D01A	Antifungals for topical use					3,958	4,038	4,209	4,166	6,823	6,931	7,216	7,138
D01AA	Antibiotics					42	43	46	43	74	76	81	76
D01AA02	Natamycin					42	43	46	43	74	76	81	76
D01AC	Imidazole and triazole derivatives					2,623	2,732	2,890	2,881	4,502	4,687	4,949	4,932
D01AC01	Clotrimazole					253	247	223	213	448	436	392	376
D01AC02	Miconazole					898	909	922	931	1,555	1,571	1,593	1,608
D01AC07	Tioconazole					13	4	29	26	23	6	50	45
D01AC08	Ketoconazole					942	1,045	1,143	1,153	1,590	1,768	1,928	1,945
D01AC10	Bifonazole							39	29			69	51
D01AC20	Imidazoles/triazoles in combination with corticosteroids					517	528	535	529	886	905	917	907
D01AE	Other antifungals for topical use					1,292	1,262	1,273	1,242	2,247	2,168	2,186	2,130
D01AE15	Terbinafine					1,292	1,262	1,273	1,242	2,247	2,168	2,186	2,130
D02	Emollients and protectives					2,214	2,357	49	52	3,711	3,945	86	92
D02A	Emollients and protectives					2,214	2,357	49	52	3,711	3,945	86	92
D02AE	Carbamide products					1,183	1,271	29	32	1,981	2,124	52	57
D02AE01	Carbamide					1,183	1,271	29	32	1,981	2,124	52	57
D02AX	Other emollients and protectives					2,060	2,172	40	42	3,460	3,640	67	70

Table continued



ATC classification	Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
	D03	Preparations for treatment of wounds and ulcers				6,316	6,508	6,678	6,994	11,095	11,400	11,652
D03A	Cicatrizants				6,316	6,508	6,678	6,994	11,095	11,400	11,652	12,168
D03AX	Other cicatrizants				6,316	6,508	6,678	6,994	11,095	11,400	11,652	12,168
D03AX03	Dexpanthenol				6,316	6,508	6,678	6,994	11,095	11,400	11,652	12,168
D04	Antipruritics, incl. antihistamines, anesthetics, etc.				330	425	379	644	587	776	696	1,130
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.				330	425	379	644	587	776	696	1,130
D04AA	Antihistamines for topical use				330	425	379	644	587	776	696	1,130
D04AA04	Tripelennamine				330	425	379	644	587	776	696	1,130
D06	Antibiotics and chemotherapeutics for dermatological use				3,087	3,028	2,839	2,935	5,370	5,257	4,924	5,087
D06A	Antibiotics for topical use				1,243	1,202	1,167	1,280	2,185	2,114	2,051	2,245
D06AX	Other antibiotics for topical use				1,243	1,202	1,167	1,280	2,185	2,114	2,051	2,245
D06AX04	Neomycin				1,243	1,202	1,167	1,280	2,185	2,114	2,051	2,245
D06B	Chemotherapeutics for topical use				1,844	1,826	1,672	1,655	3,186	3,143	2,873	2,842
D06BB	Antivirals				1,637	1,621	1,480	1,468	2,837	2,799	2,550	2,530
D06BB03	Aciclovir				1,125	1,114	1,089	1,095	1,956	1,925	1,882	1,890
D06BB06	Penciclovir				202	245	195	190	352	427	334	329
D06BB53	Aciclovir, combinations				310	262	196	183	528	448	334	312
D06BX	Other chemotherapeutics				207	205	192	187	348	344	322	312
D06BX01	Metronidazole				207	205	192	187	348	344	322	312

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D07	Corticosteroids, dermatological preparations					5,153	5,225	5,312	5,586	9,068	9,179	9,321	9,797
D07A	Corticosteroids, plain					3,472	3,535	3,677	3,946	6,149	6,246	6,488	6,956
D07AA	Corticosteroids, weak (group i)					3,472	3,535	3,677	3,946	6,149	6,246	6,488	6,956
D07AA02	Hydrocortisone					3,472	3,535	3,677	3,946	6,149	6,246	6,488	6,956
D07B	Corticosteroids, combinations with antiseptics					744	731	711	701	1,303	1,280	1,243	1,225
D07BA	Corticosteroids, weak, combinations with antiseptics					744	731	711	701	1,303	1,280	1,243	1,225
D07BA04	Hydrocortisone and antiseptics					744	731	711	701	1,303	1,280	1,243	1,225
D07C	Corticosteroids, combinations with antibiotics					643	659	653	665	1,090	1,115	1,106	1,125
D07CA	Corticosteroids, weak, combinations with antibiotics					643	659	653	665	1,090	1,115	1,106	1,125
D07CA01	Hydrocortisone and antibiotics					643	659	653	665	1,090	1,115	1,106	1,125
D07X	Corticosteroids, other combinations					294	300	272	274	526	538	484	491
D07XA	Corticosteroids, weak, other combinations					294	300	272	274	526	538	484	491
D07XA01	Hydrocortisone					294	300	272	274	526	538	484	491
D08	Antiseptics and disinfectants					390	331	315	302	684	578	555	530
D08A	Antiseptics and disinfectants					390	331	315	302	684	578	555	530
D08AC	Biguanides and amidines					46	29	4	6	77	46	7	10
D08AC02	Chlorhexidine					46	29	4	5	77	45	7	7
D08AC52	Chlorhexidine, combinations					0	0	0	1	0	0	0	2
D08AG	Iodine products					344	302	311	296	607	532	548	521
D08AG02	Povidone-iodine					344	302	311	296	607	532	548	521
D09	Medicated dressings					98	110	108	106	157	176	173	170
D09A	Medicated dressings					98	110	108	106	157	176	173	170
D09AB	Zinc bandages					98	110	108	106	157	176	173	170
D09AB01	Zinc bandage without supplements					98	110	108	106	157	176	173	170

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
D10	Anti-acne preparations					472	450	460	459	799	762	777	777
D10A	Anti-acne preparations for topical use					472	450	460	459	799	762	777	777
D10AE	Peroxides					472	450	460	459	799	762	777	777
D10AE01	Benzoyl peroxide					472	450	460	459	799	762	777	777
D11	Other dermatological preparations					821	887	1,000	1,078	1,306	1,410	1,580	1,699
D11A	Other dermatological preparations					821	887	1,000	1,078	1,306	1,410	1,580	1,699
D11AC	Medicated shampoos					96	107	113	107	170	187	198	188
D11AC03	Selenium compounds					96	107	113	107	170	187	198	188
D11AX	Other dermatologicals					725	780	886	971	1,136	1,222	1,382	1,512
D11AX01	Minoxidil					725	780	886	971	1,136	1,222	1,382	1,512



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
G	Genito urinary system and sex hormones	11.08	11.04	10.79	9.67	12,101	12,756	12,696	9,208	20,012	21,052	20,928	15,258
G01	Gynecological antiinfectives and antiseptics	0.55	0.55	0.51	0.51	1,849	1,959	1,785	1,808	3,154	3,330	3,037	3,077
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	0.55	0.55	0.51	0.51	1,849	1,959	1,785	1,808	3,154	3,330	3,037	3,077
G01AF	Imidazole derivatives	0.55	0.55	0.51	0.51	1,849	1,959	1,785	1,808	3,154	3,330	3,037	3,077
G01AF02	Clotrimazole	0.40	0.42	0.41	0.43	1,659	1,783	1,664	1,707	2,826	3,025	2,828	2,902
G01AF04	Miconazole	0.14	0.13	0.09	0.08	190	176	121	101	328	305	208	175
G03	Sex hormones and modulators of the genital system	6.46	6.79	6.59	5.57	8,591	9,316	9,491	6,055	14,110	15,273	15,528	9,955
G03A	Hormonal contraceptives for systemic use	0.05	0.04	0.04	0.04	1,077	1,055	942	853	1,804	1,751	1,591	1,438
G03AD	Emergency contraceptives	0.05	0.04	0.04	0.04	1,077	1,055	942	853	1,804	1,751	1,591	1,438
G03AD01	Levonorgestrel	0.03	0.03	0.02	0.02	541	506	456	419	923	863	779	718
G03AD02	Ulipristal	0.02	0.02	0.02	0.02	536	549	486	434	881	888	812	720
G03C	Estrogens	6.41	6.75	6.54	5.53	7,514	8,261	8,549	5,202	12,305	13,522	13,937	8,518
G03CA	Natural and semisynthetic estrogens, plain	6.41	6.75	6.54	5.53	7,514	8,261	8,549	5,202	12,305	13,522	13,937	8,518
G03CA03	Estradiol	1.03	1.08	1.07	0.53	5,700	5,979	5,891	2,836	9,234	9,686	9,547	4,601
G03CA04	Estriol	5.38	5.67	5.48	5.01	1,814	2,282	2,658	2,366	3,071	3,836	4,390	3,916
G04	Urologicals	4.07	3.69	3.69	3.59	1,661	1,481	1,420	1,344	2,749	2,449	2,364	2,226
G04B	Urologicals	3.22	3.05	3.13	3.08	1,044	986	999	983	1,745	1,648	1,683	1,640
G04BX	Other urologicals	3.22	3.05	3.13	3.08	1,044	986	999	983	1,745	1,648	1,683	1,640
G04BX01	Magnesium hydroxide	3.22	3.05	3.13	3.08	1,044	986	999	983	1,745	1,648	1,683	1,640
G04C	Drugs used in benign prostatic hypertrophy	0.85	0.64	0.56	0.51	618	495	421	361	1,004	801	681	586
G04CX	Other drugs used in benign prostatic hypertrophy	0.85	0.64	0.56	0.51	618	495	421	361	1,004	801	681	586
G04CX02	Sabalisserrulataefructus	0.85	0.64	0.56	0.51	618	495	421	361	1,004	801	681	586



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
H	Systemic hormonal preparations, excl. sex hormones and insulins	0.68	0.57	0.46	0.46	1,029	837	677	688	1,922	1,606	1,227	1,239
H02	Corticosteroids for systemic use	0.68	0.57	0.46	0.46	1,029	837	677	688	1,922	1,606	1,227	1,239
H02A	Corticosteroids for systemic use, plain	0.68	0.57	0.46	0.46	1,029	837	677	688	1,922	1,606	1,227	1,239
H02AB	Glucocorticoids	0.68	0.57	0.46	0.46	1,029	837	677	688	1,922	1,606	1,227	1,239
H02AB09	Hydrocortisone	0.68	0.57	0.46	0.46	1,029	837	677	688	1,922	1,606	1,227	1,239



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
J	Antiinfectives for systemic use	0.18	0.19	0.18	0.19	2,497	2,371	1,986	1,994	4,420	4,183	3,551	3,503
J02	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,296	1,123	909	893	2,344	2,016	1,662	1,604
J02A	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,296	1,123	909	893	2,344	2,016	1,662	1,604
J02AC	Triazole and tetrazole derivatives	0.09	0.09	0.09	0.09	1,296	1,123	909	893	2,344	2,016	1,662	1,604
J02AC01	Fluconazole	0.09	0.09	0.09	0.09	1,296	1,123	909	893	2,344	2,016	1,662	1,604
J05	Antivirals for systemic use	0.09	0.10	0.10	0.10	1,201	1,248	1,077	1,101	2,076	2,167	1,889	1,899
J05A	Direct acting antivirals	0.09	0.10	0.10	0.10	1,201	1,248	1,077	1,101	2,076	2,167	1,889	1,899
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0.09	0.10	0.10	0.10	1,201	1,248	1,077	1,101	2,076	2,167	1,889	1,899
J05AB01	Aciclovir	0.03	0.04	0.04	0.04	312	323	286	280	550	579	515	495
J05AB11	Valaciclovir	0.06	0.06	0.06	0.06	889	925	791	821	1,525	1,588	1,375	1,405



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
M	Musculo-skeletal system	24.19	24.62	23.02	23.44	33,060	33,850	33,201	33,662	58,541	59,755	58,131	59,013
M01	Antiinflammatory and antirheumatic products	24.19	24.62	23.02	23.44	22,285	23,058	21,296	21,309	40,362	41,679	38,349	38,453
M01A	Antiinflammatory and antirheumatic products, non-steroids	24.19	24.62	23.02	23.44	22,285	23,058	21,296	21,309	40,362	41,679	38,349	38,453
M01AE	Propionic acid derivatives	24.19	24.62	23.02	23.44	22,285	23,058	21,296	21,309	40,362	41,679	38,349	38,453
M01AE01	Ibuprofen	23.47	23.86	22.38	22.97	21,114	21,820	20,277	20,536	38,256	39,454	36,522	37,057
M01AE02	Naproxen	0.04	0.03	0.02	0.03	83	73	56	62	145	127	97	108
M01AE03	Ketoprofen	0.18	0.17	0.15	0.14	312	298	272	256	594	567	517	487
M01AE51	Ibuprofen, combinations	0.51	0.56	0.46	0.31	776	867	691	456	1,367	1,531	1,214	801
M02	Topical products for joint and muscular pain					10,775	10,792	11,905	12,353	18,179	18,076	19,782	20,561
M02A	Topical products for joint and muscular pain					10,775	10,792	11,905	12,353	18,179	18,076	19,782	20,561
M02AA	Antiinflammatory preparations, non-steroids for topical use					9,844	9,937	11,072	11,583	16,600	16,625	18,369	19,254
M02AA07	Piroxicam					471	437	447	405	815	754	771	698
M02AA13	Ibuprofen					616	1,116	760	1,034	1,182	1,915	1,304	1,749
M02AA15	Diclofenac					8,757	8,384	9,865	10,144	14,604	13,956	16,294	16,808
M02AC	Preparations with salicylic acid derivatives					1,861	1,711	1,665	1,540	3,158	2,902	2,826	2,612



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
N	Nervous system	11.24	10.84	13.03	12.10	25,984	23,851	27,488	25,024	34,122	31,073	36,230	31,842
N01	Anesthetics					268	287	295	334	462	495	507	575
N01B	Anesthetics, local					268	287	295	334	462	495	507	575
N01BB	Amides					268	287	295	334	462	495	507	575
N01BB20	Combinations					268	287	295	334	462	495	507	575
N02	Analgesics	8.05	7.62	8.57	7.36	18,194	16,465	18,977	16,447	32,671	29,656	33,943	29,415
N02B	Other analgesics and antipyretics	8.04	7.62	8.57	7.36	18,170	16,446	18,965	16,435	32,629	29,622	33,922	29,394
N02BA	Salicylic acid and derivatives	1.67	1.02	1.32	1.12	4,559	1,496	3,377	2,704	8,020	2,666	5,916	4,742
N02BA01	Acetylsalicylic acid	0.82	0.77	0.73	0.66	1,132	988	1,022	955	2,034	1,774	1,831	1,710
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	0.85	0.25	0.59	0.45	3,427	508	2,354	1,748	5,986	891	4,085	3,032
N02BE	Anilides	6.37	6.60	7.24	6.24	13,611	14,950	15,589	13,732	24,609	26,957	28,006	24,652
N02BE01	Paracetamol	6.20	6.32	7.05	6.13	13,131	14,089	14,995	13,385	23,760	25,433	26,965	24,044
N02BE51	Paracetamol, combinations excl. psycholeptics	0.17	0.28	0.20	0.12	480	861	593	346	849	1,524	1,041	608
N02C	Antimigraine preparations	0.00	0.00	0.00	0.00	24	19	12	12	42	34	21	21
N02CC	Selective 5ht1-receptor agonists	0.00	0.00	0.00	0.00	24	19	12	12	42	34	21	21
N02CC01	Sumatriptan	0.00	0.00	0.00	0.00	24	19	12	12	42	34	21	21
N05	Psycholeptics	1.33	1.52	2.58	2.89	536	490	989	1,025	989	922	1,779	1,851
N05C	Hypnotics and sedatives	1.33	1.52	2.58	2.89	536	490	989	1,025	989	922	1,779	1,851
N05CH	Melatonin receptor agonists	1.12	1.42	2.37	2.70	227	343	538	609	458	669	1,018	1,147
N05CH01	Melatonin	1.12	1.42	2.37	2.70	227	343	538	609	458	669	1,018	1,147
N05CM	Other hypnotics and sedatives	0.21	0.09	0.21	0.19	309	147	451	416	531	254	761	705
N05CM09	Valerianae radix	0.21	0.09	0.21	0.19	309	147	451	416	531	254	761	705



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
P	Antiparasitic products, insecticides and repellents	0.25	0.29	0.27	0.24	2,843	3,170	3,026	3,232	4,601	5,118	4,886	5,214
P02	Anthelmintics	0.25	0.29	0.27	0.24	1,427	1,678	1,515	1,370	2,318	2,722	2,453	2,217
P02C	Antinematodal agents	0.25	0.29	0.27	0.24	1,427	1,678	1,515	1,370	2,318	2,722	2,453	2,217
P02CX	Other antinematodals	0.25	0.29	0.27	0.24	1,427	1,678	1,515	1,370	2,318	2,722	2,453	2,217
P02CX01	Pyvvinium	0.25	0.29	0.27	0.24	1,427	1,678	1,515	1,370	2,318	2,722	2,453	2,217
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents					1,416	1,492	1,511	1,862	2,283	2,396	2,432	2,997
P03A	Ectoparasiticides, incl. scabicides					1,416	1,492	1,511	1,862	2,283	2,396	2,432	2,997
P03AC	Pyrethrines, incl. synthetic compounds					1,416	1,492	1,511	1,862	2,283	2,396	2,432	2,997
P03AC04	Permethrin					1,416	1,492	1,511	1,862	2,283	2,396	2,432	2,997



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R	Respiratory system	42.15	44.16	42.86	46.76	31,759	32,526	29,048	29,756	56,864	57,650	51,036	52,226
R01	Nasal preparations	13.87	14.36	12.13	12.96	7,334	8,401	7,703	8,109	13,452	15,338	13,767	14,494
R01A	Decongestants and other nasal preparations for topical use	13.87	14.36	12.13	12.96	7,334	8,401	7,703	8,109	13,452	15,338	13,767	14,494
R01AA	Sympathomimetics, plain	10.62	10.99	9.08	9.51	4,834	5,799	5,244	5,317	9,059	10,751	9,447	9,665
R01AA05	Oxymetazoline	0.78	0.81	0.75	0.73	267	283	260	253	496	516	474	461
R01AA07	Xylometazoline	9.84	10.17	8.33	8.77	4,567	5,516	4,984	5,064	8,562	10,235	8,973	9,205
R01AB	Sympathomimetics, combinations excl. corticosteroids	0.80	0.83	0.64	0.69	539	612	492	517	961	1,097	892	915
R01AB06	Xylometazoline	0.80	0.83	0.64	0.69	539	612	492	517	961	1,097	892	915
R01AC	Antiallergic agents, excl. corticosteroids	0.34	0.33	0.22	0.29	313	301	246	351	552	533	422	602
R01AC01	Cromoglicic acid	0.20	0.19	0.03		142	132	21		259	242	38	
R01AC02	Levocabastine	0.07	0.07	0.09	0.14	104	98	137	212	177	168	234	363
R01AC03	Azelastine	0.07	0.08	0.09	0.15	67	71	87	138	115	123	151	239
R01AD	Corticosteroids	1.84	1.99	2.01	2.28	1,507	1,565	1,624	1,813	2,621	2,727	2,824	3,106
R01AD01	Beclometasone	0.34	0.30	0.31	0.30	241	208	231	230	418	354	393	390
R01AD08	Fluticasone	0.61	0.62	0.59	0.64	605	608	621	674	1,056	1,064	1,086	1,160
R01AD09	Mometasone	0.57	0.72	0.70	0.91	355	418	403	521	623	735	708	892
R01AD11	Triamcinolone	0.33	0.36	0.40	0.43	306	331	369	389	524	574	638	664
R01AX	Other nasal preparations	0.26	0.23	0.18	0.20	139	124	98	111	259	229	181	206
R01AX10	Various	0.26	0.23	0.18	0.20	139	124	98	111	259	229	181	206

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R02	Throat preparations	3.67	3.27	2.50	2.28	7,917	7,531	5,686	5,357	14,069	13,285	9,976	9,374
R02A	Throat preparations	3.67	3.27	2.50	2.28	7,917	7,531	5,686	5,357	14,069	13,285	9,976	9,374
R02AA	Antiseptics	1.60	1.52	1.06	1.12	4,235	4,250	2,969	3,008	7,559	7,520	5,219	5,281
R02AA03	Dichlorobenzyl alcohol	1.57	1.51	1.05	1.11	3,567	3,636	2,626	2,781	6,362	6,387	4,603	4,870
R02AA05	Chlorhexidine	0.03	0.02	0.01	0.00	46	25	12	4	84	46	21	8
R02AA20	Various					623	588	332	223	1,113	1,087	595	403
R02AB	Antibiotics	1.37	1.17	1.06	0.87	2,440	2,216	2,050	1,840	4,343	3,897	3,588	3,205
R02AB30	Gramicidin	1.37	1.17	1.06	0.87	2,440	2,216	2,050	1,840	4,343	3,897	3,588	3,205
R02AX	Other throat preparations	0.70	0.58	0.38	0.29	1,241	1,065	667	508	2,167	1,869	1,169	888
R02AX01	Flurbiprofen	0.06	0.06	0.04	0.03	285	275	169	132	488	470	288	226
R02AX03	Benzydamine	0.64	0.52	0.35	0.26	956	790	498	376	1,679	1,399	881	663

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R05	Cough and cold preparations	3.70	3.34	2.42	2.05	7,434	6,827	5,122	4,449	13,130	11,974	8,958	7,794
R05C	Expectorants, excl. combinations with cough suppressants	2.02	1.88	1.37	1.12	2,587	2,465	1,813	1,495	4,580	4,346	3,183	2,631
R05CA	Expectorants	0.17	0.09	0.06	0.06	248	157	112	111	450	287	201	197
R05CA03	Guaifenesin	0.06	0.01			81	14			146	25		
R05CA10	Combinations	0.11	0.08	0.06	0.06	167	143	112	111	303	262	201	197
R05CB	Mucolytics	1.85	1.78	1.31	1.06	2,338	2,307	1,701	1,385	4,130	4,059	2,982	2,434
R05CB01	Acetylcysteine	0.65	0.66	0.50	0.39	731	744	543	436	1,281	1,302	951	763
R05CB02	Bromhexine	1.13	1.01	0.72	0.59	1,500	1,346	959	780	2,658	2,361	1,683	1,375
R05CB03	Carbocisteine	0.06	0.06	0.03	0.03	107	94	57	48	192	164	100	84
R05CB06	Ambroxol		0.06	0.06	0.05		123	142	120		231	249	211
R05D	Cough suppressants, excl. combinations with expectorants	0.91	0.80	0.53	0.49	1,658	1,454	978	838	2,995	2,579	1,731	1,492
R05DA	Opium alkaloids and derivatives	0.72	0.64	0.41	0.41	1,079	964	619	626	1,969	1,712	1,097	1,115
R05DA09	Dextromethorphan	0.72	0.64	0.41	0.41	1,079	964	619	626	1,969	1,712	1,097	1,115
R05DB	Other cough suppressants	0.19	0.16	0.12	0.07	579	490	359	213	1,026	867	634	377
R05DB05	Pentoxyverine	0.19	0.16	0.12	0.07	579	490	359	213	1,026	867	634	377
R05F	Cough suppressants and expectorants, combinations	0.77	0.65	0.52	0.44	2,480	2,305	1,837	1,541	4,349	4,024	3,205	2,692
R05FA	Opium derivatives and expectorants	0.21	0.22	0.19	0.18	513	544	461	430	918	972	824	768
R05FA02	Opium derivatives and expectorants	0.21	0.22	0.19	0.18	513	544	461	430	918	972	824	768
R05FB	Other cough suppressants and expectorants	0.56	0.43	0.33	0.27	1,967	1,761	1,376	1,112	3,431	3,052	2,381	1,924
R05FB02	Cough suppressants and expectorants	0.56	0.43	0.33	0.27	1,967	1,761	1,376	1,112	3,431	3,052	2,381	1,924
R05X	Other cold preparations					1,419	1,206	988	1,150	2,413	2,051	1,678	1,956

Table continued



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
R06	Antihistamines for systemic use	20.91	23.19	25.81	29.47	9,074	9,767	10,536	11,840	16,213	17,053	18,335	20,565
R06A	Antihistamines for systemic use	20.91	23.19	25.81	29.47	9,074	9,767	10,536	11,840	16,213	17,053	18,335	20,565
R06AE	Piperazine derivatives	14.46	15.87	17.62	19.76	5,646	6,023	6,524	7,212	10,152	10,490	11,331	12,621
R06AE03	Cyclizine	0.05		0.00	0.01	93		14	34	164		25	61
R06AE05	Meclozine	0.14	0.19	0.09	0.08	319	439	233	232	556	765	414	400
R06AE07	Cetirizine	13.70	15.10	16.90	18.99	4,870	5,238	5,928	6,569	8,801	9,127	10,289	11,520
R06AE09	Levocetirizine	0.58	0.59	0.63	0.68	363	347	350	377	630	598	602	639
R06AX	Other antihistamines for systemic use	6.44	7.32	8.19	9.71	3,428	3,744	4,012	4,629	6,061	6,564	7,004	7,944
R06AX13	Loratadine	1.21	1.19	1.37	1.39	388	374	437	436	710	677	780	759
R06AX18	Acrivastine	0.05	0.08	0.08	0.08	90	144	144	152	163	260	260	275
R06AX22	Ebastine	2.59	2.87	3.26	3.73	1,390	1,455	1,568	1,761	2,391	2,474	2,653	3,014
R06AX26	Fexofenadine	1.58	2.14	2.27	2.73	1,009	1,194	1,216	1,435	1,804	2,131	2,147	2,441
R06AX27	Desloratadine	1.01	1.05	1.21	1.78	551	576	647	844	994	1,021	1,164	1,455



ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
S	Sensory organs					14,573	15,225	14,437	15,400	24,598	25,658	24,254	25,746
S01	Ophthalmologicals					13,921	14,562	13,826	14,814	23,474	24,519	23,206	24,742
S01G	Decongestants and antiallergics					3,268	3,310	2,894	3,426	5,629	5,736	5,010	5,829
S01GA	Sympathomimetics used as decongestants					247	251	201	212	450	452	356	370
S01GA02	Tetryzoline					247	251	201	212	450	452	356	370
S01GX	Other antiallergics					3,021	3,059	2,693	3,215	5,179	5,284	4,654	5,459
S01GX01	Cromoglicic acid					2,506	2,601	2,286	2,644	4,298	4,474	3,938	4,480
S01GX02	Levocabastine					206	122	175	257	357	211	304	443
S01GX05	Lodoxamide					36	56	35	44	63	98	61	76
S01GX07	Azelastine					23	26			40	43		
S01GX08	Ketotifen					249	254	197	270	421	457	351	460
S01X	Other ophthalmologicals					10,653	11,252	10,932	11,388	17,845	18,783	18,196	18,913
S01XA	Other ophthalmologicals					10,653	11,252	10,932	11,388	17,845	18,783	18,196	18,913
S01XA02	Retinol					395	503	512	492	687	866	882	848
S01XA20	Artificial tears and other indifferent preparations					10,258	10,750	10,420	10,896	17,157	17,917	17,314	18,066
S02	Otologicals					652	663	612	586	1,124	1,139	1,048	1,004
S02A	Antiinfectives					431	460	498	473	744	790	852	808
S02AA	Antiinfectives					431	460	498	473	744	790	852	808
S02AA03	Boric acid					431	460	498	473	744	790	852	808
S02D	Other otologicals					221	203	114	113	380	350	196	196
S02DA	Analgesics and anesthetics					221	203	114	113	380	350	196	196
S02DA04	Cinchocaine					221	203	114	113	380	350	196	196




ATC classification		Consumption, DDD/1.000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
V	Various					186	246	359	226	308	405	591	372
V03	All other therapeutic products					97	151	257	102	160	247	422	166
V03A	All other therapeutic products					97	151	257	102	160	247	422	166
V03AB	Antidotes					97	151	257	102	160	247	422	166
V03AB21	Potassium iodide					97	151	257	102	160	247	422	166
V07	All other non-therapeutic products					89	95	102	124	147	157	169	205
V07A	All other non-therapeutic products					89	95	102	124	147	157	169	205
V07AB	Solvents and diluting agents, incl. irrigating solutions					177	190	204	247	293	314	338	411

Figures on sales statistics


Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2021

DDD/1,000 inhabitants/day



- Esomeprazole (A02BC05)
- Rabeprazole (A02BC04)
- Lansoprazole (A02BC03)
- Pantoprazole (A02BC02)
- Omeprazole (A02BC01)

Wholesale price (VAT excluded) thousand euros



- Proton pump inhibitors (A02BC)
- Esomeprazole (A02BC05)
- - - Rabeprazole (A02BC04)
- - - Lansoprazole (A02BC03)
- . . . Pantoprazole (A02BC02)
- . . . Omeprazole (A02BC01)

Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2021

Whole country 74.66 DDD/1,000 inhabitants/day






Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2021

DDD/1,000 inhabitants/day



- Insulins and analogues for injection, long-acting (A10AE)
- Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)


Wholesale price (VAT excluded) thousand euros




- Insulins and analogues (A10A)
- Insulins and analogues for injection, long-acting (A10AE)
- Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)

Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2021

DDD/1,000 inhabitants/day



Wholesale price (VAT excluded) thousand euros




- Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- Combinations of oral blood glucose lowering drugs (A10BD)
- Sulfonylureas (A10BB)
- Biguanides (A10BA)

- Blood glucose lowering drugs, excl. Insulins (A10B)
- - - Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- . . . Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- . . . Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- - - Combinations of oral blood glucose lowering drugs (A10BD)
- . . . Sulfonylureas (A10BB)
- . . . Biguanides (A10BA)




Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2021

DDD/1,000 inhabitants/day



- Agents acting on the renin-angiotensin system (C09)
- Calcium channel blockers (C08)
- Beta blocking agents (C07)
- Diuretics (C03)


Wholesale price (VAT excluded) thousand euros



- Agents acting on the renin-angiotensin system (C09)
- - - Calcium channel blockers (C08)
- . . . Beta blocking agents (C07)
- . - . Diuretics (C03)


Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2021

DDD/1,000 inhabitants/day



- Angiotensin II antagonists, combinations (C09D)
- Angiotensin II antagonists (C09C)
- ACE inhibitors, combinations (C09B)
- ACE inhibitors, plain (C09A)

Wholesale price (VAT excluded) thousand euros



- Angiotensin II antagonists, combinations (C09D)
- - - Angiotensin II antagonists (C09C)
- . - . - ACE inhibitors, combinations (C09B)
- . . . ACE inhibitors, plain (C09A)

Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2021

Whole country 280.96 DDD/1,000 inhabitants/day






Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2021

DDD/1,000 inhabitants/day



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)

Wholesale price (VAT excluded) thousand euros



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)

Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2021

Whole country 167.25 DDD/1,000 inhabitants/day




Figure 7.10. Consumption of hormonal contraceptives in 2006-2021

DDD/1,000 inhabitants/day




Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2021

Whole country 121.00 DDD/1,000 women aged over 45/day




Figure 7.12. Consumption of antibacterials (J01) in 2006–2021

DDD/1,000 inhabitants/day




Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2021

Whole country 11.27 DDD/1,000 inhabitants/day




Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006-2021

DDD/1,000 inhabitants/day




Figure 7.15. Consumption of most common OTC analgesics in 2006–2021




Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2021





Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2021



1 Only products with marketing authorization.

Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2021

Whole country 47.42 DDD/1,000 inhabitants/day






Figure 7.19. Consumption of antidepressants (N06A) in 2006–2021




Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2021




Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2021

Whole country 83.92 DDD/1,000 inhabitants/day





Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2021


DDD/1,000 inhabitants/day



- Anticholinergics (R03BB)
- Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)

1 From 2010.
2 From 2014.

Wholesale price (VAT excluded) thousand euros




- Anticholinergics (R03BB)
- ⋯ Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- - - Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- ⋯ Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)

1 From 2010.
2 From 2014.




Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2021

Whole country 80.99 DDD/1,000 inhabitants/day



Appendices





Appendix 1. Alterations to ATC classification, valid as of January 2022

Substance	Previous ATC code	New ATC code
Raxibacumab	J06BB18	J06BC02
Bezlotoxumab	J06BB21	J06BC03
Obiltoxaximab	J06BB22	J06BC04
Palivizumab	J06BB16	J06BD01
Motavizumab	J06BB17	J06BD02
Erdaftinib	L01EX16	L01EN01
Pemigatinib	L01EX20	L01EN02
Rituximab	L01XC02	L01FA01
Ofatumumab	L01XC10	L01FA02
Obinutuzumab	L01XC15	L01FA03
Inotuzumab ozogamicin	L01XC26	L01FB01
Moxetumomab pasudotox	L01XC34	L01FB02
Daratumumab	L01XC24	L01FC01
Isatuximab	L01XC38	L01FC02
Trastuzumab	L01XC03	L01FD01
Pertuzumab	L01XC13	L01FD02
Trastuzumab emtansine	L01XC14	L01FD03
Trastuzumab deruxtecan	L01XC41	L01FD04
Cetuximab	L01XC06	L01FE01
Panitumumab	L01XC08	L01FE02
Necitumumab	L01XC22	L01FE03
Nivolumab	L01XC17	L01FF01
Pembrolizumab	L01XC18	L01FF02

Substance	Previous ATC code	New ATC code
Durvalumab	L01XC28	L01FF03
Avelumab	L01XC31	L01FF04
Atezolizumab	L01XC32	L01FF05
Cemiplimab	L01XC33	L01FF06
Dostarlimab	L01XC40	L01FF07
Prolgolimab	L01XC42	L01FF08
Bevacizumab	L01XC07	L01FG01
Ramucirumab	L01XC21	L01FG02
Edrecolomab	L01XC01	L01FX01
Gemtuzumab ozogamicin	L01XC05	L01FX02
Catumaxomab	L01XC09	L01FX03
Ipilimumab	L01XC11	L01FX04
Brentuximab vedotin	L01XC12	L01FX05
Dinutuximab beta	L01XC16	L01FX06
Blinatumomab	L01XC19	L01FX07
Elotuzumab	L01XC23	L01FX08
Mogamulizumab	L01XC25	L01FX09
Olaratumab	L01XC27	L01FX10
Bermekimab	L01XC29	L01FX11
Tafasitamab	L01XC35	L01FX12
Enfortumab vedotin	L01XC36	L01FX13
Polatuzumab vedotin	L01XC37	L01FX14
Belantamab mafodotin	L01XC39	L01FX15



Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2022

No DDD alterations 2022



Appendix 3. Deflators for converting expenditure items to 2021 money, 2000–2021

In the tables of the Finnish Statistics on Medicines, the euro amounts are presented in the current currency for each year. If necessary, the effects of changes in the money value may be eliminated by changing the euro amounts by means of a conversion factor appropriate to the monetary value on a given date (a so-called deflation coefficient). The coefficients below have been calculated from indices based on the situation on 31 December 2021.

Year	Consumer price index	Consumer health index/health care	Year	Consumer price index	Consumer health index/health care
2000	1.3442	1.5194	2011	1.1135	1.2123
2001	1.3108	1.4783	2012	1.0832	1.2083
2002	1.2903	1.4096	2013	1.0674	1.1877
2003	1.2792	1.3665	2014	1.0565	1.1524
2004	1.2768	1.3381	2015	1.0586	1.1173
2005	1.2657	1.3109	2016	1.0548	1.0455
2006	1.2440	1.3048	2017	1.0468	1.0281
2007	1.2136	1.3104	2018	1.0357	1.0158
2008	1.1663	1.2893	2019	1.0249	1.0066
2009	1.1661	1.2466	2020	1.0224	0.9985
2010	1.1521	1.2234	2021	1.0000	1.0000

Source: Statistics Finland.